Therapeutic cannabinoids: Using Dictyostelium discoideum to investigate the mechanism of action of cannabigerol by Oddy, Joseph
1	
	
Therapeutic	cannabinoids:	Using	Dictyostelium	
discoideum	to	investigate	the	mechanism	of	action	
of	cannabigerol	
	
	
	
Joseph	Oddy	
	
	
	
	
	
	
	Research	thesis	submitted	for	the	degree	of	Doctor	of	Philosophy	at	the	Royal	Holloway	
University	of	London	in	May	2020	
	 	
2	
	
Declaration	of	Authorship	
I,	Joseph	Laurence	Damstra-Oddy,	hereby	declare	that	the	work	presented	in	this	thesis	is	my	
own	unless	otherwise	stated,	and	that	all	published	work	has	been	acknowledged.	Furthermore,	
I	affirm	that	I	have	neither	fabricated	nor	falsified	the	results	reported	herein.	
Signed:	
Date:	 	 	 22/05/2020	
	 	
3	
	
Abstract	
Cannabis	 has	 been	 used	 to	 treat	 many	 diseases	 for	 centuries.	 Recent	 medical	 interest	 has	
focused	on	the	potential	of	cannabinoids	to	treat	diseases	such	as	multiple	sclerosis,	epilepsy,	
and	 cancer	 where	 research	 has	 focused	 on	 investigating	 cannabidiol	 (CBD).	 However,	 other	
cannabinoids,	such	as	cannabigerol	(CBG),	remain	poorly	characterised	and	are	being	explored	
as	 potential	 treatments.	 The	 molecular	 mechanisms	 by	 which	 cannabinoids	 treat	 diseases	
remain	 unclear,	 despite	 suggested	 targets	 including	 adenosine,	 mTOR,	 transient	 receptor	
potential	 transporters	 and	 cannabinoid	 receptors.	 This	 study	 aimed	 to	 identify	 molecular	
mechanisms	of	CBG,	using	Dictyostelium	discoideum	as	a	model	system	and	translating	results	
to	a	clinical	setting.	Initially,	a	targeted	approach	was	undertaken	where	the	effects	of	CBG	on	
adenosine	transport	(and	DNA	methylation)	was	investigated.	From	this	approach,	CBG	elevated	
DNA	methylation	 in	D.	discoideum	dependent	upon	adenosine	transport	via	the	equilibrative	
nucleoside	transporter	1	(ENT1).	In	addition,	an	unbiased	approach	was	taken	in	which	screening	
of	a	mutant	library	for	CBG	resistance	identified	inositol	polyphosphate	multikinase	(IPMK),	a	
known	regulator	of	mTOR	activity,	as	a	potential	target.	Both	CBG	and	CBD	increased	mTORC1	
activity	 in	 wild	 type	 cells.	 Elevated	 expression	 of	 IPMK	 increased	 mTORC1	 activity,	 but	
surprisingly,	 subsequent	 treatment	 with	 both	 CBG	 and	 CBD	 reduced	 mTORC1	 activity,	
suggesting	 that	 cannabinoids	 functioned	 as	 pro-homeostatic	 regulators	 of	 mTORC1	 activity	
through	 IPMK.	Translating	these	results	 into	mouse	embryonic	 fibroblasts,	CBG	and	CBD	also	
increased	mTORC1	activity	in	an	IPMK-dependent	manner.	Finally,	in	primary	human	peripheral	
blood	mononuclear	cells	(PBMCs)	derived	from	healthy	volunteers	CBG	and	CBD	also	increased	
mTORC1	 activity,	 but	 decreased	 mTORC1	 activity	 in	 primary	 human	 PBMCs	 derived	 from	
patients	with	multiple	sclerosis.	Thus,	this	study	identifies	a	pro-homeostatic	role	for	CBG	and	
CBD	in	mTORC1	regulation	via	IPMK,	conserved	between	D.	discoideum	and	humans,	providing	
new	insights	into	the	potential	therapeutic	mechanism	of	these	cannabinoids.	
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1	Introduction	
1.1	Cannabinoids	
1.1.1	History	of	C.	sativa	
Cannabis	sativa	is	an	annual	herbaceous	plant	native	to	east,	south	and	central	Asia.	C.	sativa	
was	originally	cultivated	as	fibre	for	clothing	and	oil	for	cooking,	lamps	and	paints	(Li,	1973).	The	
flowers	of	the	plant	also	contain	the	psychoactive	chemical	compound,	tetrahydrocannabinol	
(THC),	which	can	have	a	euphoric	effect	if	the	flower	is	either	smoked	or	cooked	(Mansouri	et	
al.,	2009;	Perrotin-Brunel	et	al.,	2011).	In	addition	to	these	effects,	C.	sativa	has	been	used	as	a	
natural	remedy	for	many	ailments	for	thousands	of	years	(Vinet	and	Zhedanov,	2011).	C.	sativa	
from	1700	BC	 to	 the	modern	day	has	been	suggested	as	a	 remedy	 for	a	variety	of	ailments,	
including	senility	(Russo,	2007),	glaucoma	(Colasanti,	1990),	inflammation	(Osbaldeston,	2000),	
pain	 relief	 (Lozano,	 2001),	 infection	 (Russo,	 2007),	 anxiety	 (Devinsky	 et	 al.,	 2014),	 diarrhoea	
(Russo,	2007),	anorexia	(McCoy	et	al.,	2018),	consumption	(Butrica,	2002),	and	convulsion	(for	
rabies	 or	 epilepsy)	 (Perucca,	 2017).	 However,	 research	 now	 focuses	 on	 the	 molecular	
mechanisms	of	specific	chemical	compounds	derived	from	C.	sativa,	called	phytocannabinoids,	
and	how	these	mechanisms	can	have	therapeutic	effects.		
1.1.2	Economic	Value	of	Cannabinoid-Based	Therapeutics	
Therapeutic	 cannabinoids	 are	 currently	 prescribed	 as	 legal	 and	 controlled	 treatments	 for	
anorexia	in	patients	with	AIDs	or	undergoing	cancer	treatment	(Calhoun	et	al.,	1998),	multiple	
sclerosis	(Etges	et	al.,	2016),	and	epilepsy	(Gray	et	al.,	2019).	Over	€500	million	has	been	invested	
in	 the	 C.	 sativa	 industry,	 much	 of	 which	 has	 gone	 into	 medical	 research	 and	 production	
(Consultancy.eu,	2019).	The	medical	C.	sativa-based	market	could	be	worth	€58	billion	annually	
by	2028	(Consultancy.eu,	2019).	In	the	US,	it	is	estimated	that	the	legal	C.	sativa	market	could	
be	worth	$73.6	Billion	By	2027,	71%	of	which	is	in	the	medical	sector	(GVR,	2020).	
1.1.3	Chemistry	of	cannabinoids	
Phytocannabinoids	are	a	diverse	class	of	chemical	compounds	that	are	defined	by	the	ability	to	
act	on	cannabinoid	receptors.	Phytocannabinoids	are	derived	from	C.	sativa	(Taura	et	al.,	2007)	
and	endocannabinoids	are	similar	compounds	found	in	the	body	(Bermudez-Silva	et	al.,	2016).	
From	here	on	out	“cannabinoids”	refers	to	phytocannabinoids,	and	endocannabinoids	will	be	
termed	as	such.	There	are	113	different	cannabinoids	that	have	been	 isolated	from	C.	sativa	
plants	(Vinet	and	Zhedanov,	2011).	There	are	two	main	forms	of	cannabinoid,	all	are	produced	
from	 geranyl	 pyrophosphate	 along	with	 either	 olivetolic	 acid	 (OLA)	 or	 divarinolic	 acid	 (DVA)	
(Figure	1.1)	(Mechoulam	et	al.,	2014).	From	OLA	and	geranyl	pyrophosphate,	cannabigerolic	acid	
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synthase	produces	cannabigerolic	acid	(CBGA)	(Degenhardt	et	al.,	2017).	CBGA	can	readily	de-
carboyxylate	into	CBG.	From	CBGA,	synthases	can	produce	tetrahydrocannabinolic	acid	(THCA),	
cannabidiolic	 acid	 (CBDA)	 or	 cannabichromenic	 acid	 (CBCA),	 all	 of	 which	 can	 readily	 de-
carboyxlate	into	the	non-acidic	forms	of	THC,	cannabidiol	(CBD),	and	cannabichromene	(CBC)	
(Degenhardt	et	al.,	2017).	CBG,	CBD	and	THC	all	contain	an	aromatic	ring	and	a	five	carbon	side	
chain,	however,	CBD	and	THC	both	also	contain	a	cyclohexene	ring.		
Cannabinoids	are	not	equally	abundant	in	C.	sativa	extracts	and	different	plants	contain	varying	
levels	 of	 each	 cannabinoid,	 usually	 the	 most	 abundant	 cannabinoid	 is	 either	 THC,	 CBD	 or	
cannabigerol	(CBG)	(De	Meijer	and	Hammond,	2005).	The	relative	cannabinoid	level	in	extracts	
varies	widely	depending	upon	the	breeding	purpose	of	C.	sativa	and	conditions	grown	(Table	
1.1)	(Potter	et	al.,	2008;	Swift	et	al.,	2013;	Vandrey	et	al.,	2015;	Valdeolivas	et	al.,	2015).	For	
instance,	if	a	C.	sativa	strain	has	been	selectively	bred	to	produce	a	more	potent	psychoactive	
effect	then	an	extract	will	contain	relatively	more	THC	(Swift	et	al.,	2013),	while	some	plants	are	
bred	to	contain	more	CBD	to	make	them	more	saleable	(Valdeolivas	et	al.,	2012).	However,	CBG	
is	present	at	higher	 levels	 in	some	forms	of	C.	sativa	(Swift	et	al.,	2013)	and	CBG	is	relatively	
under-researched	 compared	 to	 CBD	 and	 THC.	 This	 search	was	 performed	 on	 Pubmed	 using	
“cannabigerol”,	 “cannabidiol”	 and	 “tetrahydrocannabinol”	 on	 [07/05/2020]	 indicated	 144	
research	articles	have	been	published	relating	to	CBG,	while	2985	and	9492	research	articles	
have	been	published	relating	to	CBD	and	THC	respectively	(PubMed,	2020).	Given	that	CBG	is	
often	present	in	C.	sativa	extracts	used	therapeutically	(Vandrey	et	al.,	2015;	Valdeolivas	et	al.,	
2015)	and	is	understudied	amongst	cannabinoids,	this	project	aimed	to	investigate	molecular	
mechanisms	of	CBG.		
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Study Form	of	C.	sativa THC	% CBD	% CBG	%
Potter	et	al.,	2008 Powder 95.83 0.42 3.75
Potter	et	al.,	2008 Resin 44.25 52.13 3.63
Potter	et	al.,	2008 Herbal 87.35 4.08 8.57
Potter	et	al.,	2008 Sinsemilla 96.48 0.69 2.83
Vandrey et	al.,	2015 Medical 91.53 3.39 5.08
Swift	et	al.,	2013 Marijuana	police	seizures,	USA 89.28 6.13 4.59
Swift	et	al.,	2013 Sinsemilla	police	seizures,	USA 95.04 1.65 3.31
Swift	et	al.,	2013 Marijuana	police	seizures,	UK 87.50 4.17 8.33
Swift	et	al.,	2013 Sinsemilla	police	seizures,	UK 96.55 0.69 2.76
Swift	et	al.,	2013 Indoor	grown	police	seizures,	Australia	(NSW) 95.75 0.70 3.55
Swift	et	al.,	2013 Outdoor	grown	police	seizures,	Australia	(NSW) 86.81 0.17 13.02
Valdeolivas et	al.,	2012 Huntington’s	disease	model	treatment	(THC-based) 98.31 0.42 1.27
Valdeolivas et	al.,	2012 Huntington’s	disease	model	treatment	(CBD-based) 3.40 94.98 1.62
Table	 1.1:	 Cannabinoid	 content	 in	 C.	 sativa	extracts.	Cannabinoid	 content	 in	C.	 sativa	 extracts	 in	
previous	studies	is	shown	here	to	indicate	the	variation	in	cannabinoid	content	between	extracts,	and	
the	relatively	high	level	of	CBG	in	extracts	not	specifically	bred	for	enhanced	CBD	or	THC.	This	data	is	
represented	as	a	ratio	between	the	three	cannabinoids	THC,	CBD	and	CBG,	due	to	the	many	different	
ways	the	original	data	is	demonstrated	 in	Potter	et	al.,	2008,	Vandrey	et	al.,	2015,	Swift	et	al.,	2013	
and	Valdeolivas	et	al.,	2012.		
Figure	1.1:	Cannabinoid	biosynthesis.	Cannabinoids	are	produced	by	the	addition	of	either	olivetolic	
acid	(OLA)	or	divarinolic	acid	(DVA)	to	geranyl	pyrophosphate.	Cannabigerol	 (CBG),	cannabidiolic	acid	
(CBDA)	and	tetrahydrocannbinol	(THC)	are	produced	with	olivetolic	acid,	while	cannabidivarin	(CBDV)	is	
produced	with	diverinolic	acid.	CBGA	–	cannabigerolic	acid,	THCA	–	tetrahydrocannabinloc	acid,	CBCA	–	
cannabichromenic	acid,	CBGVA	–	cannabigerovarinic	acid,	THCVA	–	tetrahydrocannabivarinic	acid,	CBCV	
–	cannabichromevarinic	acid.	Underlined	are	cannabinoids	that	are	examined	in	this	thesis.	Data	derived	
from	Mechoulam	et	al.,	2014.	
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1.1.4	Efficacy	of	THC	and	CBD	in	disease	treatment	
1.1.4.1	Pathology	of	epilepsy	
One	pathology	that	cannabinoids	are	effective	in	treating	is	epilepsy.	This	is	a	disorder	of	the	
central	nervous	system	resulting	in	seizures	and	is	defined	as	at	least	two	unprovoked	seizures	
occurring	more	 than	 24	 hours	 apart	 (Fisher	 et	 al.,	 2014).	 Epilepsy	 affects	 65	million	 people	
worldwide	 and	 results	 in	 increased	 mortality,	 comorbidities	 and	 disability	 (World	 Health	
Organization,	2016).	A	seizure	is	defined	as	an	abnormal,	synchronous	excitation	of	a	neuronal	
population,	typically	lasting	seconds	or	minutes	but	can	be	prolonged	and	continuous	(Helen	E.	
Scharfman,	2007).		
Seizures	 can	 occur	 anywhere	 in	 the	 brain,	 however,	 in	 children	 seizures	 often	 occur	 in	 the	
temporal	and	frontal	lobes	(Rzezak	et	al.,	2007).	In	adults,	the	mesial	part	of	the	temporal	lobe	
is	a	common	region	of	seizure	origin	(Cendes,	2005).	The	mesial	temporal	lobe	is	made	up	of	the	
hippocampus	and	amygdala	which	control	emotion	and	the	uncus	controlling	smell.	Therefore,	
seizures	originating	in	this	region	can	result	in	strong	emotions	like	fear	or	the	sensation	of	a	
unpleasant	 smells	 (Hamasaki	 et	 al.,	 2014).	 Wherever	 seizures	 originate,	 they	 can	 rapidly	
propagate	through	the	brain	 into	different	regions,	for	example	from	the	temporal	to	frontal	
lobes,	and	each	spread	increases	the	further	risk	of	spread	of	seizure.	If	a	seizure	spreads	wide	
enough	throughout	the	brain,	it	can	be	classified	as	a	general	seizure	involving	the	entire	brain	
and	 altering	 consciousness.	 During	 epilepsy,	 neuronal	 loss	 often	 occurs	 in	 the	 hippocampus	
(Kälviäinen	 et	 al.,	 1998).	 Neuronal	 loss	 is	 often	 accompanied	 by	 gliosis	 (proliferation	 or	
hypertrophy	 of	 multiple	 glial	 cell	 types),	 granule	 cell	 dispersion	 and	 an	 atrophy	 of	 the	
hippocampus	(Spencer	and	Spencer,	1994;	Blümcke	et	al.,	2002).		
A	seizure	is	essentially	caused	due	to	an	imbalance	or	inability	to	balance	the	ionic	levels	either	
side	of	a	neuronal	membrane	(Scharfman,	2007).	This	is	important	because	healthy	brain	signals	
are	spread	through	a	controlled	change	in	ionic	levels.	Normally	potassium	levels	are	at	a	high	
concentration	within	neurons	and	sodium	at	a	high	concentration	extracellularly.	This	leads	to	a	
net	 negative	 transmembrane	 potential	 (Hill	 et	 al.,	 2014).	 If	 this	 balance	 is	 altered,	 then	
depolarisation	of	the	membrane	can	occur	and	transmitted	through	the	neuron	(Kaplan	et	al.,	
2017).	This	 leads	to	neurotransmitter	release	and	further	action	potentials	 (Fišar,	2009).	One	
key	 component	 in	 maintaining	 and	 renewing	 the	 membrane	 balance	 is	 sodium-potassium	
ATPase	pumps,	which	transport	sodium	ions	out	of	the	cell	and	potassium	ions	into	the	cell	(Hill	
et	al.,	2014).	Blocking	these	pumps	is	sufficient	to	cause	a	seizure	 in	experimental	conditions	
(Vaillend	et	al.,	2002).	 In	addition,	glia	may	be	key	regulators	of	 ion	concentration	outside	of	
neurons	(Duffy	and	MacVicar,	1999).		
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Seizures	themselves	can	also	change	transmembrane	gradients,	as	a	seizure	is	often	followed	by	
a	rise	in	extracellular	potassium	ion	which	can	lead	to	a	further	depolarisation	of	neurons	(Sypert	
and	 Ward,	 1974).	 Therefore	 seizures	 can	 result	 in	 a	 vicious	 cycle	 where	 a	 transmembrane	
potential	 perturbation	 can	 create	 more	 and	 more	 perturbations	 (Scharfman,	 2007).	
Furthermore,	abnormalities	in	the	sodium	channels	could	result	in	a	decreased	threshold	for	an	
action	 potential,	 this	 is	 the	 case	 in	 generalised	 epilepsy	with	 febrile	 seizures	 (Meisler	 et	 al.,	
2001).	
Another	factor	that	impacts	the	spread	and	severity	of	seizures	is	synaptic	transmission.	In	the	
synapse,	 an	 action	 potential	 is	 carried	 forward	 to	 another	 neuron	 through	 the	 release	 of	
neurotransmitters,	such	as	γ-aminobutyric	acid	(GABA)	and	glutamate	(Kullmann	and	Semyanov,	
2002).	 GABA	 is	 an	 inhibitory	 transmitter	 and	 glutamate	 is	 an	 excitatory	 transmitter.	 GABA	
receptors	becoming	desensitised	to	GABA	can	result	in	a	reduced	inhibitory	effect	(Butler	et	al.,	
2018).	Chloride	ions	are	usually	transported	through	GABA	receptors	into	cells,	however,	if	other	
chloride	ion	transporters	are	defective	then	this	is	not	possible	and	can	lead	to	seizures	(Dzhala	
et	al.,	2005).	Glutamate	 innervates	many	neuron	types	and	exposure	to	glutamate	may	have	
little	effect	overall,	and	may	even	increase	inhibition	of	principal	cells	because	they	require	less	
glutamate	to	reach	threshold	for	depolarisation	(Sun	et	al.,	2002).		
Synchronisation	 of	 a	 network	 of	 neurons	 is	 key	 to	 causing	 a	 seizure	 (Li	 et	 al.,	 2012).	 The	
pyramidal	cells	of	the	cortex	are	 interconnected	by	glutaminergic	synapses,	therefore	a	 large	
amount	of	glutmate	released	in	postsynaptic	spaces	can	result	 in	numerous	cells	activated	at	
one	time	(Johnston	and	Brown,	1984).	Gap	junctions,	which	connect	neighbouring	cells	through	
direct	 intercellular	 channels,	 may	 also	 aid	 in	 synchronisation	 of	 neuronal	 action	 potentials	
(Traub	et	al.,	2004).	
One	 major	 contributor	 to	 the	 development	 of	 epilepsy	 is	 calcium	 ion	 accumulation	 in	
hippocampal	neurons	(Nazıroğlu	et	al.,	2012).	Transient	receptor	potential	vanilloid	1	(TRPV1)	is	
a	 calcium-permeable	 channel	 and	 epilepsy	 mediator	 in	 the	 hippocampus.	 This	 protein	 is	
activated	by	high	temperature	(Muller	et	al.,	2019),	anandamide	(Umathe	et	al.,	2012),	oxidative	
stress	(Aviello	et	al.,	2012),	capsaicin	(Maiese,	2017)	and	inflammatory	products	(Muller	et	al.,	
2019).	Activation	of	TRPV1	can	result	in	glutamate	release	(Fawley	et	al.,	2014),	therefore,	the	
duration	of	postsynaptic	stimulation	is	 increased	by	activation	of	TRPV1	channels	(Shoudai	et	
al.,	 2010).	 This	 finding	 led	 to	 the	 exploration	 of	 TRPV1	 as	 a	 potential	 treatment	 target	 for	
epilepsy.	 In	 temporal	 lobe	 epilepsy	 there	 is	 an	 increased	 expression	 of	 TRPV1	 in	 the	
hippocampus	(Sun	et	al.,	2013).	
Cannabinoids	 receptors,	 such	 as	 CB1,	 CB2	 and	 GPR55	 are	 also	 key	 regulators	 of	 neuronal	
transmission	and	implicated	in	disease	control	of	epilepsy	(Galiazzo	et	al.,	2018).	The	two	most	
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commonly	studied	endocannabinoids	in	humans	are	anandamide	and	2-arachidonoylglycerol	(2-
AG)	(McPartland	et	al.,	2006).	CB1	receptors	are	abundant	in	the	CNS,	particularly	the	cortex,	
basal	ganglia,	hippocampus	and	cerebellum,	mostly	on	axon	terminals	and	pre-axonal	segments	
(Holm	et	al.,	1980;	Liu	et	al.,	2009;	Jones	et	al.,	2010;	Pandolfo	et	al.,	2011;	Busquets-Garcia	et	
al.,	 2018).	 CB2	 receptors	 are	 expressed	 at	 a	 lower	 level	 in	 the	 CNS	 and	 is	 more	 present	 in	
microglia,	vasculature,	immune	cells	and	some	neurons,	such	as	dopaminergic	neurons	in	the	
ventral	 tegmental	 area	 and	 hippocampal	 CA3	 neuronal	 cells	 (Arévalo-Martín	 et	 al.,	 2003;	
O’Sullivan	et	al.,	2009;	Chen	et	al.,	2017).	GPR55	are	located	primarily	in	the	brain	and	peripheral	
nervous	system	(PNS),	GPR55	activation	in	the	PNS	an	result	in	increased	intracellular	calcium	
release	 in	 neurons	 leading	 to	 neuronal	 excitability	 (Lauckner	 et	 al.,	 2008).	 Expression	of	 CB1	
receptors	is	reduced	in	epileptic	hippocampal	regions	(Ludányi	et	al.,	2008).	Low	and	high	dose	
anandamide-induced	effects	on	correlate	with	CB1	receptors	and	TRPV1	activation	(Umathe	et	
al.,	2012).	Endocannabinoid	signalling	can	be	used	as	negative	feedback	by	neurons	to	halt	an	
action	 potential	 and	 reduce	 release	 of	 glutamate	 across	 the	 synapse	 (Figure	 1.2)	 (Busquets-
Garcia	 et	 al.,	 2018).	 Therefore,	 CB1	 receptor	 activation	 by	 endocannabinoids	 produces	
neuroprotection	 in	 the	 hippocampus	 and	 inhibits	 epileptic	 seizures	 in	models	 (Romigi	 et	 al.,	
2010;	Citraro	et	al.,	2013).	However,	endocannabinoid	signalling	may	reduce	seizure	threshold,	
which	would	allow	progression	of	epilepsy	(Wallace	et	al.,	2002).	Mice	with	just	the	CB1	receptor	
knocked	out	show	heightened	seizure	sensitivity,	mice	with	just	the	CB2	receptor	knocked	out	
do	not,	but	mice	with	both	receptors	knocked	out	resulted	in	80%	of	them	becoming	epileptic	
(Rowley	et	al.,	2017).		
Adenosine	is	another	key	signalling	molecular	involved	in	epilepsy.	Adenosine	is	an	endogenous	
anticonvulsant,	 released	 after	 a	 seizure	 as	 a	 terminator	 and	 works	 through	 the	 adenosine	
receptor	 1	 protein	 (During	 and	 Spencer,	 1992;	 Lado	 and	Moshé,	 2008).	 The	 anti-convulsant	
effect	 of	 adenosine	 occurs	 through	 the	 upregulation	 of	 presynaptic	 neuron	 inhibition,	
preventing	 runaway	excitement	 in	 feed-forward	synaptic	circuits	 (Huber	et	al.,	2001;	Boison,	
2012),	 thus	adenosine	 stabilises	 the	post-synaptic	membrane	potential.	Adenosine	 therefore	
acts	 to	 stop	 the	 spread	 of	 a	 seizure	 and	 elevated	 extracellular	 adenosine	 levels	 can	 reduce	
seizure	frequency	(Li	et	al.,	2008;	Fukuda	et	al.,	2010).	A	reduction	of	extracellular	adenosine	
can	 be	 caused	 by	 over-expression	 of	 adenosine	 kinase,	 which	 phosphorylates	 adenosine	 to	
produce	 adenosine	monophosphate	 (AMP)	 (Lovatt	 et	 al.,	 2012).	 An	 increased	 expression	 of	
adenosine	kinase	(ADK),	can	result	in	a	much	quicker	progression	of	the	disease,	as	it	reduces	
the	 inhibitory	 tone	of	 adenosine	 in	 the	brain,	 reducing	 the	 threshold	 for	 seizure	generation.	
Inhibition	of	adenosine	receptors,	for	example	through	long	term	used	of	the	asthma	treatment	
theophylline,	can	result	in	seizures	and	epilepsy	development	(Korematsu	et	al.,	2008;	Fukuda	
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et	al.,	2010).	Experimental	data	in	mice	found	that	kainic	acid-induced	epilepsy	in	animals	lacking	
the	adenosine	receptor	led	to	massive	neuronal	cell	loss	and	death	within	5	days	compared	to	a	
non-convulsive	status	epilepticus	in	wild	type	mice	(Fedele	et	al.,	2006).			
	
Furthermore,	 ADK	overexpression	 is	 linked	 to	 epileptogenesis.	 ADK	 is	 primarily	 expressed	 in	
astrocytes	 and	 is	 a	 major	 metabolic	 clearance	 protein	 for	 adenosine	 (Studer	 et	 al.,	 2006).	
Neurological	injuries	or	inflammation	can	result	in	astrogliosis,	in	which	astroglia	proliferation	
and	increase	is	size	(Pekny	and	Nilsson,	2005).	Many	in	vivo	studies	have	found	that	astrogliosis	
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Figure	 1.2:	 Cannabinoid	 receptors.	 Endocannabinoids	 control	 neuronal	 transmission	 and	 action	
potentials.	An	action	potential	causes	the	release	of	glutamate	across	the	synapse	from	the	presynaptic	
neuron.	 Glutamate	 stimulates	 an	 action	 potential	 in	 the	 postsynaptic	 neuron	 through	 glutamate	
receptors	and	sodium	ion	channels.	However,	this	also	creates	a	feedback	in	which	endocannabinoids	
are	produced	from	fatty	acids	in	the	postsynaptic	neuron.	These	then	release	into	the	synapse	and	inhibit	
the	 further	 release	 of	 glutamate	 from	 the	 presynaptic	 neuron,	 thus	 inhibiting	 neuronal	 signalling.	
Adapted	from	(Busquets-Garcia	et	al.,	2018).	AC	=	adenylyl	cyclase,	A	=	anandamide,	G	=	glutamate,	ERK	
=	extracellular	signal-regulated	kinase,	PKA	=	protein	kinase	A,	cAMP	=	cyclic	adenosine	monophosphate.	
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results	in	ADK	overexpression	(Steinhäuser	and	Boison,	2012;	Boison	and	Aronica,	2015;	Boison	
and	Steinhäuser,	2018),	and	in	humans	with	temporal	lobe	epilepsy	there	is	an	overexpression	
of	ADK.	In	the	immediate	aftermath	of	a	brain	injury,	stroke	or	seizure,	adenosine	is	released	
from	cells	to	attempt	to	halt	neuronal	transmission	(Weltha	et	al.,	2019).	After	this	inflammation	
occurs	which	triggers	astrogliosis	and	ADK	overexpression	and	therefore	adenosine	deficiency	
(Li	 et	 al.,	 2012).	 In	 addition,	 this	 increases	 the	 abundance	 of	 methyl	 groups	 in	 the	
transmethylation	pathway,	 resulting	 in	 increased	DNA	methylation	 (Williams-Karnesky	et	 al.,	
2013).	DNA	methylation	 has	 an	 inhibitory	 effect	 on	 gene	 expression,	 reducing	 expression	of	
nearby	 genes	 and	 increasing	 the	 likelihood	 of	 further	 inhibitory	 epigenetic	 changes	 such	 as	
histone	deacetylation	(Rountree	et	al.,	2000).	In	general,	DNA	methylation	is	a	key	regulator	of	
gene	control	and	is	often	cell-type	specific	(Moore	et	al.,	2013).	DNA	methylation	is	also	a	key	
regulator	of	development	 (Pucci	et	al.,	 2013),	 cell	 fate	 (Kredich	and	Martin,	1977),	 cell	 cycle	
(Müller	et	al.,	2013)	and	 is	dysregulated	 in	many	diseases,	such	as	cancer	 (Jaenisch	and	Bird,	
2003).	
DNA	methylation	has	been	studied	as	a	possible	marker	or	controller	of	epilepsy	since	it	was	
discovered	that	DNA	methylation	inhibitor	treatment	reduced	spontaneous	neurotransmission	
and	network	activity	 in	hippocampal	slices	 (Levenson	et	al.,	2006).	A	global	 increase	 in	DNA-
methyltransferase	 activity	 and	DNA	methylation	was	 correlated	with	 spontaneous	 recurrent	
seizures	 in	 mice	 and	 reversed	 by	 adenosine	 augmentation	 (Williams-Karnesky	 et	 al.,	 2013).	
However,	 increased	 DNA	 methylation	 may	 not	 be	 sufficient	 to	 cause	 epilepsy	 alone,	 as	
pharmacological	inhibition	of	DNA	methylation	did	not	alter	epilepsy	in	a	rat	model	(Parrish	et	
al.,	2013).		
Another	key	cellular	signalling	mechanisms	associated	with	epilepsy	is	a	modified	mechanistic	
target	 of	 rapamycin	 (mTOR)	 pathway.	 Mutations	 in	 the	 tuberous	 sclerosis	 complex	 (TSC)	
proteins	 or	 phosphatase	 and	 tensin	 homolog	 (PTEN)	 protein	 lead	 to	 abnormal	 neuronal	
proliferation	and	growth	in	animal	models	(LaSarge	and	Danzer,	2014).	Humans	with	mutations	
in	either	of	the	two	TSC	proteins	develop	cortical	tubers	found	in	the	cortex	or	subcortical	white	
matter	 and	 lead	 to	 the	 development	 of	 refractory	 seizures,	 surgical	 removal	 of	which	 often	
reduces	 seizure	 occurrence	 (Weiner	 et	 al.,	 2006).	 These	 tubers	 promote	 hyperexcitability	 of	
neurons	and	seizures	(Mühlebner	et	al.,	2016).	Dysregulation	of	mTOR	signalling		can	also	lead	
to	changes	in	gene	and	protein	expression	that	increase	the	likelihood	of	neuronal	excitability	
and	 seizures	 (Boer	 et	 al.,	 2010).	 In	Hemimegaloencephaly	 there	 is	 an	 overreaction	 of	mTOR	
signalling	in	some	neural	tissue,	potentially	caused	by	somatic	mutations	in	genes	involved	in	
the	 pathway	 (Crino,	 2015;	 Ikeda	 and	Mirsattari,	 2017).	 Focal	 dypslasias	 are	 another	 type	 of	
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epilepsy	with	cortical	development	malformations	and	are	associated	with	mutations	in	either	
the	mTOR	gene	itself	or	other	components	of	the	pathway	(Lim	et	al.,	2015).	
The	many	disparate	pathways	and	cellular	components	involved	in	epilepsy	has	led	to	multiple	
treatments	being	found.	In	30-40%	of	cases,	the	disorder	is	not	adequately	controlled,	leaving	
potentially	20	million	epilepsy	patients	without	a	means	of	properly	controlling	their	disorder	
(Cook	 et	 al.,	 2013).	 One	 target	 for	 AEDs	 is	 voltage-gated	 sodium	 channels.	 These	 channels	
control	 the	 rising	 phase	 of	 neuronal	 action	 potentials.	 AEDs	 that	 target	 these	 channels	 are	
oxcarbazepine,	 zonisamide,	 phenytoin,	 carbamazepine,	 lamotrigine	 and	 possibly	 valproate	
(Yaari	et	al.,	1986;	Schmutz	et	al.,	1994;	Ambrósio	et	al.,	2002;	Leppik,	2004).	The	other	main	
mechanism	 of	 action	 of	 AEDs	 is	 to	 act	 on	 γ-aminobutyric	 acid	 (GABA)	 transmission	 (Davies,	
1995).	 The	 spread	 of	 seizure	 activity	 across	 the	 nervous	 system	 is	 due	 to	 high-frequency	
repetitive	spike	firing,	which	these	drugs	block.	Impairment	of	GABAergic	transmission	by	GABA	
antagonists	or	by	genetics	induces	epileptic	seizures	(Sperk	et	al.,	2004).	This	is	the	mechanism	
of	action	of	both	benzodiazepines	and	barbiturates	(Davies,	1995).	
A	 potential	 treatment	 for	 epilepsy,	 that	may	 reduce	 the	 number	 of	 patients	 with	 the	 AED-
resistant	disease	is	cannabinoids.	Cannabis	has	been	suggested	as	a	treatment	for	epilepsy	since	
at	least	900	CE,	but	was	probably	in	use	long	before	(Meier	and	Rosenthal,	1976).	In	modern	
times	Cannabis	was	listed	in	the	US	1854	dispensatory	as	a	possible	remedy	for	muscle	spasms	
(Szaflarski	and	Martina	Bebin,	2014).	In	recent	years	research	into	Cannabis	and	cannabinoids	
as	 potential	 therapeutics	 for	 epilepsy	 has	 increased,	 in	 addition,	 self-medicating	 epilepsy	
patients	have	begun	to	use	Cannabis	to	alleviate	symptoms	(Szaflarski	and	Bebin,	2014).	Some	
studies	 have	 found	 that	 Cannabis	 use	 can	 make	 epilepsy	 symptoms	 worse	 (Gordon	 and	
Devinsky,	 2001).	 This	 may	 be	 because	 of	 the	 THC	 present	 in	 the	 self-medicated	 Cannabis	
(Szaflarski	and	Martina	Bebin,	2014).	Another	reason	 in	which	Cannabis	may	have	a	negative	
effect	on	those	self-medicating	is	that	these	are	often	people	who	are	suffering	from	the	worst	
kinds	of	epilepsy	that	no	drug	has	treated	and	are	desperately	trying	alternative	medications.	
CBD,	a	non-psychoactive	constituent	of	Cannabis	decreases	 frequency	of	 seizures	 in	patients	
suffering	 from	 epilepsy	 that	 AEDs	 could	 not	 control	 (Devinsky,	 Patel,	 et	 al.,	 2018).	 Potential	
mechanisms	 of	 action	 for	 treatment	 of	 epilepsy	 with	 CBD	 are	 through	 the	 equilibrative	
nucleoside	transporter,	orphan	G-protein-coupled	receptor	GPR55,	transient	receptor	potential	
of	vanilloid	type-1	channel,	5-HT1a	receptor	and	α3	and	α1	glycine	receptors	 (Bisogno	et	al.,	
2001;	Russo,	2005;	Hejazi	et	al.,	2006;	Carrier	et	al.,	2006;	Ryberg	et	al.,	2007)	.	
An	initial	study	into	the	efficacy	of	cannabinoids	on	epilepsy	found	that	CBD	reduced	convulsant	
activity	and	abolished	jaw	and	limb	cramping	in	a	cobalt-induced	epilepsy	rat	model	(Chiu	et	al.,	
1979).	However,	THC	treatment	of	the	cobalt-induced	epilepsy	rat	model	resulted	in	increased	
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neuronal	firing	and	excitation,	indicating	that	CBD	may	be	an	effective	treatment	for	epilepsy,	
but	that	THC	may	exacerbate	the	disease	(Chiu	et	al.,	1979).	In	mice	induced	into	an	epilepsy-
like	state	by	electroshocks	or	with	convulsant	drugs,	CBD	pre-treatment	prevented	convulsions,	
seizure	spread	and	lethality	of	seizures	(Consroe	et	al.,	1982).	CBD	was	also	found	to	have	anti-
seizure	 properties	 in	 acute	 seizure	 models	 (electroshock	 mice	 and	 rats)	 and	 a	 chronic	
neuroprotective	effect	in	a	corneal	kindled-epilepsy	model	mouse	(Klein	et	al.,	2017).	In	a	mouse	
model	of	Dravet	syndrome,	CBD	was	found	to	reduce	seizure	frequency,	duration	and	severity	
and	autistic-like	social	deficits	 (Kaplan	et	al.,	2017).	Similarly,	 in	a	mouse	model	of	Angelman	
syndrome,	a	genetic	disorder	with	epilepsy-like	symptoms,	CBD	was	found	to	attenuate	seizures	
and	neuronal	signalling	(Gu	et	al.,	2019).	Finally,	CBD	has	recently	been	found	to	reduce	seizures	
in	a	zebrafish	model	of	epilepsy-related	tuberous	sclerosis	complex	disease	(Serra	et	al.,	2019).	
CBD	 has	 therefore	 been	 found	 to	 have	 anti-seizure	 effects	 in	 animal	 models	 of	 epilepsy,	
providing	a	potential	treatment	for	the	disease.	
As	certain	cannabinoids	 (in	particular	CBD)	were	 found	 to	be	safe	and	efficacious	 in	 treating	
epilepsy	in	animal	models,	clinical	trials	examined	how	effective	the	treatment	was	in	humans.	
In	 an	 early	 study	 on	 the	 efficacy	 of	 cannabinoids	 on	 epilepsy,	 CBD	 was	 found	 to	 reduce	
convulsive	episodes	in	most	patients,	and	50	%	of	patients	treated	with	CBD	remained	free	of	
convulsive	episodes	(Cunha	et	al.,	1980).	In	a	clinical	trial	using	a	highly	purified	CBD-enhanced	
C.	sativa	extract,	called	Epidiolex®,	cannabinoid	treatment	reduced	seizures	by	around	50	%	at	
12	and	48	weeks	of	treatment	(Devinsky	et	al.,	2018(b)).	The	efficacy	of	CBD	treatment	was	also	
assessed	by	clinical	trial	on	a	rare	and	severe	form	of	childhood-onset	epilepsy,	Lennox-Gastaut	
syndrome	(Halford	et	al.,	2018).	Here,	CBD	treatment	over	60	weeks	was	found	to	reduce	total	
seizures	by	48-62	%	and	drop	seizures,	where	the	child	collapses	during	the	seizure,	by	48-70	%	
(Halford	 et	 al.,	 2018).	 In	 addition,	 88	 %	 of	 caregivers	 reported	 an	 improvement	 in	 overall	
condition	 of	 the	 Lennox-Gastaut	 syndrome	 patients	 (Halford	 et	 al.,	 2018).	 To	 examine	 the	
potential	of	CBD	to	treat	another	rare	form	of	epilepsy,	a	clinical	trial	examined	the	effects	of	
CBD	on	patients	with	Dravet	syndrome,	which	is	a	severe	infant	epilepsy	in	which	seizures	are	
triggered	by	hot	temperature	or	fevers	(Devinsky	et	al.,	2019).	Here,	CBD	was	found	to	reduce	
total	seizures	by	39-51	%	after	48	weeks	of	treatment,	and	85	%	of	caregivers	reported	that	the	
overall	condition	of	the	patient	improved	(Devinsky	et	al.,	2019).	In	another	study,	the	efficacy	
and	safety	of	cannabidiol	preparations	containing	THC	(at	a	proportion	of	50:1	for	CBD:THC),	
were	found	to	be	effective	at	reducing	seizures	by	70	%	and	the	treatment	was	well	tolerated	
(McCoy	 et	 al.,	 2018).	 This	 efficacy	 has	 led	 to	 Epidiolex®	 prescription	 legalisation	 in	 many	
countries,	 most	 commonly	 for	 the	 treatment	 of	 drug-resistant	 epilepsy	 (Abu-Sawwa	 and	
Stehling,	2020).		
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1.1.4.2	Pathology	of	multiple	sclerosis	
Another	pathology	that	cannabinoids	are	effective	in	providing	symptomatic	relief	 is	multiple	
sclerosis.	 This	 is	 a	 chronic,	 inflammatory	 and	 neurodegenerative	 disease	 which	 begins	 with	
demyelination	of	neurons	and	 leads	 to	variable	axonal	and	neuronal	 injury	 (Wingerchuk	and	
Carter,	 2014).	 Multiple	 sclerosis	 (MS)	 causes	 disability	 in	 young	 adults	 and	 reduces	 life	
expectancy	 by	 5	 to	 10	 years	 (Riccio	 and	 Rossano,	 2015;	 NHS,	 2018).	 The	 disease	 causes	 an	
interruption	of	myelin	tracts	in	the	CNS,	initially	causing	weakness,	diminished	dexterity,	visual	
loss,	 instability	and	ataxia	 (Hauser	and	Oksenberg,	2006).	This	can	then	develop	 into	bladder	
dysfunction,	chronic	fatigue,	pain,	vertigo,	spasms,	memory	loss	and	reduced	ability	to	carry	out	
cognitive	tasks	(Hauser	and	Oksenberg,	2006).	The	damage	generally	occurs	in	the	white	matter	
of	the	brain,	which	has	a	higher	proportional	of	myelinated	neurons	to	grey	matter	(Kornek	et	
al.,	2000).		
Although	neuronal	demyelination	can	occur	throughout	the	central	nervous	system	in	multiple	
sclerosis,	 some	 regions	 are	 more	 commonly	 damaged	 than	 others.	 Where	 veins	 become	
inflamed	in	the	brain,	due	to	increased	inflammatory	cytokine	release	and	immune	response,	
white	matter	 lesions	 form	 (Tallantyre	 et	 al.,	 2008).	 Cortical	 lesions	 are	 also	 associated	with	
peripheral	vein	inflammation	and	demyelination	within	the	brain	was	associated	with	proximity	
to	inflammation	in	the	blood-brain	barrier	(Kutzelnigg	et	al.,	2005;	Howell	et	al.,	2011;	Choi	et	
al.,	2012).	Legions	in	the	brain	are	also	associated	with	areas	of	low	perfusion,	this	is	thought	to	
increase	the	likelihood	of	oxidative	damage	and	therefore	demyelination	through	this	method	
(Holland	et	al.,	2012).	While	demyelination	can	occur	anywhere	in	the	brain,	the	areas	of	low	
perfusion	are	less	likely	to	remyelinate	and	therefore	have	longer,	sustained	damage.		
MS	 is	 characterised	 by	 inflammation	 at	 the	 blood-brain	 barrier	 due	 to	 the	 auto-reaction	 of	
multiple	immune	cells	(T	cells,	B	lymphocytes,	macrophages	and	microglial	cells)	against	brain	
and	spinal	cord	white	matter	(Rajesh	et	al.,	2007).	This	causes	one	or	two	relapses	annually	into	
neurological	 dysfunction	 in	 85	 %	 of	MS	 patients	 in	 the	 early	 phases	 of	 the	 disease,	 usually	
followed	by	remission	(Riccio	and	Rossano,	2015).	However,	these	cause	neurological	 injuries	
that	eventually	build	up	and	increase	the	risk	of	disability	over	time	(Rudick	et	al.,	2006).		
Immune	cells,	which	are	constituent	 in	peripheral	blood	mononuclear	cells	 (PBMCs)	produce	
pro-inflammatory	cytokines	which	increase	the	progression	of	MS	(Simpson	et	al.,	2015).	These	
cells	include	T	lymphocytes,	B	cells	and	monocytes	(Yu	et	al.,	2007)	and	in	individuals	with	MS,	
the	immune	cells	become	activated	and	breakdown	the	blood-brain	barrier,	eventually	crossing	
it	and	leading	to	axonal	degradation	and	myelin	damage	in	the	central	nervous	system	(CNS)	
(Bar-Or	et	al.,	2003).	 In	 immune	cells,	mTORC1	activity	 is	often	at	a	much	higher	rate	than	in	
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healthy	 individuals,	 which	 contributes	 to	 the	 overproduction	 of	 pro-inflammatory	 cytokines	
(Carbone	 et	 al.,	 2014).	 Therefore,	 many	 MS	 therapies	 are	 immunomodulatory	 and	 target	
peripheral	immune	cells.	
The	causes	of	MS	are	still	unknown,	there	is	a	correlation	of	familial,	geographical	and	ethnic	
inheritance.	One	gene	locus	strongly	associated	with	MS	is	the	HLA-DRB1	locus,	as	does	the	copy	
number	of	HLA-DR2	(GAMES	and	Transatlantic	Multiple	Sclerosis	Genetics	Cooperative,	2003;	
Modin	 et	 al.,	 2004).	 Both	 protein	 products	 of	 these	 genes	 are	 components	 of	 the	 human	
leukocyte	antigen	(HLA)	complex,	which	helps	the	immune	system	distinguish	between	self	and	
pathogens.	They	attach	to	proteins	outside	the	cell	and	display	them	to	the	 immune	system,	
which	then	will	either	recognise	them	as	foreign	or	self	and	trigger	an	appropriate	response.	
However,	there	is	a	possibility	that	mutations	in	these	proteins	could	result	in	a	presentation	of	
the	encephalitogenic	peptide	(present	in	myelin)	as	a	foreign	protein,	resulting	in	an	immune	
response	and	attack	 to	 that	protein	 (Oksenberg	and	Barcellos,	 2005).	However,	 exact	 causal	
mutations	are	not	yet	understood.		
There	 are	multiple	 disease-modifying	 therapies	 (DMTs)	 currently	 available	 that	 slow	 disease	
progression	and	relieve	some	symptoms.	One	of	the	main	DMTs	available	as	a	therapeutic	for	
MS	 is	 interferon	 beta	 and	 glatiramer	 acetate.	 The	 exact	 mechanism	 of	 action	 for	 these	
treatments	are	unknown	but	they	reduce	blood	brain	barrier	disruption,	modulate	T-	and	B-cells	
and	 cytokine	 functions	 and	 the	 glatiramer	 acetate	 stimulates	 regulatory	 T	 cells	 (Dhib-Jalbut,	
2002).	These	drugs	reduce	clinical	relapse	rate	by	a	third,	but	have	little	effect	on	progressive	
MS	(Wingerchuk	and	Carter,	2014).	A	general	immunosuppression	drug	can	be	used	for	rapidly	
worsening	MS:	mitoxantrone.	However,	 its	use	 is	 limited	to	two	years	due	to	the	cumulative	
dose-related	cardiomyopathy	(Hartung	et	al.,	2002).	The	use	of	mitoxantrone	is	associated	with	
leukaemia,	which	has	prevented	doctors	prescribing	it	in	all	but	necessary	cases	(Marriott	et	al.,	
2010).	Natalizumab	is	a	monoclonal	antibody	that	targets	the	α4	subunit	of	an	antigen	expressed	
on	 lymphocyte	 and	 monocyte	 surfaces	 (Haarmann	 et	 al.,	 2015).	 Natalizumab	 prevents	
interaction	with	this	antigen	and	a	cell	adhesion	molecule	on	the	brain	vascular	endothelium.	
This	prevents	 lymphocytes	entering	the	central	nervous	system	and	therefore	prevents	them	
from	triggering	acute	MS	lesions.	However,	use	of	natalizumab	increases	the	risk	of	a	central	
nervous	 system	 infection	 by	 the	 John	 Cunningham	 virus	 (Kleinschmidt-DeMasters	 and	 Tyler,	
2005).	This	can	lead	to	multifocal	leukoencephalopathy	and	death	or	irreversible	neurological	
disability.	 Therefore,	 patients	 on	 natalizumab	 are	 monitored	 closely	 to	 prevent	 this	 from	
occurring.	Mitoxantrone,	natalizumab	and	interferon	beta	are	all	intravenous	DMTs,	however,	
other	forms	of	DMTs	can	be	used	by	MS	patients.	
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Oral	DMTs	are	used	for	relapsing	MS.	Fingolimod	reduces	relapse	by	around	50%	compared	to	
interferon	treatment	(Cohen	et	al.,	2010).	Fingolimod	traps	lymphocytes	in	lymph	nodes,	this	
prevents	them	from	entering	the	CNS	and	therefore	prevents	MS	lesions.	However,	it	can	result	
in	mild	lymphopenia	and	an	increased	risk	of	viral	infections	(Ratchford	et	al.,	2012).	Fingolimod	
also	has	significant	effects	of	cardiac	smooth	muscle	and	for	this	reason	is	not	recommended	to	
patients	with	 heart	 disease	 (Cohen	 et	 al.,	 2010).	 Another	 orally	 taken	DMT	 is	 terifunomide.	
Terifunomide	 is	 also	 taken	 as	 a	 treatment	 for	 rheumatoid	 arthritis	 (Greene	 et	 al.,	 1995).	 It	
inhibits	dihydroorotate	dehydrogenase	which	is	required	for	proliferating	cells,	thereby	reducing	
immune	system	response.	Terifunomide	can	cause	diarrhoea,	nausea,	alopecia	and	increased	
risk	of	infection	(O’Connor	et	al.,	2011).	An	additional	orally	ingested	DMT	is	dimethyl	fumarate.	
Dimethyl	 fumarate	 has	 little	 impact	 on	 the	 liver,	 since	 once	 ingested	 it	 is	 hydrolysed	 to	
monomethyl	fumarate	which	is	eliminated	through	respiration.	It	reduces	oxidative	cell	stress	
and	modulates	nuclear	 factor	κB,	both	could	provide	anti-inflammatory	effects	 (Linker	et	al.,	
2011;	Albrecht	et	al.,	2012).	The	main	side	effects	of	terifunomide	are	gastrointestinal,	but	it	is	
well	tolerated	in	general	(Fox	et	al.,	2016).	A	reduction	by	around	one	third	in	mean	lymphocyte	
cell	 count	 is	usually	observed	with	 terifunomide	treatment,	and	 lymphopenia	can	develop	 in	
patients	 on	 this	 drug,	 therefore	 blood	 cell	 count	 is	 monitored	 for	 patients	 who	 take	 this	
(Berkovich	 and	 Weiner,	 2015).	 In	 addition,	 infection	 risk	 could	 by	 increased	 by	 taking	 this	
treatment.	There	are	also	MS	DMTs	that	are	emerging	in	recent	years.		
Alemtuzumab	 is	 a	 new	 drug	 that	 has	 a	 lower	 relapse	 rate	 than	 interferon	 treatment.	
Alemtuzumab	 is	a	humanised	anti-CD52	monoclonal	antibody	(Coles	et	al.,	2012).	 It	depletes	
and	 repopulates	 circulating	 T	 lymphocytes	 and	 B	 lymphocytes.	 This	 changes	 the	 number,	
proportions	and	function	of	the	lymphocyte	subsets.	This	does	produce	a	risk	of	infection,	but	
the	risk	appears	to	decrease	with	time	(Wray	et	al.,	2018).	There	is	also	a	cumulative	risk	for	
autoimmune	diseases	in	patients	with	alemtuzumab	treatment	for	MS	(Cossburn	et	al.,	2011).	
Ocrelizumab	 is	 a	 humanised	 monoclonal	 antibody	 for	 CD20	 (Montalban	 et	 al.,	 2017).	
Ocrelizumab	is	effective	at	reducing	the	rate	of	disability	in	MS	patients,	through	depletion	of	
CD20-expressing	B	cells.	However,	infection	rate	increased	on	taking	the	drug	(Montalban	et	al.,	
2017).	There	are	multiple	drugs	in	use	to	treat	MS.	Many	produce	side	effects	that	would	not	be	
tolerated	for	other	drugs,	however,	given	the	severity	of	MS	it	is	still	beneficial	for	patients	to	
take	the	drugs.	There	is	still	research	going	on	to	try	to	find	drugs	with	fewer	side	effects	and	
possibly	that	can	stop	MS.		
There	 has	 also	 been	 a	 suggestion	 that	 the	 endocannabinoid	 system	may	 be	 involved	 in	MS	
disease	development	and	a	potential	target	for	treatment.	In	many	experimental	models	of	MS	
and	 in	patients,	 there	was	a	 large	amount	of	change	 in	CB1	and	CB2	expression	compared	to	
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healthy	controls	(Chiurchiù	et	al.,	2018).	In	fact,	THC	treatment	of	a	mouse	model	of	MS	reduced	
neurodegeneration	 and	 chronic	 disability	 (Pryce	 et	 al.,	 2003).	 Activation	 of	 CB2	 receptors	 in	
autoreactive	T	cells	was	also	essential	for	the	control	of	inflammation	in	a	mouse	model	of	MS	
by	reducing	T	cell	differentiation	and	immune	cell	accumulation	in	the	CNS	(Maresz	et	al.,	2007;	
Kong	et	al.,	2014).	In	addition,	CB2	receptor	inhibition	of	ex	vivo	T	lymphocytes	from	MS	patients	
inhibited	cell	proliferation	and	immune	response	without	causing	cell	death	(Malfitano	et	al.,	
2013).	Mice	lacking	CB1	receptors	poorly	tolerated	inflammatory	insults	and	were	more	likely	to	
develop	 neurodegeneration	 (Pryce	 et	 al.,	 2003;	 Chiurchiù	 et	 al.,	 2018),	 while	 CB2	 receptor	
deletion	in	T	cells	from	MS	model	mice	led	to	increased	T	cell	proliferation,	reduced	apoptosis,	
elevated	inflammatory	cytokine	release	and	worsened	symptoms	(Maresz	et	al.,	2007).	THC	was	
found	 to	 limit	 inflammation,	 disease	 development,	 CNS	 infiltration	 and	microglial	 activation	
while	promoting	myelin	repair,	potentially	through	THC	activation	of	CB1	receptors	(Pryce	et	al.,	
2015;	 Moreno-Martet	 et	 al.,	 2015).	 It	 is	 unclear	 as	 yet,	 how	 much	 involvement	 the	
endocannabinoid	system	has	in	modulating	the	response	of	MS	to	phytocannabinoid	treatment.	
A	potential	target	for	MS	treatment	is	the	mTOR	pathway.	mTOR	promotes	the	myelination	of	
the	CNS	(Wahl	et	al.,	2014).	In	MS	oligodendrocytes	can	fail	to	differentiate	and	therefore	do	
not	produce	new	myelin,	thus	resulting	in	a	demyelinated	lesion	and	reduced	myelin	repair	over	
time	 (Kornek,	 2000).	 A	 study	 in	 2017	 on	mouse	 experimental	 autoimmune	 echepalomyelitis	
(EAE)	cells	found	that	the	disease	model	had	a	lower	activation	of	the	PI3K/Akt/mTOR	pathway	
(Giacoppo	et	al.,	2017).	The	phosphorylation	of	these	proteins	found	lower	levels	in	the	disease	
model,	 but	 when	 treated	 with	 CBD	 there	 was	 an	 increase	 in	 phosphorylation.	 Non-
phosphorylated	PI3K/Akt/mTOR	proteins	did	not	significantly	change	with	treatment,	meaning	
there	was	an	 increase	 in	activation	of	 the	pathway,	but	not	protein	 levels.	CBD	treatment	of	
these	cells	found	a	reduction	in	inflammatory	cell	infiltration	of	CNS	tissues.	It	is	thought	that	
this	could	be	through	CBD	activation	of	CB1	and	CB2	receptors	(Keating,	2017).	In	addition,	the	
side	effects	of	CBD	and	other	cannabinoids	(such	as	THC)	could	be	much	more	tolerated	than	
other	drugs.	For	example,	one	study	found	that	common	side	effects	of	Sativex®	treatment	(CBD	
and	THC)	were	confusion,	dizziness,	fatigue,	increased	appetite	(Ferrè	et	al.,	2016).	In	the	trial	
Sativex®	reduce	spasticity	and	pain.	The	full	effect	of	cannabinoids	on	the	treatment	of	MS	has	
yet	 to	be	explored,	but	 they	provide	a	potential	 treatment	of	 symptoms	and	potentially	 the	
causes	of	the	disease	with	few	side	effects.		
One	 common	 and	 effective	 animal	 model	 for	 MS	 is	 the	 experimental	 allergic	 autoimmune	
encephalomyelitis	 (EAE)	mouse	model	 (Robinson	 et	 al.,	 2014).	 In	 this	 model,	 mice	 undergo	
active	immunisation	with	myelin-derived	proteins	such	that	mice	T-lymphocytes	recognise	the	
endogenous	myelin	sheaths	of	neurons	as	foreign	bodies	and	begin	to	attack	them	(Robinson	et	
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al.,	 2014).	 The	effect	 created	 in	 an	EAE	model	mouse	 is	 very	 similar	 to	 that	which	occurs	 in	
patients	with	MS	(Robinson	et	al.,	2014).	In	EAE	model	mice,	treatment	with	Sativex®	(which	is	
a	 complex	 botanical,	 the	 therapeutic	 effects	 of	 which	 are	 derived	 from	 the	 totality	 of	 the	
product,	and	not	THC/CBD	alone.)was	found	to	reduce	spasticity	by	40	%	and	was	as	effective	
as	 baclofen	 (a	 known	 MS	 treatment)	 (Hilliard	 et	 al.,	 2012).	 Another	 study	 found	 that	 CBD	
effectively	diminished	inflammation,	demyelination,	axonal	damage	and	inflammatory	cytokine	
expressive	in	an	EAE	model	of	MS	(Rahimi	et	al.,	2015).	Purified	CBD	was	found	to	have	anti-
apoptotic,	neuroprotective	effects	in	the	EAE	model	of	MS	(Grassi	et	al.,	2016)	while	reducing	
inflammatory	cytokine	production	(Giacoppo	et	al.,	2017).	Interestingly,	application	of	a	topical	
CBD	cream	also	exerted	neuroprotective	effects	and	reduced	paralysis	of	hind	limbs	in	an	EAE	
model	of	MS,	as	well	as	reducing	cytokine	release	and	tissue	damage	in	the	spleen	(Giacoppo	et	
al.,	2015).	CBD	treatment	of	EAE	mouse	models	of	MS	was	found	to	potentially	work	through	
decreased	T	cell	infiltration	into	the	central	nervous	system	and	an	increase	in	myeloid-derived	
suppressor	cells,	which	would	remyelinate	neurons	(Elliott	et	al.,	2018).	Although	the	efficacy	of	
cannabinoid	treatment	of	MS	has	been	illustrated	in	animal	models,	clinical	trials	are	necessary	
to	determine	if	these	effects	remain	in	a	clinical	setting.		
As	cannabinoids	were	found	to	be	safe	and	efficacious	in	treating	MS	in	animal	models,	clinical	
trials	examined	whether	this	effect	occurred	in	humans.	One	clinical	study	revealed	that	Sativex®	
was	effective	in	reducing	pain	and	sleep	disturbance	in	MS	for	up	to	five	weeks	(Rog	et	al.,	2005).	
In	a	follow-up	study	two	years	later,	patients	who	continued	with	treatment	were	found	to	have	
positive	benefits	on	pain	reduction	and	sleep	(Rog	et	al.,	2007).	In	a	clinical	trial	in	Germany,	a	
similar	mixture	 of	 THC	 and	 CBD	was	 found	 to	 decrease	 spasticity	 in	MS	 patients	 as	 add-on	
therapy	or	monotherapy	 (Koehler	 et	 al.,	 2014).	 Sativex®	 is	 provided	 as	 an	oromucosal	 spray	
which	 is	an	add-on	therapy	for	patients	with	moderate	to	severe	multiple	sclerosis	spasticity	
resistant	to	other	medications	(Flachenecker	et	al.,	2014).	Furthermore,	a	clinical	trial	of	Sativex®	
for	MS	patients	found	that	the	therapeutic	was	both	well-tolerated	and	effective	against	MS-
related	spasticity,	from	one	to	three	months	of	treatment	(Flachenecker	et	al.,	2014).	Overall,	
THC	and	CBD	mixture	mucosal	spray	has	been	effective	for	around	half	of	patients	in	all	clinical	
trials	 at	 reducing	MS-related	 spasticity	 (Zettl	 et	 al.,	 2016).	 This	 efficacy	 has	 led	 to	 Sativex®	
prescription	legalisation	in	many	countries,	for	the	treatment	of	MS-related	symptoms	(Etges	et	
al.,	2016).		
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1.2	Mechanisms	of	action	of	cannabinoids	
1.2.1	Cannabinoid	interaction	with	cannabinoid	receptors	
The	 first	 known	 targets	 of	 cannabinoids	 in	 animals	 were	 cannabinoid	 receptors.	 These	 are	
G-protein-coupled	receptors	that	mediate	the	effect	of	endocannabinoids	in	the	body	(Howlett	
et	 al.,	 2002).	 Cannabinoid	 receptor	 1	 (CB1)	 is	 prominent	 in	 the	 central	 nervous	 system	
(Herkenham	et	al.,	1991)	while	cannabinoid	receptor	2	(CB2)	is	expressed	in	the	brain,	testes	and	
spleen	 (Liu	 et	 al.,	 2009).	 In	 the	 absence	of	 exogenous	 cannabinoids,	 these	proteins	 regulate	
synaptic	transmission	(Paradisi	et	al.,	2008).	However,	THC	activates	these	receptors,	while	CBD	
acts	 as	 an	 indirect	 antagonist	 (Laprairie	 et	 al.,	 2015).	One	 study	 found	 that	 pharmacological	
cannabinoid	receptor	antagonism	ameliorated	tremor	and	spasticity	in	MS	model	mice	(Baker	
et	 al.,	 2000).	 Another	 study	 found	 that	 expression	 of	 CB1	 in	 neurons	 was	 required	 for	
cannabinoid-mediated	 suppression	 of	MS-like	 symptoms	 in	 an	 EAE	model	mouse,	while	 CB2	
expression	 on	 T	 cells	 was	 required	 for	 a	 cannabinoid-mediated	 reduction	 in	 immune	 cell-
mediated	 inflammation	 (Maresz	 et	 al.,	 2007).	 Loss	 of	 CB1	 expression	was	 found	 to	 decrease	
motor	performance	in	a	mouse	model	of	Huntington’s	disease	(Mievis	et	al.,	2011).	However,	as	
only	THC	has	been	found	to	activate	CB1,	the	mechanism	of	action	of	non-THC	cannabinoids	for	
the	treatment	of	diseases	is	unlikely	to	occur	through	CB1	or	CB2.	CBD	treatment	elevated	the	
production	of	endogenous	anandamide	in	schizophrenic	patients,	which	if	a	similar	effect	was	
found	in	epilepsy	patients,	could	potentially	reduce	seizures,	as	anandamide	is	typically	low	in	
the	CNS	of	epilepsy	patients	(Romigi	et	al.,	2010;	Leweke	et	al.,	2012).		
Another	cannabinoid	receptor	has	been	discovered	in	the	form	of	G-protein	coupled	receptor	
55	(GPR55),	which	again	is	activated	by	THC,	but	not	CBD	(Lauckner	et	al.,	2008).	However,	one	
study	 found	 that	 CBD	 may	 inhibit	 neurotransmission	 through	 GPR55,	 as	 pharmacological	
inhibition	of	the	protein	blocked	the	effects	(Kaplan	et	al.,	2017).	The	potential	of	CBD	to	block	
intracellular	calcium	release	through	GRP55	indicates	a	potential	use	of	CBD	as	a	treatment	of	
epilepsy,	as	this	would	reduce	depolarisation	of	neurons	and	the	reduction	of	action	potential	
transmission	 or	 an	 increased	 threshold	 (Devinsky	 et	 al.,	 2014).	 Research	 on	 the	 effects	 of	
cannabinoids	 on	 GPR55,	 therefore,	 remains	 unclear,	 but	 both	 CBD	 and	 THC	 may	 have	
antagonistic	effects	on	this	protein.	
1.2.2	Cannabinoid	interaction	with	transient	receptor	potential	channels	
Another	 protein	 family	 that	 are	 known	 to	 be	 biochemical	 targets	 of	 cannabinoids	 are	 the	
transient	receptor	potential	(TRP)	channels.	These	are	a	family	of	membrane	proteins	involved	
in	 the	 transport	 of	 ion	 entry	 into	 cells,	mediating	 the	 sensing	 of	 temperature,	 pressure,	 pH,	
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smell,	taste,	vision	and	pain	(Ishimaru	and	Matsunami,	2009;	Muller	et	al.,	2019).	TRP	channels	
are	ionotropic	cannabinoid	receptors,	as	endocannabinoids	modulate	TRP	vanilloid	1	(TRPV1)	
(Zygmunt	et	al.,	1999)	and	TRP	melastatin	8	(TRPM8)	(De	Petrocellis	et	al.,	2007).	In	contrast,	
THC	acts	potently	at	TRPV2,	moderately	at	TRPV3	and	TRPV4,	but	does	not	modulate	TRPV1	(De	
Petrocellis	 et	 al.,	 2011),	 and	both	CBD	and	CBG	 stimulate	 TRPV1	and	TRPV2	and	 antagonise	
TRPM8	(De	Petrocellis	et	al.,	2011).	CBD	was	found	to	reduce	seizure	sensitization	from	repeated	
pentylenetetrazol	 (PTZ)	 treatment	 in	 a	 TRPV1-dependent	 manner	 (Vilela	 et	 al.,	 2017).	
Furthermore,	in	another	mouse	model	of	epilepsy,	CBD	increased	the	seizure	threshold	in	wild	
type	 mice,	 while	 this	 effect	 was	 not	 observed	 in	 TRPV1-ablated	 mice,	 except	 at	 high	
concentrations	of	CBD	(Gray	et	al.,	2019).	This	would	reduce	extracellular	calcium	release	and	
downregulate	 neuronal	 hyperexcitability,	 which	 would	 also	 reduce	 epileptogenesis	 (De	
Petrocellis	et	al.,	2011).	Therefore,	the	anti-seizure	properties	of	CBD	may	be	regulated	through	
TRPV1.		
1.2.3	Cannabinoid	interaction	with	adenosine	transport	and	signalling	
Many	previous	studies	have	indicated	that	cannabinoids	may	exert	therapeutic	action	through	
adenosine	transport	and	signalling.	Adenosine	is	a	nucleoside,	a	regulator	of	inflammation	and	
an	endogenous	anticonvulsant	(Weltha	et	al.,	2019).	This	molecule	is	released	during	seizures	
and	terminates	seizures	through	activation	of	adenosine	receptors	(Boison,	2013).	Adenosine	
kinase	over-expression	in	epilepsy	can	result	in	an	elevation	of	adenosine	storage	in	astroglial	
cells	 (Williams-Karnesky	 et	 al.,	 2013).	 This	 reduces	 free	 extracellular	 adenosine	 available	 to	
inhibit	seizures	and	therefore	can	result	in	increased	frequency	and	severity	of	seizures	(Weltha	
et	al.,	2019).	Furthermore,	intracellular	adenosine	levels	are	linked	to	DNA	methylation	(Kredich	
and	Martin,	1977;	Hermes	et	al.,	2007).	DNA	methylation	occurs	when	a	DNA	methyltransferase	
transfers	a	methyl	group	from	S-adenosyl	methionine	to	DNA,	resulting	in	the	production	of	S-
adenosylhomocysteine	 which	 is	 converted	 into	 adenosine	 and	 homocysteine	 (Figure	 1.3).	
Therefore,	elevated	intracellular	adenosine	results	in	decreased	DNA	methylation,	and	likewise,	
decreased	 intracellular	 adenosine	 results	 in	 increased	 DNA	 methylation.	 The	 links	 between	
adenosine	 and	 DNA	 methylation	 are	 important	 to	 the	 progression	 of	 epilepsy,	 known	 as	
epileptogenesis.	 This	 is	 because	 elevated	 DNA	 methylation	 results	 in	 epileptogenesis,	 and	
adenosine	 treatment	 inhibits	 epileptogenesis	 through	 reducing	 DNA	 methylation	 (Williams-
Karnesky	et	al.,	2013).		
Previous	studies	have	indicated	that	cannabinoids	may	block	adenosine	uptake.	CBD	has	been	
found	to	 increase	extracellular	adenosine	 in	rat	nucleus	accumbens	 (Mijangos-Moreno	et	al.,	
2014)	 and	 inhibit	 the	 uptake	 of	 adenosine	 into	macrophages	 and	microglia	 by	 inhibition	 of	
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equilibrative	 nucleoside	 transporter	 1	 (ENT1)	 (Carrier	 et	 al.,	 2006;	 Liou	 et	 al.,	 2008).	 CBD-
dependent	 inhibition	 of	 adenosine	 uptake	 through	 ENT1	 was	 found	 to	 have	 an	 anti-
inflammatory	effect	in	rat	retinal	microglial	cells	and	reduced	diabetes-related	retinal	damage	
in	 this	model	 (Liou	et	 al.,	 2008).	 The	neuroprotective	effect	of	CBD	 treatment	on	hypoxia	 in	
newborn	mice	was	also	found	to	be	dependent	upon	adenosine	signalling,	as	pharmacological	
inhibition	of	an	adenosine	receptor	 (A2A)	 reversed	the	neuroprotective	effects	 (Castillo	et	al.,	
2010).	 CBD	 may,	 therefore,	 act	 to	 reduce	 seizures	 by	 modulating	 adenosine	 transport	 or	
signalling.	The	extent	to	which	cannabinoid	modulation	of	adenosine	transport	could	affect	DNA	
methylation	 is	 not	well	 characterised,	 however,	 one	 study	 found	 that	 THC	 exposure	 of	 rats	
resulted	in	dysregulation	of	DNA	methylation	in	the	nucleus	accumbens	(Watson	et	al.,	2015).		
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1.2.4	Cannabinoid	interaction	with	mTOR	signalling	
In	previous	studies,	cannabinoids	have	been	found	to	regulate	mechanistic	target	of	rapamycin	
(mTOR)-related	 signalling.	 The	 signalling	 cascade	 through	 mTOR	 integrates	 intra-	 and	
extracellular	signals	and	regulates	metabolism,	growth,	proliferation	and	survival	(Figure	1.4	and	
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Figure	1.3:	Adenosine	transporter	and	DNA	methylation.	ENT1	(and	other	adenosine	transporters)	can	
transport	adenosine	 into	or	out	of	 the	 cell	down	 concentration	gradients.	 Inside	 the	 cell,	 adenosine	 is	
rapidly	phosphorylated	by	ADK	into	AMP,	which	can	activate	AMPK.	Adenosine	is	a	substrate	and	inhibitor	
of	 S-adenosylhomocysteine	 hydrolase.	 S-adenosylhomocysteine	 is	 an	 inhibitor	 of	 methyltransferases.	
Therefore,	an	elevated	level	of	intracellular	adenosine	rapidly	results	in	inhibition	of	the	methyltransferase	
pathway	and	as	a	result,	decreased	DNA	methylation	(Hermes	et	al.,	2007).	TH-Folate:	tetrahydrofolate;	
MEHT:	 5-methyltetrahydrofolate–homocysteine	 S-methyltransferase;	 MAT:	 methionine	 adenosyl	
transferase;	BHMT:	betaine–homocysteineS-methyltransferase,5ʹ-Nu:	-5ʹ-nucleotidase.	 
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Figure	1.5)	 (Laplante	and	Sabatini,	2009).	mTOR	signalling	usually	occurs	 through	one	of	 two	
complexes,	mTORC1	or	mTORC2,	which	regulates	apoptosis	and	cell	survival	(Shaw	and	Cantley,	
2006;	Saiki	et	al.,	2011;	Kim	et	al.,	2011;	Saxton	and	Sabatini,	2017).	Growth	factors	stimulate	
mTORC1	through	insulin	and	Ras	signalling	pathways,	while	energy	depletion	results	in	AMPK	
activation	which	inhibits	mTORC1	(Shaw	and	Cantley,	2006;	Chakraborty	et	al.,	2010;	Pal	et	al.,	
2019).	Amino	acids	regulate	mTORC1,	when	leucine	is	imported	into	cells	this	activates	mTORC1	
through	inositol	polyphosphate	multikinase	(IPMK)	(Kim	et	al.,	2011).	mTORC1	can	then	regulate	
protein	synthesis,	 lipid	biosynthesis	and	organelle	creation	 (Laplante	and	Sabatini,	2009)	and	
limits	catabolic	processes	such	as	autophagy	(Bort	et	al.,	2019).	Protein	synthesis	activation	by	
mTORC1	is	promoted	by	phosphorylation	of	the	eukaryotic	initiation	factor	4E	(eIF4E)-binding	
protein	1	(4EBP1)	and	the	p70	ribosomal	S6	kinase	1	(S6)	(Kim	et	al.,	2011).	mTORC2	regulates	
cell	survival,	metabolism	and	proliferation	through	protein	kinase	B	(PKB,	also	known	as	Akt)	
(Kazyken	 et	 al.,	 2019).	 PKB	 inhibition	 results	 in	 activation	 of	 forkhead	 box	 protein	 (FOXO)	
transcription	factors	which	control	the	expression	of	genes	involved	in	these	processes	(Wu	et	
al.,	2016).	PKB	can	also	regulate	mTORC1	activity	through	inhibition	of	downstream	effectors	or	
inhibition	of	upstream	inhibitors	(tuberous	sclerosis	complex	(TSC))	(Huang	and	Manning,	2009).	
PKB	 itself	 is	 activated	 by	 growth	 factor	 signalling,	 which	 results	 in	 the	 production	 of	
phosphatidylinositol	(3,4,5)-trisphosphate	(PIP3)	by	phosphoinositide	3-kinases	(PI3K),	including	
IPMK	 (Chang	et	al.,	2014;	Herrero-Sánchez	et	al.,	2016).	While	 insulin	 signalling	can	 result	 in	
inhibition	 of	 PKB	 by	 diphosphoinositol	 pentakisphosphate	 (IP7),	 which	 is	 produced	 by	 a	
combination	of	inositol	kinase	proteins	including	IPMK,	inositol	hexakisphosphate	(IP6)	kinase	1	
(IP6K1)	 and	 inositol	 hexakisphosphate	 and	 diphosphoinositol-pentakisphosphate	 kinase	 2	
(PPIP5K2)	(Mackenzie	and	Elliott,	2014;	Kim	et	al.,	2017;	Yousaf	et	al.,	2018).	mTOR	complexes	
are	 therefore	 seen	 as	 key	 regulators	 of	 many	 cellular	 activities	 and	 are	 often	 examined	 as	
potential	therapeutic	targets.	
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Preclinical	 studies	have	 suggested	 that	CBD	upregulates	mTORC1	activity,	 through	PI3K-	 and	
PKB-dependent	 manner	 in	 neurons	 of	 a	 mouse	 model	 of	 MS,	 while	 treating	 the	 disease	
(Giacoppo	et	al.,	2017).	In	addition,	CBD	was	found	to	reduce	symptoms	of	psychosis	in	a	rat	
model	while	elevating	mTORC1	activity	(Renard	et	al.,	2016).	On	the	other	hand,	THC	exposure	
led	to	an	increase	in	schizophrenia-	and	psychosis-like	symptoms	in	rats	while	reducing	mTORC1	
activity	in	neurons	(Renard	et	al.,	2017(a);	Renard	et	al.,	2017(b)).	In	addition,	some	studies	have	
found	 that	 cannabinoids	 reduce	mTORC1	 activity	 in	 certain	models.	 In	 a	 zebrafish	model	 of	
tuberous	sclerosis	complex-associated	epilepsy,	mTORC1	activity	was	found	to	be	constitutively	
elevated,	while	CBD	treatment	both	reduced	seizures	and	mTORC1	activity	in	the	brain	(Serra	et	
al.,	 2019).	 Furthermore,	 in	a	mouse	model	of	breast	 cancer,	CBD	 induced	apoptosis	 through	
downregulation	of	mTORC1	activity	(Sultan	et	al.,	2018).	Together,	these	studies	indicate	that	
CBD	 may	 have	 therapeutic	 effects	 through	 regulation	 of	 mTORC1	 activity.	 However,	 these	
previous	studies	also	suggest	contradictory	effects	of	CBD	treatment	on	mTORC1	activity	and	
provide	no	mechanism	for	this	action.		
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Figure	1.4:	mTORC1	signalling	components.	The	protein	components	of	the	mTOR	signalling	pathways	
are	diverse.	Often	components	such	as	PKB	and	IPMK	can	have	multiple	and	opposite	roles.	Here	is	a	
simplified	diagram	of	key	components	of	both	mTORC1	and	mTORC2.	
37	
	
	
	
1.1.3	CBG	and	therapeutic	potential	
Recent	research	has	focused	on	the	potential	therapeutic	effects	of	CBG,	given	the	level	of	CBG	
present	 in	 therapeutically	 effective	 C.	 sativa	 extracts.	 In	 one	 study,	 CBG	 was	 found	 to	 be	
effective	as	a	neuroprotectant	in	a	mouse	Huntington’s	disease	model	(Valdeolivas	et	al.,	2015).	
In	addition,	CBG	reduced	reactive	oxygen	species	production	in	colonic	epithelial	cells	and	nitrite	
production	 in	 peritoneal	 macrophages,	 suggesting	 it	 could	 have	 a	 beneficial	 effect	 on	
inflammatory	 bowel	 disease	 (Borrelli	 et	 al.,	 2013).	 Similarly,	 CBG	 has	 been	 shown	 to	 have	
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Figure	 1.5:	mTORC1	 and	mTORC2	 signalling.	mTORC1	 and	mTORC2	 are	 keystones	 in	 cell	 signalling.	
Regulation	 of	 proliferation,	 survival,	 metabolism,	 biosynthesis	 occurs	 through	mTOR	 signalling.	 This	
brings	together	energy,	insulin,	amino	acid,	glucose	and	growth	factor	signalling.		
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neuroprotective	effects	 in	 an	 in	 vitro	model	of	neuroinflammation	 (Gugliandolo	et	 al.,	 2018)	
where	 it	 reduced	 oxidative	 stress	 and	 increased	 cell	 viability	 (Gugliandolo	 et	 al.,	 2018).	
Furthermore,	CBG	reduced	tumour	growth	in	colorectal	cancer	cells	and	the	number	of	tumours	
formed	in	a	murine	model	of	colon	cancer	(Borrelli	et	al.,	2014).	Another	potential	therapeutic	
role	for	CBG	has	been	the	appetite-stimulant	effects	of	CBG	treatment	found	in	a	healthy	mouse	
model	 (Brierley	 et	 al.,	 2016).	 This	 appetite-stimulant	 effect	 held	 in	 a	 chemotherapy	 mouse	
model,	where	CBG	also	partially	normalised	glucose,	amino	acid	and	lipid	metabolism	(Brierley	
et	al.,	2019).	CBG,	therefore,	has	numerous	potential	therapeutic	functions.	
1.3	Dictyostelium	discoideum	as	a	pharmacogenetic	model		
Dictyostelium	discoideum	is	a	eukaryotic	social	amoeba	commonly	used	as	a	pharmacogenetic	
model	organism.	D.	discoideum	was	first	found	living	in	forest	detritus	in	North	America	(Raper,	
1941)	and	further	characterisation	revealed	that	this	species	was	part	of	the	Amoebozoa	phylum	
(Schilde	and	Schaap,	2013).	This	organism	is	often	used	as	a	model	for	chemotaxis	(Chisholm	
and	Firtel,	2004),	cell	differentiation	(Uchinomiya	and	Iwasa,	2013),	motility	(Robery	et	al.,	2011)	
and	signal	transduction	(Chang	et	al.,	2020).	Phylogenetic	analysis	revealed	that	D.	discoideum	
was	more	evolutionarily	close	to	animals	than	plants,	but	that	fungi	split	from	the	animal	line	
more	 recently	 than	D.	 discoideum	 (Bapteste	 et	 al.,	 2002;	 Eichinger	 et	 al.,	 2005).	However,	 a	
common	 fungal	model	organism,	 yeast,	has	undergone	a	higher	 rate	of	evolutionary	 change	
than	D.	 discoideum,	 meaning	 that	 the	 amoeba	 is	 in	 many	 ways	 genetically	 more	 similar	 to	
animals	than	yeast	(Insall,	2005).	The	genome	of	D.	discoideum	contains	around	12500	genes	
and	 the	genome	 is	34	megabases	 long	 (Eichinger	et	al.,	2005).	The	D.	discoideum	genome	 is	
haploid	and	fully	sequenced,	allowing	the	use	of	this	organism	as	a	pharmacogenetic	model	to	
examine	the	molecular	mechanisms	of	many	natural	compounds.	This	approach	allows	rapid	
identification	of	proteins	responsible	for	sensitivity	to	a	compound	and	examination	of	related	
signalling	pathways.		
D.	discoideum	has	a	lifecycle	with	both	single-	and	multicellular	aspects,	allowing	the	organism	
to	be	used	as	a	model	of	development,	social	behaviour	and	cell	differentiation.	In	a	nutrient-
rich	environment,	D.	discoideum	grows	as	a	single-celled	organism,	phagocytosing	bacteria	and	
dividing	by	binary	fission	(Raper,	1941).	However,	during	starvation	D.	discoideum	can	aggregate	
into	a	multicellular	structure	(Figure	1.6),	whereby	cyclic	cAMP	release	acts	as	a	chemoattractant	
such	that	cells	migrate	towards	each	other	(Brenner	and	Thoms,	1984).	Following	aggregation,	
cells	form	a	multicellular	motile	slug	(pseudoplasmodium)	which	moves	towards	attractants	that	
indicate	 potentially	 nutrient-rich	 areas	 (Kourtis	 and	 Tavernarakis,	 2009).	 Development	 of	D.	
discoideum	then	occurs	through	the	formation	of	fruiting	bodies,	which	consist	of	viable	spores	
and	a	stalk	made	up	of	dead	cells	(Marée	and	Hogeweg,	2002).	During	development,	due	to	the	
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change	 in	nutrient	availability	and	morphology	of	 cells,	protein	content	and	gene	expression	
changes,	 potentially	 indicating	 a	 distinct	 range	 of	 drug	 targets	 in	 pharmacogenetic	 studies	
(Sekine	 et	 al.,	 2018).	 Furthermore,	 pharmacogenetic	 studies	 can	 also	 be	 used	 to	 assess	 the	
toxicity	of	a	 compound,	alongside	any	 inhibitory	effects	 it	may	have	on	growth	 (Perry	et	al.,	
2020).	The	development	of	D.	discoideum	has	been	used	as	a	simple	model	for	the	development	
of	higher	eukaryotes	to	test	the	safety	of	epilepsy	treatment	(Tillner	et	al.,	1998).	More	recently,	
characterisation	 of	 the	 g-secretase	 complex,	 which	 is	 involved	 in	 Alzheimer’s	 disease,	 also	
employed	development	in	D.	discoideum	as	a	phenotypical	readout	for	protein	function	(Sharma	
et	al.,	2019).	The	multiple	aspects	of	the	D.	discoideum	lifecycle,	therefore,	allow	this	amoeba	
to	be	a	useful	simple	biomedical	model.	
D.	discoideum	has	 also	been	a	useful	 organism	 for	 studying	 cell-cell	 signalling.	 Cyclic	AMP	 is	
released	 by	 starving	 D.	 discoideum	 (Chang	 et	 al.,	 2020).	 Starving	 cells	 aggregate	 through	
chemotaxis,	guided	by	waves	of	cAMP	(Singer	et	al.,	2019).	During	early	aggregation,	cells	at	the	
centre	of	an	aggregate	periodically	release	cAMP.	This	is	then	detected	by	cells	further	away	and	
relayed	by	surrounding	cells	in	waves	(Wessels	et	al.,	1996).	Cells	chemotax	towards	the	cAMP	
signal	 centre,	 up	 the	 gradient	 during	 the	 rising	 phase	 of	 the	 waves,	 resulting	 in	 a	 periodic	
movement	to	the	centre.	Initial	variations	in	cell	density	cause	a	further	increase	in	cell	density	
in	the	densest	areas,	and	this	results	in	a	centre	of	aggregation	(Levine	and	Reynolds,	1991).	D.	
discoideum	 have	 evolved	 to	 begin	 the	 process	 of	 aggregation	 by	 cAMP	 signalling	 upon	
starvation,	 therefore,	 gene	 expression	 begins	 to	 change	 at	 the	 point	 of	 starvation	 and	
components	involved	in	cAMP	detection,	amplification	and	breakdown	are	expressed	(Dinauer	
et	al.,	1980).	cAMP	is	detected	by	G	protein	coupled	cAMP	receptors	and	when	cAMP	is	present	
a	transmembrane	adenylyl	cyclase	(AcA).	AcA	produces	cAMP	which	is	then	secreted	amplifying	
the	cAMP	signal	and	receptor	activation,	which	causes	a	negative	feedback	and	reduces	cyclase	
activity	in	this	wave	(Dinauer	et	al.,	1980).	As	cAMP	concentration	rises	and	falls	this	process	is	
repeated.	cAMP	is	degraded	outside	the	cell	by	continuously	excreted	cAMP	phosphodiesterase,	
reducing	 the	 extracellular	 concentration	 of	 cAMP	 further,	 allowing	 the	 cycle	 to	 begin	 again	
(Parent	 and	 Devreotes,	 1996).	 These	 findings	 have	 helped	 in	 the	 understanding	 of	 cell-cell	
communication	and	coordination	of	cell	movements	within	a	multicellular	organism	(Singer	et	
al.,	2019).	
Due	 to	 the	 sequencing	 of	 the	D.	 discoideum	 genome	 and	 that	 the	 genome	 is	 haploid,	 this	
organism	has	been	useful	for	carrying	out	pharmacogenetic	studies.	To	this	end,	a	mutagenic	
library	was	created	in	D.	discoideum	by	random	genomic	disruption	through	restriction	enzyme-
mediated	 integration	 of	 plasmid	 DNA	 (Kuspa	 and	 Loomis,	 1992).	 The	mutant	 library	 can	 be	
examined	for	resistance	to	a	pharmacological	compound,	to	identify	its	molecular	mechanism.	
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Such	a	method	has	been	used	 to	establish	molecular	mechanisms	of	a	 range	of	compounds,	
including	naringenin	 (Misty	 et	 al.,	 2006;	Waheed	et	 al.,	 2014),	 curcumin	 (Cocorocchio	 et	 al.,	
2018),	CBD	(Perry	et	al.,	2020).		
	
In	fact,	D.	discoideum	 is	a	well-established	model	for	use	in	epilepsy	research	and	discoveries	
made	using	D.	discoideum	have	been	confirmed	in	mammalian	models	and	impacted	the	clinical	
process.	Using	D.	discoideum	 the	anti-epileptic	drug	valproic	 acid	 (VPA)	was	 found	 to	 inhibit	
phosphoinositide	 signalling,	 which	 indicated	 that	 VPA	 may	 treat	 epilepsy	 through	
phosphoinositide	 regulation	 (Chang	 et	 al.,	 2012).	 A	 structure-activity	 relationship	 in	 D.	
Figure	1.6:	The	D.	discoideum	life	cycle.	During	the	growth	phase,	D.	discoideum	exists	as	a	free	living	
single	celled	organism.	Red	represents	D.	discoideum	which	have	the	capability	of	a	free	living	lifecycle.	
In	 blue	 are	 cells	 that	 have	 differentiated	 into	 becoming	 future	 stalk	 cells.	 During	 times	 of	 nutrient	
depletion	 D.	 discoideum	 aggregate	 through	 cAMP	 signalling,	 producing	 waves	 and	 a	 concentration	
gradient,	highest	at	the	centre	of	the	aggregate.	In	the	tight	aggregation,	differentiation	cells	are	mixed,	
however,	eventually	the	cells	form	a	motile	slug	and	the	pre-stalk	cells	are	at	the	leading	edge.	Once	
favourable	conditions	are	sensed	cells	undergo	differentiation	into	spore	and	stalk	cells,	initially	forming	
a	Mexican	hat	shape	and	eventually	a	fully	formed	fruiting	body.		
Free-living	amoebae
Tight	aggregation
Motile	slug
Fruiting	body
Mexican	hat
Aggregation
Waves	of	cAMP	signalling
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discoideum	found	that	decanoic	acid	reduced	phosphoinositide	production	more	potently	than	
VPA	and	this	led	to	the	discovery	that	decanoic	acid	was	more	effective	in	seizure	models	than	
VPA	(Chang	et	al.,	2013;	Augustin	et	al.,	2018).		
Lithium	 is	 a	 common	 treatment	 for	 bipolar	 disorder,	 however	 the	mechanism	of	 action	was	
relatively	unknown	(Shaltiel	et	al.,	2004).	Using	D.	discoideum	both	lithium	and	VPA	were	found	
to	 block	 development	 (Williams	 et	 al.,	 2002).	 Screening	 the	mutant	 library	 in	D.	 discoideum	
identified	a	lithium-resistant	mutant	and	an	inactive	prolyl	oligopeptidase	protein	responsible	
for	this	resistance.	An	orthologue	of	this	protein	has	been	linked	to	patients	with	bipolar	disorder	
previously	 (Breen	 et	 al.,	 2004).	 Loss	 of	 prolyl	 oligopeptidase	 was	 found	 to	 elevate	 inositol	
triphosphate	 levels	 (IP3),	which	 appeared	 to	 overcome	 the	 reduction	 of	 IP3	 levels	 caused	 by	
lithium	 treatment	 (King	et	al.,	 2009).	 This	mechanism	was	 found	 to	also	exist	 in	mammalian	
neurons	where	lithium	caused	an	enlargement	of	neuronal	growth	cones	and	IP3	treatment	or	
inhibition	of	prolyl	oligopeptidase	reversed	this	(Williams	et	al.,	2002).		
In	addition,	this	technique	has	previously	been	used	to	examine	the	molecular	mechanism	of	
the	cannabinoid	CBD	(Perry	et	al.,	2020).	Using	the	mutant	library	screen,	proteins	responsible	
for	 the	 action	 of	 CBD	 were	 identified	 as	 part	 of	 the	 glycine	 cleavage	 system.	 Using	 gas	
chromatography-mass	 spectrometry	 (GC-MS)	 analysis	 CBD	 was	 found	 to	 reduce	 cellular	
methionine	levels,	while	CBD	did	not	affect	methionine	levels	in	cells	lacking	the	glycine	cleavage	
system	H	protein	1	(GCVH1).	CBD	modulation	of	methionine	levels	was	found	to	be	conserved	
in	rat	cells	(Perry	et	al.,	2020).		
Furthermore,	 an	 examination	 of	 the	 molecular	 mechanisms	 of	 caffeine	 found	 that	 caffeine	
inhibits	PI3K	and	mTORC2	activity	in	D.	discoideum,	which	in	turn	inhibits	the	synthesis	of	cyclic	
adenosine	monophosphate	(cAMP)	(Tariqul	Islam	et	al.,	2019),	confirming	a	mechanism	found	
previously	 in	 mouse	 embryonic	 fibroblasts	 (Saiki	 et	 al.,	 2011).	 In	 another	 study,	 mTORC1	
inhibition	of	two-pore	channel	protein	opening	was	examined	using	D.	discoideum	(Chang	et	al.,	
2020)	and	confirmed	a	mechanism	previously	suggested	in	mammalian	cells	(Cang	et	al.,	2013;	
Ogunbayo	et	al.,	2018).	DNA	methylation	has	also	been	examined	in	D.	discoideum	and	a	DNA	
methyltransferase	 (DNMA)	 found	 to	 be	 responsible	 for	 the	 silencing	 of	 retrotransposons	
(Kuhlmann	 et	 al.,	 2005).	 D.	 discoideum	 has	 therefore	 previously	 been	 used	 to	 identify	 a	
molecular	target	for	a	cannabinoid	and	other	compounds	and	these	effects	were	found	to	be	
conserved	in	mammalian	systems.		
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1.5	Aims	and	Objectives	
This	research	project	aims	to	investigate	and	characterise	potential	molecular	mechanisms	of	
the	cannabinoid,	CBG.	Initially,	the	effect	of	CBG	on	D.	discoideum	growth	and	development	will	
be	investigated,	to	indicate	the	potency	in	this	model	and	potential	developmental	effects.	This	
information	will	then	be	employed	in	a	targeted	approach	to	investigating	CBG	function	relating	
to	 the	D.	 discoideum	 ENT1	 protein	 in	 adenosine	 transport	 and	 downstream	 effects	 on	 DNA	
methylation.	 The	 CBG	 growth	 sensitivity	 will	 also	 be	 employed	 to	 carry	 out	 an	 unbiased	
approach	to	identify	components	of	signalling	pathways	(mTOR)	that	are	involved	in	the	CBG	
molecular	mechanism.	Finally,	mammalian	and	clinical	models	will	be	used	to	examine	whether	
the	findings	in	D.	discoideum	are	conserved.	
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2	Methods	
(See	Appendix	9.1	for	Materials)	
2.1	Assessment	of	relative	research	output	for	cannabinoids	
To	assess	the	relative	research	output	for	each	cannabinoid,	a	literature	search	was	performed	
using	“cannabigerol”,	“cannabidiol”	and	“tetrahydrocannabinol”	on	PubMed	(PubMed,	2020).	
2.2	Storage	of	cell	lines	
D.	discoideum	cell	lines	were	stored	at	-80	°C	in	freezing	media	(Horse	serum,	7%	DMSO).	
2.3	Maintenance	of	cell	lines	
Cells	 were	 taken	 from	 storage	 monthly	 and	 grown	 on	 SM	 agar	 plates	 in	 the	 presence	 of	
Raoultella	planticola	before	being	grown	axenically	in	HL5	media	with	1	%	glucose.	HL5	media	
was	 supplemented	 with	 100	 µg/ml	 penicillin	 and	 100	 µg/ml	 streptomycin,	 and	 cells	 were	
maintained	at	22	 °C	 in	 shaking	 suspension	at	220	 rpm	 in	 flasks,	 or	without	 shaking	 in	 tissue	
culture	dishes.	Cells	in	shaking	culture	were	maintained	in	100	ml	flasks	in	10	ml	media	to	ensure	
aeration,	bunged	with	cotton	wool	and	covered	with	foil.	
2.4	Growth	assays	of	D.	discoideum	cells	
Wild	type	(AX3	and	AX2),	dIPMK+,	hIPMK+,	PKBA-,	PKBA-IPMK+,	ENT1-	and	DNMA-	D.	discoideum	
cells	were	harvested	and	diluted	in	axenic	to	2	x	104	cells/ml.	Aliquots	of	cells	(10	ml)	were	grown	
(at	22	°C)	 in	shaking	culture	 in	the	presence	of	 increasing	concentrations	of	CBG	dissolved	 in	
DMSO	(0.5	%	v/v	for	all	concentrations	and	control).	Cells	were	maintained	in	100	ml	flasks	in	
10	ml	media	to	ensure	aeration,	bunged	with	cotton	wool	and	covered	with	foil.	Cell	number	
was	recorded	between	72	and	168	hours,	cell	numbers	were	normalised	to	the	solvent	(DMSO)-
only	control	at	168	hours	(control).	A	secondary	plot	was	calculated	using	the	rate	of	exponential	
growth,	from	96-144	hours,	at	each	concentration	and	normalised	to	the	no	compound	vehicle	
control	 (DMSO	 only).	 Each	 replicate	 (n)	 is	 a	 separate	 biological	 replicate.	 Experiments	were	
carried	out	with	mutant	cells	at	the	same	time	as	wild	type	cells,	and	one	biological	replication	
(n)	was	carried	out	per	week,	in	which	a	cell	line	was	grown	in	the	presence	of	all	concentrations	
of	CBG	(and	DMSO	only).	Therefore,	if	n=7	is	stated,	seven	separate	biological	replicates	were	
carried	out,	at	different	times.		
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To	count	cells,	10	µl	was	taken	from	each	flask	and	placed	in	a	haemocytometer	(depth	0.1	mm,	
Neubauer).	 Using	 a	 Nikon	 TMS,	 25	 squares	 in	 the	 haemocytometer	 were	 counted,	 which	
represented	cells	in	1/10000	mls.	Therefore,	the	number	was	multiplied	by	104	to	find	cells	per	
ml.	If	a	sample	was	contaminated	it	was	not	counted,	and	initially	there	were	some	replicates	
missed	as	it	was	unclear	which	concentrations	would	be	key	to	finding	the	IC50.	
2.5	Development	assays	of	D.	discoideum	cells	
Wild	 type	 (AX3)	D.	 discoideum	 cells	 were	 washed	 in	 phosphate	 buffer	 twice	 (2.2	 g	 KH2PO4	
(monobasic),	0.7	g	K2HPO4	(dibasic)	per	litre)	then	resuspended	in	phosphate	buffer	at	1	x	107	
cells/ml.	Cells	 (1	x	107)	were	 then	 loaded	onto	nitrocellulose	 filters	and	placed	on	absorbent	
filter	pads	with	500	µl	of	phosphate	buffer	containing	specific	concentrations	of	DMSO	and	CBG.	
Filters	were	left	at	22	°C	for	24	hours	and	then	imaged	to	record	developmental	phenotypes.	
Development	assays	were	recorded	with	a	Dissection	microscope	 (Leica)	with	a	QICAM	FAST	
1394	camera	(QImaging).	Successful	development	was	measured	as	an	array	of	fully	developed	
fruiting	bodies	at	24	hours,	regardless	of	specific	shape	or	size.	
2.6	Bioinformatics	protein	analysis	
To	identify	homologous	proteins	across	species	the	Protein	function	of	the	Basic	Local	Alignment	
Search	Tool	(BLAST)	was	used	from	the	National	Centre	for	Biotechnology	Information	(NCBI)	
(https://blast.ncbi.nlm.nih.gov).	Primary	protein	sequences	were	obtained	from	uniprot.org	and	
cross	 referenced	against	 the	non-redundant	protein	 sequences	 (nr)	database	of	BLAST	using	
blastp	(protein-protein	BLAST).		
Sequences	were	aligned	using	ClustalW	(http://www.ebi.ac.uk/Tools/msa/clustalo/)	which	was	
used	to	align	amino	acid	sequences.	
Molecular	Evolutionary	Genetic	Analysis	version	7	(MEGA	7)	was	used	to	carry	out	phylogenetic	
analysis	of	each	protein	studied.	To	produce	phylogenetic	trees	the	neighbour-joining	statistical	
method	was	performed	with	the	bootstrap	method	test	of	phylogeny	with	500	replications.	
Protein	 domains	 were	 identified	 based	 on	 annotations	 from	 InterPro	
(https://www.ebi.ac.uk/interpro/).	
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2.7	Transfection	of	D.	discoideum	by	electroporation	
D.	discoideum	cells	were	washed	 twice	 times	 in	 ice-cold	electroporation	buffer	H50	 (20	mM	
HEPES,	50	mM	KCl,	10	mM	NaCl,	1	mM	MgSO4,	5	mM	NaHCO3,	1	mM	NaH2PO4,	pH	7.0)	and	
resuspended	 to	a	concentration	of	5	x	107	cells/ml.	100	µl	of	cells	and	10	µg	of	vector	were	
added	to	a	chilled	1	mm	gap	electroporation	cuvette	and	incubated	on	ice	for	5	minutes.	Then,	
a	pulse	of	850	V	(capacitance	25	µF)	was	carried	out.	Cells	were	incubated	on	ice	for	5	minutes	
before	being	transferred	into	HL5	media.	Transfected	knockout	cells	were	selected	for	after	24	
hours	with	10	µg/ml	blasticidin,	and	over-expressor	cells	were	selected	for	with	10	µg/ml	G418.	
2.8	Polymerase	chain	reaction	(PCR)	amplification	
Amplification	of	DNA	was	carried	out	using	GoTaq®	G2	Flexi	DNA	polymerase	or	Q5	high	fidelity	
DNA	polymerase.	A	standard	20	µl	reaction	was	carried	out	using	0.1-5	µg	of	DNA	template,	4	µl	
of	GoTaq®	Flexi	buffer,	2	mM	MgCl2,	0.5	mM	dNTP	mix,	0.5	µM	primers	and	0.1	µl	GoTaq®	Flexi	
DNA	polymerase	(5	units/µl),	made	up	to	20	µl	with	nuclease-free	water.	For	creation	of	over-
expressor	plasmids,	Q5	high	fidelity	DNA	polymerase	was	used	for	PCR	reactions.	Here,	a	20	µl	
reaction	contained	0.5	µg	of	DNA	template,	0.5	μM	primers,	4	μl	5x	Q5	buffer,	0.5	mM	dNTP	
mix,	0.2	μl	Q5®	DNA	polymerase	(2	units/μl),	made	up	to	20	μl	with	nuclease-free	water.	DNA	
amplifications	were	carried	out	using	a	PCR	machine	with	an	initial	denaturing	step	for	1	minute	
at	95	°C,	followed	by	32	cycles	of	95	°C	for	30	s	(denaturation),	50-65	°C	for	30	s	(annealing)	and	
6	8°C	for	1	minute	per	1000	bps	(extension)	before	a	final	extension	step	at	68	°C	for	10	minutes.	
2.9	Restriction	digests	
Restriction	 digests	 were	 carried	 out	 according	 to	manufacturer’s	 instructions	 (all	 restriction	
enzymes	 were	 obtained	 from	 Thermo	 Scientific).	 In	 cases	 where	 multiple	 enzymes	 were	
required,	appropriate	buffer	conditions	were	found	using	the	DoubleDigest	Calculator	(Thermo	
Scientific).		
2.10	Agarose	gel	electrophoresis	
To	visualise	and	separate	DNA,	gel	electrophoresis	was	carried	out.	Gels	contained	1	%	agarose	
in	TAE	buffer	supplemented	with	ethidium	bromide.	Loading	buffer	was	added	to	DNA	samples	
before	running	and	1	kb	hyperladder	was	used	as	a	marker	for	DNA	size.	Gels	were	run	at	110	V	
for	30	minutes	in	1X	TAE	(Tris	base,	acetic	acid	and	EDTA)	buffer	and	DNA	was	visualised	using	
UV	illumination.		
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2.11	Bacterial	transformation	
Chemically	 competent	 Escherichia	 coli	 cells	 (from	 TOP10	 chemically	 competent	 E.	 coli,	
Thermofisher,	C4040-10)	were	thawed	on	ice	and	1-10	μg	of	plasmid	was	placed	directly	into	
the	cells.	Contents	were	mixed	gently	and	incubated	on	ice	for	5	minutes,	heat-shocked	for	1	
minute	at	42	°C.	Samples	were	transferred	to	ice	again	and	incubated	for	a	further	5	minutes	
and	250	μl	of	LB	media	was	added	to	each	vial	and	incubated	at	37	°C	for	1	hour.	Cells	were	
plated	onto	LB	agar	plates	containing	100	μg/ml	ampicillin.		
2.12	Plasmid	extraction	from	bacterial	cells	
Bacterial	cells	were	grown	overnight	(in	5	ml	of	LB	media	containing	100	μg/ml	ampicillin)	at	
37	°C	on	a	shaker	at	220	rpm.	Bacteria	were	collected	by	centrifugation	at	17000	g	for	2	minutes	
at	room	temperature	and	the	supernatant	discarded.	Plasmid	was	extracted	from	the	cell	pellet	
by	 GeneJet®	 plasmid	mini-prep	 kit	 (according	 to	manufacturer’s	 protocol),	 HiSpeed	 Plasmid	
Maxi	Kit	or	by	a	non-commercial	method.	The	non-commercial	method	began	with	adding	200	µl	
of	resuspension	solution	to	cells	collected	by	centrifugation	(10	ml	0.5	M	EDTA,	90	g	glucose,	
6.25	ml	2	M	Tris.	pH	8.0,	made	up	to	500	ml),	which	was	mixed	by	vortex.	Then	200	µl	of	lysis	
solution	 (50	ml	10%	SDS,	 20	ml	0.5	M	NaOH,	made	up	 to	500	ml)	was	added	and	mixed	by	
inversion	 followed	 by	 incubation	 for	 5	 minutes.	 300	 µl	 of	 neutralisation	 solution	 (147	 g	
potassium	acetate,	57.5	ml	glacial	acetate	acid,	made	up	to	500	ml)	was	added	and	mixed	by	
inversion.	Samples	were	then	centrifuged	at	17000	g	for	15	minutes	at	room	temperature	and	
supernatant	was	collected	into	new	tubes	containing	420	μl	of	isopropanol	and	mixed.	This	was	
centrifuged	 at	 17000	 g	 for	 a	 further	 15	 minutes	 at	 room	 temperature	 and	 supernatant	
discarded.	Next,	500	μl	of	70	%	ethanol	was	added	and	samples	mixed	before	centrifugation	at	
17000	g	for	5	minutes	at	room	temperature	and	the	supernatant	discarded.	Samples	were	then	
placed	on	a	heat	block	at	50	°C	for	10	minutes	to	dry	the	DNA.	DNA	was	resuspended	in	30	μl	
nuclease-free	water.		
2.13	Extraction	of	genomic	DNA	
D.	discoideum	cells	were	collected	from	flasks	and	centrifuged	at	500	g	for	3	minutes.	Cells	were	
then	washed	twice	 in	a	phosphate	buffer	(16.2	mM	KH2PO4,	4	mM	K2HPO4.	pH	6.8)	and	then	
DNA	was	extracted	using	DNeasy®	Blood	and	tissue	kit	or	Wizard	Genomic	DNA	Purification	Kit	
(according	to	manufacturers’	protocols).		
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2.2.14	Creation	of	knockout	cell	lines	in	D.	discoideum	
To	knock	out	ENT1	(and	attempt	to	knockout	IPMK),	a	knockout	cassette	was	generated	by	PCR	
amplification	of	the	5’	and	3’	arms	of	the	ENT1	gene.	This	created	homologous	regions	that	could	
be	used	to	recombine	with	each	target	gene	(Figure	2.1).	NcoI	and	KpnI	cut	sites	were	inserted	
into	the	5’	arm	of	the	ENT1	gene	(5’	and	3’	of	the	arm	respectively)	and	SpeI	and	PstI	cut	sites	
were	inserted	into	the	3’	arm	of	the	ENT1	gene	(5’	and	3’	of	the	arm	respectively).	These	cut	
sites	 were	 inserted	 by	 adding	 them	 to	 primers	 used	 to	 create	 the	 knockout	 cassette.	 This	
ensured	that	during	PCR	amplification	of	the	regions	of	ENT1	in	interest,	each	cut	site	was	added.	
The	 arms	 were	 sequentially	 cloned	 into	 the	 pLPBLP	 vector	 at	 sites	 flanking	 the	 blasticidin-
resistance	 gene.	 Transfection	 of	 this	 knockout	 construct	 into	wild	 type	 (AX3)	D.	 discoideum	
resulted	in	a	disruption	to	the	ENT1	gene	via	homologous	recombination,	which	was	checked	by	
PCR	amplification	of	genomic	control,	vector	control	and	knockout	bands	(Figure	2.2).	
Cells	transfected	with	knockout	constructs	were	then	grown	in	10	μg/ml	blasticidin	in	96	well	
plates.	Cells	resistant	to	blasticidin	were	collected	and	centrifuged	in	PCR	tubes	before	lysis	with	
24	μl	lyse	B	solution	(10	mM	TRIS-HCL	pH	8.3,	50	mM	KCL,	2.5	mM	MgCl2,	0.45%	TWEEN,	0.45%	
NP40	substitute)	and	1	μl	proteinase	K.	Cells	were	incubated	at	room	temperature	for	5	minutes	
Figure	2.1:	ENT1	gene	before	and	after	ablation.	A:	In	wild	type	(WT)	cells,	the	ENT1	gene	has	three	
exams.	PCR	amplification	was	carried	out	with	primer	pair	4	and	5	and	primer	pair	3	and	2	(see	primer	
table,	Appendix	9.1)	to	create	homologous	arms	to	the	ENT1	gene	to	allow	the	insertion	of	a	blasticidin	
resistance	gene	 into	the	centre	of	ENT1,	thus	ablating	the	gene.	B:	 In	ENT1	KO	cells	the	blasticidin	
resistance	gene	has	removed	exon	2	and	some	of	exons	1	and	3.	Correct	 insertion	of	the	knockout	
cassette	can	be	analysed	by	PCR	using	primer	pair	6	and	13	and	primer	pair	15	and	1.	
Dark	orange	boxes	represent	exons	that	are	either	part	of,	or	altered	by,	the	knockout	cassette.	Light	
orange	boxes	and	arrows	are	parts	of	exons	that	remain	intact	in	the	genome.	In	black	is	the	blasticidin	
resistance	cassette. 
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before	 heat	 inactivation	 for	 5	minutes	 at	 95	 °C.	 2	 µl	 of	 the	 cell	 lysate	was	 analysed	 by	 PCR	
amplification	to	confirm	successful	homologous	integration.		
To	confirm	that	homologous	recombination	resulted	in	ablation	of	ENT1	expression,	RT-PCR	was	
carried	 out.	 RNA	 was	 extracted	 from	 wild	 type	 and	 knockout	 cells	 using	 RNeasy	 mini	 kit	
(according	to	manufacturer’s	protocol).	To	avoid	DNA	contamination	in	RNA	extracts	the	DNA-
free	kit	(according	to	manufacturer’s	protocol).	cDNA	was	synthesised	using	the	RevertAid	First	
Strand	cDNA	synthesis	kit	using	oligo(dT)18	primers	(according	to	manufacturer’s	protocol).	PCR	
amplification	was	carried	out	of	the	knockout	gene	and	Ig7	(positive	control	housekeeping	gene,	
which	produces	the	mitochondrial	large	subunit	rRNA	(DDB_G0294034)	(Fukuzawa	et	al.,	2006)).		
	
2.2.15	 Analysis	 of	 intra-	 and	 extracellular	 adenosine	 in	 microglia	 (carried	 out	 at	
Reading	University)	
This	was	carried	out	by	Dr	Nicola	Gray,	Martina	Cherubin	and	Dr	Mark	Dallas	at	the	University	
of	Reading.	To	determine	whether	CBG	blocked	adenosine	transport,	a	mammalian	cell	line	was	
employed	(Jimmerson	et	al.,	2017).	Cell	suspension	was	collected	(approx.	500,000	cells)	in	500	
µL	methanol	and	centrifuged	at	13	400	rpm	for	10	minutes.	For	targeted	LC-MS	profiling,	100	µl	
sample	was	then	combined	with	300	µl	water	in	a	96-well	plate	and	mixed	before	analysis.	Cell	
medium	was	also	collected	and	centrifuged	for	10	minutes	and	diluted	1	in	10	with	water.	Where	
quantification	was	performed,	25	µl	internal	standard	solution	was	added	to	20	µl	sample	and	
155	µL	water	and	vortexed	mixed	before	LC-MS	analysis.		
Figure	2.2:	ENT1	gene	after	ablation	with	primer	pairs	used	for	checking.	Using	the	labelled	PCR	pairs	
(Appendix	9.1),	in	PCR	amplification,	genomic	control	bands	on	an	electrophoresis	gel	are	visible	in	
wild	type,	knockout	and	non-homologous	integrant	cell	lines.	Vector	control	bands	are	visible	in	non-
homologous	integrant	and	knockout	cell	lines.	KO	bands	are	only	visible	in	knockout	cell	lines.	This	is	
because	the	pale	orange	is	not	present	in	the	knockout	cassette,	so	any	plasmid	in	cells	or	incorrect	
insertion	sites	would	not	give	a	KO	band.	
Dark	orange	boxes	represent	exons	that	are	either	part	of	the	knockout	cassette.	Light	orange	boxes	
and	arrows	are	parts	of	exons	that	 remain	 intact	 in	the	genome	and	are	not	part	of	the	knockout	
casstte.	In	black	is	the	blasticidin	resistance	cassette. 
5’	genomic	control	(563	bp)
5’	vector control	(632	bp)
5’	KO	fragment	(662	bp)
3’	genomic	control	(542	bp)
3’	vector control	(680	bp)
3’	KO	fragment	(717	bp)
Primer	1
Primer	2
Primer	15
Primer	3
Primer	13
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Liquid	chromatography-tandem	mass	spectrometry	analysis	was	performed	using	a	Shimadzu	
Nexera	UHPLC	system	and	LCMS-8050	triple	quadrupole	mass	spectrometer	(Shimadzu	Corp.,	
Japan).	Chromatography	was	performed	using	a	Discovery	HS	F5	150	x	2.1	mm,	3.0	µm	column	
(Supelco,	UK).	Gradient	elution	was	performed	using	0.1	%	formic	acid	in	water	(mobile	phase	
A)	and	0.1	%	 formic	acid	 in	acetonitrile	 (mobile	phase	B)	at	a	 flow	 rate	of	0.25	mL/minutes,	
starting	at	0%	B	for	2	minutes,	increasing	to	25%	B	at	5.0	minutes,	35%	B	at	11.0	minutes,	95%	
B	at	15.0	minutes	and	holding	for	5.0	minutes	before	returning	to	0%	B	for	a	5.0	minutes	re-
equilibration.	Column	temperature	was	maintained	at	40	°C	and	an	injection	volume	of	0.5	µl	
was	used.	
The	mass	spectrometer	was	operated	in	electrospray	ionisation	(ESI)	mode	using	positive	and	
negative	polarity	switching.	Data	was	acquired	using	multiple	reaction	monitoring	(MRM).	The	
electrospray	voltages	applied	were	4.5	 kV	 (positive	mode)	and	 -3.5	 kV	 (negative	mode).	 The	
interface	temperature,	heat	block	temperature	and	desolvation	line	temperature	were	300	°C,	
400	°C	and	250	°C	respectively.	The	nebulising	gas	and	drying	gas	were	nitrogen	at	3.0	l/minute	
and	10	l/minute	respectively,	and	the	heating	gas	(air)	was	delivered	at	10	l/minute.	Data	were	
acquired	and	processed	using	LabSolutions	software	(Shimadzu	Corp.).	
Cell	medium	samples	were	analysed	using	the	same	LC-MS	system	as	described	above	using	a	
Discovery	HS	F5	150	x	2.1	mm,	3.0	µm	column	(Supelco,	UK).	Gradient	elution	was	performed	
using	0.1	%	formic	acid	in	water	(mobile	phase	A)	and	0.1	%	formic	acid	in	acetonitrile	(mobile	
phase	B)	at	a	flow	rate	of	0.35	mL/minute,	starting	at	0%	B	for	1.4	minutes,	increasing	to	25%	B	
at	3.5	minutes,	35%	B	at	7.5	minutes,	95%	B	at	10.3	minutes	and	holding	for	3.4	minutes	before	
returning	to	0%	B	for	a	3.2	minutes	re-equilibration.	Column	temperature	was	maintained	at	
40	°C	and	an	injection	volume	of	1	µL	was	used.	
The	mass	spectrometer	was	operated	in	electrospray	ionisation	(ESI)	mode	using	positive	and	
negative	polarity	switching.	Data	was	acquired	using	multiple	reaction	monitoring	(MRM)	and	
analyte	 transitions	 are	 shown	 in	 Supplementary	 Information	 (Table	 S1).	 The	 electrospray	
voltages	 applied	 were	 4.5	 kV	 (positive	 mode)	 and	 -3.5	 kV	 (negative	 mode).	 The	 interface	
temperature,	heat	block	temperature	and	desolvation	line	temperature	were	300	°C,	400	°C	and	
250	 °C	 respectively.	 The	 nebulising	 gas	 and	 drying	 gas	 were	 nitrogen	 at	 3.0	 L/minute	 and	
10	 L/minute	 respectively,	 and	 the	 heating	 gas	 (air)	 was	 delivered	 at	 10	 L/minute.	 Data	was	
acquired	 using	 LabSolutions	 software	 and	 processed	 using	 LabSolutions	 Insight	 (Shimadzu	
Corp.).	
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2.2.16	Analysis	of	DNA	methylation	in	D.	discoideum	
To	 identify	 whether	 CBG	 modulated	 DNA	 methylation	 in	 D.	 discoideum,	 the	 effect	 of	 CBG	
treatment	was	examined	in	this	model.	To	carry	this	out,	wild	type	cells	(AX3)	were	maintained	
in	control	conditions	(in	the	presence	of	solvent	only)	or	 in	the	presence	of	0.25	µM	CBG	for	
24	hours.	Genomic	DNA	was	then	extracted	(using	the	Wizard	Genomic	DNA	Purification	Kit),	
200	 ng	DNA	was	 used	 per	 sample	 (measured	 by	Nanodrop)	 and	 total	DNA	methylation	was	
quantified	by	colorimetry-based	immunochemical	binding	of	methylated	DNA	(Antonini	et	al.,	
2019).	 A	 commercial	 plate	 reader	 kit	 specific	 for	 DNA	 methylation	 was	 used	 (according	 to	
manufacturer’s	protocol)	with	colorimetric	reading	at	450	nm.	
2.2.17	D.	discoideum	mutant	screen	
To	identify	D.	discoideum	mutants	resistant	to	CBG	a	restriction	enzyme-mediated	insertional	
(REMI)	library	containing	11,000	mutants	was	employed	(provided	by	Cardiff	and	Manchester	
Universities).	 This	 library	 was	 created	 at	 Cardiff	 University	 by	 transfection	 of	 wild	 type	 D.	
discoideum	(AX4)	with	the	restriction	enzymes	DpnII	and	NlaIII	and	 linearized	DNA	(the	REMI	
plasmid	 digested	 with	 BamH1)	 containing	 a	 blasticidin-resistance	 gene.	 This	 resulted	 in	 the	
incorporation	of	the	blasticidin-resistance	gene	into	the	D.	discoideum	genome	at	compatible	
sites,	disrupting	the	genes	at	the	site	of	integration.	Successfully	created	mutants	were	selected	
for	in	the	presence	of	blasticidin.	
To	find	mutants	resistant	to	CBG	during	growth,	the	pool	of	mutant	cells	(11,000)	was	incubated	
for	10	days	with	8,	10	and	12	µM	CBG.	These	concentrations	were	chosen	as	they	are	in	excess	
of	CBG	needed	to	inhibit	growth	by	>90%	in	wild	type	cells	after	7	days.	Cells	were	seeded	at	2.5	
x	104	cells/ml.	Resulting	CBG-resistant	cells	were	isolated	and	made	isogenic	by	growth	at	10	
cells/plate	 on	 R.	 planticola	 on	 SM	 plates.	 Once	 isogenic,	 the	 location	 of	 the	 REMI	 insert	
determined	using	an	inverse	PCR	technique	to	isolate	the	flanking	DNA	(Keim	et	al.,	2004).	
Genomic	DNA	was	extracted	from	CBG-resistant	mutants	using	Qiagen	DNeasy	kit,	according	to	
manufacturer’s	protocol.	Genomic	DNA	(10	µl	or	approximately	20	µg)	was	then	digested	with	
5	 units	 of	 RsaI	 at	 37	 ᵒC	 for	 1	 hour	 in	 Tango	 buffer.	 The	 digest	 was	 purified	 by	 ethanol	
precipitation,	where	DNA	was	incubated	for	16	hours	in	0.3	M	sodium	acetate	and	20	µl	100	%	
ethanol	at	-20	°C,	which	was	collected	by	centrifugation	at	5	°C,	16000	g	for	15	minutes.	The	
DNA	was	then	resuspended	 in	nuclease-free	water	and	circularised	by	 ligation	with	0.5	µl	T4	
DNA	ligase	in	10	µ	reactions	at	room	temperature	for	1	hour.	PCR	was	used	to	amplifying	the	D.	
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discoideum	genomic	sequence	flanking	the	blasticidin-resistance	gene	with	primers	P9	and	P10,	
with	an	annealing	temperature	of	50	°C.		
PCR	products	were	then	analysed	through	one	of	 two	methods.	Either	purified	by	QIAquick®	
PCR	purification	kit	(according	to	manufacturer’s	protocol	and	sent	directly	for	sequencing	with	
the	p9	and	p10	primers	(13	and	14	in	Appendix	Figure	9.1). Alternatively,	PCR	products	were	
ligated	into	the	TOPO	pCR®	2.1	vector	and	cloned	into	bacteria	using	the	TOPO	TA	cloning®	kit	
(according	to	manufacturer’s	protocol).	The	plasmid	was	then	sent	for	sequencing	with	the	T7	
and	M13	primers	(16	and	17	in	Appendix	Figure	9.1).	
2.2.18	qPCR	analysis	of	CBG-resistant	mutants	
RNA	was	extracted	from	wild	type	and	mutant	cells	maintained	in	control	conditions	using	the	
RNeasy	kit,	and	cDNA	was	produced	First-strand	cDNA	synthesis	kit.	cDNA	was	then	analysed	by	
qPCR	using	primers	100	bp	apart	from	the	gene	of	interest	(IPMK).	Total	expression	levels	were	
quantified	 by	 qPCR	 using	 SYBR®	 Green	 Jump	 StartTM	 Taq	 Ready	Mix,	 as	 per	manufacturer’s	
instructions.	 Fold	 changes	 were	 calculated	 using	 the	 ∆∆-Ct	 method.	 Expression	 levels	 were	
normalized	 to	 the	 constitutively	 expressed	 Ig7	 housekeeping	 gene,	 which	 produces	 the	
mitochondrial	large	subunit	rRNA	(DDB_G0294034)	(Fukuzawa	et	al.,	2006).	
2.2.19	Creation	of	dIPMK-RFP	and	hIPMK-RFP	cell	lines	and	imaging	(and	attempt	at	
ENT1-RFP)	
RNA	 was	 extracted	 from	 wild	 type	 D.	 discoideum	 using	 RNeasy	 mini	 kit	 (according	 to	
manufacturer’s	protocol).	DNA	was	removed	from	the	RNA	using	the	DNA-free	kit.	cDNA	was	
synthesised	 using	 the	 RevertAid	 First	 Strand	 cDNA	 Synthesis	 Kit	 using	 oligo(dT)18	 primers	
(according	 to	 the	 manufacturer’s	 protocol).	 The	 D.	 discoideum	 IPMK	 (DDB_G0281737)	 was	
amplified	by	PCR	of	the	dIPMK	gene	cDNA	and	the	human	IPMK	(hIPMK:	Uniprot	Q8NFU5,	NCBI	
GeneID	55847)	was	synthesised	with	D.	discoideum	codon	bias	(GenScript)	and	both	genes	were	
cloned	 into	 the	 pDM324	 plasmid	 containing	 a	 C-terminal	 red	 fluorescent	 protein	 (RFP)	 tag	
(Veltman	et	al.,	2009)	to	create	an	over-expressor	construct.	The	vector	was	electroporated	into	
wild	type	(AX3)	D.	discoideum	cells	and	selected	by	growth	in	the	presence	of	geneticin	(G418)	
at	10	μg/mL.	Cells	expressing	the	plasmids	were	imaged	using	fluorescent	microscopy	under	1%	
agar.		
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2.2.20	RFP	expression	confirmation	by	Western	Blot	
To	confirm	the	expression	of	RFP	constructs,	Western	blot	analysis	was	carried	out.	The	cells	
were	then	harvested	and	resuspended	in	western	blot	loading	buffer	(total	volume	30	ml	of	2X	
Laemmli	Sample	Buffer	containing:	bromophenol	blue	approx.	0.001	g,	2-mercaptoethanol	(2-
ME)	3	ml,	100	%	glycerol	6	ml,	10%	SDS	solution	12	ml,	0.5	M	Tris-HCl	7.5	ml,	H2O	1.5	ml)	at	a	
concentration	of	2.5x107	cells/ml.	The	samples	were	boiled	at	98	°C	for	6.5	minutes	and	then	
frozen	at	-20	°C.	Samples	were	then	loaded	onto	a	15%	polyacrylamide	gel	and	run	at	70	volts	
for	30	minutes	and	100	volts	for	1	hour.	The	gel	was	transferred	for	17	hours	onto	a	PVDF	0.2	μm	
membrane	at	15	volts	at	5	°C.	The	membrane	was	blocked	twice	for	1	hour	each	with	5%	milk	
Tris-buffer	saline	with	1%	Tween	(TBST).	The	blots	were	incubated	with	primary	antibody	(anti-
RFP),	at	1	in	1000	concentration	in	5%	milk	TBST	for	18	hours,	washed	with	TBST,	then	incubated	
with	fluorescently	labelled	(800)	secondary	antibody	(anti-rat)	at	1	in	10000	concentration	in	5%	
milk	TBST	for	1	hour,	washed	with	TBST	and	imaged.	Streptavidin	(1:5000	Streptavidin)	was	used	
as	a	loading	control	(Davidson	et	al.,	2013).	
2.2.21	Western	blot	analysis	of	mTORC1	activity	in	D.	discoideum	
Wild	type	(AX3),	 IPMK+,	PKBA-	and	PKB-/PKGB-	D.	discoideum	cells	were	treated	with	purified	
CBG,	 CBD,	 cannabidiolic	 acid	 (CBDA)	 and	 cannabidivarin	 (CBDV)	 (phytocannabinoids	 at	 a	
concentration	of	0.25	µM)	or	a	PI3K	inhibitor	(60	µM)	(LY294002)	for	1	hour	or	with	solvent	only	
(DMSO).	The	cells	were	then	harvested	and	resuspended	in	western	blot	loading	buffer	(total	
volume	30	ml	of	2X	Laemmli	Sample	Buffer	containing:	bromophenol	blue	approx.	0.001	g,	2-
mercaptoethanol	(2-ME)	3	ml,	100	%	glycerol	6	ml,	10%	SDS	solution	12	ml,	0.5	M	Tris-HCl	7.5	
ml,	H2O	1.5	ml)	at	a	concentration	of	2.5x107	cells/ml.	The	samples	were	boiled	at	98	°C	for	6.5	
minutes	and	then	frozen	at	-20	°C.	Samples	were	then	loaded	onto	a	15%	polyacrylamide	gel	
and	run	at	70	volts	for	30	minutes	and	100	volts	for	1	hour.	The	gel	was	transferred	for	17	hours	
onto	a	PVDF	0.2	μm	membrane	at	15	volts	at	5	°C.	The	membrane	was	blocked	twice	for	1	hour	
each	 with	 5%	milk	 Tris-buffer	 saline	 with	 1%	 Tween	 (TBST).	 The	 blots	 were	 incubated	 with	
primary	antibody	(p4EBP1),	at	1	 in	1000	concentration	in	5%	milk	TBST	for	18	hours,	washed	
with	 TBST,	 then	 incubated	 with	 secondary	 antibody	 (anti-rabbit	 (horseradish	 peroxidase	
conjugated))	 at	 1	 in	 5000	 concentration	 in	 5%	milk	 TBST	 for	 1	 hour,	washed	with	 TBST	 and	
imaged	 using	 chemifluorescent	 substrate.	 Streptavidin	 (1:5000	 Streptavidin)	 was	 used	 as	 a	
loading	control	(Davidson	et	al.,	2013).	
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2.2.22	Higher	order	inositol	phosphate	analysis	in	D.	discoideum	
Wild	type	(AX3)	and	IPMK+	cells	(1	x	107)	were	treated	with	vehicle	solvent	only	control	(DMSO)	
or	0.25	μM	CBG	or	CBD	for	1	or	24	hours.	Inositol	polyphosphates	were	analysed	as	previously	
described	(Pisani	et	al.,	2014).	Cell	pellets	were	dissolved	in	1	M	perchloric	acid	(40	µl)	containing	
3	mM	EDTA,	incubated	on	ice	for	10	minutes,	centrifuged	(10	minutes,	20000	g	at	4	˚C)	and	the	
supernatant	was	neutralised	with	1	M	potassium	carbonate	(18	µl).	Samples	were	incubated	on	
ice	for	2	hours,	centrifuged	at	20000	g	and	the	supernatants	collected.	Samples	were	mixed	with	
OrangeG	and	run	on	a	35	%	polyacrylamide	gel	for	17	hours	at	4	°C	at	600	V	and	6	mA.	Gels	were	
stained	with	 toluidine	 blue,	 then	 scanned	with	 a	 desktop	 computer	 for	 image	 analysis	with	
ImageStudio	Lite	(Li-Cor,	version	5.0).	
2.2.23	Mouse	embryonic	fibroblast	cell	culture	
Mouse	embryonic	fibroblasts	were	grown	in	tissue	culture	flasks	(in	Dulbecco's	Modified	Eagle	
Medium	 (DMEM)	 containing	 10%	 fetal	 bovine	 serum	 (FBS))	 at	 37	 ˚C,	 5%	 CO2,	 and	 regularly	
passaged.	Fresh	cells	were	used	monthly.	Cells	were	collected	using	Trypsin	(0.25	%	Trypsin,	0.1	
%	EDTA).	
2.2.24	Western	blot	analysis	of	mTORC1	activity	in	mouse	embryonic	fibroblasts	
Wild	type	and	IPMK-/-	mouse	embryonic	fibroblasts	(Maag	et	al.,	2011)	were	treated	with	solvent	
control	only	(DMSO)	or	4	μM	CBG	or	CBD	or	PI3K	inhibitor	(10	µM)	(Pictilisib)	for	24	hours	in	
Dulbecco's	Modified	Eagle	Medium	(DMEM)	containing	10%	fetal	bovine	serum	(FBS).	Cells	were	
seeded	at	1.5	x	105	per	sample,	and	following	a	24-hour	treatment,	cells	were	collected	(Trypsin)	
and	lysed	using	RIPA	buffer	containing	2%	phosphatase	inhibitor	and	1%	protease	inhibitor.	Cell	
lysates	were	boiled	 in	western	blot	 loading	buffer	at	96°C	 for	6.5	minutes	and	 then	proteins	
were	separated	by	15%	polyacrylamide	gel	run	at	70	volts	for	30	minutes	and	100	volts	for	1	
hour	and	transferred	to	a	0.2μm	PVDF	membrane	for	17	hours.	The	membrane	was	blocked	with	
5%	 milk	 Tris-buffered	 saline	 and	 incubated	 overnight	 at	 4°C	 with	 1:1000	 diluted	 primary	
antibody	p4EBP1,	total	4EBP1,	actin	(loading	control)	in	TBS	with	Tween	20	(TBST)	for	2	hours	at	
room	temperature	with	1:5000	diluted	horseradish	peroxidase-conjugated	secondary	antibody	
anti-rabbit	 and	 anti-mouse.	 The	 signals	 were	 detected	with	 chemifluorescent	 substrate	 and	
recorded	on	an	Odyssey	CLx.		
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2.2.25	Primary	peripheral	blood	mononuclear	cell	collection	from	human	volunteers	
(carried	out	at	Trinity	College	Dublin)	
Healthy	 volunteers	 (Hv)	 and	 people	 with	 multiple	 sclerosis	 (pwMS)	 attending	 clinics	 at	
Beaumont	Hospital,	Dublin,	Ireland,	were	recruited	for	this	study.	This	experiment	was	carried	
out	by	Lisa	Costelloe,	Dr	Eric	Downer	and	John-Mark	Fitzpatrick.	Written	informed	consent	was	
obtained	 from	each	 participant	 and	 the	 study	 received	 ethical	 approval	 from	 the	Beaumont	
Hospital	 Ethics	 (Medical	 Research)	 and	 the	 Faculty	 of	 Health	 Sciences	 Research	 Ethics	
Committee,	Trinity	College	Dublin,	Ireland.	The	recruitment	of	pwMS	into	the	study	was	via	a	
Consultant	Neurologist	and	all	pwMS	had	a	relapsing-remitting	(RR)	form	of	MS	as	defined	by	
the	 revised	McDonald	 criteria	 (Kurtzke	 1983,	 Polman	 et	 al.,	 2011)	 including	 patient	 history,	
clinical	signs	and	symptoms,	physical	examination	and	adjunctive	diagnostic	tools	including	MRI.	
Some	pwMS	were	on	immunomodulatory	treatment	including	gilenya,	dimethyl	fumarate	and	
plegridy.	 Healthy	 volunteers	 with	 no	 history	 of	 autoimmune,	 cardiovascular,	 respiratory	 or	
degenerative	 disease	 were	 included.	 Healthy	 volunteers	 were	 matched	 based	 on	 age	 and	
gender.	Details	of	participant	demographics	are	presented	in	Table	1.	Primary	peripheral	blood	
mononuclear	 cells	 PBMCs	 were	 prepared	 from	 venous	 whole	 blood	 samples	 by	 way	 of	
venipuncture	(max	50	ml	per	donor	collected	in	EDTA	tubes)	from	healthy	control	participants	
(mean	age	42.0	±	2.6	years;	n	=	6)	and	pwMS	(mean	age	35.3	±	5.0	years;	n	=	6).	PBMCs	were	
isolated	 by	 density	 separation	 over	 Lymphoprep™.	 In	 summary,	 whole	 blood	 samples	 were	
diluted	1:1	with	sterile	PBS	and	gently	overlaid	onto	Lymphoprep.	Each	sample	was	subjected	
to	centrifugation	while	 in	 contact	with	Lymphoprep,	 the	PBMC	 layer	was	 separated,	washed	
with	PBS	and	resuspended	in	RPMI	[supplemented	with	10%	FBS,	penicillin	and	streptomycin	
(100	µg/ml	for	both)].	PBMCs	were	(1x106	cells/ml;	3	ml	per	well)	maintained	in	culture	for	at	
least	 2	 hours	 prior	 to	 treatment	 with	 highly-purified	 CBD	 or	 CBG	 (100	 nM),	 or	 THC:CBD	
combinations	(20	nM:17	nM)	for	24	hours.	
2.2.26	 Western	 blot	 analysis	 of	 mTORC1	 activity	 in	 primary	 peripheral	 blood	
mononuclear	cells	
PBMCs	 were	 lysed	 using	 RIPA	 buffer	 containing	 2%	 phosphatase	 inhibitor	 and	 1%	 protease	
inhibitor.	Cell	lysates	were	boiled	in	western	blot	loading	buffer	at	96°C	for	6.5	minutes	and	then	
proteins	were	separated	by	SDS-PAGE	gel	electrophoresis	 (15%)	and	transferred	to	a	0.2	μm	
PVDF	membrane	for	17	hours.	The	membrane	was	blocked	with	5%	milk	Tris-buffered	saline	and	
incubated	overnight	at	4°C	with	1:1000	diluted	primary	antibody	(p4EBP1),	total	4EBP1,	IPMK,	
actin	 in	Tris-buffer	saline	(TBS)	with	Tween	20	(TBST)	and	2	hours	at	room	temperature	with	
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1:5000	diluted	horseradish	peroxidase-conjugated	secondary	antibody	anti-rabbit,	anti-mouse.	
The	signals	were	detected	with	chemifluorescent	substrate	and	recorded	on	an	Odyssey	CLx	(Li-
Cor).		
2.2.27	Statistical	analysis	
Normality	tests	for	data	were	carried	out	using	Shapiro-Wilks.	If	data	were	found	to	be	normally	
distributed,	then	a	One-Way	ANOVA	with	a	Post-Hoc	Test	of	either	Dunnett’s	or	Bonferroni’s	
multiple	comparisons.	Bonferroni’s	was	used	when	each	data	set	was	compared	to	all	others,	
for	example	wild	type	(control),	mutant	(control),	mutant	(treatment	A),	mutant	(treatment	B).	
While	a	Two-Way	ANOVA	would	be	used	if	the	sample	included	wild	type	(control),	wild	type	
(treatment	 A),	 wild	 type	 (treatment	 B),	 mutant	 (control),	 mutant	 (treatment	 A),	 mutant	
(treatment	B).	As	this	full	data	set	was	not	present	in	the	first	example,	a	Two-Way	ANOVA	could	
not	be	carried	out	and	the	author	found	the	best	alternative	to	be	a	Bonferroni	Post-Hoc	Test	
on	a	One-Way	ANOVA.	Dunnett’s	was	used	to	compare	multiple	treatments	to	a	control,	 for	
example	wild	type	(control),	wild	type	(treatment	A),	wild	type	(treatment	B).	
If	 data	were	 found	 to	 not	 be	 normally	 distributed	 then	 a	 Kruskal-Wallis	 Test	 with	 a	 Dunn’s	
Multiple	 Comparison	 Post-Hoc	 Test,	 or	 Mann	 Whitney	 test	 was	 carried	 out	 to	 test	 for	
significance.	Mann	Whitney	Test	was	used	to	compare	two	data	sets	at	a	time.	Dunn’s	was	used	
to	compare	multiple	data	sets	to	a	control,	for	example	wild	type	(control),	wild	type	(treatment	
A),	wild	type	(treatment	B).		
Significance	was	found	if	P≤0.05.	In	all	graphical	representations	of	data	*	denotes	p<0.05,	**	
denotes	p<0.01.	Data	are	represented	as	mean	±	SEM.	Statistical	analysis	was	carried	out	using	
GraphPad	 Prism	 Software.	 In	 this	 thesis,	 n	 number	 represents	 biological	 replicates	 for	 all	
experiments.		
From	 visual	 inspection	 of	 the	 data,	 homogeneity	 of	 variances	 was	 assumed	 to	 be	 met.	 In	
addition,	where	ANOVA	tests	were	carried	out,	 this	 takes	 into	account	whether	 the	variance	
within	a	data	set	was	larger	than	variance	between	data	sets	when	providing	significance.	
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Chapter	 3:	 Examining	 adenosine	 transport	 regulation	 as	 a	
molecular	mechanism	of	CBG	
3.1	Introduction	
Cannabigerol	(CBG)	is	an	abundant,	non-psychotropic	cannabinoid	without	fully	characterised	
molecular	targets.	CBG	is	present	in	Cannabis	sativa	plants	often	at	a	similar	concentration	to	
cannabidiol	 (CBD),	 but	 usually	 lower	 than	 tetrahydrocannabinol	 (THC)	 (Swift	 et	 al.,	 2013).	
However,	both	CBG	and	CBD	are	non-psychoactive,	so	present	a	large	advantage	as	potential	
therapeutics	 with	 fewer	 side	 effects.	 The	 molecular	 mechanisms	 of	 CBG	 are	 relatively	
understudied	compared	to	CBD	and	THC	(Abrams,	2018),	however,	the	three	cannabinoids	share	
a	 similar	 molecular	 structure	 (Figure	 1.1)	 (Hill	 et	 al.,	 2014).	 Given	 that	 C.	 sativa	 extracts	
containing	CBG	are	effective	epilepsy	treatments	(Devinsky,	Verducci,	et	al.,	2018)	and	multiple	
sclerosis	 treatments	 (Serpell	 et	 al.,	 2013),	 it	 remains	 important	 to	 understand	 if	 CBG	 has	
therapeutic	 potential	 (Freeman	 et	 al.,	 2019).	 Therefore,	 this	 chapter	 aimed	 to	 search	 for	
molecular	mechanisms	of	CBG.		
One	molecular	mechanism	of	cannabinoids	that	has	previously	been	examined	is	the	inhibition	
of	 adenosine	 signalling	 and	 transport.	 This	 mechanism	 provides	 a	 therapeutic	 potential	 for	
cannabinoids	 in	 the	 treatment	of	 a	 range	of	diseases	where	adenosine	 signalling	pathway	 is	
impacted	by	disease	pathophysiology.	As	 a	 result,	 adenosine	 signalling	 is	 a	 therapeutic	 drug	
target	for	schizophrenia	(Rosse,	2017),	epilepsy	(Zhang	et	al.,	2018),	Alzheimer’s	disease	(Lee	et	
al.,	2018),	and	acute	kidney	 injury	 (Grenz	et	al.,	2012).	CBD,	a	similar	cannabinoid	 to	CBG,	 is	
known	 to	 inhibit	 adenosine	 transport	 through	 ENT1	 (Carrier	 et	 al.,	 2006;	 Liou	 et	 al.,	 2008).	
Furthermore,	adenosine	transport	is	linked	through	biochemical	pathways	to	DNA	methylation,	
whereby	 intracellular	 adenosine	 levels	 and	 DNA	 methylation	 have	 an	 inverse	 relationship	
(Figure	1.3)	(Hermes	et	al.,	2007;	Williams-Karnesky	et	al.,	2013).	Since	the	study	of	biochemical	
pathways	 in	mammalian	systems	can	be	time-consuming	and	expensive	 (Cosson	et	al.,	2002;	
Steinert	 and	 Heuner,	 2005),	 D.	 discoideum	 can	 be	 employed	 as	 a	 simple	 model	 system	 to	
examine	molecular	mechanisms	 of	 compounds	 (Williams,	 2005;	 R.S.B.	Williams	 et	 al.,	 2006;	
Schaf	 et	 al.,	 2019).	 Thus,	 to	 investigate	whether	 the	molecular	mechanism	 of	 CBG	 involved	
adenosine	signalling	and	to	examine	this	mechanism,	a	simple	biomedical	model	was	employed.		
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3.2	Results		
3.2.1	Effects	of	CBG	on	Dictyostelium	discoideum	growth	and	development	
As	a	first	step	to	characterise	the	effects	of	CBG	on	cells,	D.	discoideum	growth	was	measured	
in	 the	presence	of	CBG.	 In	 these	experiments,	wild	 type	cells	were	grown	 in	 the	presence	of	
increasing	concentrations	of	CBG	over	168	hours.	Cells	were	then	counted	daily.	Under	control	
conditions	(in	the	presence	of	solvent	only),	wild	type	(AX3)	D.	discoideum	cell	growth	showed	
a	lag	phase	until	96	hours,	an	exponential	phase	to	144	hours	and	a	stationary	phase	starting	at	
168	 hours	 (Figure	 3.1	 A).	 At	 low	 concentrations,	 CBG	 (0.02	 µM)	 did	 not	 significantly	 inhibit	
growth.	In	contrast,	CBG	at	0.1	µM	and	higher	concentrations	significantly	inhibited	growth	at	
168	hours	(P<0.01,	Mann	Whitney	test).	Data	arising	from	this	analysis	(rate	of	growth	and	Log	
of	concentration)	was	used	to	calculate	an	 IC50	of	0.22	µM	(Figure	3.1	B).	These	data	show	a	
dose-dependent	reduction	in	growth	of	D.	discoideum	caused	by	CBG.	
Figure	3.1:	CBG	inhibits	growth	of	D.	discoideum.	A:	Wild	type	cells	(AX3)	were	grown	in	the	presence	of	
increasing	concentrations	of	CBG	(and	solvent	only	control,	0)	for	168	hours.	CBG	inhibited	cell	growth	in	a	
concentration-dependent	manner	(n=10).	Data	were	not	normally	distributed	(Shapiro	Wilks),	therefore	a	
Mann	Whitney	 test	 was	 carried	 out	 to	 test	 for	 significance	 of	 inhibition	 by	 each	 concentration	 of	 CBG	
compared	to	control	at	168	hours,	**	-	p<0.01.	Graphs	show	mean	±	SEM.	Growth	rate	at	each	concentration	
of	CBG	was	used	to	produce	a	secondary	plot.	B:	Secondary	plot	analysis	was	used	to	determine	the	IC50	=	
0.22	μM	(n=10).	The	95	%	confidence	intervals	(CI)	for	these	data	were	0.14	to	0.31	µM. 
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To	further	analyse	the	effects	of	CBG	treatment	on	D.	discoideum,	response	of	this	model	to	CBG	
during	development	was	measured.	During	development,	a	distinct	set	of	signalling	pathways,	
and	 thus	 proteins,	 are	 involved	 compared	 to	 growth,	 potentially	 providing	 different	 cellular	
targets	 in	 the	model	 system	 (Kuspa	 and	 Loomis,	 1992).	 To	 determine	 the	 effect	 of	 CBG	 on	
development,	wild	type	D.	discoideum	cells	(AX3)	were	starved	for	24	hours	in	a	saline	solution	
containing	CBG	at	a	range	of	concentrations	up	to	five	times	the	concentration	shown	to	block	
growth	(20	µM).	The	phenotype	expected	if	development	was	occurring	correctly,	was	a	tall	thin	
stalk	 and	 round	 spore	 head,	 but	 natural	 variation	 was	 expected,	 including	 slightly	 different	
shaped	spore	heads,	a	straight,	curved	or	wavy	stalk,	and	a	variation	of	sizes.	When	development	
is	blocked	or	delayed	in	D.	discoideum,	this	is	verified	by	the	development	at	24	hours	not	being	
at	the	correct	stage,	i.e.	perhaps	at	the	slug	or	mound	stage	(Cocorocchio	et	al.,	2018;	Kelly	et	
al.,	 2018;	 Sharma	 et	 al.,	 2019).	 Under	 control	 conditions	 (in	 the	 presence	 of	 solvent	 only),	
development	occurred,	leading	to	the	formation	of	fruiting	bodies,	comprised	of	a	stalk	and	a	
spore	head	(Figure	3.2	A).	In	the	presence	of	CBG	up	to	20	µM,	no	difference	in	developmental	
phenotype	was	observed,	thus	fruiting	bodies	formed,	comprised	of	a	stalk	and	a	spore	head	
(Figure	 3.2	 B,	 C,	 D).	 These	 experiments	 indicated	 that	 CBG	 did	 not	 affect	 multicellular	
development	of	D.	discoideum	up	to	20	µM	and	implied	CBG	had	a	non-toxic	inhibitory	effect	
on	growth.	Development	of	a	stalk	and	spore	head	was	not	changed,	the	variation	in	size	and	
shape	was	expected,	but	future	work	could	determine	the	relevance	of	these	changes	 if	any.	
This	also	implied	that	CBG	was	not	lethal	to	D.	discoideum	and	instead	inhibited	a	specific	action	
involved	in	growth.	
3.2.2	Examining	adenosine	transport	modulation	as	a	potential	molecular	mechanism	
of	CBG		
One	potential	molecular	mechanism	of	CBG	is	adenosine	signalling.	A	cannabinoid	with	similar	
structure	to	CBG,	CBD,	has	previously	been	shown	to	affect	adenosine	signalling	and	adenosine	
transport	 via	 the	 equilibrative	 nucleoside	 transporter,	 ENT1	 (Carrier	 et	 al.,	 2006;	 Liou	 et	 al.,	
2008).	In	these	previous	studies,	CBD	was	found	to	inhibit	adenosine	uptake	by	ENT1	into	rat	
macrophages	and	microglia	(Liou	et	al.,	2008),	with	the	effect	conserved	in	a	whole	organism	
experiment	in	mice	(Carrier	et	al.,	2006).	The	primary	function	of	the	mammalian	ENT1	protein	
is	to	transport	adenosine,	however,	this	protein	also	has	a	low	affinity	for	general	nucleosides	
across	the	plasma	membrane	(Baldwin	et	al.,	2004).	The	D.	discoideum	proteome	was	searched	
using	BLAST	to	identify	potential	ENT1	orthologues.	One	potential	ENT1	orthologue	(Dictybase	
ID:	 DDB_G0283439)	was	 found	 in	D.	 discoideum	using	 this	method	 and	 alignment	 of	 the	D.	
discoideum	 and	H.	 sapiens	 ENT1	 proteins	 (using	 Clustal	W)	 indicated	 that	 the	 two	 proteins	
shared	30.4	%	amino	acid	identity	(Figure	3.3	A),	key	transmembrane	domains	and	a	membrane	
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localisation	motif	(Figure	3.3	B).	Phylogenetic	analysis	(using	MEGA	7	to	produce	a	neighbour-
joining	tree	with	500	Bootstrap	replications)	showed	the	H.	sapiens	and	D.	discoideum	ENT1	to	
be	within	the	same	clade,	suggesting	a	common	evolutionary	origin	 (Figure	3.3	C).	The	ENT1	
protein	 in	D.	 discoideum	was	 therefore	 identified	 as	 an	 adenosine	 signalling-related	 protein	
which	could	be	explored	to	examine	modulation	of	activity	by	CBG.	
In	order	to	examine	potential	effects	of	CBG	on	ENT1	in	D.	discoideum,	a	cell	line	lacking	ENT1	
was	made.	 This	 cell	 line	was	 created	 using	 a	 homologous	 recombination	 plasmid	 containing	
sections	 of	 ENT1	 genomic	 DNA.	 The	 ENT1	 genomic	 DNA	 sections	 were	 synthesised	 by	 PCR	
amplification	of	5’	and	3’	regions	of	the	ENT1	gene,	and	then	each	fragment	was	inserted	into	
opposite	sides	of	a	blasticidin-resistance	gene	in	the	pLPBLP	plasmid	(Figure	3.4	A).	To	ensure	
the	 plasmid	 was	 correctly	 constructed,	 a	 restriction	 digest	 was	 carried	 out	 with	 restriction	
enzymes	cleaving	at	the	5’	and	3’	ends	of	each	insert	and	across	the	whole	knockout	cassette	
(Figure	3.4	B).	The	plasmid	was	then	transfected	into	wild	type	(AX3)	D.	discoideum	cells	and	
PCR	screening	was	carried	out	to	ensure	homologous	recombination	had	occurred	at	the	ENT1	
genomic	 location	 (Figure	 3.5	 A	 and	 B).	 Cells	 found	 to	 have	 undergone	 homologous	
recombination	were	isolated	and	then	reverse	transcriptase	(RT)-PCR	was	carried	out	to	confirm	
Figure	 3.2:	 CBG	 does	 not	 affect	 development	 of	 D.	 discoideum.	 Wild	 type	 D.	 discoideum	 cells,	
developed	for	24	hours	under	starvation	conditions.	A:	 In	the	absence	of	CBG	(solvent	only),	fruiting	
bodies	formed,	viewed	from	the	side	comprised	of	a	stalk	and	a	rounded	spore	head	at	the	top	of	stalks	
(scale	bar:	250	μm	for	side	view)	and	viewed	from	top	the	field	of	view	contains	numerous	examples	of	
fruiting	 bodies	 (scale	 bar:	 1	mm	 for	 top	 view).	B,	 C,	 D:	 In	 the	 presence	 of	 CBG	 (0.5,	 4	 or	 20	 μM),	
development	 of	 the	 fruiting	 was	 unaffected.	 D.	 discoideum	 cells,	 developed	 for	 24	 hours	 under	
starvation	conditions	formed	fruiting	bodies,	viewed	from	the	side	comprised	of	a	stalk	and	a	rounded	
spore	head	at	the	top	of	stalks	and	viewed	from	the	top	a	field	of	mature	fruiting	bodies	viewed.	
Control
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μM)
CBG	(4	
μM)
CBG	(0.5	μM)
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that	ENT1	gene	expression	was	ablated	and	expression	was	lost	(Figure	3.5	C).	Therefore,	a	D.	
discoideum	cell	line	lacking	ENT1	expression	(ENT1-)	had	been	successfully	created	and	could	be	
examined	to	determine	the	effect	of	CBG	treatment	on	ENT1	activity.		
Figure	3.3:	Similarity	between	D.	discoideum	and	H.	sapiens	ENT1	proteins.	A:	D.	discoideum	(Q54R17)	and	H.	
sapiens	(Q99808)	ENT1	protein	sequence	alignment	was	carried	out	on	Clustal	Omega.	The	two	proteins	share	a	
sequence	identity	of	30.4	%.	Asterisks	identical,	colons	highly	similar	and	full	stops	are	similar.	B:	Both	the	human	
and	D.	discoideum	ENT1	proteins	share	the	plasma	membrane	localisation	PWN	motif	(green)	and	transmembrane	
domains	(orange).	C:	Phylogenetic	analysis	of	ENT1	proteins	suggests	that	the	D.	discoideum	protein	(blue	arrow)	
is	located	within	the	same	clade	as	the	Human	protein	(red	arrow),	suggesting	a	common	evolutionary	origin.	The	
D.	discoideum	ENT1	protein	appears	to	be	more	closely	related	to	H.	sapiens	protein	than	either	protein	is	to	plant	
or	yeast	orthologues. 
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In	order	to	investigate	the	role	of	ENT1	as	a	molecular	mechanism	of	CBG,	an	attempt	was	made	
to	over-express	ENT1.	In	these	experiments,	the	coding	region	of	the	D.	discoideum	ENT1	gene	
was	reverse	transcribed	and	inserted	into	a	C-terminal	RFP	over-expression	plasmid	(pDM324	
(Veltman	 et	 al.,	 2009)).	 To	 ensure	 the	 plasmid	 was	 correctly	 constructed,	 digestion	 with	
restriction	 enzymes	 that	 cleaved	 at	 the	 5’	 and	 3’	 ends	 of	 the	 ENT1	 insert	 was	 carried	 out,	
revealing	that	an	insert	of	the	correct	size	(1293	bp)	for	ENT1	was	present	in	this	plasmid	in	the	
correct	location	(Figure	3.6).	The	whole	gene	was	then	sequenced	on	both	strands	to	ensure	no	
mutations	 were	 introduced	 during	 cloning.	 Thereafter,	 the	 plasmid	 was	 transfected	 into	 D.	
discoideum,	however,	no	RFP	fluorescence	was	visible.	An	ENT1	over-expression	construct	was	
therefore	not	successfully	created.		
	To	 investigate	a	 role	 in	 regulating	 the	 response	of	D.	discoideum	 to	CBG,	ENT1-ablated	cells	
were	examined	for	a	change	in	sensitivity	to	CBG	during	growth.	In	these	experiments,	ENT1-	
Figure	3.4:	Preparing	an	ENT1	knockout	plasmid.	A:	The	ENT1	knockout	plasmid	containing	the	5’	and	
3’	 ENT1	 regions	 flanking	 the	blasticidin-resistance	 gene.	B:	Restriction	digest	analysis	was	used	 to	
confirm	the	presence	of	ENT1	regions	within	the	pLPBLP	ENT1	knockout	plasmid.	Restriction	digest	
with	NcoI	and	KpnI	resulted	in	a	542	bp	fragment	for	the	3’	end	and	restriction	digest	with	SpeI	and	
PstI	resulted	in	a	564	bp	fragment	for	the	5’	end.	A	digest	with	SpeI	and	KpnI	across	the	inserted	region	
confirmed	the	presence	of	the	knockout	construct	(2665	bp).	
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cells	were	grown	in	the	presence	of	 increasing	concentrations	of	CBG	over	168	hours.	Under	
control	conditions	(in	the	presence	of	solvent	only),	ENT1-	D.	discoideum	cell	growth	showed	a	
lag	phase	until	96	hours,	an	exponential	phase	to	144	hours	and	a	stationary	phase	starting	at	
168	hours	(Figure	3.7	A).	Similarly	to	wild	type	cells,	CBG	concentrations	from	1	µM	and	higher	
significantly	inhibited	ENT1-	cell	growth	at	168	hours	(P<0.05,	Mann	Whitney	test).	Data	arising	
from	this	analysis	(rate	of	growth	and	Log	of	concentration)	was	used	to	calculate	an	IC50	of	0.50	
µM,	which	was	significantly	higher	than	the	wild	type	IC50	of	0.22	µM	(P<0.01,	one-way	ANOVA	
with	Bonferroni’s	Multiple	Comparison	Test)	(Figure	3.7	B).	These	data	showed	ENT1	ablation	
reduced	 sensitivity	 to	 CBG	 in	 D.	 discoideum,	 implicating	 regulation	 of	 ENT1	 as	 a	 potential	
molecular	mechanism	of	CBG	in	D.	discoideum.	
To	determine	whether	CBG	blocked	adenosine	transport	through	ENT1,	a	mammalian	cell	line	
was	employed.	Here,	mouse	BV2	microglial	cells	were	maintained	in	control	conditions	(in	the	
presence	of	solvent	only)	or	treated	with	CBG	(at	0.5,	2.5,	4	and	6	µM)	for	24	hours.	Then,	cell	
and	 media	 content	 was	 analysed	 by	 liquid	 chromatography-mass	 spectrometry	 (LC-MS)	
(Jimmerson	et	al.,	2017).	This	analysis	revealed	that	CBG	treatment	of	microglia	did	not	alter	
intracellular	adenosine	levels	significantly	(Figure	3.8	A).	However,	extracellular	adenosine	levels	
significantly	increased	with	CBG	treatment	at	all	concentrations	(Figure	3.8	B)	(P<0.01,	one-way	
ANOVA	with	Dunnett’s	Multiple	Comparison	Test).	 These	data	 indicated	 that	CBG	may	block	
adenosine	transport	into	microglia.	
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Figure	3.5:	Production	of	ENT1	knockout	cell	line	in	D.	discoideum.	A:	A	blasticidin-resistance	gene	
was	inserted	into	the	ENT1	gene	using	homologous	recombination.	PCR	was	used	to	confirm	this,	using	
the	primers	 labelled	on	 the	gene	 (primers	 in	Appendix	9.1).	B	 and	C:	DNA	 from	wild	 type	 (B)	 and	
potential	ENT1	knockout	cells	(C)	was	isolated	and	PCR	amplification	was	used	to	detect	the	presence	
of	the	blasticidin-resistance	gene	inserted	into	the	correct	region	of	ENT1	to	knockout	the	gene.	The	
wild	 type	 cell	 line	 (WT)	 had	 only	 genomic	 control	 (GC)	 bands.	 The	 two	 cell	 lines	 with	 successful	
insertions	of	 the	blasticidin-resistance	gene	 into	 the	 ENT1	 gene	 (KO)	have	 genomic	 control	bands,	
vector	 control	 (VC)	 bands	 and	 knockout	 bands	 (KO).	 The	 unsuccessful	 insertion	 of	 blasticidin-
resistance	 gene	 into	 the	 ENT1	 gene	 (NHI)	 had	 only	 genomic	 control	 and	 vector	 control	 bands.	C:	
Reverse	transcriptase	PCR	of	WT	and	ENT1	KO	strains.	A	PCR	band	of	expected	size	(557	bp)	is	only	
shown	in	cDNA	derived	from	WT	cells	(ENT1	+	RT),	although	cDNA	from	both	WT	and	the	two	mutants	
contained	 control	 (Ig7)	 cDNA.	No	DNA	 contamination	was	present,	 since	 samples	without	 reverse	
transcriptase	(-RT)	did	not	show	amplified	products.		
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Figure	3.7:	Ablation	of	ENT1	in	D.	discoideum	leads	to	resistance	to	CBG	in	growth.	A:	ENT1-	cells	
were	grown	 in	the	presence	of	 increasing	concentrations	of	CBG	in	shaking	 culture	for	one	week.	
Growth	was	calculated	as	a	%	of	each	cell	line	in	control	conditions	(in	the	absence	of	CBG),	n=7.	CBG	
inhibited	growth	in	a	concentration-dependent	manner.	Data	arising	from	comparing	the	growth	rate	
at	 differing	 concentrations	 of	 CBG	was	 used	 to	 create	 a	 secondary	 plot.	 Data	were	 not	 normally	
distributed	(Shapiro-Wilks),	therefore	a	Mann	Whitney	test	was	carried	out	to	test	for	significance	of	
inhibition	by	each	concentration	of	CBG	compared	to	control	at	168	hours,	**	-	p<0.01.	Graphs	show	
mean	±	SEM.	B:	Secondary	plot	analysis	was	used	to	determine	the	IC50,	ENT1-	IC50	=	0.50	μM	(n=7)	
(95%	CI:	0.43	-	0.57	μM).	The	wild	type	(WT)	 IC50	(0.22	μM)	was	significantly	 lower	than	ENT1-	 IC50	
(p<0.01).	 Data	 were	 normally	 distributed	 according	 to	 Shapiro-Wilks.	 A	 one-way	 ANOVA	 with	
Bonferroni’s	Multiple	Comparison	Test	was	carried	out	to	test	significance.		
Figure	 3.6:	 Production	 of	 an	 ENT1-RFP	 over-expressor	 plasmid.	 A:	Map	 of	 planned	 ENT1	 over-
expressor	plasmid.	B:	An	ENT1-RFP	plasmid	was	created	in	pDM324	(7564	bp)	with	an	RFP	tag	at	the	
C-terminal	of	the	protein.	There	were	SpeI	and	BglII	restriction	enzyme	digestion	sites	at	the	5’	and	3’	
ends	of	the	ENT1	over-expressor	insert	(1293	bp),	respectively.	These	were	used	to	digest	the	ENT1	
over-expressor	plasmid	and	confirm	the	presence	of	the	ENT1	insert.	In	addition,	the	enzymes	were	
used	singularly	to	ensure	that	the	insert	was	between	the	two	and	correctly	located.	The	plasmid	was	
then	transfected	into	wild	type	D.	discoideum,	however	this	did	not	result	in	expression	of	ENT1-RFP.		
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3.2.3	Examining	DNA	methylation	modulation	as	a	potential	molecular	mechanism	of	
CBG	
As	loss	of	ENT1,	an	adenosine	transporter,	reduced	the	potency	of	CBG	in	D.	discoideum,	and	
CBG	 was	 found	 to	 elevate	 extracellular	 adenosine	 in	 microglia,	 the	 effects	 of	 CBG	 on	 a	
downstream	process	of	adenosine	 transport	were	examined.	Adenosine	has	previously	been	
found	 to	 regulate	DNA	methylation	 (Williams-Karnesky	et	 al.,	 2013),	 providing	 a	 readout	 for	
adenosine	 transport-related	 effects	 of	 CBG.	 In	 D.	 discoideum,	 there	 is	 one	 DNA	
methyltransferase	 protein,	 DNMA,	 which	 methylates	 cytosine	 residues	 in	 DNA	 (Uniprot	 ID:	
Q54JH6,	DictyBase	 ID:	DDB_G0288047,	based	 in	AX2	wild	 type	cells)	 (Kuhlmann	et	al.,	 2005;	
Katoh	et	al.,	2006).	This	enzyme	is	an	orthologue	of	the	H.	sapiens	DNMT	2	protein,	which	is	less	
active	than	other	DNA	methyltransferases.	Other,	more	active	DNA	methyltransferases	exist	in	
H.	sapiens	in	the	form	of	DNMT	1	and	DNMT	3	(Müller	et	al.,	2013).	The	H.	sapiens	DNMT	2	and	
D.	 discoideum	DNMA	 share	 43.6	%	 identity	 (Clustal	W)	 (Figure	 3.9	 A),	 the	 key	 S-adenosyl-L-
methionine-dependent	 methyltransferase	 domains	 (Figure	 3.9	 B)	 and	 phylogenetic	 analysis	
(using	MEGA	7	to	produce	a	neighbour-joining	tree	with	500	Bootstrap	replications)	showed	the	
two	proteins	to	be	within	the	same	clade,	suggesting	a	common	evolutionary	origin	(Figure	3.9	
C).	D.	discoideum	and	other	species	such	as	Drosophila	melanogaster	and	Schizosaccharomyces	
pombe	only	contain	DNA	methyltransferases	of	the	DNMT	2	family	(Müller	et	al.,	2013).			
To	determine	whether	CBG	affected	DNMA	activity	in	D.	discoideum,	a	cell	line	lacking	DNMA	
activity	was	examined	for	a	change	in	sensitivity	to	CBG	during	growth.	In	these	experiments,	
Figure	3.8:	CBG	treatment	increases	extracellular	adenosine	in	microglia.	Wild	type	microglia	
were	maintained	in	control	conditions	or	treated	with	CBG	at	0.5,	2.5,	4	or	6	µM	for	24	hours.	
Then	 cell	 and	 media	 content	 were	 analysed	 for	 adenosine	 levels	 by	 LC-MS.	 Data	 normally	
distributed	by	Shapiro-Wilks,	statistical	significance	analysed	by	Dunnett’s	multiple	comparison	
ANOVA,	**	is	p<0.01.	A:	CBG	did	not	significantly	alter	intracellular	adenosine	in	microglia,	n=5.	
B:	CBG	significantly	elevated	extracellular	adenosine	levels	of	microglia,	n=6.	
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wild	type	cells	(AX2)	and	cells	lacking	DNMA	(DNMA-)	were	grown	in	the	presence	of	increasing	
concentrations	of	CBG	over	168	hours.	Under	control	conditions	(in	the	absence	of	CBG),	wild	
type	 (AX2)	 and	 DNMA-	 D.	 discoideum	 cell	 growth	 showed	 a	 lag	 phase	 until	 96	 hours,	 an	
exponential	phase	to	144	hours	and	a	stationary	phase	starting	at	168	hours	(Figure	3.10	A	and	
B).	In	wild	type	cells	(AX2),	CBG	concentrations	from	0.5	µM	and	higher	significantly	inhibited	
cell	growth	at	168	hours	(P<0.01,	Mann	Whitney	test).	In	DNMA-	cells,	CBG	concentrations	from	
2	µM	and	higher	significantly	inhibited	cell	growth	at	168	hours	(P<0.05,	P<0.01	for	3	and	4	µM	
CBG,	 Mann	 Whitney	 test).	 Data	 arising	 from	 this	 analysis	 (rate	 of	 growth	 and	 Log	 of	
concentration)	was	used	to	calculate	a	wild	type	(AX2)	IC50	of	0.30	µM	and	an	IC50	for	DNMA-	of	
1.16	µM.	The	IC50	for	DNMA-	was	significantly	higher	than	the	wild	type	IC50	(P<0.01,	one-way	
ANOVA	with	Bonferroni’s	Multiple	Comparison	Test)	(Figure	3.10	C).	These	data	showed	DNMA	
ablation	created	a	 reduction	 in	 sensitivity	 to	CBG	 in	D.	discoideum,	 implicating	 the	 signalling	
pathway	 involved	 in	 DNA	 methylation	 and	 adenosine	 transport	 as	 a	 potential	 molecular	
mechanism	for	CBG	in	D.	discoideum.	
In	order	to	 identify	whether	CBG	modulated	DNA	methylation	in	D.	discoideum,	 the	effect	of	
CBG	 treatment	 was	 examined	 in	 this	 model.	 To	 carry	 this	 out,	 wild	 type	 cells	 (AX3)	 were	
maintained	in	control	conditions	(in	the	presence	of	solvent	only)	or	in	the	presence	of	0.25	µM	
CBG	for	24	hours.	Genomic	DNA	was	extracted	and	total	DNA	methylation	was	quantified	by	
colorimetry-based	 immunochemical	 binding	 of	 methylated	 DNA	 (Antonini	 et	 al.,	 2019).	
Treatment	with	CBG	led	to	a	1.6-fold	increase	in	DNA	methylation	in	D.	discoideum	(Figure	3.11	
A)	(P<0.05,	One-Way	ANOVA	with	Dunnett’s	Post-Hoc).	To	determine	if	this	effect	was	related	
to	 adenosine	 signalling,	 wild	 type	 cells	 were	 treated	 with	 an	 ENT	 family	 protein	 inhibitor,	
nitrobenzylthioinosine	 (NBTI).	 The	 NBTI	 inhibitor	 has	 shown	 nanomolar	 activity	 against	
mammalian	ENTs,	with	a	higher	specificity	for	ENT1	than	other	ENTs	(Boswell-Casteel	and	Hays,	
2017).	Therefore,	wild	type	cells	were	treated	with	5	nM	NBTI	for	24	hours	and	examined	for	
total	DNA	methylation.	Treatment	with	NBTI	in	this	experiment	led	to	a	1.8-fold	increase	in	DNA	
methylation	 in	D.	discoideum	 (Figure	3.11	A)	 (P<0.01,	One-Way	ANOVA	with	Dunnett’s	Post-
Hoc).	 To	 determine	 if	 these	 effects	 were	 dependent	 on	 ENT1	 transport	 of	 adenosine,	 the	
experiment	was	repeated	in	cells	lacking	the	ENT1	protein.	To	carry	this	out,	ENT1-	cells	were	
maintained	in	control	conditions	(in	the	presence	of	solvent	only)	or	treated	with	0.25	µM	CBG	
or	 5	nM	NBTI	 for	 24	hours.	 Cells	 lacking	 ENT1	had	 an	elevated	basal	 level	 (1.5-fold)	 of	DNA	
methylation	compared	to	wild	type	cells	(P<0.05,	one-way	ANOVA	with	Bonferroni’s	Multiple	
Comparison	Test)	 (Figure	3.11	B).	However,	 treatment	with	CBG	or	NBTI	did	not	significantly	
alter	 DNA	methylation	 in	 cells	 lacking	 ENT1	 (Figure	 3.11	 B).	 These	 data	 suggested	 that	 CBG	
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regulated	DNA	methylation	in	D.	discoideum	and	that	this	occurred	through	an	adenosine-ENT1	
related	mechanism.		
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Figure	 3.9:	 Similarity	 between	 D.	 discoideum	 and	 H.	 sapiens	 DNA	 methyltransferase	 proteins.	 A:	 D.	
discoideum	(Q54JH6)	and	H.	sapiens	(Q14717)	DNMT	2	family	protein	sequence	alignment	was	carried	out	
on	Clustal	Omega.	The	two	proteins	were	found	to	share	a	sequence	identity	of	43.6	%.	Asterisks	identical,	
colons	are	highly	similar	and	full	stops	are	similar.	B:	Both	the	human	and	Dictyostelium	proteins	were	found	
to	 share	 the	 S-adenosyl-L-methionine-dependent	 methyltransferase	 domains	 (orange).	 C:	 Phylogenetic	
analysis	of	DNA	methyltransferase	proteins	suggested	that	the	D.	discoideum	DNMA	protein	(blue	arrow)	was	
located	within	the	same	clade	as	the	Human	DNMT2	protein	(red	arrow),	suggesting	a	common	evolutionary	
origin.	The	D.	discoideum	DNMA	protein	appeared	to	be	more	closely	related	to	H.	sapiens	DNMT	2	protein	
than	either	protein	was	to	other	DNA	transferase	(DNMT	1	and	3)	family	proteins. 
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Figure	3.10:	Ablation	of	DNMA	in	D.	discoideum	leads	to	resistance	to	CBG	in	growth.	A	and	B:	Wild	
type	(AX2)	(A)	and	DNMA-	cells	(B)	were	grown	in	the	presence	of	increasing	concentrations	of	CBG	in	
shaking	culture	for	one	week.	Growth	was	calculated	as	a	%	of	each	cell	line	in	control	conditions	(in	
the	absence	of	CBG),	n=7	and	n=9.	CBG	inhibited	growth	in	a	concentration-dependent	manner.	Data	
arising	 from	 comparing	 the	 growth	 rate	 at	 differing	 concentrations	 of	 CBG	 was	 used	 to	 create	 a	
secondary	plot.	Data	were	not	normally	distributed	(Shapiro-sWilks),	therefore	a	Mann	Whitney	test	
was	carried	out	to	test	for	significance	of	inhibition	by	each	concentration	of	CBG	compared	to	control	
at	168	hours,	*	-	p<0.05,	**	-	p<0.01.	Graphs	show	mean	±	SEM.	C:	Secondary	plot	analysis	was	used	
to	determine	the	IC50,	wild	type	(AX2)	IC50	=	0.30	μM	(95%	CI:	0.21	-	0.41	μM)	and	DNMA-	IC50	=	1.16	μM	
(95%	CI:	0.93	-	1.44	μM).	The	wild	type	(WT)	is	significantly	lower	than	DNMA-	IC50.	Data	were	normally	
distributed	according	to	Shapiro-Wilks.	A	one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test	
was	carried	out	to	test	significance.		
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3.3	Discussion	
In	this	chapter,	the	effects	of	CBG	on	adenosine	transport	and	related	downstream	signalling	
pathways	 were	 examined.	 Using	 this	 approach,	 CBG	 was	 found	 to	 inhibit	 the	 growth	 of	
D.	discoideum	in	a	concentration-dependent	manner,	while	not	affecting	development.	These	
effects	 suggested	 that	 CBG	 had	 specific	 molecular	 mechanisms	 in	D.	 discoideum	 and	 not	 a	
general	 toxic	 effect.	 Then,	 based	 on	 previous	 literature	 identifying	 adenosine	 transport	
regulation	as	a	molecular	mechanism	of	cannabinoids	(Carrier	et	al.,	2006;	Liou	et	al.,	2008),	the	
relationship	between	CBG	and	ENT1	(an	adenosine	transporter)	was	analysed.	A	cell	line	lacking	
ENT1	was	significantly	 resistant	 to	CBG	during	growth.	Further	experiments	 in	microglia	cells	
revealed	 that	CBG	appeared	 to	block	 the	uptake	of	adenosine.	Together	 these	data	 strongly	
implied	 that	 CBG	may	 inhibit	 adenosine	 uptake	 through	 ENT1.	 To	 investigate	 whether	 CBG	
blocked	adenosine	uptake	in	D.	discoideum	the	relationship	between	CBG	and	a	downstream	
signalling	 pathway	 of	 adenosine	 transport,	 DNA	methylation,	was	 analysed.	Here,	 a	 cell	 line	
lacking	DNA	methyltransferase	was	also	found	to	be	resistant	to	CBG	during	growth.	To	confirm	
the	 relation	 between	 the	 DNA	 methylation	 and	 CBG,	 DNA	 methylation	 quantification	 was	
Figure	3.11:	CBG	treatment	and	ENT1	ablation	increase	DNA	methylation	in	D.	discoideum.	A	and	B:	
Wild	type	and	ENT1-	cells	were	maintained	in	control	conditions	(in	the	absence	of	CBG	or	NBTI	(-))	or	
treated	with	0.25	μM	CBG	or	5	nM	NBTI.	Data	were	normally	distributed	(Shapiro-Wilks),	therefore	a	
One-Way	ANOVA	with	Tukey’s	Multiple	comparison	test	was	carried	out	to	test	for	significance,	*	-	
p<0.05,	**	-	p<0.01.	Graphs	show	mean	±	SEM.	A:	CBG	and	NBTI	(ENT	inhibitor)	both	elevated	DNA	
methylation	 in	 wild	 type	 cells	 (n=8).	 B:	 ENT1-	 had	 an	 elevated	 basal	 level	 of	 DNA	 methylation	
compared	to	wild	type	cells.	In	addition,	treatment	with	CBG	or	NBTI	did	not	alter	DNA	methylation	
in	ENT1-	cells	(n=8).		
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carried	out	and	DNA	methylation	was	found	to	increase	following	CBG	treatment	in	wild	type	
cells.	This	implied	that	CBG	was	blocking	adenosine	uptake	in	these	cells.	However,	CBG	did	not	
affect	 DNA	methylation	 in	 cells	 lacking	 the	 ENT1.	 This	 suggested	 that	 in	D.	 discoideum	CBG	
upregulated	DNA	methylation	through	inhibition	of	adenosine	uptake.		
In	this	study,	CBG	inhibited	growth	of	D.	discoideum	cells	with	an	IC50	of	0.22	µM.	In	the	same	
model	system,	a	previous	study	found	that	CBD	inhibited	growth	with	an	IC50	of	1.9	µM	(Perry	
et	al.,	2020).	Other	cannabinoids,	cannabidiolic	acid	(CBDA)	and	cannabidivarin	(CBDV),	showed	
similar	potency	in	this	model	with	IC50	values	of	0.89	and	2.16	µM	respectively	(Perry,	2019).	
Therefore,	data	provided	here	suggest	that	CBG	is	between	4	and	10	times	more	potent	at	D.	
discoideum	growth	inhibition	than	CBD,	CBDV	and	CBDA.	Comparing	these	potencies	to	other	
systems,	such	as	human	keratinocyte	cells,	where	CBG	inhibited	cell	growth	with	an	IC50	of	2.3	
µM,	while	CBD,	THC,	and	cannabinol	(CBN)	inhibited	growth	of	these	cells	with	IC50s	of	2.0,	2.9	
and	 2.1	 µM	 respectively	 (Wilkinson	 and	Williamson,	 2007).	 Previous	 studies	 imply	 a	 similar	
potency	of	CBG	and	other	cannabinoids	 in	mammalian	cells.	However,	data	 in	D.	discoideum	
indicates	that	CBG	inhibits	growth	at	a	slightly	higher	potency	than	other	cannabinoids.		
In	 this	 chapter,	 CBG	 was	 found	 to	 inhibit	 the	 growth	 of	 D.	 discoideum	 cells	 at	 a	 similar	
concentration	 to	 those	 used	 previously	 in	 vivo	 animal	 model	 studies.	 In	 this	 chapter,	 CBG	
concentrations	ranging	from	0.1	to	4	µM	were	found	to	inhibit	the	growth	of	D.	discoideum	cells.	
In	rats,	100	mg/kg	and	120	mg/kg	CBD	administered	in	an	intraperitoneal	injection	1	hour	before	
experimentation	resulted	in	a	brain	concentration	of	CBD	of	9.8	µM	after	1	hour	and	21.6	µM	
after	2	hours,	which	attenuated	epileptiform	activity	 (Hill	et	al.,	2014).	 In	another	study,	120	
mg/kg	oral	 treatment	with	CBG	also	resulted	 in	 therapeutically	 relevant	effects,	as	CBG	here	
doubled	food	intake	(Brierley	et	al.,	2016).	In	a	human	study,	800	mg	(an	average	of	around	120	
mg/kg)	of	CBD	administered	orally,	resulted	in	peak	plasma	concentrations	of	CBD	(at	one	to	
two	hours	post-treatment)	ranging	between	0.006	and	0.866	µM	(with	an	average	of	0.245	µM)	
(Haney	 et	 al.,	 2016).	 Lower	 concentrations	 of	 cannabinoids	 have	 also	 been	 shown	 to	 be	
therapeutically	 effective.	 For	 example,	 in	 mice	 10	 mg/kg	 CBD	 administered	 daily	 in	 an	
intraperitoneal	injection	for	14	days	treated	MS	symptoms	(Giacoppo	et	al.,	2017).	Likewise,	in	
human	trials,	daily	10-20	mg/kg	treatment	with	CBD	administered	orally	for	14	weeks	reduced	
drop-seizure	frequency	(Devinsky	et	al.,	2018(a)).	Therefore,	while	CBG	use	in	D.	discoideum	is	
not	therapeutically	relevant,	concentrations	of	CBG	used	in	this	study	appear	to	be	consistent	
with	previous	in	vitro	and	in	vivo	cannabinoid	studies.	
To	examine	whether	a	molecular	mechanism	of	CBG	involved	the	adenosine	transporter,	ENT1,	
in	D.	discoideum,	a	cell	line	lacking	this	protein	was	tested	for	resistance	to	CBG	during	growth.	
Ablation	 of	 ENT1	 resulted	 in	 increased	 resistance	 to	 CBG	 during	 growth	 in	 D.	 discoideum,	
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indicating	that	a	molecular	mechanism	of	CBG	may	involve	ENT1	or	proteins	within	an	ENT1-
related	signalling	pathway.	The	ablation	of	ENT1	may	be	partially	compensated	for	by	the	only	
other	known	adenosine	transporters	in	D.	discoideum	(Dictybase	ID:	DDB_G0281515	(ENT2)	and	
DDB_G0281513	 (ENT3)).	 The	 two	 additional	 adenosine	 transport	 proteins	 are	 not	 normally	
expressed	during	the	unicellular	growth	phase	of	the	D.	discoideum	lifecycle,	while	ENT1	is	(Rot	
et	al.,	2009).	As	previous	studies	have	indicated	ENT1	is	a	target	of	CBD	in	rat	microglial	cells	
(Liou	et	al.,	2008)	and	in	this	chapter,	CBG	was	found	to	inhibit	growth	of	D.	discoideum,	only	
ENT1	was	explored	as	a	part	of	potential	molecular	mechanism	of	CBG.	However,	D.	discoideum	
cells	lacking	ENT1	may	compensate	by	altering	the	time	of	expression	of	ENT2	or	ENT3.	Future	
qPCR	analyses	of	this	would	provide	data	on	this	proposal	and	LC-MS	could	be	used	to	analyse	
a	change	in	adenosine	levels	after	ENT1-ablation	and	during	CBG	treatment	(Jimmerson	et	al.,	
2017).	Here,	CBG	is	found	to	regulate	growth	of	D.	discoideum	partially	through	the	adenosine	
transporter,	ENT1,	 future	experiments	may	determine	whether	 this	 is	as	a	 result	of	blocking	
adenosine	transport	or	through	another	mechanism.		
In	addition	to	ENT1	ablation,	to	further	understand	the	relationship	between	CBG	and	adenosine	
transport	an	unsuccessful	attempt	at	creating	a	cell	line	over-expressing	ENT1	and	recapitulating	
the	ablated	protein	was	made.	The	inability	to	over-express	ENT1	could	be	due	to	problems	with	
protein	 dysfunction	 when	 GFP-tagged	 (Wiedenmann	 et	 al.,	 2009),	 in	 which	 case	 a	 smaller	
fluorescent	tag	may	increase	the	likelihood	of	successful	over-expression	(Plamont	et	al.,	2016).	
Alternatively,	a	small	protein	tag	such	as	a	FLAG	tag	could	be	utilised	in	the	over-expression	of	
ENT1	in	D.	discoideum	(Veltman	et	al.,	2009;	Zhao	et	al.,	2013).	Future	research	should	address	
this	problem	and	recapitulate	the	wild	type	sensitivity	to	CBG	in	D.	discoideum,	by	using	an	ENT1	
over-expressor	in	ENT1	ablated	cells.	
In	this	chapter,	ablation	of	the	adenosine	transporter,	ENT1,	 is	 found	to	reduce	sensitivity	to	
CBG	during	growth.	Furthermore,	treatment	of	microglia	cells	with	CBG	resulted	in	an	elevated	
extracellular	 level	 of	 adenosine.	 In	 addition,	 DNA	 methylation	 which	 is	 inversely	 related	 to	
adenosine	levels	(Kredich	and	Martin,	1977;	Boison	et	al.,	2002),	is	increased	by	CBG	treatment,	
and	 ENT1	 ablation	 or	 inhibition	 in	 D.	 discoideum.	 Together,	 these	 data	 indicate	 that	 CBG	
treatment	may	inhibit	adenosine	uptake	in	both	D.	discoideum	and	microglia	cells.	This	would	
be	consistent	with	previous	studies	finding	that	a	cannabinoid	like	CBG,	CBD,	inhibits	adenosine	
uptake	via	ENT1	(Carrier	et	al.,	2006).	ENT	proteins	are	adenosine	transporters	that	allow	passive	
flow	of	adenosine	across	the	cell	membrane	along	its	gradient	(Pastor-Anglada	and	Pérez-Torras,	
2018).	In	nucleus	accumbens	of	mice	lacking	ENT1,	there	is	a	decrease	in	extracellular	adenosine	
levels,	 implying	a	higher	basal	 intracellular	concentration	of	adenosine	 in	this	brain	region	of	
mice	(Nam	et	al.,	2011).	Conversely,	in	the	striatum	of	a	mouse	model	of	Huntington’s	disease,	
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ENT1	 was	 found	 to	 be	 over-expressed,	 and	 treatment	 with	 ENT1	 inhibitors	 increased	
extracellular	adenosine,	implying	that	in	this	disease	model	intracellular	adenosine	is	lower	than	
extracellular	(Kao	et	al.,	2017).	Previous	studies,	along	with	data	found	in	this	chapter,	indicate	
that	 ENT1	 is	 an	 adenosine	 transporter	 which	 is	 more	 likely	 to	 increase	 adenosine	 uptake.	
Furthermore,	 this	 chapter	 indicates	 that	CBG	may	be	an	 inhibitor	of	ENT1-related	adenosine	
uptake,	 although	 future	experiments	analysing	adenosine	 in	D.	discoideum	 lacking	ENT1	and	
treated	with	CBG	are	needed	to	confirm	this.	
Adenosine	regulation	of	DNA	methylation	is	implicated	as	a	part	of	a	molecular	mechanism	of	
CBG	by	the	data	found	in	this	chapter.	Here,	CBG	was	found	to	increase	DNA	methylation	in	D.	
discoideum	mimicking	the	effect	of	the	adenosine	transporter	inhibitor	NBTI.	In	addition,	cells	
lacking	 the	 adenosine	 transporter	 protein	 ENT1	 are	 resistant	 to	 the	 effects	 of	 CBG	 on	 DNA	
methylation	and	have	a	constitutively	elevated	level	of	DNA	methylation.	The	dysregulation	of	
DNA	methylation	has	been	implicated	in	epileptogenesis,	which	is	the	progression	of	epilepsy,	
and	 therefore	 could	 be	 an	 important	 molecular	 mechanism	 for	 the	 treatment	 of	 epilepsy	
(Williams-Karnesky	et	al.,	2013).	Adenosine	acts	as	an	inhibitor	of	DNA	methylation,	and	through	
elevated	adenosine	and	reduced	DNA	methylation,	epileptogenesis	in	rats	is	inhibited	(Williams-
Karnesky	et	al.,	2013).	A	pathological	over-expression	of	ADK	results	in	DNA	hypermethylation,	
due	to	a	 lower	 level	of	adenosine	(Williams-Karnesky	et	al.,	2013).	The	relationship	between	
adenosine	and	DNA	methylation	is	a	result	of	both	being	components	of	the	transmethylation	
pathway	(Kredich	and	Martin,	1977).	DNA	methylation	relies	on	methyl	group	donation	from	S-
adenosylmethionine	facilitated	by	DNA	methyltransferases,	this	results	in	the	production	of	S-
adenosylhomocysteine	 which	 is	 converted	 into	 adenosine	 and	 homocysteine.	 The	 reaction	
occurs	 at	 equilibrium	 and	 therefore	 will	 only	 continue	 if	 adenosine	 and	 homocysteine	 are	
continually	 removed.	 Therefore,	 an	 increase	 in	 adenosine	 blocks	 the	 pathway	 and	 results	 in	
decreased	 DNA	methylation	 and	 conversely	 a	 decrease	 in	 adenosine	 allows	 the	 pathway	 to	
continue	and	increases	DNA	methylation	(Kredich	and	Martin,	1977;	Boison	et	al.,	2002).	In	this	
study	we	find	CBG	treatment	and	inhibition	or	removal	of	adenosine	transporters	results	in	an	
increase	 in	DNA	methylation	 in	D.	discoideum.	This	could	be	due	 to	a	decrease	 in	adenosine	
uptake	caused	by	CBG	or	adenosine	transporter	inhibition,	thus	resulting	in	the	continuation	of	
the	 transmethylation	 pathway	 and	 hypermethylation	 of	 DNA.	 As	 CBG	 appears	 to	 modulate	
adenosine	 signalling	 and	 DNA	 methylation	 in	 this	 model	 potential	 therapeutic	 role	 for	 the	
compound	in	epilepsy	treatment	could	be	further	explored	in	in	vivo	models.		
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Chapter	4:	Discovery	and	exploration	of	potential	regulators	of	
the	molecular	mechanism	of	CBG	in	D.	discoideum	
4.1	Introduction	
In	 addition	 to	 adenosine	 signalling	 explored	 in	 the	 previous	 chapter,	 there	 are	 many	 other	
molecular	 mechanisms	 suggested	 for	 cannabinoids.	 These	 proposed	 molecular	 mechanisms	
include	TRPV1	(Borrelli	et	al.,	2014),	GPR55	(Devinsky	et	al.,	2014),	and	the	one-carbon	cycle	and	
methionine	signalling	(Perry	et	al.,	2020).	However,	little	research	has	been	carried	out	into	CBG	
molecular	 mechanism	 discovery.	 Therefore,	 here	 an	 unbiased	 approach	 is	 undertaken	 to	
discover	novel	molecular	mechanisms	of	CBG.	
The	model	organism	D.	discoideum	was	employed	to	identify	molecular	pathways	affected	by	
CBG	treatment.	This	model	organism	has	a	fully	sequenced	genome	with	a	range	of	orthologous	
proteins	present	in	the	proteome,	and	mutant	libraries	which	have	previously	been	employed	
to	identify	potential	molecular	mechanisms	of	compounds	(Kuspa	and	Loomis,	1992;	Williams,	
2010).	 Screening	 of	 mutant	 libraries	 in	D.	 discoideum	 has	 been	 used	 to	 discover	 molecular	
mechanisms	for	CBD	(Perry	et	al.,	2020),	curcumin	and	its	derivatives	(Cocorocchio	et	al.,	2018),	
valproic	acid	(Chang	et	al.,	2015),	naringenin	(Waheed	et	al.,	2014),	and	bitter	tastants	(Robery	
et	al.,	2013).	In	some	cases,	molecular	mechanisms	of	compounds	identified	in	D.	discoideum	
using	 these	 methods	 have	 been	 validated	 in	 mammalian	 models	 (Perry	 et	 al.,	 2020)	 and	
provided	 an	 underlying	 molecular	 mechanism	 for	 epilepsy	 treatment	 (Chang	 et	 al.,	 2015;	
Augustin	et	al.,	2018).	The	depth	and	breadth	of	research	using	D.	discoideum	pharmacogenetics	
suggest	that	it	could	be	a	suitable	model	for	discovering	novel	molecular	mechanisms	of	CBG.		
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4.2	Results	
4.2.1	Screening	of	D.	discoideum	mutant	library	for	CBG-resistant	mutants	
To	 identify	novel	molecular	mechanisms	of	CBG	 in	D.	discoideum,	a	mutant	 library	screening	
approach	was	carried	out.	This	method	relied	on	the	growth	inhibitory	effect	of	CBG	described	
in	the	previous	chapter	and	aimed	to	identify	mutant	cells	that	were	resistant	to	the	effects	of	
CBG	during	growth.	In	these	experiments,	wild	type	and	D.	discoideum	mutant	library	cells	from	
a	library	containing	11,000	mutants	were	treated	with	CBG	at	a	range	of	concentrations	in	excess	
of	that	necessary	to	block	growth	(8	µM,	10	µM,	12	µM)	for	10	days	and	screened	for	resistance	
(Figure	4.1	A).	Under	control	conditions	(in	the	presence	of	solvent	only),	wild	type	cells	grew	to	
confluency	(Figure	4.1	B).	Wild	type	cells	in	the	presence	of	CBG	did	not	grow.	In	contrast,	D.	
discoideum	mutant	library	cells	resistant	to	CBG	grew	to	confluency	in	the	presence	or	absence	
of	CBG	(Figure	4.1	B).	In	three	screens	of	mutant	libraries	treated	with	8	µM	CBG,	12	mutants	
were	isolated	in	each	of	the	first	two	screens	and	one	mutant	in	the	last	screen.	In	three	screens	
of	mutants	treated	with	10	µM	CBG,	nine	mutants	were	isolated	in	each	of	the	first	two	screens	
and	seven	mutants	in	the	last	screen.	In	the	screen	of	mutants	treated	with	12	µM,	CBG	nine	
mutants	were	isolated.	From	this	approach,	59	isogenic	CBG-resistant	mutants	were	isolated.		
	
Following	 the	 isolation	 of	 CBG-resistant	mutants,	 each	mutant	was	 analysed	 to	 identify	 the	
molecular	 mechanisms	 controlling	 CBG	 sensitivity.	 In	 each	 mutant,	 a	 restriction	 enzyme-
Figure	 4.1:	 An	 unbiased	D.	 discoideum	 screen	 was	 employed	 to	 find	 CBG-resistant	 mutants.	 A:	
Schematic	of	a	mutant	 library	screen	to	 identify	mutants	resistant	to	the	growth	 inhibition	effect	of	
CBG,	where	wild	type	cell	growth	 is	 inhibited	by	CBG.	However,	mutants	from	an	 insertional	 library	
continue	to	grow	in	the	presence	of	CBG,	and	these	can	be	 isolated	and	the	protein	controlling	CBG	
sensitivity	identified.	B:	Wild	type	and	mutant	library	cells	were	either	maintained	in	control	conditions	
or	treated	with	CBG	(10	µM),	and	mutants	resistant	to	CBG	were	able	to	grow.	Scale	bar	=	0.25	mm. 
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mediated	mutational	 insert	 (REMI)	disrupted	expression	of	a	gene,	 leading	to	a	disruption	of	
protein	expression	controlling	CBG	sensitivity.	In	order	to	identify	this	protein,	the	location	of	
the	 mutational	 insert	 in	 the	 D.	 discoideum	 genome	 for	 each	 CBG-resistant	 mutant	 was	
determined.	Here,	iPCR	was	carried	out	and	insert	location	sequences	were	obtained	for	35	of	
the	CBG-resistant	D.	discoideum	mutants	(Figure	4.2).	Of	these	35	sequences,	23	were	too	short	
to	match	to	a	specific	region	of	the	genome,	giving	multiple	potential	locations	for	the	insert	and	
were	therefore	discarded.	However,	12	sequences	of	sufficient	length	were	found	to	match	to	
an	area	of	the	D.	discoideum	genome,	and	BLAST	(Basic	Local	Alignment	Search	Tool)	was	used	
to	 determine	 the	 location	 of	 each	 mutagenic	 insert.	 From	 the	 12	 sequences	 that	 matched	
locations	in	the	D.	discoideum	genome,	six	unique	loci	were	found	(Figure	4.3	and	Table	4.1).	
One	cell	line	contained	an	insert	in	the	5’	region	of	the	open	reading	frame	(ORF)	of	the	gene	
DDB_G0269494	encoding	a	protein	of	no	known	function	(http://dictybase.org/).	Another	cell	
line	 contained	 an	 insert	 in	 the	 5’	 region	 of	 the	ORF	 in	 the	DDB_G0292968	 gene	 encoding	 a	
putative	licheninase	protein.	Two	cell	lines	contained	inserts	80	base	pairs	(bp)	downstream	of	
the	ORF	of	the	DDB_G0295181	gene	encoding	a	tRNA-Tyr-GUA-6.	One	cell	contained	an	insert	
in	 the	5’	 region	of	 the	ORF	of	 the	DDB_G0272242	gene,	encoding	 the	 calcium	upregulated	 I	
(CupI)	 protein.	 Three	 cell	 lines	 contained	 inserts	 in	 the	 3’	 region	 of	 the	 ORF	 of	 the	
DDB_G0279435	 gene	 encoding	 a	 Regulator	 of	 chromosome	 condensation	 1	 (RCC1)	 domain-
containing	protein.	Finally,	four	cell	 lines	contained	inserts	880	bp	downstream	of	the	ORF	of	
the	DDB_G0281737	gene	encoding	the	inositol	polyphosphate	multikinase	(IPMK)	protein.	From	
this	approach,	six	proteins	that	were	potentially	involved	in	the	molecular	mechanisms	of	CBG	
in	D.	discoideum	had	been	discovered.		
Figure	4.2:	 Identification	of	 insertion	 sites	 in	CBG-resistant	mutants.	The	 iPCR	of	6	 isogenic	CBG-
resistant	mutants	and	a	wild	 type	negative	 control,	 separated	on	an	electrophoresis	 gel.	 The	PCR	
fragment	is	sequenced	as	above	to	determine	the	 location	of	the	insert,	which	 is	1.5	kb	(Faix	et	al.,	
2004),	in	each	mutant.	 
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The	proteins	that	were	potentially	involved	in	the	molecular	mechanisms	of	CBG	identified	in	
the	D.	discoideum	mutant	screen	were	examined	to	identify	possible	H.	sapiens	orthologues	and	
determine	 the	 cellular	 roles	 of	 each	 protein.	 In	 order	 to	 carry	 this	 out,	 each	D.	 discoideum	
protein	 was	 analysed	 using	 BLAST	 for	 H.	 sapiens	 orthologues.	 The	 protein	 product	 of	
DDB_G0269494	was	uncharacterised	in	D.	discoideum	with	no	known	function	and	had	no	H.	
sapiens	 orthologue,	 therefore	 was	 unlikely	 to	 provide	 a	 therapeutically	 relevant	 molecular	
mechanism	of	CBG	in	H.	sapiens.	The	putative	licheninase,	which	may	hydrolyse	the	β-(1,4)-D-
glucosidic	linkages	in	mixed-linkage	glucans	containing	both	(1,3)-	and	(1,4)-bonds	(Borriss	et	al.,	
1980),	did	not	have	a	H.	sapiens	orthologue,	therefore	was	unlikely	to	provide	a	therapeutically	
relevant	 molecular	 mechanism	 of	 CBG	 in	 H.	 sapiens.	 The	 tRNA	 (tRNA-Tyr-GUA-6),	 which	
transfers	a	tyrosine	residue	to	a	growing	polypeptide	chain	during	protein	synthesis	(Izuchi	et	
al.,	1990),	had	no	H.	sapiens	orthologues,	therefore	was	also	unlikely	to	provide	a	therapeutically	
relevant	molecular	mechanism	of	CBG	in	H.	sapiens.	The	protein	CupI,	may	have	a	role	in	calcium	
signalling	 in	D.	 discoideum	 (Farinholt	 et	 al.,	 2019),	 but	 also	 had	 no	H.	 sapiens	 orthologues,	
therefore	was	unlikely	to	provide	a	therapeutically	relevant	molecular	mechanism	of	CBG	in	H.	
sapiens.	From	this	approach,	no	H.	sapiens	orthologue	had	been	found	for	four	of	the	proteins	
potentially	 involved	 in	the	molecular	mechanism	of	CBG	in	D.	discoideum	and	therefore	they	
were	unlikely	to	represent	a	possible	therapeutic	molecular	mechanism	and	were	not	further	
explored.		
Table	 4.1:	 Insertion	 sites	 discovered	 in	 CBG-resistant	D.	 discoideum	REMI	mutants.	The	 gene	
identity	was	found	on	Dictybase.org,	as	was	the	gene	code.	The	number	of	times	 independently	
isolated	is	a	total	of	how	many	times	a	different	CBG-resistant	REMI	mutant	was	found	to	have	its	
insert	at	the	 listed	position.	Where	a	human	homologue	has	been	found	the	human	gene	name	
has	been	given.		
Protein	name Gene code Independently
identified	
(times)
Location	of insert
N/A DDB_G0269494 1 C-terminus	ORF
Putative licheninase DDB_G0292968 1 N-terminus	ORF
tRNA-Tyr-GUA-6 DDB_G0295181 2 80 bp	downstream	of	ORF
CupI DDB_G0272242 1 N-terminus ORF
RCC1-domain	containing	protein DDB_G0279435 3 C-terminus	ORF
IPMK DDB_G0281737 4 886	bp	downstream	of	ORF
78	
	
	
	
One	protein	identified	in	the	CBG-resistance	screen,	the	RCC1-containing	(RC)	protein,	provided	
a	 likely	 orthologue	 of	 an	 interesting	 H.	 sapiens	 protein	 domain.	 This	 RC	 protein	 is	 likely	 to	
function	as	a	GTPase	regulator	(Cubillos-Rojas	et	al.,	2014).	In	order	to	determine	the	similarity	
between	 the	 D.	 discoideum	 RC	 protein	 (Uniprot	 ID:	 Q54WU2;	 DDB_G0279435)	 and	 the	 H.	
sapiens	HERC2	protein	(Uniprot	ID:	O95714)	containing	RCC1	domains	(Figure	4.4	A),	an	amino	
acid	alignment	(using	Clustal	W)	was	carried	out.	The	H.	sapiens	HERC2	protein	contained	three	
RCC1	domains	and	these	domains	shared	amino	acid	identity	compared	to	the	RCC1	domain	of	
the	RC	protein	in	D.	discoideum	of	24.6%	with	RCC1	1,	25.3%	with	RCC1	2	and	23.6%	with	RCC1	
3	(Figure	4.4	B).	Phylogenetic	analysis	(using	MEGA	7	to	produce	a	neighbour-joining	tree	with	
500	Bootstrap	replications)	showed	the	H.	sapiens	and	D.	discoideum	RCC1	domains	to	be	within	
the	same	clade,	suggesting	a	common	evolutionary	origin	(Figure	4.4	C).	Each	of	the	H.	sapiens	
RCC1	domains	 in	 the	HERC2	protein	and	 the	RCC1	domain	 in	 the	D.	discoideum	protein	also	
shared	a	proline	residue,	which	 if	mutated	 in	 the	 first	RCC1	domain	of	 the	H.	sapiens	HERC2	
Figure	4.3:	A:	Diagram	of	discovered	insertion	sites	of	mutational	inserts	in	CBG-resistant	mutants.	
Arrows	and	boxes	represent	the	exons	of	the	above	genes,	the	straight	lines	through	them	represent	
genomic	DNA	and	where	a	straight	line	is	between	an	arrow	and	a	box,	or	two	boxes,	it	represents	an	
intron.	The	red	triangle	on	each	gene	is	the	location	of	the	REMI	mutational	insert	in	that	mutant,	which	
is	1.5	kb	(Faix	et	al.,	2004).	Size	of	boxes	and	arrows	is	in	scale	with	the	size	of	the	gene.	
RCC1-containing	protein	gene	
DDB_G0279435	
REMI	Insert
ipmk gene	
DDB_G0281737 REMI	Insert
cupI
DDB_G0272242
REMI	Insert
Putative	licheninase
DDB_G0292968
REMI	Insert
tRNA-Tyr-GUA-6				
DDB_G0295181
REMI	Insert
DDB_G0269494 REMI	Insert
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protein	 can	 cause	Angelman	 syndrome	 (HERC2P594L)	 (Cubillos-Rojas	 et	 al.,	 2016).	 In	 the	CBG-
resistant	mutant,	the	mutational	insert	was	located	in	the	open	reading	frame	of	the	gene,	which	
suggested	that	the	protein	would	not	be	correctly	expressed.	Thus,	the	RCC1	domain-containing	
protein	provided	a	potential	molecular	mechanism	with	possible	therapeutic	relevance	 if	 the	
effects	were	conserved	in	the	RCC1	domains	of	the	H.	sapiens	HERC2	protein.	
Another	protein	identified	in	the	CBG-resistance	screen,	IPMK,	provided	a	likely	orthologue	of	
an	 interesting	 H.	 sapiens	 protein.	 This	 IPMK	 protein	 functions	 as	 a	 phospholipid	 and	
phosphatidylinositol	kinase	(Kim	et	al.,	2016).	In	order	to	determine	the	similarity	between	the	
IPMK	in	D.	discoideum	(Uniprot	 ID:	Q54TI0)	and	the	single	orthologue	in	the	H.	sapiens	 IPMK	
protein	(Uniprot	ID:	Q8NFU5),	an	amino	acid	alignment	was	carried	out	(using	Clustal	W)	which	
indicated	that	the	two	IPMK	proteins	share	33.2	%	amino	acid	identity	(Figure	4.5	A)	and	both	
contain	 inositol	 phosphate-binding	 domains	 and	 ATP-binding	 domains	 (Figure	 4.5	 B).	
Phylogenetic	analysis	 (using	MEGA	7	to	produce	a	neighbour-joining	tree	with	500	Bootstrap	
replications)	 showed	 the	H.	 sapiens	and	D.	discoideum	 IPMK	proteins	 to	be	within	 the	 same	
clade,	 suggesting	 a	 common	 evolutionary	 origin	 (Figure	 4.5	 C).	 This	 may	 be	 of	 potential	
therapeutic	interest	as	the	IPMK	protein	in	H.	sapiens	has	many	functions	varying	from	mTORC1	
regulation	(Kim	et	al.,	2002;	Kim	et	al.,	2011)	to	histone	de-acetylase	regulation	(Watson	et	al.,	
2012),	and	5'	AMP-activated	protein	kinase	(AMPK)	and	Liver	Kinase	B1	(LBK1)	regulation	(Bang	
et	 al.,	 2012;	 Dailey	 and	 Kim,	 2012;	 Bang	 et	 al.,	 2014).	 The	 IPMK	 protein	 was,	 therefore,	 a	
potential	 molecular	 mechanism	 with	 possible	 therapeutic	 relevance	 if	 the	 effects	 were	
conserved	in	the	H.	sapiens	IPMK	protein.		
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Figure	 4.4:	 Protein	 sequence	 alignment	 of	 the	H.	 sapiens	HERC2	 protein	 RCC1	 domains	 and	 the	
D.	discoideum	RC	protein.	A:	The	D.	discoideum	RC	protein	the	H.	sapiens	HERC2	protein.	In	black	are	
RCC1	 domains,	 in	 red	 are	 HECT	 domains.	B:	 Clustal	 Omega	 analysis	 was	 carried	 out	 on	 the	 RCC1	
domains	in	the	D.	discoideum	RC	protein	(Q54WU2)	and	the	Homo	sapiens	HERC2	protein	(O95714)	
and	were	found	to	be	similar	in	sequence.	Asterisks	identical,	colons	are	highly	similar	and	full	stops	
are	similar.	Highlighted	in	green	is	the	proline	(RCC1	1	of	HERC2)	that	when	mutated	is	responsible	for	
the	cause	of	Angelman	syndrome	in	HERC2.	C:	Phylogenetic	analysis	of	RCC1	domains	suggests	that	
the	D.	discoideum	protein	(blue	arrow)	 is	 located	within	the	same	clade	as	the	Human	protein	 (red	
arrow),	suggesting	a	common	evolutionary	origin.	The	D.	discoideum	RCC1	appears	to	be	more	closely	
related	to	H.	sapiens	RCC1	domains	in	HERC2	than	the	H.	sapiens	RCC1	protein	is	to	any	of	them. 
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Figure	4.5:	Similarity	between	D.	discoideum	and	H.	sapiens	IPMK	proteins.	A:	D.	discoideum	(Q54TI0)	
and	H.	sapiens	(Q8NFU5)	IPMK	sequence	alignment	was	carried	out	on	Clustal	Omega.	They	share	an	
amino	acid	identity	of	33.2%.	Asterisks	identical,	colons	are	highly	similar	and	full	stops	are	similar.	B:	
Comparison	 of	 Homo	 sapiens	 and	 Dictyostelium	 discoideum	 IPMK	 proteins.	 Both	 the	 human	 and	
Dictyostelium	proteins	 share	 inositol	binding	domains	 (blue)	and	ATP	binding	domains	 (orange).	C:	
Phylogenetic	analysis	of	IPMK	proteins	suggests	that	the	D.	discoideum	protein	(blue	arrow)	is	located	
within	the	same	clade	as	the	Human	protein	(red	arrow),	suggesting	a	common	evolutionary	origin.	
The	D.	discoideum	IPMK	protein	appears	to	be	more	closely	related	to	H.	sapiens	protein	than	either	
protein	is	to	plant	or	yeast	orthologues. 
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4.2.2	The	effects	of	IPMK	over-expression	on	sensitivity	to	CBG	during	growth	
To	determine	how	the	mutagenic	insert	880	bp	downstream	of	the	IPMK	led	to	resistance	to	
CBG,	 the	 effect	 of	 the	 insert	 on	 IPMK	 expression	 had	 to	 be	 measured.	 To	 carry	 this	 out,	
quantitative	polymerase	chain	reaction	(qPCR)	analysis	was	used	to	measure	IPMK	mRNA	levels	
in	wild	type	and	mutant	cells.	To	this	end,	wild	type	and	mutant	cells	were	grown	under	the	
same	conditions	and	RNA	was	extracted	from	both	cell	types.	Analysis	by	qPCR	revealed	that	
the	expression	levels	of	IPMK	in	the	mutant	cells	were	significantly	higher	than	wild	type	cells	
(Figure	4.6)	(P<0.05,	Mann-Whitney	Test).	This	suggested	that	disruption	of	the	D.	discoideum	
genome	at	this	position	resulted	in	three-fold	increased	IPMK	expression	and	that	this	increase	
in	expression	resulted	in	resistance	to	CBG.	
To	validate	that	CBG-resistance	 in	 the	mutant	was	due	to	elevation	of	 IPMK	expression,	a	D.	
discoideum	cell	line	over-expressing	IPMK	was	created.	This	cell	line	was	created	using	an	RFP	
over-expression	plasmid	which	contained	a	D.	discoideum	 IPMK	(dIPMK)	insert	(Figure	4.7	A).	
The	dIPMK	insert	was	created	by	reverse	transcription	(RT-PCR)	of	IPMK	mRNA	and	then	cloned	
into	the	RFP-containing	plasmid	(pDM324	(Veltman	et	al.,	2009)).	To	ensure	the	plasmid	was	
correctly	constructed,	digestion	with	restriction	enzymes	that	cleaved	at	the	5’	and	3’	ends	of	
the	dIPMK	insert	was	carried	out.	This	restriction	enzyme	digestion	revealed	that	an	insert	of	
the	correct	size	(856	bp)	for	dIPMK	was	present	in	this	plasmid	in	the	correct	location	(Figure	4.7	
B).	The	whole	gene	was	then	sequenced	to	ensure	no	mutations	had	occurred.	Thereafter,	the	
plasmid	 was	 transfected	 into	 D.	 discoideum	 and	 presence	 of	 the	 dIPMK-RFP	 protein	 was	
examined	 by	western	 blot	 using	 an	 anti-RFP	 antibody.	 This	 analysis	 found	 that	 dIPMK+	 cells	
showed	 a	 specific	 50	 kDa	 RFP-containing	 protein	 which	 was	 absent	 in	 wild	 type	 cells	 and	
consistent	with	 the	expression	of	 full-length	dIPMK-RFP	 (Figure	4.7	C).	 Furthermore,	 protein	
extracts	from	wild	type	and	dIPMK	over-expressing	cells	(dIPMK+)	cells	contained	a	similar	level	
Figure	4.6:	 IPMK	levels	 in	 the	CBG-resistant	mutant.	The	CBG-resistant	mutant	found	to	contain	a	
mutagenic	insert	880	bp	downstream	of	IPMK	was	examined	by	qPCR	analysis	for	a	change	in	IPMK	
expression	compared	to	wild	type	cells.	Total	mRNA	was	collected	from	each	cell	line	and	RT-PCR	was	
used	to	create	 cDNA.	Then	qPCR	was	 carried	out	and	the	CBG-resistant	mutant	was	found	to	have	
elevated	 IPMK	mRNA	 levels	 compared	 to	 the	wild	 type	 (P<0.05,	 unpaired	 t-test),	 n=3.	 Expression	
levels	were	normalized	to	the	constitutively	expressed	Ig7	housekeeping	gene,	which	produces	the	
mitochondrial	large	subunit	rRNA	(Fukuzawa	et	al.,	2006).		
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of	protein,	as	evidenced	by	the	control	protein	(streptavidin).	This	experiment	confirmed	that	
the	D.	discoideum	IPMK-RFP	protein	was	present	in	D.	discoideum	cells.	
To	determine	where	in	D.	discoideum	cells	dIPMK	localised,	fluorescent	microscopy	was	carried	
out.	Cells	expressing	dIPMK-RFP	were	imaged	using	a	wide-field	fluorescence	microscope.	This	
analysis	 indicated	 that	dIPMK-RFP	was	 localised	 in	 the	cytoplasm	and	nucleus	 (Figure	4.7	D).	
Therefore,	a	D.	discoideum	cell	line	over-expressing	dIPMK	had	been	successfully	created	and	a	
cell	line	was	available	to	examine	the	role	of	human	IPMK	in	the	molecular	mechanism	of	CBG.	
To	confirm	that	the	CBG-resistance	observed	in	the	D.	discoideum	mutant	was	due	to	elevated	
IPMK	expression,	dIPMK+	 cells	were	examined	 for	 resistance	 to	CBG	during	growth.	 In	 these	
experiments,	dIPMK+	cells	were	grown	in	the	presence	of	increasing	concentrations	of	CBG	over	
168	hours.	Under	control	conditions	(in	the	presence	of	solvent	only),	dIPMK+	growth	showed	a	
lag	phase	until	96	hours,	an	exponential	phase	to	144	hours	and	a	stationary	phase	starting	at	
168	hours	(Figure	4.8	A).	Similarly	to	wild	type	cells,	CBG	concentrations	above	1	µM	significantly	
Figure	4.7:	Production	of	an	IPMK-RFP	over-expressor	cell	line.	A:	An	IPMK-RFP	plasmid	was	created	
in	pDM324	(7564	bp)	with	an	RFP	tag	at	the	C-terminal	of	the	protein.	B:	There	were	SpeI	and	BglII	
restriction	enzyme	digestion	sites	at	the	5’	and	3’	ends	of	 the	 IPMK	over-expressor	 insert	 (856	bp),	
respectively.	These	were	used	to	digest	the	IPMK	over-expressor	plasmid	and	confirm	the	presence	of	
the	IPMK	insert.	In	addition,	the	enzymes	were	used	singularly	to	ensure	that	the	insert	was	between	
the	two	and	correctly	located.	The	plasmid	was	then	transfected	into	wild	type	D.	discoideum.	C:	The	
presence	 of	 IPMK-RFP	was	 confirmed	 by	 western	 blot	 analysis,	 using	 an	 antibody	 against	 RFP.	 No	
protein	was	detected	by	the	anti-RFP	antibody	in	wild	type	cells.	A	protein	the	expected	size	of	IPMK	
and	RFP	was	detected	in	the	IPMK-RFP	expressing	cells.	Loading	control	protein	was	streptavidin.	C:	
Cellular	 localisation	of	IPMK	in	 IPMK-RFP	expressing	cells	was	confirmed	by	fluorescent	microscopy.	
The	IPMK	protein	localised	to	the	cytoplasm.	Scale	bar	10	µm.	
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inhibited	 dIPMK+	 cell	 growth	 at	 168	 hours	 (P<0.01,	 Mann	Whitney	 test).	 Data	 arising	 from	
comparing	the	growth	rate	at	differing	concentrations	of	CBG	was	used	to	calculate	a	dIPMK+	
IC50	for	CBG	of	0.64	µM	(Figure	4.8	B),	which	was	significantly	higher	than	the	wild	type	IC50	of	
0.22	 µM	 (P<0.01,	 one-way	 ANOVA	with	 Bonferroni’s	Multiple	 Comparison	 Test	 (Figure	 3.1).	
These	 data	 showed	 dIPMK	 over-expression	 created	 a	 reduction	 in	 sensitivity	 to	 CBG	 in	 D.	
discoideum,	 recapitulating	 the	 effect	 seen	 in	 the	 mutant	 screen	 and	 confirming	 IPMK	 as	 a	
regulator	of	D.	discoideum	response	to	CBG.	
In	addition	to	a	dIPMK	over-expressor	cell	line,	attempts	were	made	to	create	a	cell	line	lacking	
IPMK	to	further	examine	the	role	of	IPMK	in	regulating	D.	discoideum	cellular	response	to	CBG.	
To	this	end,	a	plasmid	designed	to	ablate	IPMK	expression	in	D.	discoideum	was	designed	(Figure	
4.9	A)	and	transfected	into	D.	discoideum	cells	(Figure	4.9	B).	However,	after	960	potential	knock	
Figure	 4.8:	 Elevated	 IPMK	 leads	 to	 resistance	 to	 CBG	 during	 growth	 in	D.	 discoideum.	A:	 Cells	
over-expressing	dIPMK	(dIPMK+)	were	grown	in	the	presence	of	increasing	concentrations	of	CBG	(and	
solvent	only	control;	0)	for	one	week.	CBG	inhibited	cell	growth	in	a	concentration-dependent	manner	
(n=6).	 This	 data	 was	 used	 to	 produce	 a	 secondary	 plot.	 B:	 Secondary	 plot	 analysis	 was	 used	 to	
determine	the	IC50	=	0.64	μM	(95	%	confidence	 intervals	0.14	to	0.31	µM)	(n=6),	while	 in	wild	type	
cells	this	was	 IC50	=	0.22	μM	(n=10).	Cells	over-expressing	 IPMK	were	found	to	have	a	significantly	
higher	IC50	compared	to	wild	type	cells	(p<0.01).	Data	were	normally	distributed	according	to	Shapiro-
Wilks.	 A	 one-way	 ANOVA	 with	 Bonferroni’s	 Multiple	 Comparison	 Test	 was	 carried	 out	 to	 test	
significance.		
-3 -2 -1 0 1
0
20
40
60
80
100
120
IPMK+	IC50 = 0.64 µM
WT	IC50	=	0.22 µM
CBG (Log10 µM)
G
ro
w
th
 ra
te
 (%
 c
on
tr
ol
)
A
B 0 24 48 72 96 120 144 168
0
20
40
60
80
100
120
0
0.02
0.1
0.5
1
4
[CBG]	µM
Time (Hours)
C
el
l G
ro
w
th
(%
 o
f c
on
tr
ol
)
**
**
85	
	
out	cell	lines	had	been	examined	and	only	non-homologous	integrants	found	(Figure	4.9	C)	this	
experiment	was	 halted.	 A	 cell	 line	 lacking	 IPMK	 expression	was	 therefore	 not	 created	 in	D.	
discoideum,	potentially	due	to	the	IPMK	protein	being	essential	for	D.	discoideum	survival.	
	
	
	
	
	
	 	
Figure	4.9:	Production	of	plasmid	for	the	ablation	of	IPMK.	A:	An	IPMK	ablation	plasmid	was	created	
using	the	pLPBLP	plasmid,	the	5’	and	3’	IPMK	regions	are	PCR	amplified	from	genomic	DNA	and	ligated	
into	the	pLPBLP	plasmid	either	side	of	the	blasticidin-resistance	cassette.	B:	This	plasmid	was	then	
transfected	into	D.	discoideum	so	that	through	homologous	recombination	the	blasticidin-resistance	
gene	could	replace	a	section	of	the	IPMK	gene	in	the	genome.	C:	The	knockout	cassette	was	transfected	
into	wild	type	D.	discoideum.	DNA	from	IPMK	knockout	screen	cells	was	isolated	and	PCR	amplification	
was	used	to	detect	the	presence	of	the	blasticidin-resistance	gene	inserted	into	the	correct	region	of	
IPMK	to	knockout	the	gene.	Genomic	control	(GC)	and	vector	control	(VC)	bands	were	present	in	non-
homologous	integrants	(NHI),	while	a	knockout	band	(KO)	was	not	present.	960	cell	lines	were	tested,	
with	only	non-homologous	integrants	found.		
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4.3	Discussion	
In	 this	 chapter,	 a	 D.	 discoideum	mutant	 library	 was	 employed	 to	 discover	 potential	 novel	
molecular	mechanisms	of	CBG.	In	the	previous	chapter,	CBG	was	found	to	inhibit	the	growth	of	
D.	discoideum	but	not	development.	These	effects	suggested	that	CBG	had	specific	molecular	
mechanisms	 in	D.	discoideum	and	not	a	general	 toxic	effect.	To	 identify	which	proteins	were	
involved	in	this	effect,	a	D.	discoideum	mutant	library	was	screened	for	CBG-resistant	mutants	
and	two	proteins	possibly	 involved	in	the	molecular	mechanisms	of	CBG	were	identified	with	
the	 potential	 for	 translational	 activity.	 Following	 the	 identification	 of	 IPMK	 as	 a	 protein	
potentially	involved	in	the	molecular	mechanism	of	CBG	in	D.	discoideum,	elevated	IPMK	was	
found	to	be	a	possible	cause	of	CBG-resistance.	This	effect	was	recapitulated	with	the	expression	
of	dIPMK-RFP	in	D.	discoideum	cells,	leading	to	an	increase	in	resistance	to	CBG.	Therefore,	IPMK	
was	confirmed	as	a	regulator	of	the	effects	of	CBG	on	D.	discoideum	growth	and	potentially	a	
target	for	the	molecular	mechanism	of	CBG.	
Although	the	mutant	screen	carried	out	in	this	study	identified	six	potential	proteins	that	may	
be	involved	in	the	molecular	mechanism	of	CBG	in	D.	discoideum,	it	is	likely	that	this	is	not	a	full	
representation	of	proteins	that	regulate	the	molecular	mechanism	of	CBG	 in	this	model.	The	
limitations	of	the	screen	used	in	this	study	result	from	the	creation	of	the	mutant	library	using	
restriction	 enzyme-mediated	 insertion	 (REMI)	 (Kuspa	 and	 Loomis,	 1992).	Within	 this	mutant	
library,	some	insertion	sites	are	duplicated	and	only	57	%	of	the	sites	are	estimated	to	be	unique.	
Within	the	pool	of	mutants	containing	unique	insertion	sites,	71	%	of	inserts	(40	%	of	the	total	
inserts)	were	found	within	coding	regions	of	genes	and	15	%	(9	%	of	total)	were	found	within	
promoter	 regions	of	genes.	 In	 total,	 insertion	sites	 in	 the	mutant	 library	are	estimated	 to	be	
present	 in	 43	%	of	 the	 genes	 in	 the	D.	 discoideum	 and	 some	genes	 contain	multiple	 unique	
insertion	sites	(Gruenheit	et	al.,	2019).	That	there	is	only	a	43	%	coverage	of	D.	discoideum	genes	
in	 the	 mutant	 library	 limits	 the	 potential	 to	 discover	 proteins	 that	 regulate	 the	 molecular	
mechanism	 of	 CBG	 that	 are	 likely	 to	 be	 lethal	 if	 expression	 is	 ablated	 or	 altered.	 As	 the	
underlying	principle	of	 a	mutant	 screen	 is	 that	 loss	of	 a	protein	necessary	 for	 the	molecular	
mechanism	of	a	compound	results	in	cells	becoming	resistant	to	the	effects	of	the	compound,	
then,	by	definition,	a	vital	protein	would	not	be	 found	using	 this	method	(Kelly	et	al.,	2018).	
Therefore,	an	essential	protein	for	D.	discoideum	survival	that	interacts	with	CBG	is	unlikely	to	
be	 identified	 using	 this	method.	 Consequently,	 use	 of	 the	D.	 discoideum	mutant	 library	 had	
limitations	and	was	unlikely	to	find	every	potential	protein	involved	in	the	molecular	mechanism	
of	CBG	in	this	model	organism,	however,	this	method	can	be	used	to	discover	some	proteins	
involved	in	the	molecular	mechanism	of	CBG	with	potential	therapeutic	relevance.		
87	
	
One	protein	potentially	 involved	 in	 regulating	 the	molecular	mechanism	of	CBG	found	 in	 the	
mutant	 screen	was	 the	RC	protein,	which	 contains	an	RCC1	domain	orthologous	 to	domains	
found	in	the	H.	sapiens	HERC2	protein.	 Importantly,	the	human	protein	has	clinical	relevance	
since	the	mutation	of	one	proline	residue	in	the	first	RCC1	domain	causes	Angelman	syndrome	
and	that	proline	residue	is	shared	with	the	D.	discoideum	RCC1	domain.	Angelman	syndrome	is	
a	complex	genetic	disorder	associated	with	epilepsy	that	mainly	affects	the	nervous	system	with	
symptoms	including	delayed	intellectual	development	and	cranial	deformities	(C.A.	Williams	et	
al.,	 2006).	 In	H.	 sapiens,	HERC2	has	ubiquitin	 ligase	activity,	 regulates	 the	activity	of	 tumour	
proteins	p53,	and	is	involved	in	DNA	repair,	cell	cycle,	regulation	and	iron	metabolism	(Cubillos-
Rojas	et	al.,	2016).	Recent	experiments	have	found	that	CBD	has	the	potential	to	treat	Angelman	
syndrome	by	 attenuating	 seizures	 in	mice	models	of	Angelman	 syndrome,	but	 suggested	no	
potential	mechanism	(Gu	et	al.,	2019).	This	effect	could	be	through	the	HERC2	protein,	as	the	
proline	mutation	is	likely	to	cause	a	conformational	change	in	the	protein	structure,	leading	to	
lack	of	function	or	decrease	in	function	of	HERC2	(Harlalka	et	al.,	2013).	If	CBG	binds	to	the	RCC1	
domain	it	may	alter	the	protein	structure,	further	biochemical	binding	affinity	assays	could	be	
used	to	examine	this	(Carrier	et	al.,	2006).	Although	 it	 is	unclear	how	cannabinoid	treatment	
could	alter	the	HERC2	protein	structure,	due	to	the	similarities	between	the	D.	discoideum	and	
H.	sapiens	RCC1	domains	in	the	two	proteins,	CBG	could	potentially	target	the	RCC1	domains	of	
both	proteins.	Therefore,	the	RC	and	HERC2	proteins	represent	exciting	prospects	to	explore	as	
regulators	of	a	molecular	mechanism	of	CBG.	
Another	protein	potentially	involved	in	the	regulation	of	the	molecular	mechanism	of	CBG	found	
in	the	mutant	screen	was	the	IPMK	protein.	The	H.	sapiens	orthologue	of	the	D.	discoideum	IPMK	
protein	 has	many	 functions	 such	 as	mTORC1	 regulation	 (Kim	 et	 al.,	 2002;	 Kim	 et	 al.,	 2011),	
inositol	phosphate	production	(Saiardi	et	al.,	1999;	Resnick	et	al.,	2005),	histone	de-acetylase	
regulation	(Watson	et	al.,	2012),	and	AMPK	and	LBK1	regulation	(Bang	et	al.,	2012;	Dailey	and	
Kim,	2012;	Bang	et	al.,	2014).	The	involvement	of	IPMK	in	all	these	biological	processes,	suggests	
a	role	for	CBG	in	the	treatment	of	tuberous	sclerosis	(Bang	et	al.,	2012;	Samueli	et	al.,	2016),	
epilepsy	(Russo	et	al.,	2013),	cancer	(Shaw	and	Cantley,	2006),	multiple	sclerosis	(Giacoppo	et	
al.,	2017),	schizophrenia	(Renard	et	al.,	2016),	Alzheimer’s	disease	(Xu	et	al.,	2011),	obesity	and	
diabetes	(Bang	et	al.,	2012).	Due	to	these	numerous	cellular	roles	and	potential	involvement	in	
so	many	diseases,	IPMK	represented	an	exciting	prospect	to	explore	as	a	protein	involved	in	the	
regulation	of	the	molecular	mechanism	of	CBG.		
The	CBG-resistant	mutant	containing	a	mutational	insert	880	bp	downstream	of	the	IPMK	open	
reading	frame	was	examined	by	qPCR	to	determine	if	the	insert	affected	IPMK	expression,	with	
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the	aim	to	recapitulate	the	phenotype	in	wild	type	cells.	The	CBG-resistant	mutant	discovered	
in	the	mutant	screen	was	found	to	have	an	elevated	level	of	IPMK	expression	compared	to	wild	
type	 cells.	 An	 insertion	 in	 this	 location	 may	 have	 interfered	 with	 the	 suppression	 of	 IPMK	
expression,	however,	the	scope	of	this	study	meant	that	no	further	research	could	be	carried	
out	to	determine	why	an	insert	in	this	location	resulted	in	elevated	IPMK	expression.	Therefore,	
dIPMK	over-expression	was	experimentally	recapitulated	using	the	RFP	over-expression	vector,	
pDM324	(Veltman	et	al.,	2009).	This	over-expression	plasmid	has	previously	been	used	to	over-
express	vacuole	membrane	protein	1	in	D.	discoideum	(Calvo-Garrido	et	al.,	2014).	Once	over-
expressed,	 the	dIPMK-RFP	protein	was	 found	 to	 localise	 to	 the	 cytoplasm	and	nucleus	of	D.	
discoideum	cells,	an	expected	result	as	it	lacked	the	specific	nuclear	localisation	signal	found	in	
the	H.	sapiens	form	of	the	IPMK	protein	(Nalaskowski	et	al.,	2002).	Therefore,	the	D.	discoideum	
CBG-resistant	mutant	was	confirmed	to	have	elevated	IPMK	expression	and	an	experimentally	
created	cell	line	recapitulated	this	IPMK	over-expression.	
In	addition,	an	attempt	was	made	to	create	a	cell	line	lacking	IPMK	to	further	examine	the	role	
of	this	protein	in	regulating	response	to	CBG	treatment.	However,	this	attempt	was	ended	after	
960	cell	lines	were	examined	for	loss	of	IPMK	and	no	cell	lines	were	found	with	ablated	IPMK.	
Loss	of	IPMK	could	be	lethal	to	D.	discoideum	as	IPMK	loss	is	lethal	in	Drosophila	melanogaster	
(Malabanan	and	Blind,	2016),	Trypanosoma	brucei	(Cestari	et	al.,	2018),	and	the	early	embryonic	
stages	of	Mus	musculus	development	(Maag	et	al.,	2011).	Therefore,	IPMK	is	likely	to	be	crucial	
for	 the	 survival	of	D.	discoideum	 (Maag	et	al.,	2011).	The	vital	 role	 for	 IPMK	could	be	 in	 the	
production	 of	 inositol	 pentakisphosphate	 (IP5)	 or	 inositol	 hexaphosphate	 (IP6)	 in	 specific	
morphogenetic	processes	and	cellular	survival	(Frederick	et	al.,	2005).	This	is	likely	to	be	the	case	
as	 IPMK	 from	 Arabidopsis	 thaliana	 expressed	 in	 D.	 melanogaster	 can	 rescue	 the	 lethal	
phenotype	of	IPMK	loss,	and	the	only	activity	of	A.	thaliana	 IPMK	in	D.	melanogaster	was	IP4	
production	(Malabanan	and	Blind,	2016).	Therefore,	efforts	at	creating	a	D.	discoideum	cell	line	
lacking	 IPMK	were	halted	at	 960	attempts.	However,	 future	methods	 could	be	used	 such	as	
reduced	 expression	 through	 siRNA	 (Saiki	 et	 al.,	 2011),	 expression	 of	 non-endogenous	 IPMK	
(Malabanan	and	Blind,	2016)	or	artificial	replacement	of	inositol	phosphates	in	D.	discoideum	
when	ablating	the	native	protein	to	maintain	essential	functions	(Miyamoto	et	al.,	2002;	Jackson	
et	al.,	2007).	
To	 determine	 if	 IPMK	 over-expression	 in	 the	 CBG-resistant	 mutant	 was	 responsible	 for	
resistance	to	CBG	during	growth,	a	growth	assay	was	carried	out	with	the	recapitulated	IPMK	
over-expressing	cell	line.	In	this	experiment,	over-expression	of	IPMK	in	D.	discoideum	was	found	
to	 confer	 a	 three-fold	 increase	 in	 resistance	 during	 growth	 to	 CBG	 at	 the	 50	 %	 inhibition	
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concentration.	 Given	 the	many	 cellular	 roles	 of	 IPMK	 already	 described,	 the	mechanism	 by	
which	CBG	inhibited	growth	through	IPMK	could	not	be	determined.	Thus,	the	next	aim	was	to	
determine	if	CBG	modified	downstream	effectors	of	IPMK,	such	as	mTORC1	activity	and	higher	
order	inositol	phosphate	production.	
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Chapter	 5:	 Exploration	 of	 IPMK	 as	 a	 target	 for	 CBG	 in	 D.	
discoideum	
5.1	Introduction		
In	the	previous	chapter,	IPMK	activity	was	suggested	to	be	involved	in	the	molecular	mechanism	
of	CBG.	 Initially,	an	 insertional	mutant	 library	was	screened	for	mutant	cells	resistant	to	CBG	
during	growth.	From	this	approach,	six	mutagenic	insert	locations	were	found	in	CBG-resistant	
mutants,	and	these	provided	six	potential	target	proteins,	one	of	which	was	the	IPMK	protein.	
The	D.	discoideum	IPMK	has	an	orthologue	in	H.	sapiens	involved	in	mTORC1	regulation	(Kim	et	
al.,	2002;	Kim	et	al.,	2011),	 inositol	phosphate	production	(Saiardi	et	al.,	1999;	Resnick	et	al.,	
2005),	histone	de-acetylase	 regulation	 (Watson	et	al.,	 2012),	 and	AMPK	and	LBK1	 regulation	
(Bang	et	al.,	2012;	Dailey	and	Kim,	2012;	Bang	et	al.,	2014).	In	the	mutant	screen,	the	mutagenic	
insert	 location	 880	 bp	 downstream	 of	 the	 D.	 discoideum	 IPMK	 gene	 was	 identified	
independently	four	times	and	found	to	elevate	IPMK	expression.	To	confirm	this,	an	IPMK	over-
expressing	cell	line	was	created	and	found	to	be	resistant	to	CBG	during	growth.	To	discover	the	
mechanism	of	IPMK	targeting	by	CBG,	downstream	signalling	pathways	were	examined.		
The	H.	 sapiens	 IPMK	 protein	 has	many	 cellular	 roles	 and	 functions,	making	 it	 an	 interesting	
potential	therapeutic	target.	One	of	the	functions	of	IPMK	is	to	act	as	a	PI3-kinase,	this	regulates	
phosphatidylinositol	 (3,4,5)-trisphosphate	(PIP3)	production	and	may	regulate	transcription	 in	
the	nucleus	 in	yeast	 (Resnick	et	al.,	2005).	The	PI3-kinase	 function	of	 IPMK	activates	protein	
kinase	B	 (PKB)	which	goes	on	 to	activate	mTORC1	activity	 (Maag	et	 al.,	 2011).	 Furthermore,	
through	 non-catalytic	 binding	 with	 mTOR	 and	 Raptor,	 IPMK	 regulates	 mTORC1	 signalling	
independently	of	 this	catalytic	activity	 (Kim	et	al.,	2011).	Therefore,	 through	many	functions,	
IPMK	regulates	mTORC1	activity	(Figure	1.4).	The	function	of	mTORC1	is	to	regulate	cell	growth	
and	 protein	 synthesis	 through	 the	 eukaryotic	 translation	 initiation	 factor	 4E	 (eIF4E)-binding	
protein	(4EBP)	and	cell	size	through	ribosomal	protein	S6	kinase	(S6K)	(Yang	et	al.,	2014).	The	
regulation	 of	 mTORC1	 activity	 could	 be	 therapeutically	 relevant	 as	 preclinical	 studies	 have	
suggested	that	cannabinoids	up-regulate	mTORC1	in	the	treatment	of	both	multiple	sclerosis	
(Arévalo-Martín	et	al.,	2003;	Serpell	et	al.,	2013;	Giacoppo	et	al.,	2017)	and	psychosis	(Renard	
et	al.,	2016;	Renard	et	al.,	2017(a))	and	down-regulate	mTORC1	 in	the	treatment	of	epilepsy	
(Serra	et	al.,	2019)	and	cancer	(Franz	et	al.,	2013;	Sultan	et	al.,	2018).	Therefore,	the	ability	of	
CBG	to	regulate	mTORC1	activity	through	IPMK	was	analysed	in	this	chapter.		
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5.2	Results	
5.2.1	CBG	and	CBD,	but	not	CBDA	or	CBDV,	elevate	mTORC1	activity	in	D.	discoideum	
To	validate	IPMK	as	a	potential	target	for	CBG,	the	effect	of	CBG	treatment	on	an	IPMK-regulated	
cellular	 process	 was	 analysed.	 The	 ability	 of	 IPMK	 to	 non-catalytically	 bind	 mTOR	 and	 to	
catalytically	regulate	mTOR	activity	through	PIP3	production	provided	a	mechanism	by	which	to	
measure	the	effect	of	CBG	on	IPMK	activity	(Kim	et	al.,	2011;	Blind	et	al.,	2012).	To	carry	this	out,	
4EBP1	 phosphorylation	 (a	 downstream	 effector	 of	mTORC1	 Figure	 5.1	 A)	 was	measured	 by	
western	blot	analysis,	using	an	antibody	which	binds	to	phosphorylated	threonine	46	in	the	H.	
sapiens	4EBP1	protein.	An	amino	acid	alignment	(using	Clustal	W)	indicated	that	this	threonine	
is	 shared	 by	 both	 the	 H.	 sapiens	 and	 D.	 discoideum	 4EBP1	 proteins	 (Figure	 5.1	 B)	 and	
phylogenetic	analysis	 (using	MEGA	7	to	produce	a	neighbour-joining	tree	with	500	Bootstrap	
replications)	indicated	that	both	proteins	share	an	evolutionary	origin	(Figure	5.1	C).		
Therefore,	to	measure	mTORC1	signalling,	wild	type	cells	were	kept	in	control	conditions	(in	the	
presence	of	solvent	only	and	in	the	absence	of	CBG)	or	in	the	presence	of	0.25	µM	CBG	for	1	
hour.	Treatment	with	CBG	in	this	experiment	led	to	a	1.5-fold	increase	in	mTORC1	activity,	as	
evidenced	 by	 an	 increase	 in	 the	 phosphorylation	 of	 4EBP1	 compared	 to	 control	 conditions	
(P<0.01,	One-Way	ANOVA	with	Dunnett’s	Post-Hoc)	(Figure	5.2).	To	determine	if	cannabinoids	
with	a	similar	structure	to	CBG	also	increased	mTORC1	activity,	the	same	experiment	was	carried	
out	with	the	treatment	of	D.	discoideum	cells	with	0.25	µM	CBD,	cannabidiolic	acid	(CBDA)	or	
cannabidivarin	(CBDV)	for	one	hour.	From	this,	CBD	was	also	found	to	increase	mTORC1	activity	
1.3-fold,	 as	 evidenced	 by	 an	 increase	 in	 the	 phosphorylation	 of	 4EBP1	 compared	 to	 control	
conditions	(P<0.05,	One-Way	ANOVA	with	Dunnett’s	Post-Hoc)	(Figure	5.2).	However,	CBDA	and	
CBDV	did	not	increase	4EBP1	phosphorylation	compared	to	control	conditions.	Together,	these	
data	 showed	 that	 CBG	 and	 CBD,	 and	 not	 CBDA	 or	 CBDV,	 regulated	 mTORC1	 activity	 in	 D.	
discoideum.	
5.2.2	The	effects	of	CBG	and	CBD	are	IPMK-,	PKB-	and	PI3K-dependent	
To	determine	whether	CBG-	and	CBD-dependent	regulation	of	mTORC1	in	D.	discoideum	was	
dependent	on	IPMK,	mTORC1	activity	 in	cells	over-expressing	dIPMK	was	measured.	To	carry	
this	out,	wild	type	cells	and	dIPMK+	cells	were	maintained	in	control	conditions	(in	the	presence	
of	solvent	only)	for	one	hour	and	dIPMK+	cells	were	treated	with	0.25	µM	CBG	or	CBD	for	one	
hour,	 then	 levels	 of	 phosphorylated	 4EBP1	 were	 measured	 by	 western	 blot.	 In	 control	
conditions,	 cells	 over-expressing	 dIPMK	 had	 a	 1.9-fold	 elevated	 level	 of	 mTORC1	 activity	
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compared	to	wild	type	cells	as	evidenced	by	an	elevated	level	of	phosphorylated	4EBP1	(P<0.01,	
one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test)	(Figure	5.3).	Treatment	of	dIPMK+	
cells	with	CBG	or	CBD,	both	resulted	in	a	45	%	reduction	of	mTORC1	activity,	as	evidenced	by	a	
decrease	in	the	level	of	phosphorylated	4EBP1	compared	to	control	conditions	(P<0.05,	one-way	
ANOVA	with	Bonferroni’s	Multiple	Comparison	Test)	(Figure	5.3).	Therefore,	these	data	further	
suggested	that	CBG-	and	CBD-dependent	regulation	of	mTORC1	occurred	through	IPMK.	
Dictyostelium discoideum --------MSTTRAIPVS-------LKDRSDIDFSTSLGGTLYGTTPGGTKIVYDRNALL 45
Homo sapiens            MSGGSSCSQTPSRAIPATRRVVLGDGVQLPPGDYSTTPGGTLFSTTPGGTRIIYDRKFLM 60
: :****.:         :    *:**: ****:.******:*:***: *:
Dictyostelium discoideum QYRNSPLSKTPPPQLAHITNTELNKKVEKSTTTPTTTTPPTTTAK---------PKPTND 96
Homo sapiens            ECRNSPVTKTPPRDLPTIPGVTSP----------SSDEPPMEASQSHLRNSPEDKRAGGE 110
: ****::**** :*  * ..             ::  **  :::          :  .:
Dictyostelium discoideum DDIFPME- 103
Homo sapiens            ESQFEMDI 118
:. * *: 
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Figure	5.1:	Similarity	between	D.	discoideum	and	H.	sapiens	4EBP1	proteins.	A:	Since	binding	of	IPMK	
directly	 to	mTOR	 in	 complex	 1	 (mTORC1)	 with	 Raptor	 and	 Lst8	 enables	 the	 phosphorylation	 of	 the	
eukaryotic	translation	initiation	factor	4E-binding	protein	1	(4EBP1),	this	provided	an	indirect	means	to	
monitor	 IPMK	activity,	which	was	analysed	to	determine	the	effects	of	CBG,	CBD,	CBDA	and	CBDV	on	
this	cellular	signalling	pathway.	B:	D.	discoideum	(Q54DU8)	and	H.	sapiens	(Q60876)	4EBP1	sequence	
alignment	was	carried	out	on	Clustal	Omega.	The	two	proteins	shared	an	amino	acid	identity	of	38.7%.	
Asterisks	identical,	colons	are	highly	similar	and	full	stops	are	similar.	Both	proteins	share	the	threonine	
(46	 in	 Homo	 sapiens)	 recognised	 by	 the	 anti-p4EBP1	 antibody	 used	 in	 this	 study	 (green	 box).	 C:	
Phylogenetic	analysis	of	4EBP1	proteins	suggests	that	the	D.	discoideum	protein	(blue	arrow)	is	located	
within	the	same	clade	as	the	Human	protein	(red	arrow),	suggesting	a	common	evolutionary	origin.		
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Figure	 5.3:	 Elevation	 of	 IPMK	 abrogates	 the	 effects	 of	 CBG	 and	 CBD	 on	 mTORC1	 activity	 in	 D.	
discoideum.	dIPMK+	cells	were	kept	in	control	conditions	or	treated	with	0.25	μM	CBG	or	CBD	for	1	
hour	and	then	samples	were	analysed	for	phosphorylation	of	4EBP1	by	western	blot,	n=8.	In	control	
conditions,	 dIPMK+	 cells	 had	 elevated	mTORC1	 activity	 compared	 to	 untreated	 wild	 type	 cells,	 as	
evidenced	 by	 an	 elevated	 level	 of	 phosphorylated	 4EBP1.	 In	 dIPMK+	 cells	 both	 cannabinoids	
significantly	 reduced	mTORC1	activity,	 as	 evidenced	by	a	 reduction	 in	 the	 level	of	phosphorylated	
4EBP1.	Streptavidin	was	used	as	a	control	protein	to	show	that	protein	levels	were	consistent	between	
samples.	Data	shown	represents	mean±standard	error	of	the	mean.	Data	were	normally	distributed	
with	Shapiro-Wilks.	A	one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test	was	carried	out	to	
test	significance,	*	-	p<0.05,	**	-	p<0.01.	
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Figure	5.2:	CBG	 and	CBD	upregulate	mTORC1	activity	 in	D.	discoideum.	Wild	 type	 (WT)	cells	were	
maintained	in	control	conditions	(in	the	absence	of	CBG,	CBD,	CBDV	or	CBDA	(-))	or	treated	with	0.25	
μM	CBG,	CBD,	 CBDA	or	CBDV	 for	1	hour.	 Samples	were	analysed	 for	phosphorylation	of	4EBP1	by	
western	blot,	n=7.	CBG	and	CBD	significantly	increased	mTORC1	activity,	as	evidenced	by	an	increase	
in	phosphorylated	4EBP1,	however,	CBDA	and	CBDV	did	not	have	this	effect.	Data	shown	represents	
mean±standard	error	of	the	mean.	Data	were	normally	distributed	with	Shapiro-Wilks	and	significance	
provided	by	One-Way	ANOVA	with	Dunnett’s	Post-Hoc,	*	-	p<0.05,	**	-	p<0.01.	Streptavidin	was	used	
as	a	control	protein	to	show	that	protein	levels	were	consistent	between	samples.	
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5.2.3	The	mechanism	of	action	of	CBG	is	PKB-	and	PI3K-dependent	
As	PKB	is	a	key	regulator	of	the	mTORC1	pathway	and	orthologous	PKB	proteins	exist	in	both	D.	
discoideum	and	H.	sapiens,	PKB	was	examined	for	a	role	in	regulating	the	molecular	mechanism	
of	CBG.	From	the	two	PKB	proteins	 in	D.	discoideum,	amino	acid	alignment	(using	Clustal	W)	
indicated	that	PKBA	shared	45	%	amino	acid	identity	(Figure	5.4	A)	and	all	three	main	domains	
(pleckstrin	 homology	 domain,	 protein	 kinase	 domain	 and	 AGC-kinase	 domain)	 with	 the	 H.	
sapiens	protein	 (Figure	5.4	B).	Phylogenetic	analysis	 (using	MEGA	7	 to	produce	a	neighbour-
joining	 tree	with	500	Bootstrap	 replications)	 indicated	 that	PKBA	was	more	 similar	 to	 the	H.	
sapiens	protein	than	PKGB	(Figure	5.4	C).		
Therefore,	 CBG	 growth	 assays	were	 carried	 out	 using	 a	D.	 discoideum	 cell	 line	 lacking	 PKBA	
(PKBA-)	 in	 addition	 to	 a	 cell	 line	 lacking	 PKBA	 and	 over-expressing	 dIPMK	 (PKBA-dIPMK+),	 to	
examine	if	a	reduction	in	PKB	affected	D.	discoideum	sensitivity	to	CBG	during	growth.	In	these	
experiments,	 PKBA-	 and	 PKBA-dIPMK+	 cells	 were	 grown	 in	 the	 presence	 of	 increasing	
concentrations	of	 CBG	over	 168	hours.	Under	 control	 conditions	 (in	 the	presence	of	 solvent	
only),	PKBA-	and	PKBA-dIPMK+	D.	discoideum	cell	growth	showed	a	lag	phase	until	96	hours,	an	
exponential	phase	to	144	hours	and	a	stationary	phase	starting	at	168	hours	(Figure	5.5	A	and	
B).	Similarly	to	wild	type	cells,	CBG	concentrations	above	4	µM	significantly	inhibited	PKBA-	cell	
growth	 at	 168	 hours	 (P<0.05	 for	 PKBA-,	 Mann-Whitney	 test),	 however,	 CBG	 concentrations	
below	4	µM	did	not	significantly	 inhibit	PKBA-	cell	growth.	Furthermore,	 in	PKBA-dIPMK+	cells	
concentrations	higher	than	2	µM	CBG	significantly	inhibited	growth	at	168	hours	(P<0.01,	Mann-
Whitney	test),	however,	concentrations	below	2	µM	had	no	significant	effect	on	growth.	Data	
arising	from	this	analysis	(rate	of	growth	and	Log	of	concentration)	were	used	to	calculate	an	
IC50	 for	 PKBA-	 cells	 of	 2.16	 µM	 and	 for	 PKBA-dIPMK+	 cells	 of	 1.74	 μM,	 both	 of	 which	 were	
significantly	 higher	 than	 the	 wild	 type	 IC50	 of	 0.22	 µM	 (P<0.01,	 one-way	 ANOVA	 with	
Bonferroni’s	Multiple	Comparison	Test)	(Figure	5.5	C).	In	these	experiments,	over-expression	of	
IPMK	in	PKBA-ablated	cells	did	not	significantly	alter	the	IC50	of	D.	discoideum	treated	with	CBG	
during	 growth	 (one-way	 ANOVA	 with	 Bonferroni’s	 Multiple	 Comparison	 Test).	 These	 data	
showed	PKBA	ablation	created	a	reduction	in	sensitivity	to	CBG	in	D.	discoideum	and	that	over-
expression	of	dIPMK	did	not	alter	this	reduction	in	sensitivity,	which	suggested	that	both	PKBA	
and	IPMK	regulated	D.	discoideum	response	to	CBG	through	a	shared	mechanism.	
As	PKBA	and	IPMK	regulated	the	D.	discoideum	response	to	CBG	during	growth,	the	role	of	PKB	
was	 examined	 for	 an	 effect	 in	 mediating	 CBG	 regulation	 of	 mTORC1	 signalling.	 Here,	 PKB	
regulates	mTORC1	through	TSC1/2/Rheb	or	sequestration	into	mTORC2	(Gunn	and	Hailes,	2008)	
(Figure	5.6	A).	To	examine	the	role	of	PKB	in	CBG-	and	CBD-dependent	mTORC1	regulation,	wild	
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type	cells	and	PKBA-	cells	and	cells	lacking	both	PKBA	and	PKGB	(PKBA-PKGB-)	were	maintained	
in	control	conditions	(in	the	presence	of	solvent	only)	for	one	hour	and	PKBA-	and	PKBA-PKGB-	
cells	were	treated	with	0.25	µM	CBG	or	CBD	for	one	hour,	then	levels	of	phosphorylated	4EBP1	
were	measured	by	western	blot.	In	control	conditions,	cells	lacking	PKBA	had	1.9-fold	elevated	
mTORC1	 activity	 compared	 to	 wild	 type	 cells,	 as	 evidenced	 by	 an	 increase	 in	 4EBP1	
phosphorylation	(P<0.01,	one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test)	(Figure	
5.6	 B).	 In	 control	 conditions,	 cells	 lacking	 both	 PKBA	 and	 PKGB	 did	 not	 have	 a	 significantly	
different	level	of	mTORC1	activity,	as	evidenced	by	a	similar	level	of	4EBP1	phosphorylation	to	
wild	type	cells	(Figure	5.6	C).	Following	CBG	or	CBD	treatment	of	PKBA-	cells,	mTORC1	activity	
increased	 a	 further	 1.3-	 and	 1.6-fold	 respectively,	 as	 evidenced	 by	 an	 increase	 in	 4EBP1	
phosphorylation	(P<0.05	for	CBG,	P<0.01	for	CBD,	one-way	ANOVA	with	Bonferroni’s	Multiple	
Comparison	Test).	However,	treatment	with	either	CBG	or	CBD	did	not	alter	mTORC1	activity	in	
cells	 lacking	 both	 PKBA	 and	 PKGB,	 as	 evidenced	 by	 no	 change	 in	 the	 level	 of	 4EBP1	
phosphorylation	(one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test).	In	combination,	
these	 data	 suggested	 that	 PKB	 was	 necessary	 for	 CBG-	 and	 CBD-dependent	 regulation	 of	
mTORC1	activity	in	D.	discoideum.		
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Figure	5.4:	Similarity	between	D.	discoideum	and	H.	sapiens	PKB	proteins.	A:	D.	discoideum	(P54644)	
and	H.	sapiens	(P13749)	PKB	sequence	alignment	was	carried	out	on	Clustal	Omega.	The	two	proteins	
share	a	sequence	 identity	of	44.5	%.	Asterisks	 identical,	 colons	highly	similar,	 full	stops	 similar.	B:	
Comparison	 of	 H.	 sapiens	 PKB	 and	 D.	 discoideum	 PKBA	 proteins.	 Both	 proteins	 share	 pleckstrin	
homology	domains	 (black),	protein	kinase	domains	 (orange)	and	AGC-kinase	domains	 (purple).	C:	
Phylogenetic	analysis	of	PKB	proteins	suggest	that	the	D.	discoideum	protein	(blue	arrow)	is	located	
within	the	same	clade	as	the	H.	sapiens	protein	(red	arrow),	suggesting	a	common	evolutionary	origin.	
The	D.	discoideum	PKBA	protein	appears	to	be	more	closely	related	to	H.	sapiens	PKB	protein	than	
the	D.	discoideum	PKGB	protein.	
Dictyostelium discoideum      MSTAPIKHEGFLTKEGGGFKSWKKRWFILKGGDL-SYYKTKGELV-----PLGVIHLNTS 54
Homo sapiens                  MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQC 60
** . * :**:* *.*  :*:*: *:*:**...    ** : : *     **. : :  .
Dictyostelium discoideum      GHIKNSDRKKRVNGFEVQTPSR----TYFLCSETEEERAKWIEILINERE---------L 101
Homo sapiens                  QLMKT--ERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEM 118
:*.  .: * * * ::  .        :  ** *** :*   : .  :         :
Dictyostelium discoideum      LLNGGK-------------QPKKSEKVGVADFELLNLVGKGSFGKVIQVRKKDTGEVYAM 148
Homo sapiens     DFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAM 178
:..*.               * ..:* : :** *:*:***:***** *::* **. ***
Dictyostelium discoideum      KVLSKKHIVEHNEVEHTLSERNILQKINHPFLVNLNYSFQTEDKLYFILDYVNGGELFYH 208
Homo sapiens                  KILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFH 238
*:*.*: ** ::** ***:*..:**: .****. *:*****.*:* *:::*.******:*
Dictyostelium discoideum      LQKDKKFTEDRVRYYGAEIVLALEHLHL-SGVIYRDLKPENLLLTNEGHICMTDFGLCKE 267
Homo sapiens                  LSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKE 298
*.::: *:***.*:****** **::**  ..*:***** ***:* ::*** :********
Dictyostelium discoideum      GLLTPTDKTGTFCGTPEYLAPEVLQGNGYGKQVDWWSFGSLLYEMLTGLPPFYNQDVQEM 327
Homo sapiens                  GIKDG-ATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKL 357
*:     .  **************:.*.**: ****.:* ::***: *  ****** :::
Dictyostelium discoideum      YRKIMMEKLSFPHFISPDARSLLEQLLERDPEKRLAD----PNLIKRHPFFRSIDWEQLF 383
Homo sapiens                  FELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVY 417
:. *:**:: **: :.*:*:***. **::**::**..     : * :* ** .* *::::
Dictyostelium discoideum      QKNIPPPFIPNVKGSADTSQIDPVFTDEAPSLTMA-----GECALNPQQQKDFEGFTYVA 438
Homo sapiens                  EKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMEC-VDSERRPHFPQFSYSA 476
:*:: *** *:*...:**  :*  ** :  ::*        ** :: ::: .*  *:* *
Dictyostelium discoideum      ESEHLR* 444
Homo sapiens                  SGTA--- 480
.. 
PKB	proteins
Homo	sapiens
Dictyostelium	discoideum
Protein	kinase	domain AGC-kinase	domainPleckstrin homology	domain
(P54644)
A
B
C
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As	PKB	had	been	implicated	in	the	CBG-	and	CBD-dependent	regulation	of	mTORC1	and	PI3K	
signalling	regulates	PKB,	the	role	of	PI3K	signalling	on	cannabinoid	regulation	of	mTORC1	was	
examined.	In	this	experiment,	wild	type	cells	were	treated	with	a	PI3K	inhibitor	(60	μM	LY294002	
(Van	Haastert	et	al.,	2007))	in	control	conditions	(in	the	presence	of	solvent	only)	for	one	hour	
and	treated	with	0.25	µM	CBG	or	CBD	for	one	hour,	then	levels	of	phosphorylated	4EBP1	were	
measured	 by	 western	 blot.	 This	 analysis	 found	 no	 change	 in	 mTORC1	 activity	 in	 cells	 with	
pharmacologically	 inhibited	PI3K	activity	when	 treated	with	CBG	or	CBD,	as	evidenced	by	no	
Figure	5.5:	PKB	ablation	 leads	 to	resistance	to	CBG	in	growth	 in	D.	discoideum.	A	and	B:	Growth	
assays	were	carried	out	using	PKBA-	(n=7)	and	PKBA-dIPMK+	(n=5)	cells.	Growth	was	calculated	as	a	%	
of	each	cell	line	in	control	conditions	(in	the	absence	of	CBG).	CBG	inhibited	growth	in	a	concentration-
dependent	manner.	Data	arising	from	comparing	the	growth	rate	at	differing	concentrations	of	CBG	
was	used	to	create	a	secondary	plot.	Data	were	not	normally	distributed	(Shapiro-Wilks),	therefore	a	
Mann	Whitney	test	was	carried	out	to	test	for	significance	of	inhibition	by	each	concentration	of	CBG	
compared	to	control	at	168	hours,	*	-	p<0.05,	**	-	p<0.01.	Graphs	show	mean	±	SEM.	C:	Secondary	
plot	analysis	was	used	to	determine	the	IC50,	PKBA-	IC50	of	2.16	μM	(n=7),	and	PKBA-dIPMK+	IC50	of	1.74	
μM	are	significantly	higher	than	wild	type	(WT)	IC50	of	0.22	μM	(n=10).	No	significant	difference	was	
found	 between	 PKBA-	 and	 PKBA-dIPMK+	 cells.	 Data	 were	 normally	 distributed	 with	 Shapiro-Wilks	
therefore	one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test	was	carried	out	to	determine	
significance.		
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change	in	the	level	of	4EBP1	phosphorylation	(Kruskal-Wallis	test)	(Figure	5.6	D).	This	indicated	
that	PI3K	activity	was	necessary	for	CBG-	and	CBD-dependent	regulation	of	mTORC1	signalling.		
Figure	 5.6:	 Cannabinoid-dependent	 effects	 on	 mTORC1	 activation	 are	 regulated	 by	 PKB	 and	 PI3K	
activity	in	D.	discoideum.	A:	Regulation	of	mTORC1	activity	occurs	through	a	complex	pathway,	initiated	
by	PI3K,	and	proceeding	through	PKB	(in	D.	discoideum	PKBA	(P54644)	and	PKGB	(P28178)),	and	mTORC1	
and	mTORC2,	where	multiple	components	are	shared	between	the	two	complexes.	B	and	C:	Wild	type	D.	
discoideum	and	cells	lacking	either	PKBA	or	both	PKBA	and	PKGB	were	maintained	in	control	conditions	
(in	the	presence	of	solvent	only	and	in	the	absence	of	CBG	or	CBD	(-))	or	treated	with	0.25	μM	CBG	or	
CBD	for	1	hour	and	then	analysed	for	levels	of	phosphorylated	4EBP1	by	western	blot,	n=8	and	n=10.	
Streptavidin	was	used	as	a	control	protein	to	show	that	protein	levels	were	consistent	between	samples.	
Data	shown	represents	mean±	standard	error	of	the	mean.	Data	were	normally	distributed	with	Shapiro-
Wilks	and	significance	provided	by	One-Way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test,	where	
*	is	p<0.05	and	**	is	p<0.01.	B:	PKBA-	cells	in	control	conditions	had	significantly	elevated	mTORC1	activity	
compared	to	wild	type	cells,	as	evidenced	by	an	elevated	level	of	4EBP1	phosphorylation.	In	these	cells	
CBG	and	CBD	treatment	significantly	reduced	mTORC1	activity.	C:	PKBA-PKGB-	cells	in	control	conditions	
had	 a	 similar	 level	 of	 mTORC1	 activity	 to	 wild	 type	 cells,	 as	 evidenced	 by	 a	 similar	 level	 of	 4EBP1	
phosphorylation.	In	these	cells	CBG	and	CBD	treatment	did	not	significantly	alter	mTORC1	activity.	D:	Wild	
type	cells	were	treated	with	a	pharmacological	 inhibitor	of	PI3K	activity	(LY294002:	60µM),	and	either	
maintained	in	control	conditions	(in	the	absence	of	CBG	or	CBD	(-))	or	treated	with	0.25	μM	CBG	or	CBD	
for	1	hour	and	then	analysed	for	levels	of	phosphorylated	4EBP1	by	western	blot,	n=5.	Streptavidin	was	
used	as	a	 control	protein	 to	 show	 that	protein	 levels	were	 consistent	between	 samples.	Data	 shown	
represents	mean±standard	error	of	the	mean.	Normality	of	data	was	determined	by	the	Shapiro-Wilk	test	
and	 found	 to	 be	 not	 normally	 distributed.	 Significance	 was	 tested	 by	 Kruskal-Wallis	 test	 and	 no	
significance	was	found.	 
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5.2.4	CBG	regulates	the	IPMK-dependent	activity	of	higher	order	inositol	phosphate	
production	in	D.	discoideum	
To	distinguish	between	a	CBG-	and	CBD-dependent	effect	on	IPMK	or	PI3K/PKB	signalling,	the	
effect	 of	 CBG	 or	 CBD	 treatment	 on	 production	 of	 higher	 order	 inositol	 phosphates	 in	 D.	
discoideum	was	examined.	IPMK	is	essential	for	the	synthesis	of	higher	order	inositol	phosphates	
such	as	IP4-6	(Figure	5.7	A)	(Saiardi	et	al.,	1999;	Maag	et	al.,	2011;	Kim	et	al.,	2011).	Therefore,	
wild	type	cells	and	cells	over-expressing	dIPMK	were	maintained	in	control	conditions	(in	the	
presence	of	solvent	only	and	the	absence	of	CBG	or	CBD)	or	treated	with	CBG	or	CBD	(0.25	μM	
for	1	and	24	hours)	(Figure	5.7	B)	and	inositol	phosphates	were	extracted	and	separated	using	
polyacrylamide	gel	electrophoresis	(Losito	et	al.,	2009),	and	IP6	levels	were	quantified.	Here,	CBD	
significantly	elevated	IP6	levels	following	acute	(1	hour)	exposure	(15	%)	(p<0.05,	Kruskal-Wallis	
test	with	Dunn’s	Multiple	Comparison	Post-test),	and	both	CBG	and	CBD	significantly	elevated	
IP6	levels	following	chronic	(24	hours)	exposure	(15	%)	(Figure	5.7	B)	(p<0.05,	Kruskal-Wallis	test	
with	 Dunn’s	Multiple	 Comparison	 Post-test).	 Repeating	 this	 analysis	 in	 cells	 over-expressing	
dIPMK	found	that	 the	CBG-	and	CBD-dependent	elevated	of	 IP6	 levels	are	 lost	 (Figure	5.7	C).	
Figure	 5.7:	 Cannabinoids	 upregulate	 catalytic	 activity	 of	 IPMK	 in	D.	 discoideum.	 A:	 IPMK	 has	 a	
catalytic	role	in	the	creation	of	higher	order	inositol	phosphates,	the	protein	can	catalyse	IP4	and	IP5	
creation,	which	are	essential	for	the	creation	of	IP6.	B:	Wild	type	D.	discoideum	cells	were	maintained	
in	control	conditions	or	treated	with	0.25	μM	CBG	or	CBD	for	1	or	24	hours.	The	one-hour	treatment	
of	wild	type	with	CBD	(p<0.05)	and	24-hour	treatment	with	either	CBG	or	CBD	significantly	increased	
IP6	 levels	 (p<0.05)	 compared	 to	 wild	 type	 untreated,	 n=6.	 Data	 were	 not	 normally	 distributed	
(Shapiro-Wilks),	therefore	a	Kruskal-Wallis	test	with	Dunn’s	Multiple	Comparison	Post-test	was	used	
to	evaluate	significance.	C:	IPMK+	D.	discoideum	cells	were	exposed	to	0.25	μM	CBG	or	CBD	or	vehicle	
(-)	control	for	1	or	24	hours,	n=6.	No	significant	effects	were	found	of	cannabinoid	treatment	on	IP6	
levels	in	IPMK+	cells.	Data	were	not	normally	distributed	(Shapiro-Wilks),	therefore	a	Kruskal-Wallis	
test	with	Dunn’s	Multiple	Comparison	Post-test	was	used	to	evaluate	significance.	
m
TO
RC
1 mTOR
Raptor
LST8IPMK
IPMK
IP3IP4IP5IP6
A B
- CBG CBD CBG CBD
0
50
100
150
1	h 24	h
Re
la
tiv
e	
IP
6	
le
ve
ls
- CBG CBD CBG CBD
0
50
100
150 *
1	h 24	h
Re
la
ti
ve
	IP
6	
le
ve
ls
C dIPMK+
1	h 24	h
CBG CBD CBG CBD-
IP
6
IP6
CBD
Wild	type
1	h 24	h
CBG CBD CBG-
100	
	
Together,	 these	 data	 indicate	 a	 role	 for	 CBG	 and	 CBD	 in	 activating	 IPMK	 to	 elevate	 the	
production	of	higher	order	inositol	phosphates.		
	
5.3	Discussion	
In	this	chapter,	the	effects	of	CBG	on	the	mTORC1	pathway	in	D.	discoideum	were	characterised	
and	 the	 roles	of	 IPMK,	PKB	and	PI3K	 in	 these	effects	were	examined.	As	 IPMK	 is	 involved	 in	
mTORC1	 signalling,	 the	 effects	 of	 CBG	 and	 other	 cannabinoids	 on	 mTORC1	 activity	 were	
measured	through	phosphorylation	of	4EBP1.	Using	this	approach,	CBG	and	CBD	were	found	to	
elevate	mTORC1	activity	in	wild	type	D.	discoideum	cells,	an	effect	not	shared	by	CBDA	or	CBDV.	
Following	 this,	 dIPMK-overexpression	 was	 found	 to	 result	 in	 an	 elevated	 level	 of	 mTORC1	
activity,	 however,	 CBG	 and	 CBD	 reduced	mTORC1	 activity	 in	 dIPMK	over-expressing	 cells.	 In	
addition,	 PKBA	 ablation	 resulted	 in	 an	 increased	 mTORC1	 activation,	 while	 CBG	 and	 CBD	
treatment	 in	PKBA	ablated	cells	 further	 increased	mTORC1	activity.	Furthermore,	ablation	of	
both	PKB	proteins	or	chemical	inhibition	of	PI3K	activity	in	D.	discoideum	blocked	any	increase	
in	mTORC1	activity	by	CBG	or	CBD.	Therefore,	a	potential	mechanism	of	action	for	CBG	and	CBD	
of	mTORC1	regulation	through	IPMK,	PI3K	and	PKB	in	D.	discoideum	was	discovered.		
To	measure	mTORC1	activity	in	D.	discoideum,	4EBP1	phosphorylation	was	analysed	by	western	
blot.	Phosphorylation	of	4EBP1	is	routinely	used	as	a	readout	for	mTORC1	activation	in	many	
organisms	(Qin	et	al.,	2016;	Woodcock	et	al.,	2019;	Chang	et	al.,	2020).	The	protein	4EBP1	is	a	
major	translational	repressor,	which	inhibits	cap-dependent	translation	and	therefore	reduces	
protein	production	and	cell	growth	(Woodcock	et	al.,	2019).	Once	phosphorylated	by	an	active	
mTORC1,	4EBP1	no	 longer	 inhibits	cellular	protein	production.	Phosphorylation	of	4EBP1	has	
previously	been	measured	in	D.	discoideum	to	determine	mTORC1	activity	(Rosel	et	al.,	2012;	
Cardenal-Muñoz	et	 al.,	 2017;	Chang	et	 al.,	 2020).	However,	 in	D.	discoideum	an	antibody	 to	
detect	total	levels	of	the	4EBP1	protein	is	not	available	(Chang	et	al.,	2020).	Therefore,	it	is	not	
possible	 to	 determine	 whether	 a	 proportion	 of	 phosphorylated	 4EBP1	 is	 changed	 or	 if	 the	
proportion	 of	 phosphorylated	 protein	 remains	 the	 same	 but	 the	 total	 amount	 of	 protein	
changes.	However,	 during	 this	 study,	 the	 aim	was	 to	 translate	 any	 findings	 into	mammalian	
systems	where	the	phosphorylation	of	4EBP1	and	total	4EBP1	protein	can	be	measured	(So	et	
al.,	2016).	Therefore,	in	this	study,	the	phosphorylation	of	4EBP1	in	D.	discoideum	was	used	to	
measure	mTORC1	activity,	with	the	aim	to	validate	the	results	in	mammalian	models.		
Investigation	of	 the	molecular	mechanisms	of	CBG	was	the	main	aim	of	 this	study,	however,	
other	 cannabinoids	 were	 also	 examined	 to	 determine	 any	 shared	 molecular	 targets	 in	 D.	
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discoideum.	 Interestingly,	 CBG	 and	 CBD	 both	 increased	 mTORC1	 activity	 in	 wild	 type	 D.	
discoideum	cells,	however,	two	closely	related	cannabinoids,	CBDV	and	CBDA	did	not	have	this	
effect.	 The	differential	 response	of	D.	discoideum	mTORC1	activity	 to	different	 cannabinoids	
may	arise	from	the	structural	differences	between	the	molecules.	The	active	cannabinoids	both	
have	five-carbon	chains	on	the	third	carbon	of	the	benzyl	ring	and	no	carboxylic	acid	group	(Citti	
et	al.,	2018).	The	combination	of	an	absence	of	an	acidic	group	and	the	presence	of	a	five-carbon	
chain	on	these	cannabinoids	could	be	responsible	for	the	ability	to	activate	mTORC1,	through	
steric	or	charge-related	hindrance	effects	in	target	binding	or	in	reaching	the	molecular	target	
within	a	cell.	In	a	previous	study,	both	CBG	and	CBD	in	intraperitoneal	administration	were	found	
at	 higher	 concentrations	 in	 the	 blood	 and	 brain	 of	 mice	 than	 CBDV	 (Deiana	 et	 al.,	 2012),	
consistent	with	a	difference	in	transport	across	the	plasma	membrane.	There	is	a	possibility	that	
higher	concentrations	of	CBDV	and	CBDA	would	be	capable	of	regulating	mTORC1	activation,	
which	could	be	explored	in	future	studies	in	disease	models.	However,	this	study	finds	that	CBG	
and	CBD	share	a	role	in	mTORC1	activation	in	D.	discoideum.	
In	 addition	 to	 CBG	 activation	 of	 mTORC1	 activity,	 dIPMK	 over-expression	 in	 D.	 discoideum	
increased	mTORC1	activity,	mimicking	the	treatment	of	wild	type	cells	with	CBG	or	CBD.	In	this	
model,	 treatment	 of	 the	 dIPMK	 over-expressing	 cells	 with	 CBG	 or	 CBD	 decreased	 mTORC1	
activity.	Conversely,	while	ablation	of	PKBA	also	led	to	an	increase	in	mTORC1	activity,	treatment	
of	PKBA	ablated	cells	with	CBG	or	CBD	further	increased	mTORC1	activity.	These	data	suggest	
that	in	D.	discoideum,	CBG	and	CBD	treatment	may	enhance	the	direct	role	of	IPMK	in	mTORC1	
function.	In	wild	type	cells,	this	would	increase	mTORC1	activity	and	suggest	that	IPMK	is	a	rate-
limiting	factor	for	mTORC1	activation.	In	dIPMK	over-expressing	cells,	to	maintain	homeostasis,	
there	could	be	an	 increased	reliance	on	PIP3	production	by	IPMK	(Blind	et	al.,	2012),	thereby	
leaving	 cells	 with	 a	 reduced	 PI3K/PKB	 signalling	 pathway	 necessary	 for	 the	 activation	 of	
mTORC1.	 In	 this	 case,	 CBG	 or	 CBD	 treatment	 would	 increase	 IPMK	 direct	 involvement	 in	
mTORC1	function,	and	a	reduction	in	PIP3	production	in	the	cell,	therefore	reducing	mTORC1	
activation	overall.	While	 this	model	 suggests	CBG-	 and	CBD-dependent	 activation	of	 IPMK	 is	
PI3K/PKB-independent,	 functional	PI3K/PKB	signalling	remains	necessary	for	the	activation	of	
mTORC1,	supported	by	pharmacological	inhibition	of	PI3K	activity	and	ablation	of	PKB	activity	
(in	PKBA-PKGB-	cells)	leading	to	a	block	of	mTORC1	activation.	In	addition	to	previous	reports	of	
cannabinoids	functioning	through	PI3K/PKB	signalling	(Giacoppo	et	al.,	2017,	Zuardi	et	al.,	2009),	
these	 data	 suggest	 a	 novel	 mechanistic	 insight	 into	 CBG-	 and	 CBD-dependent	 regulation	 of	
mTORC1	 through	 enhanced	 IPMK	 activity	 in	 the	 presence	 of	 a	 functionally	 active	 PI3K/PKB	
signalling	pathway.	
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In	the	previous	chapter,	over-expression	of	dIPMK	was	found	to	increase	the	resistance	of	D.	
discoideum	to	CBG	during	growth,	and	in	this	chapter	ablation	of	PKBA	also	resulted	in	resistance	
to	this	effect.	However,	PKBA	ablated	cells	were	found	to	be	ten-fold	more	resistant	to	CBG	than	
wild	 type	cells	and	three-fold	more	resistant	 than	dIPMK	over-expressing	cells.	This	could	be	
because	PKB	is	a	regulator	of	mTORC1	activity	(Gunn	and	Hailes,	2008),	a	downstream	effector	
of	mTORC2	signalling	(Oh	and	Jacinto,	2011),	and	regulates	between	cell	division,	apoptosis	or	
survival	 (Hövelmann	et	 al.,	 2004).	Given	 the	 complexity	of	PKB	 involvement	 in	 cell	 signalling	
pathways,	it	is	difficult	to	discern	the	specific	mechanism	by	which	ablation	of	PKBA	results	in	
an	increase	in	resistance	to	CBG	during	growth	in	D.	discoideum.	However,	in	H.	sapiens,	PKB	
over-expression	can	result	in	tumour	formation,	due	to	a	reduced	ability	of	cells	to	halt	division,	
demonstrating	the	necessity	of	normal	PKB	function	for	correct	cell	growth	(Hövelmann	et	al.,	
2004).	In	D.	discoideum	on	the	other	hand,	the	two	PKB	proteins	may	work	redundantly	(Meili	
et	al.,	2000;	Suess	et	al.,	2017),	such	that	loss	of	one	protein	results	in	a	change	in	expression	or	
activity	 of	 the	 other	 protein.	 If	 CBG	 acts	 on	 an	 activity	 specific	 to	 PKBA,	while	 PKGB	 acts	 to	
regulate	cellular	processes	 independently	of	CBG,	 this	would	 result	 in	an	 increased	ability	of	
PKBA-	cells	to	grow	in	the	presence	of	CBG.	Although	further	studies	are	necessary	to	examine	
the	complex	roles	of	PKB	in	growth	regulation,	in	this	study	PKB	was	found	to	be	a	key	regulator	
of	D.	discoideum	response	to	CBG	during	growth.	
To	 further	 determine	 the	 effect	 of	 CBG	 on	 IPMK	 and	 PKB	 activities,	 higher	 order	 inositol	
phosphate	levels	were	measured.	IPMK	catalyses	the	production	of	IP4	and	IP5	and	is	therefore	
necessary	for	both	IP6	and	IP7	production	(Chakraborty	et	al.,	2010).	Both	CBG	and	CBD	were	
found	 to	 significantly	 increase	 IP6	 levels	 after	 24-hour	 treatment	 in	wild	 type	D.	discoideum,	
while	over-expression	of	dIPMK	blocked	this	effect.	Furthermore,	one-hour	treatment	with	CBD	
significantly	increased	IP6	levels.	This	increase	is	likely	to	be	highly	relevant	to	cell	function	since	
a	previously	reported	18%	increase	in	IP6	levels	indicated	that	this	change	in	IP6	levels	may	alter	
calcium	influx	over	the	plasma	membrane	signal	 (Larsson	et	al.,	1997).	Therefore,	these	data	
suggest	that	CBG	and	CBD	target	IPMK	activity	and	that	CBG	and	CBD	regulate	mTORC1	through	
IPMK	activity	independently	of	PI3K/PKB	(Kim	et	al.,	2011,	Saiardi	et	al.,	1999,	Maag	et	al.,	2011b,	
Chakraborty	et	al.,	2010).	Inositol	phosphate	regulation	is	a	key	cellular	process	necessary	for	
the	regulation	of	histone	modification	(Watson	et	al.,	2012),	calcium	signalling	(Frederick	et	al.,	
2005),	and	PKB	regulation	(Maag	et	al.,	2011).	The	key	roles	of	IPMK	in	these	cellular	processes	
could	explain	the	reduction	in	CBG	sensitivity	during	growth	in	PKB	ablated	cells	as	IP7	inhibits	
PKB	activity	(Mackenzie	and	Elliott,	2014).	In	this	chapter,	CBG	is	shown	to	increase	IP6	levels	in	
D.	discoideum	after	24	hours,	if	these	levels	remain	elevated	then	PKB	would	be	inhibited	and	
unable	to	signal	for	continued	growth	(Litman	et	al.,	2007).	However,	IP7	inhibits	PKB	by	binding	
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to	the	pleckstrin	homology	domain	which	blocks	the	ability	of	PIP3	to	bind	this	domain	(Calleja	
et	al.,	2007;	Chakraborty	et	al.,	2010).	The	PKGB	protein	does	not	contain	this	domain,	therefore,	
if	PKGB	replaces	some	of	the	activity	of	PKBA	after	ablation	of	the	latter,	then	IP7	levels	would	
no	longer	inhibit	PKB	activity	and	the	cell	would	be	more	capable	of	growing	in	the	presence	of	
CBG.	 The	 observed	 change	 in	 IP6	 levels	 in	 this	 chapter	 suggests	 that	 CBG	 and	CBD	 alter	 the	
production	of	 inositol	phosphates	and	 therefore	may	affect	 IP7	 levels.	 Therefore,	 a	potential	
mechanism	of	action	of	CBG	through	regulation	of	mTORC1	through	IPMK	in	D.	discoideum	 is	
identified,	 however,	 a	 mammalian	 model	 was	 necessary	 to	 validate	 this	 mechanism	 and	
determine	potential	therapeutic	relevance.	
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Chapter	6:	Translation	of	the	mechanisms	of	action	of	CBG	from	
D.	discoideum	into	mammalian	models	
6.1	Introduction	
In	the	previous	chapter,	a	molecular	mechanism	of	action	of	CBG	and	CBD	was	suggested	to	be	
regulation	of	mTORC1	activity	through	IPMK	in	D.	discoideum.	Here,	in	wild	type	cells	when	IPMK	
expression	was	at	a	normal	level,	CBG	and	CBD	elevated	mTORC1	activity.	However,	when	IPMK	
expression	was	elevated,	CBG	and	CBD	 inhibited	mTORC1	activity,	which	suggested	that	CBG	
and	CBD	regulated	mTORC1	in	a	homeostatic	manner	through	IPMK.	Furthermore,	the	CBG-	and	
CBD-regulated	elevation	of	mTORC1	activity	in	wild	type	cells	was	found	to	be	dependent	upon	
PI3K	 activity.	While	 these	mechanisms	 of	 action	 for	 CBG	 and	 CBD	were	 demonstrated	 in	D.	
discoideum,	further	analysis	with	mammalian	proteins	and	in	mammalian	cells	were	needed	to	
confirm	the	conservation	of	the	effect.		
To	determine	if	CBG	and	CBD	regulation	of	mTORC1	activity	was	conserved	in	mammals,	three	
models	were	used,	expression	of	the	H.	sapiens	IPMK	in	D.	discoideum,	examination	of	mouse	
embryonic	 fibroblasts	 (MEFs)	 and	primary	peripheral	blood	mononuclear	 cells	 (PBMCs)	 from	
healthy	volunteers	and	patients	with	multiple	sclerosis	(MS).	MEFs	were	highly	useful	since	a	
cell	line	lacking	IPMK	in	MEFs	was	available	for	comparative	analysis	(Kim	et	al.,	2011),	allowing	
the	assessment	of	MEF	cells	 lacking	IPMK	or	with	pharmacologically	 inhibited	PI3K	activity	to	
determine	the	dependence	of	CBG-	and	CBD-dependent	mTORC1	regulation	on	these	signalling	
components.	Primary	peripheral	blood	mononuclear	cells	(PBMCs)	from	healthy	volunteers	and	
patients	with	multiple	sclerosis	(MS)	were	used	to	determine	whether	regulation	of	mTORC1	in	
a	disease	model	occurred	following	treatment	with	CBG,	CBD,	or	a	combination	of	THC	and	CBD	
(THC:CBD)	at	concentrations	similar	to	the	plasma	concentrations	achieved	in	patients	with	MS	
who	take	Sativex®	(Leussink	et	al.,	2012).	PBMCs	are	the	primary	producers	of	pro-inflammatory	
cytokines	which	 increase	 the	progression	of	MS	 (Simpson	et	 al.,	 2015).	 These	 cells	 include	T	
lymphocytes,	B	cells	and	monocytes	(Yu	et	al.,	2007)	that	become	activated	in	individuals	with	
MS,	crossing	the	blood-brain	barrier	and	leading	to	axonal	degradation	and	myelin	damage	in	
the	 central	 nervous	 system	 (CNS)	 (Bar-Or	 et	 al.,	 2003).	 In	 these	 cells,	 there	 is	 often	 an	
overactivation	of	mTORC1	activity	and	overproduction	of	pro-inflammatory	cytokines	(Carbone	
et	 al.,	 2014).	 Therefore,	 many	 MS	 therapies	 are	 immunomodulatory	 and	 target	 peripheral	
immune	cells.	In	this	study,	the	aim	was	to	investigate	if	CBG,	CBD,	or	a	combination	of	THC	and	
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CBD,	 treatment	 of	 PBMCs	 could	 similarly	 regulate	 mTORC1	 activation	 as	 observed	 in	 D.	
discoideum	and	determine	potential	therapeutic	relevance.		
6.2	Results	
6.2.1	The	effect	of	CBG	and	CBD	on	human	IPMK-expressing	D.	discoideum	
To	 examine	 if	 the	 CBG	 molecular	 mechanism	 involving	 IPMK	 was	 conserved	 between	 D.	
discoideum	and	H.	sapiens,	the	human	IPMK	protein	was	expressed	in	D.	discoideum.	This	cell	
line	was	created	using	a	C-terminal	RFP	over-expression	plasmid	which	contained	a	human	IPMK	
(hIPMK)	insert,	synthesized	using	a	D.	discoideum	codon	bias	(Genscript)	and	then	cloned	into	
the	 RFP-containing	 plasmid	 (Figure	 6.1	 A)	 (pDM324	 (Veltman	 et	 al.,	 2009)).	 To	 ensure	 the	
plasmid	was	constructed	correctly,	digestion	with	restriction	enzymes	that	cleaved	at	the	5’	and	
3’	ends	of	 the	hIPMK	 insert	confirmed	that	an	 insert	of	 the	correct	size	 (1260	bp)	 for	hIPMK	
existed	in	this	plasmid	in	the	correct	location	(Figure	6.1	B).	The	whole	gene	was	sequenced	to	
ensure	no	mutations	had	occurred.	Thereafter,	the	plasmid	was	transfected	into	D.	discoideum	
and	 presence	 of	 the	 hIPMK-RFP	 protein	 was	 examined	 by	 western	 blot	 using	 an	 anti-RFP	
antibody.	This	analysis	revealed	that	hIPMK-expressing	cells	(hIPMK+)	showed	a	specific	75	kDa	
RFP-containing	protein,	absent	in	wild	type	cells	and	consistent	with	the	expression	of	full-length	
hIPMK-RFP	 (Figure	 6.1	 C).	 Furthermore,	 wild	 type	 and	 hIPMK+	 contained	 a	 similar	 level	 of	
protein,	as	evidenced	by	the	control	protein	(streptavidin).	This	experiment	confirmed	that	a	
heterologous	H.	sapiens	IPMK-RFP	protein	was	present	in	D.	discoideum	cells.	
To	determine	the	localisation	of	the	hIPMK-RFP	protein	in	D.	discoideum,	fluorescent	microscopy	
was	carried	out.	Growing	cells	expressing	RFP-only,	and	hIPMK-RFP	were	imaged	using	a	wide-
field	fluorescence	microscope	under	agar	to	flatten	cells,	enabling	clear	cellular	localisation.	This	
analysis	 indicated	 that	 RFP-only	 localised	 mainly	 to	 the	 cytoplasm	 (Figure	 6.1	 D),	 while	
hIPMK-RFP	was	primarily	localised	in	the	nucleus,	with	some	cytoplasmic	localisation	(Figure	6.1	
E)	 as	 occurs	 in	 human	 cells	 (Nalaskowski	 et	 al.,	 2002).	 This	 contrasts	 with	 the	 previously	
examined	 dIPMK-RFP	 protein	 (Figure	 4.7)	which	 localised	 evenly	 to	 both	 the	 cytoplasm	 and	
nucleus.	Therefore,	D.	discoideum	cells	were	confirmed	to	express	a	correctly	localised	hIPMK-
RFP	protein.	This	was,	therefore,	an	IPMK	over-expressor	cell	line,	but	with	the	human	IPMK.	
To	determine	whether	hIPMK	expression	in	D.	discoideum	regulated	sensitivity	to	CBG	during	
growth,	the	hIPMK+	cell	 line	was	examined	for	resistance	to	CBG	treatment	during	growth.	In	
these	experiments,	hIPMK+	cells	were	grown	in	the	presence	of	increasing	concentrations	of	CBG	
over	168	hours.	Under	control	conditions	(in	the	presence	of	solvent	only),	hIPMK+	D.	discoideum	
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cell	 growth	 showed	 a	 lag	 phase	 until	 96	 hours,	 an	 exponential	 phase	 to	 144	 hours	 and	 a	
stationary	phase	starting	at	168	hours	(Figure	6.2	A).	Similarly	to	wild	type	cells	(Figure	3.1),	CBG	
concentrations	 above	 1	 µM	 significantly	 inhibited	 hIPMK+	 cell	 growth	 at	 168	 hours	 (P<0.05,	
Mann-Whitney	test	and	P<0.01	for	2,	3	and	4	µM).	Data	arising	from	comparing	the	growth	rate	
at	differing	concentrations	of	CBG	was	used	to	calculate	a	hIPMK+	IC50	for	CBG	of	1.03	µM	(Figure	
6.2	B),	which	was	significantly	higher	than	the	wild	type	IC50	of	0.22	µM	(P<0.01,	one-way	ANOVA	
with	Bonferroni’s	Multiple	Comparison	Test	 (Figure	3.1)	and	dIPMK+	 IC50	of	0.64	µM	(P<0.01,	
one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test	(Figure	4.8)).	These	data	showed	
expression	of	the	human	IPMK	reduced	sensitivity	to	CBG	in	D.	discoideum	during	growth	and	
potentially	indicated	that	CBG	could	target	both	IPMK	proteins.	
Figure	6.1:	Production	of	a	human	IPMK-RFP	expressing	D.	discoideum	cell	 line.	A:	H.	sapiens	IPMK	
(hIPMK)-RFP	plasmid	was	created	in	pDM324	(7564	bp)	with	an	RFP	tag	at	the	C-terminal	of	the	protein.	
B:	SpeI	and	BglII	restriction	enzyme	digestion	sites	at	the	5’	and	3’	ends	of	the	hIPMK	gene	insert	(1260	
bp),	respectively	were	used	to	digest	the	plasmid	and	confirm	the	presence	of	the	hIPMK	insert.	The	
plasmid	was	then	transfected	into	wild	type	D.	discoideum.	C:	Western	blot	analysis	using	an	anti-RFP	
antibody	was	used	to	confirm	that	the	hIPMK-RFP	protein	was	expressed.	Streptavidin	was	used	as	a	
control	protein	to	show	that	protein	levels	were	consistent	between	samples.	D:	Fluorescent	images	of	
RFP-only	expressing	cells,	showing	a	mainly	cytosolic	localisation.	E:	Fluorescent	images	of	hIPMK+	cells.	
The	hIPMK	protein	localised	to	the	nucleus,	unlike	the	D.	discoideum	IPMK	protein	which	 localised	to	
the	cytoplasm	(Figure	4.7).	Scale	bar	10	µm.	
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To	determine	if	hIPMK	expression	altered	mTORC1	activity	in	D.	discoideum	cells	following	CBG	
and	CBD	 treatment,	4EBP1	phosphorylation	was	measured	 in	wild	 type	and	hIPMK+	cells.	 To	
evaluate	a	potential	change	in	the	basal	 level	of	mTORC1	activity,	wild	type	and	hIPMK+	cells	
were	maintained	in	control	conditions	(in	the	presence	of	solvent	only)	for	one	hour,	then	levels	
of	phosphorylated	4EBP1	were	measured	by	western	blot.	Here,	cells	expressing	hIPMK	showed	
a	 2.2-fold	 increase	 in	 mTORC1	 activity,	 as	 evidenced	 by	 an	 elevated	 level	 of	 4EBP1	
phosphorylation	 compared	 to	 wild	 type	 cells	 (Figure	 6.3)	 (P<0.01,	 one-way	 ANOVA	 with	
Bonferroni’s	Multiple	Comparison	Test).	This	showed	that	expression	of	hIPMK	in	wild	type	D.	
discoideum	had	a	similar	effect	to	over-expression	of	the	endogenous	protein	(Figure	5.2).	To	
evaluate	the	response	to	CBG	and	CBD,	hIPMK+	cells	were	treated	with	0.25	µM	CBG	or	CBD	for	
Figure	6.2:	Expression	of	H.	sapiens	IPMK	in	D.	discoideum	leads	to	resistance	to	CBG	in	growth.	A:	
hIPMK+	cells	were	grown	in	the	presence	of	increasing	concentrations	of	CBG	in	shaking	culture	for	
one	week.	Growth	was	calculated	as	a	%	of	each	cell	line	in	control	conditions	(in	the	absence	of	CBG),	
n=7.	CBG	inhibited	growth	in	a	concentration-dependent	manner.	Data	arising	from	comparing	the	
growth	rate	at	differing	concentrations	of	CBG	was	used	to	create	a	secondary	plot.	Data	were	not	
normally	 distributed	 (Shapiro-Wilks),	 therefore	 a	 Mann	Whitney	 test	 was	 carried	 out	 to	 test	 for	
significance	of	inhibition	by	each	concentration	of	CBG	compared	to	control	at	168	hours,	*	-	p<0.05,	
**	-	p<0.01.	Graphs	show	mean	±	SEM.	B:	Secondary	plot	analysis	was	used	to	determine	the	 IC50,	
hIPMK+	IC50	=	1.03	μM	(n=7).	The	wild	type	(WT)	IC50	(0.22	μM)	is	significantly	lower	than	hIPMK+	IC50	
(p<0.01)	and	dIPMK+	 IC50	(0.64	μM)	(p<0.01).	 In	addition,	the	dIPMK+	IC50	is	significantly	lower	than	
hIPMK+	IC50	(p<0.01).	Data	were	normally	distributed	according	to	Shapiro-Wilks.	A	one-way	ANOVA	
with	Bonferroni’s	Multiple	Comparison	Test	was	carried	out	to	test	significance.		
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one	hour,	then	levels	of	phosphorylated	4EBP1	were	measured	by	western	blot.	Treatment	of	
hIPMK+	 cells	with	CBG	or	CBD	 resulted	 in	 a	 significant	 35	%	and	50	%	 reduction	 in	mTORC1	
activity,	respectively,	as	evidenced	by	a	decrease	in	the	level	of	4EBP1	phosphorylation	(Figure	
6.3)	(P<0.01,	one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test).	This	result	showed	
that	elevated	IPMK	levels	(using	the	human	protein)	increased	basal	mTORC1	activity	and	CBG	
or	CBD	treatment	reduced	this	mTORC1	activity	to	wild	type	levels.	
		
6.2.2	The	effect	of	CBG	and	CBD	on	mTORC1	activity	in	mouse	embryonic	fibroblasts	
To	 examine	 if	 the	 CBG-	 and	 CBD-dependent	 regulation	 of	mTORC1	 activity	 was	 shared	 in	 a	
mammalian	model,	mouse	embryonic	fibroblasts	(MEFs)	were	examined.	Here,	wild	type	MEF	
cells	were	maintained	 in	 control	 conditions	 (in	 the	presence	of	 solvent	only)	or	 treated	with	
4	 µM	 CBG	 or	 CBD	 for	 24	 hours,	 then	 the	 levels	 of	 phosphorylated	 and	 total	 4EBP1	 were	
quantified	by	western	blot.	In	these	cells,	mTORC1	activity	was	significantly	elevated	1.5-fold	by	
CBG	or	CBD	treatment,	as	evidenced	by	an	increase	in	the	proportion	of	phosphorylated	4EBP1	
to	 total	 4EBP1	 (Figure	 6.4	 A)	 (P<0.01,	 one-way	 ANOVA	with	 Dunnett's	Multiple	 Comparison	
Figure	6.3:	Expression	of	hIPMK	reverses	the	CBG-	and	CBD-dependent	elevation	of	mTORC1	activity	
in	D.	discoideum.	D.	discoideum	cells	expressing	the	human	IPMK	protein	(hIPMK+)	were	maintained	
in	control	conditions	(in	the	absence	of	CBG	or	CBD	(-))	or	treated	with	0.25	μM	CBG	or	CBD	for	1	hour	
and	then	analysed	for	levels	of	phosphorylated	4EBP1	by	western	blot,	n=7.	hIPMK+	cells	in	control	
conditions	had	significantly	higher	mTORC1	activity	than	untreated	wild	type	cells.	 In	hIPMK+	 cells,	
CBG	and	CBD	treatment	 significantly	 reduced	mTORC1	activity.	 Streptavidin	was	used	as	a	 control	
protein	to	show	that	protein	levels	were	consistent	between	samples.	Data	shown	represents	mean±	
standard	error	of	the	mean.	Data	were	normally	distributed	with	Shapiro-Wilks.	A	one-way	ANOVA	
with	Bonferroni’s	Multiple	Comparison	Test	was	carried	out	to	test	significance,	**	-	p<0.01.	
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Test).	This	increase	in	the	proportion	of	phosphorylated	4EBP1	was	caused	by	a	significant	1.3-
fold	 increase	 in	the	phosphorylation	of	4EBP1	(Figure	6.4	B)	(P<0.01	and	P<0.05	respectively,	
one-way	 ANOVA	with	Dunnett's	Multiple	 Comparison	 Test)	 and	 an	 unchanged	 level	 of	 total	
4EBP1	 (Figure	 6.4	 C)	 (one-way	 ANOVA	 with	 Dunnett's	 Multiple	 Comparison	 Test).	 In	
combination,	 these	 data	 showed	 CBG-	 and	 CBD-dependent	 elevation	 of	 mTORC1	 activity	
occurred	in	wild	type	MEFs.	
To	assess	whether	 IPMK	signalling	was	necessary	 for	CBG-	and	CBD-dependent	 regulation	of	
mTORC1	activity,	MEF	cells	lacking	the	IPMK	protein	were	examined	for	response	to	CBG	and	
CBD.	Here,	MEF	cells	 lacking	 the	 IPMK	protein	 (Kim	et	al.,	 2011)	were	maintained	 in	 control	
conditions	(in	the	presence	of	solvent	only)	or	treated	with	4	µM	CBG	or	CBD	for	24	hours,	then	
the	levels	of	phosphorylated	and	total	4EBP1	were	quantified	by	western	blot.	In	these	cells,	no	
significant	 change	 was	 observed	 in	 mTORC1	 activity	 after	 treatment	 with	 CBG	 or	 CBD,	 as	
evidenced	by	no	change	in	the	proportion	of	phosphorylated	4EBP1	to	total	4EBP1	(Figure	6.5	
A)	(one-way	ANOVA	with	Dunnett's	Multiple	Comparison	Test).	Treatment	with	CBG	or	CBD	did	
not	 significantly	 alter	 the	 phosphorylation	 of	 4EBP1	 (Figure	 6.5	 B)	 (one-way	 ANOVA	 with	
Dunnett's	Multiple	Comparison	Test)	or	total	4EBP1	levels	(Figure	6.5	C)	(one-way	ANOVA	with	
Dunnett's	 Multiple	 Comparison	 Test).	 In	 combination,	 these	 data	 showed	 CBG-	 and	
CBD-dependent	regulation	of	mTORC1	was	dependent	on	the	existence	of	the	IPMK	protein.	
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Figure	6.4:	CBG	and	CBD	upregulate	mTORC1	activity	 in	mouse	embryonic	fibroblasts.	A-C:	Wild	
type	MEF	cells	were	maintained	in	control	conditions	(in	the	absence	of	CBG	or	CBD	(-))	or	treated	
with	4	μM	CBG	or	CBD	for	24	hours	and	then	were	analysed	for	phosphorylated	and	total	4EBP1	levels.	
Actin	was	used	as	a	control	protein	to	show	that	protein	levels	were	consistent	between	samples.	
Data	 shown	 represents	mean±	 standard	 error	 of	 the	mean.	 Data	 were	 normally	 distributed	 with	
Shapiro-Wilks	 and	 significance	 was	 tested	 using	 a	 One	 -Way	 ANOVA	 with	 Dunnett's	 Multiple	
Comparison	Test,	significance,	*	-	p<0.05,	**	-	p<0.01,	n=9.	A:	mTORC1	activity	significantly	increased	
in	cells	treated	with	CBG	or	CBD,	as	evidenced	by	an	increase	in	the	proportion	of	phosphorylated	to	
total	4EBP1.	B:	Phosphorylation	of	4EBP1	significantly	increased	in	cells	treated	with	CBG	or	CBD.	C:	
Total	4EBP1	did	not	significantly	change	in	cells	treated	with	CBG	or	CBD.	
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To	 determine	 if	 PI3K	 signalling	 was	 necessary	 for	 CBG	 regulation	 of	 mTORC1	 activity	 in	
mammalian	cells,	as	observed	in	D.	discoideum,	MEF	cells	were	examined.	Here,	wild	type	MEF	
cells	were	treated	with	a	PI3K	inhibitor	(10	µM	Pictilisib	(Yu	et	al.,	2015;	Beale	et	al.,	2016)),	and	
either	maintained	in	control	conditions	(in	the	presence	of	solvent	only)	or	treated	with	4	µM	
CBG	or	CBD	for	24	hours,	then	the	levels	of	phosphorylated	and	total	4EBP1	were	quantified	by	
western	 blot.	 These	 experiments	 showed	 that	 no	 significant	 change	 in	mTORC1	 activity	was	
observed	in	MEF	cells	lacking	PI3K	activity	when	treated	with	CBG	or	CBD,	as	evidenced	by	no	
change	 in	 the	 proportion	 of	 phosphorylated	 4EBP1	 to	 total	 4EBP1	 (Figure	 6.6	 A)	 (one-way	
ANOVA	with	Dunnett's	Multiple	Comparison	Test).	In	PI3K	inhibitor-treated	MEF	cells,	CBG	or	
CBD	treatment	did	not	alter	the	phosphorylation	of	4EBP1	(Figure	6.6	B)	(one-way	ANOVA	with	
Dunnett's	Multiple	Comparison	Test)	or	total	4EBP1	levels	(Figure	6.6	C)	(one-way	ANOVA	with	
Dunnett's	Multiple	Comparison	Test).	 In	combination,	 these	data	showed	PI3K	signalling	was	
necessary	for	CBG-	and	CBD-dependent	regulation	of	mTORC1.	
6.2.3	The	effect	of	CBG,	CBD	and	a	THC:CBD	mixture	on	mTORC1	activity	in	primary	
peripheral	mononuclear	cells	derived	from	humans	
Since	CBG-	and	CBD-dependent	regulation	of	mTORC1	activity	was	shown	to	be	shared	between	
D.	 discoideum	 and	 M.	 musculus	 MEF	 cells,	 primary	 H.	 sapiens	 PBMCs	 were	 examined	 to	
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Figure	6.5:	CBG	and	CBD	do	not	upregulate	mTORC1	in	the	absence	of	IPMK	in	mouse	embryonic	
fibroblasts.	A-C:	MEF	 cells	 lacking	 the	 IPMK	protein	were	maintained	 in	 control	 conditions	 (in	 the	
absence	 of	 CBG	 or	 CBD	 (-))	 or	 treated	 with	 4	 μM	 CBG	 or	 CBD	 for	 24	 hours	 were	 analysed	 for	
phosphorylated	and	total	4EBP1	levels.	Actin	was	used	as	a	control	protein	to	show	that	protein	levels	
were	consistent	between	samples.	Data	shown	represents	mean±	standard	error	of	the	mean.	Data	
were	normally	distributed	with	Shapiro-Wilks	and	significance	was	tested	using	a	One	-Way	ANOVA	
with	Dunnett's	Multiple	Comparison	Test,	n=9.	A:	mTORC1	activity	did	not	significantly	change	in	cells	
lacking	 IPMK	 when	 treated	 with	 CBG	 or	 CBD,	 as	 evidenced	 by	 no	 change	 in	 the	 proportion	 of	
phosphorylated	to	total	4EBP1.	B:	Phosphorylation	of	4EBP1	did	not	significantly	change	in	cells	lacking	
IPMK	when	treated	with	CBG	or	CBD.	C:	Total	4EBP1	did	not	significantly	change	in	cells	lacking	IPMK	
when	treated	with	CBG	or	CBD.		
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determine	if	this	effect	was	conserved	in	human	cells	in	a	clinical	context.	Here,	primary	PBMCs	
were	extracted	from	healthy	volunteers	(demographics	in	Table	6.1	A)	and	maintained	in	control	
conditions	 (in	 the	 presence	 of	 solvent	 only)	 or	 treated	with	 CBG	or	 CBD	 (0.1	 µM),	 or	 plant-
derived	highly	purified	THC:CBD	combinations	(0.02	µM:0.017	µM)	for	24	hours	(carried	out	by	
Trinity	College	Dublin).	Following	this,	mTORC1	activity	was	analysed	 in	primary	PBMCs	from	
healthy	volunteers	by	quantification	of	phosphorylated	and	total	4EBP1	levels	by	western	blot.	
In	 this	analysis,	mTORC1	activity	was	significantly	elevated	1.3-fold	 following	CBG	treatment,	
1.2-fold	following	CBD	treatment	and	1.6-fold	following	THC:CBD	treatment,	as	evidenced	by	an	
increase	in	the	proportion	of	phosphorylated	4EBP1	to	total	4EBP1	(Figure	6.7	A,	B,	C)	(P<0.05,	
Mann-Whitney	Test).	Surprisingly,	this	change	in	ratio	was	not	driven	by	a	significant	change	in	
the	level	of	phosphorylated	(Figure	6.7	D,	E,	F)	or	total	4EBP1	(Figure	6.7	G,	H,	I).	In	fact,	the	level	
of	4EBP1	phosphorylation	appeared	to	not	change	following	CBG	treatment	(P=0.48),	however,	
a	nonsignificant	 trend	 towards	an	 increase	 in	phosphorylated	4EBP1	was	observed	 following	
CBD	treatment	(P=0.18)	and	following	THC:CBD	(P=0.10)	(Mann-Whitney	Test).	In	addition,	the	
observed	change	in	mTORC1	activity	did	not	result	from	a	significant	change	in	the	level	of	total	
4EBP1	(Figure	6.7	G,	I).	In	fact,	the	level	of	total	4EBP1	appeared	to	not	change	following	CBD	
treatment	 (P=0.59),	 however,	 a	 nonsignificant	 trend	 towards	 a	 decrease	 in	 total	 4EBP1	was	
observed	following	CBG	treatment	(P=0.13)	and	following	THC:CBD	treatment	(P=0.13)	(Mann-
Whitney	 Test).	 In	 combination,	 these	 data	 showed	 a	 CBG-,	 CBD-	 and	 THC:CBD-dependent	
elevation	 of	 mTORC1	 activity	 occurred	 in	 peripheral	 blood	 mononuclear	 cells	 from	 healthy	
volunteers.	
To	determine	the	potential	therapeutic	relevance	of	mTORC1	regulation	in	primary	PBMCs,	cells	
from	healthy	volunteers	and	patients	with	multiple	sclerosis	were	compared.	In	this	study,	the	
volunteers	and	patients	were	age-	and	gender-matched	and	information	on	the	disease	duration	
and	treatment	was	attained	for	the	patients	with	MS	(Table	6.1	A	and	B).	In	control	conditions	
(in	the	presence	of	solvent	only),	cells	from	patients	with	multiple	sclerosis	were	found	to	have	
a	significant	1.7-fold	higher	level	of	mTORC1	activity	compared	to	cells	from	healthy	volunteers,	
as	 evidenced	 by	 the	 proportion	 of	 phosphorylated	 4EBP1	 compared	 to	 total	 4EBP1	 (P<0.05,	
Mann-Whitney	 Test)	 (Figure	 6.8	 A).	 Furthermore,	 cells	 derived	 from	 patients	 with	 multiple	
sclerosis	 showed	 a	 significant	 3.5-fold	 higher	 level	 of	 phosphorylated	 4EBP1	 than	 cells	 from	
healthy	 volunteers	 (P<0.01,	Mann-Whitney	 Test)	 (Figure	 6.8	 B).	 In	 addition,	 a	 nonsignificant	
trend	 towards	 an	 elevated	 level	 of	 total	 4EBP1	 was	 observed	 between	 cells	 from	 healthy	
volunteers	and	patients	with	multiple	sclerosis	 (P=0.13)	 (Figure	6.8	C).	 In	combination,	 these	
data	showed	that	mTORC1	activity	was	at	a	constitutively	elevated	level	in	PBMCs	from	patients	
with	MS.
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Since	PBMCs	from	patients	with	MS	were	found	to	have	elevated	mTORC1	activity	compared	to	
cells	 from	 healthy	 volunteers,	 cells	 from	 patients	 with	MS	 were	 tested	 for	 CBG-,	 CBD-	 and	
THC:CBD-dependent	regulation	of	mTORC1	activity.	Here,	primary	PBMCs	were	extracted	from	
patients	with	multiple	sclerosis	and	maintained	in	control	conditions	(in	the	presence	of	solvent	
only)	 or	 treated	 with	 CBG	 or	 CBD	 (0.1	 µM),	 or	 plant-derived	 highly	 purified	 THC:CBD	
combinations	(0.02	µM:0.017	µM)	for	24	hours	(carried	out	by	Trinity	College	Dublin).	 In	this	
analysis,	mTORC1	activity	was	significantly	reduced	1.4-fold	following	CBG	treatment,	2.2-fold	
following	CBD	treatment	and	2.0-fold	following	THC:CBD	treatment,	as	evidenced	by	a	decrease	
in	the	proportion	of	phosphorylated	4EBP1	to	total	4EBP1	(Figure	6.9	A,	B,	C)	(P<0.05	for	CBG	
treatment,	P<0.01	for	CBD	or	THC:CBD	treatment,	Mann-Whitney	Test).	This	reduction	was	due	
to	a	reduction	in	phosphorylation	of	4EBP1,	which	significantly	reduced	2.2-fold	following	CBG	
treatment,	2.4-fold	following	CBD	treatment	and	2.8-fold	following	THC:CBD	treatment	(Figure	
6.9	D,	E,	F)	(P<0.01,	Mann-Whitney	Test).	In	addition,	no	significant	change	in	total	4EBP1	levels	
was	observed	following	CBG,	CBD	or	THC:CBD	treatment	(Figure	6.9	G,	H,	I).	More	specifically,	
no	 trend	 in	 total	4EBP1	change	was	observed	 following	CBD	 treatment	 (P=0.59),	however,	 a	
nonsignificant	trend	towards	an	increase	in	total	4EBP1	following	CBG	treatment	(P=0.09)	and	
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Figure	6.6:	PI3K	signalling	is	necessary	for	CBG	and	CBD	activation	of	mTORC1	in	mouse	embryonic	
fibroblasts.	A-C:	Wild	type	MEF	cells	treated	with	a	PI3K	inhibitor	(Pictilisib)	and	maintained	in	control	
conditions	(in	the	absence	of	CBG	or	CBD	(-))	or	treated	with	4	μM	CBG	or	CBD	for	24	hours	were	
analysed	 for	 phosphorylated	 and	 total	 4EBP1	 levels	 by	western	 blot.	 Actin	was	 used	 as	 a	 control	
protein	to	show	that	protein	levels	were	consistent	between	samples.	Data	shown	represents	mean±	
standard	error	of	the	mean.		Data	were	normally	distributed	with	Shapiro-Wilks	and	significance	was	
tested	using	a	One	-Way	ANOVA	with	Dunnett's	Multiple	Comparison	Test,	n=9.	A:	mTORC1	activity	
did	not	significantly	change	in	cells	treated	with	PI3K	inhibitor	compared	with	both	the	PI3K	inhibitor	
and	CBG	or	CBD	treatment,	as	evidenced	by	no	change	in	the	proportion	of	phosphorylated	to	total	
4EBP1.	B:	Phosphorylation	of	4EBP1	did	not	significantly	change	in	cells	treated	with	PI3K	inhibitor	
compared	with	the	inhibitor	and	CBG	or	CBD	treatment.	C:	Total	4EBP1	did	not	significantly	change	in	
cells	treated	with	PI3K	inhibitor	compared	with	the	inhibitor	and	CBG	or	CBD	treatment.		
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following	 THC:CBD	 treatment	 (P=0.24)	 treatment	 was	 observed.	 In	 combination,	 these	 data	
showed	 a	 CBG-,	 CBD-	 and	 THC:CBD-dependent	 decrease	 of	 mTORC1	 activity	 occurred	 in	
peripheral	blood	mononuclear	cells	from	patients	with	multiple	sclerosis.	
To	determine	if	levels	of	IPMK	were	responsible	for	the	difference	in	mTORC1	activity	seen	in	
PBMCs	from	healthy	volunteers	and	patients	with	multiple	sclerosis,	samples	from	both	groups	
were	analysed	for	total	IPMK	levels	by	Western	blot	analysis.	From	this	analysis,	the	47	kDa	IPMK	
protein	was	not	visualised	 (Figure	6.10),	and	no	additional	 sample	 from	this	experiment	was	
available	 to	 test	 for	 IPMK	 levels	 using	 other	 methodologies.	 The	 antibody	 used	 in	 this	
experiment	has	been	used	in	previous	studies	to	confirm	the	presence	of	the	IPMK	protein	in	
human-derived	cells	(KB-3-1)	and	absence	of	the	protein	in	IPMK-ablated	cells	(Pan	et	al.,	2019).	
Thus,	with	the	methodology	and	materials	available,	it	was	not	possible	to	monitor	differences	
in	 total	 IPMK	 levels	 between	 PBMCs	 from	 healthy	 volunteers	 and	 patients	 with	 multiple	
sclerosis.	
Table	6.1:	Demographic	breakdown	for	PBMC	donation	origin	of	healthy	volunteers	and	patients	with	
MS.	A:	The	age	and	gender	of	each	of	the	healthy	volunteers.	B:	The	age,	gender,	current	treatment,	and	
disease	duration	for	the	MS	patients.	Gilenya	is	a	fingolimod	and	has	an	uncharacterised	mechanism	of	
action,	suggested	to	have	both	immunological	and	nervous	system	activities	(Chun	and	Brinkmann,	2011).	
Tecfidera	is	suggested	to	reduce	oxidative	stress	and	regulates	antioxidant	production	(Robinson,	2014).	
Plegridy	 is	 an	 interferon	 beta-1a	 conjugated	 to	 a	 methoxy	 polyethylene	 glycol	 molecule	 and	 has	 an	
uncharacterised	immunomodulatory	effect	(Hoy,	2015).	
	
Age Sex
41 F
53 F
34 M
40 M
45 F
39 F
Age Sex Treatment Disease	
duration	
(months)
37 Male Previously	on	Gilenya- stopped	recently 120
21 Female None 48
55 Male Tecfidera 20+years
41 Female Plegridy 13
25 Female None 6
Not	reported Female not	reported not	reported
Healthy	Volunteers	 Patients	with	MSA B
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Figure	6.7:	CBG-,	CBD-	and	THC:CBD-dependent	elevation	of	mTORC1	activity	occurs	 in	primary	
PBMCs	from	healthy	volunteers.	A-I:	Primary	PBMCs	from	healthy	volunteers	were	maintained	in	
control	 conditions	 (in	the	absence	of	CBG,	CBD	or	THC	 (-))	or	treated	with	0.1	μM	CBG	or	CBD	or	
0.02:0.017	µM	THC:CBD	for	24	hours	and	analysed	for	phosphorylated	and	total	4EBP1	levels.	Actin	
was	used	as	a	control	protein	to	show	that	protein	levels	were	consistent	between	samples.	Data	
shown	represents	mean±	standard	error	of	the	mean.		Data	were	not	distributed	normally	according	
to	Shapiro-Wilks,	therefore	a	Mann	Whitney	test	was	carried	out	to	test	for	significance,	*	-	p<0.05.	
A,	B,	C:	mTORC1	activity	significantly	increased	with	CBG,	CBD	or	THC:CBD	treatment	of	PBMC	cells	
originating	 from	 healthy	 volunteers,	 as	 evidenced	 by	 an	 elevated	 proportion	 of	 phosphorylated	
4EBP1	to	total	4EBP1	(n=6).	D,	E,	F:	CBG,	CBD	or	THC:CBD	treatment	of	PBMC	cells	originating	from	
healthy	volunteers	did	not	significantly	alter	phosphorylated	4EBP1	levels	(n=6).	G,	H,	I:	CBG,	CBD	or	
THC:CBD	treatment	of	PBMC	cells	originating	from	healthy	volunteers	did	not	significantly	alter	total	
4EBP1	levels	(n=6).		
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Figure	 6.8:	 PBMCs	 from	 healthy	 volunteers	 and	 patients	 with	 multiple	 sclerosis	 have	 different	
constitutive	 mTORC1	 activity.	 A-C:	 To	 examine	 the	 therapeutic	 relevance	 of	mTORC1	 activity	 in	
multiple	sclerosis,	mTORC1	activity	was	measured	in	PBMCs	derived	from	healthy	volunteers	(Hv)	and	
patients	with	multiple	sclerosis	 (PwMS).	Data	shown	represents	mean±	standard	error	of	the	mean.		
Data	were	not	distributed	according	to	Shapiro-Wilks,	therefore	a	Mann	Whitney	test	was	carried	out	
to	test	for	significance,	*	-	p<0.05,	**	-	p<0.01.	Actin	was	used	as	a	control	protein	to	show	that	protein	
levels	were	consistent	between	samples.	A:	PBMCs	originating	in	patients	with	multiple	sclerosis	were	
found	to	have	a	significantly	higher	level	of	mTORC1	activity,	as	evidenced	by	an	elevated	proportion	
of	phosphorylated	4EBP1	to	total	4EBP1	than	cells	from	healthy	volunteers.	B:	PBMCs	originating	in	
patients	with	multiple	sclerosis	were	found	to	have	a	significantly	higher	level	of	phosphorylated	4EBP1	
than	from	cells	from	healthy	volunteers.	C:	PBMCs	originating	in	patients	with	multiple	sclerosis	were	
not	found	to	have	a	significantly	different	total	4EBP1	compared	to	cells	from	healthy	volunteers.	
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Figure	6.9:	CBG-,	CBD-	and	THC:CBD-dependent	decrease	of	mTORC1	activity	occurs	 in	primary	
PBMCs	 from	 patients	 with	 MS.	 A-I:	 Primary	 PBMCs	 from	 patients	 with	multiple	 sclerosis	 were	
maintained	in	control	conditions	(in	the	absence	of	CBG,	CBD	or	THC	(-))	or	treated	with	0.1	μM	CBG	
or	CBD	or	0.02:0.017	µM	THC:CBD	for	24	hours	and	analysed	for	phosphorylated	and	total	4EBP1	
levels.	Actin	was	used	as	a	 control	protein	 to	 show	 that	protein	 levels	were	 consistent	between	
samples.	Data	 shown	 represents	mean±	 standard	 error	of	 the	mean.	 	Data	were	not	distributed	
according	to	Shapiro-Wilks,	therefore	a	Mann	Whitney	test	was	carried	out	to	test	for	significance,	
*	-	p<0.05,	**	-	p<0.01.	A,	B,	C:	mTORC1	activity	significantly	reduced	with	CBG,	CBD	or	THC:CBD	
treatment	of	PBMC	cells	originating	from	patients	with	multiple	sclerosis,	as	evidenced	by	a	reduced	
proportion	of	phosphorylated	4EBP1	to	total	4EBP1	(n=6).	D,	E,	F:	CBG,	CBD	or	THC:CBD	treatment	
of	PBMCs	from	patients	with	multiple	sclerosis	significantly	reduced	phosphorylated	4EBP1	 levels	
(n=6).	G,	H,	I:	CBG,	CBD	or	THC:CBD	treatment	of	PBMC	cells	originating	from	patients	with	multiple	
sclerosis	did	not	significantly	alter	total	4EBP1	levels	(n=6).		
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Figure	6.10:	Attempt	to	measure	IPMK	levels	in	PBMCs	from	healthy	volunteers	(Hv)	and	patients	
with	multiple	sclerosis	(PwMS).	A:	Protein	 ladder	(Pageruler	Plus	Prestained	 ladder),	 indicating	the	
size	of	proteins	in	the	western	blot.	B:	Western	blot	showing	the	presence	of	phosphorylation	4EBP1	
and	actin	in	PBMCs.	C:	Western	blot	showing	the	presence	of	total	4EBP1	in	PBMCs.	D:	Western	blot	
attempt	 to	 detect	 total	 IPMK	 protein	 in	 PBMCs	 using	 anti-IPMK	 antibody	 (ab96753),	 no	 band	 is	
detected	at	47	kDa.	 
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6.3	Discussion	
In	 this	 chapter,	 the	 effects	 of	 CBG	 and	 CBD	 on	 the	mTORC1	 pathway	were	 examined	 in	D.	
discoideum,	M.	musculus	and	H.	sapiens	cells.	In	D.	discoideum,	expression	of	the	human	IPMK	
protein	(over-expressing	IPMK	overall)	was	found	to	have	elevated	mTORC1	activity	compared	
to	wild	type	cells.	In	addition,	treatment	of	hIPMK-expressing	D.	discoideum	cells	with	CBG	or	
CBD	resulted	 in	a	decrease	 in	mTORC1	activity,	 in	contrast	to	an	 increase	 in	mTORC1	activity	
following	CBG	or	CBD	treatment	of	wild	type	cells	(Figure	5.2).	The	effect	of	CBG	and	CBD	on	
mTORC1	 activity	was	 then	 examined	 in	wild	 type	mouse	 embryonic	 fibroblasts.	 In	wild	 type	
MEFs,	 CBG	 and	 CBD	 elevated	 mTORC1	 activity,	 while	 in	 cells	 lacking	 IPMK	 or	 with	
pharmacologically	inhibited	PI3K	activity,	CBG	and	CBD	did	not	alter	mTORC1	activity.	Primary	
human	peripheral	blood	mononuclear	cells	from	healthy	volunteers	and	patients	with	MS	were	
then	examined	to	determine	if	CBG-	and	CBD-dependent	mTORC1	regulation	was	conserved	in	
human	cells.	 In	 cells	 from	healthy	volunteers	CBG,	CBD	and	a	mixture	of	THC	and	CBD	were	
found	 to	elevate	mTORC1	activity.	However,	 in	 cells	 from	patients	with	MS	which	 showed	a	
constitutively	elevated	level	of	mTORC1	activity,	CBG,	CBD	and	THC:CBD	were	found	to	reduce	
mTORC1	activity.	
In	this	chapter	expression	of	the	human	IPMK	protein	in	D.	discoideum	was	examined	for	its	role	
in	 regulating	 response	 to	 CBG	 and	 CBD.	 In	 the	 previous	 chapter	 over-expression	 of	 the	
endogenous	D.	 discoideum,	 IPMK	 protein	 in	D.	 discoideum	 led	 to	 resistance	 to	 CBG	 during	
growth	and	reversed	the	effects	of	CBG	and	CBD	treatment	on	mTORC1	activity.	In	contrast	to	
the	conservation	of	 these	phenotypes	of	dIPMK	over-expression	and	hIPMK	expression	 in	D.	
discoideum,	several	differences	were	observed.	These	differences	include	cellular	localisation	of	
IPMK	(hIPMK	primarily	in	the	nucleus,	dIPMK	in	cytoplasm	and	nucleus),	the	degree	of	resistance	
to	CBG	during	growth	(hIPMK+	1.6-fold	higher	than	dIPMK+)	and	the	degree	of	mTORC1	activity	
increase	(2.2-fold	for	hIPMK+	and	1.9-fold	for	dIPMK+).	Although	a	rationale	for	these	differences	
has	not	been	experimentally	confirmed,	they	could	arise	from	a	difference	of	CBG	or	CBD	binding	
to	IPMK,	differential	binding	of	IPMK	to	other	proteins,	or	cellular	localisation	of	each	protein.	
One	approach	to	investigate	this	could	be	to	examine	the	possible	binding	of	CBG,	CBD	and	THC	
to	IPMK	and	subsequently	investigate	whether	the	IPMK	proteins	have	different	cannabinoid-
binding	affinities,	which	could	be	examined	by	biochemical	binding	affinity	assays	(Carrier	et	al.,	
2006).	Another	potential	cause	of	the	differences	between	dIPMK+	and	hIPMK+	cells	could	be	a	
differential	binding	affinity	of	each	 IPMK	to	protein	binding	partners	such	as	mTOR.	Previous	
studies	have	found	that	the	human	IPMK	may	have	a	higher	binding	affinity	for	mTOR	than	the	
D.	discoideum	IPMK	(Kim	et	al.,	2011),	this	could	result	in	the	elevated	mTORC1	activity	observed	
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in	 hIPMK+	 cells.	 Alternatively,	 the	 difference	 could	 be	 a	 result	 of	 the	 increased	 nuclear-
localisation	 of	 the	 human	 protein	 (Nalaskowski	 et	 al.,	 2002),	 as	 observed	 by	 fluorescence	
microscopy.	 In	 the	 nucleus,	 IPMK	may	 act	 through	 PI3K	 activities	 to	mediate	 transcriptional	
control	 or	 export	 of	 nuclear	mRNA	 (Blind	 et	 al.,	 2012).	 Furthermore,	 IPMK	may	 act	 to	 alter	
chromatin	 structure	 and	 global	 transcription	 through	 inositol	 phosphate	 production,	 which	
increases	histone	deacetylation	(Watson	et	al.,	2012;	Millard	et	al.,	2013).	Finally,	IPMK	directly	
binds	 transcription	 factors,	 such	 as	 serum	 response	 factor	 (SRF)	 (Kim	 et	 al.,	 2013),	 cAMP-
response	element-binding	protein	(CREB)	binding	protein	(CBP)	(Xu	et	al.,	2013(a)),	and	p53	(Xu	
et	al.,	2013(b))	and	could,	therefore,	lead	to	the	transcriptional	control	of	a	specific	set	of	genes.	
The	 role	of	 IPMK	 in	 transcriptional	 regulation	was	beyond	 the	 scope	of	 this	 study,	however,	
future	experiments	could	examine	the	links	between	cannabinoid	treatment	and	transcriptional	
differences	 in	 IPMK-regulated	 gene	 expression.	 Regardless,	 this	 chapter	 shows	 a	 conserved	
mechanism	 of	 action	 of	 CBG	 and	 CBD	 in	 regulating	mTORC1,	 and	 resistance	 to	 CBG	 during	
growth,	through	both	the	D.	discoideum	and	H.	sapiens	IPMK	proteins.		
In	this	chapter,	CBG	and	CBD	were	found	to	elevate	mTORC1	activity	in	wild	type	mouse	cells	
and	human	cells	from	healthy	volunteers.	In	MEFs,	a	concentration	of	4	µM	of	CBG	or	CBD	was	
chosen	since	this	concentration	was	used	in	a	variety	of	previous	in	vitro	experiments	(Rajesh	et	
al.,	2007;	Qin	et	al.,	2008;	O’Sullivan	et	al.,	2009;	Kozela	et	al.,	2011).	The	concentration	of	4	µM	
CBG	and	CBD	was	found	to	increase	mTORC1	activation	in	wild	type	MEF	cells.	However,	this	
study	did	not	examine	lower	concentrations	of	the	cannabinoids,	therefore,	it	is	unclear	if	lower	
concentrations	of	CBG	and	CBD	would	activate	mTORC1	in	MEF	cells.	The	concentration	of	CBG	
and	CBD	at	0.1	µM	used	to	treat	primary	PBMCs	in	this	chapter	was	based	upon	in	vivo	plasma	
levels	of	cannabinoids	in	treated	patients	from	previous	studies	(Consroe	et	al.,	1991;	Haney	et	
al.,	2016).	 In	one	study,	CBD	administered	orally	at	10	mg/kg	was	present	at	0.03	µM	 in	 the	
plasma	of	healthy	human	volunteers	(Consroe	et	al.,	1991).	 In	another	study,	800	mg	of	CBD	
administered	orally,	resulted	in	peak	plasma	concentrations	of	CBD	(at	one	to	two	hours	post-
treatment)	ranging	between	0.006	and	0.866	µM	(with	an	average	of	0.245	µM)	(Haney	et	al.,	
2016).	These	previous	studies	imply	that	0.1	µM	is	a	concentration	that	occurs	in	the	plasma	of	
humans	 when	 cannabinoids	 are	 orally	 administered,	 and	 therefore	 was	 chosen	 for	 these	
experiments.	Interestingly,	a	much	lower	concentration	of	0.02	µM:0.017	µM	of	a	combination	
of	 THC	 and	 CBD	 showed	 the	 same	 effect.	 Previous	 studies	 investigating	 the	 anti-emetic	
properties	of	CBD	and	THC	in	Suncus	murinus	have	suggested	a	synergistic	effect	of	this	kind	on	
a	different	mechanism	(Rock	and	Parker,	2015),	which	could	be	a	future	focus	in	the	research	of	
cannabinoids	as	therapeutics.	Nevertheless,	the	CBG-,	CBD-	and	THC:CBD-dependent	regulation	
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of	 mTORC1	 found	 in	 this	 chapter	 occurs	 at	 therapeutically	 relevant	 concentrations	 of	
cannabinoid,	providing	a	basis	for	future	clinical	trials.	
MEFs	were	used	in	this	study	to	examine	a	role	for	IPMK	and	PI3K	signalling	in	CBG-	and	CBD-
dependent	regulation	of	mTORC1	activity	in	a	mammalian	cell	line.	MEFs	were	previously	used	
to	explore	IPMK-regulation	of	mTORC1	activity,	and	a	null	mutant	was	available	to	specify	a	role	
for	this	protein	in	CBG	and	CBD	function	(Kim	et	al.,	2011).	In	this	chapter,	mTORC1	activity	was	
found	to	be	present	in	MEF	cells	lacking	IPMK,	however,	this	was	not	altered	following	CBG	or	
CBD	treatment.	This	 indicated	that	 IPMK	activity	was	necessary	 for	 the	elevation	of	mTORC1	
activity	found	in	wild	type	cells.	In	addition,	treatment	with	a	pharmacological	PI3K	inhibitor	also	
resulted	in	a	block	of	CBG-	and	CBD-dependent	elevation	of	mTORC1	activity,	suggesting	that	
PI3K	 signalling	 is	 necessary	 for	 these	 effects.	 Previous	 research	 has	 indicated	 that	 the	 PI3K	
activity	of	IPMK	may	be	responsible	for	50	%	of	the	production	of	PIP3	in	MEF	cells	(Maag	et	al.,	
2011).	Therefore,	the	block	in	CBG-	and	CBD-dependent	elevation	of	mTORC1	activity	 in	cells	
lacking	 IPMK	 or	 PI3K	 activity	 could	 be	 directly	 related.	 This	 would	 imply	 that	 CBG	 and	 CBD	
regulate	the	PI3K	activity	of	IPMK	and	that	this	is	responsible	for	the	increase	in	mTORC1	activity	
observed	 in	 wild	 type	MEFs.	 Alternatively,	 CBG	 and	 CBD	may	 alter	 another	 aspect	 of	 IPMK	
activity,	such	as	mTORC1	binding	(Kim	et	al.,	2011)	or	IP6	production	(Kim	et	al.,	2017),	and	this	
activity	 in	 addition	 to	 a	 functional	 PI3K	 signalling	 pathway	 is	 necessary	 for	 CBG-	 and	 CBD-
dependent	 elevation	 of	 mTORC1	 activity.	 Further	 experiments	 could	 use	 High-Performance	
Liquid	Chromatography	to	measure	PIP3	levels	in	wild	type	MEFs	and	MEFs	lacking	IPMK	treated	
with	CBG	and	CBD	to	determine	the	role	of	IPMK-related	PI3K	activity	in	cannabinoid-regulation	
of	mTORC1	activity	(Maag	et	al.,	2011).	This	chapter	has	indicated	that	both	IPMK	and	functional	
PI3K	signalling	are	necessary	for	CBG-	and	CBD-dependent	elevation	of	mTORC1	activity	and	that	
the	two	could	be	linked.	
Findings	 in	 this	 study	 indicate	 that	 PBMCs	 from	MS	 patients	 contain	 constitutively	 elevated	
mTORC1	activity	compared	to	cells	from	healthy	volunteers	and	that	treatment	with	CBG,	CBD	
or	THC:CBD	reduced	mTORC1	activity	in	cells	from	patients	with	MS.	Previous	research	found	
that	 activation	 of	 immune	 cells,	 such	 as	 those	 present	 in	 PBMCs,	 occurs	 through	 elevated	
mTORC1	signalling	(Gao	et	al.,	2015;	Herrero-Sánchez	et	al.,	2016).	The	activation	of	cells	present	
in	 PBMCs	 leads	 to	 the	 autoimmune	 inflammation	 that	 causes	 demyelination	 of	 neurons	
(Hasheminia	et	al.,	2014).	Previous	studies	found	that	CBD	can	decrease	the	activation	of	these	
cells	 (Kozela	 et	 al.,	 2011),	 consistent	 with	 the	 results	 found	 in	 this	 study.	 Furthermore,	 the	
activation	of	cells	subtypes	found	in	PBMCs	is	associated	with	bipolar	disorder	(Drexhage	et	al.,	
2011),	potentially	indicating	therapeutic	uses	for	CBG,	CBD	and	THC	beyond	multiple	sclerosis.	
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Previously	discovered	CBD	deactivation	of	immune	cells	is	therefore	consistent	with	the	CBG-,	
CBD-	and	THC:CBD-dependent	downregulation	of	mTORC1	activity	in	PBMCs	from	patients	with	
MS	found	in	this	chapter	and	indicates	therapeutic	targets	for	cannabinoids	in	MS	treatment.		
In	 immune	 cells	 constituent	 in	 PBMCs,	 mTOR	 activation	 results	 in	 NF-κB	 (nuclear	 factor)	
activation	and	nuclear	translocation	(Gao	et	al.,	2015).	NF-κB	is	a	pro-inflammatory	transcription	
factor,	binding	specific	DNA	sequences	and	promoting	the	transcription	of	inflammatory	actors,	
such	 as	 TNF-α	 (tumour	 necrosis	 factor)	 and	 IL-6	 (interleukin)	 (Wu	 et	 al.,	 2011;	 Hayden	 and	
Ghosh,	2012).	Blocking	mTOR	activity	in	bone	marrow,	the	progenitor	tissue	of	immune	cells,	
results	in	an	inhibition	of	cell	proliferation	(Costa	et	al.,	2006).	mTOR	inhibition	has	also	been	
found	 to	 supress	NF-κB	and	as	a	 result	 reduce	 IL-6	expression	 (Müller-Krebs	et	 al.,	 2013).	 In	
immune	cells,	the	mTOR	pathway	controls	proliferation,	cell	cycle	progression,	differentiation,	
survival,	migration	 and	metabolism	 (Herrero-Sánchez	 et	 al.,	 2016).	 In	 fact,	 PI3K	 inhibitors	 or	
mTOR	inhibition	are	capable	of	blocking	T	cell	proliferation	and	activation	(Herrero-Sánchez	et	
al.,	2016).	mTOR	inhibition	in	T	cells	also	reduces	the	total	4EBP1	(Herrero-Sánchez	et	al.,	2016),	
consistent	with	 the	 similar	 finding	 for	 CBG	or	 THC:CBD	 treatment	 of	 PBMCs	 in	 this	 chapter.	
mTOR	inhibitors,	as	well	as	reducing	T	cell	activation,	exert	beneficial	effects	on	models	of	MS	
(Russo	et	al.,	2016).	Indicating	the	potential	therefore	of	cannabinoids	as	a	treatment	of	MS,	if	
the	effect	of	mTOR	inhibition	is	found	in	vivo	as	well.		
In	addition	to	MS,	cannabinoids	have	been	found	to	modulate	mTOR	signalling	in	other	disease	
models.	In	these	models,	mTOR	dysregulation	has	often	been	implicated	as	a	potential	causative	
or	 aggravative	 factor	 and	 therefore	modulation	 of	mTOR	 is	 seen	 as	 a	 potential	 therapeutic	
pathway.	 In	 some	 studies,	 cannabinoids	 have	 been	 found	 to	 reduce	 mTOR	 activity,	 as	 is	
consistent	with	the	finding	in	this	chapter	that	CBG,	CBD	and	THC:CBD	reduce	mTOR	activity	in	
PBMCs	 from	patients	with	MS.	 In	 a	 zebrafish	model	 of	 tuberosclerosis	 complex	 disease,	 the	
disease	model	was	found	to	have	constitutively	elevated	mTOR	signalling	and	CBD	reduced	this	
mTOR	pathway	activation	(as	assessed	by	abundance	of	phosphorylated	S6	kinase)	(Serra	et	al.,	
2019).	 In	addition,	 in	breast	cancer	cell	 lines	 in	which	constitutively	elevated	mTOR	signalling	
occurs,	 CBD	 reduced	 mTOR	 pathway	 activation	 (assessed	 by	 analysis	 of	 the	 proportion	 of	
phosphorylated	4EBP1)	(Shrivastava	et	al.,	2011;	Sultan	et	al.,	2018).	In	other	disease	models,	
mTORC1	 activity	 is	 activated	 during	 treatment	with	 cannabinoids,	 consistent	with	 the	 CBG-,	
CBD-dependent	activation	of	mTORC1	activity	observed	in	wild	type	mouse	cells	and	primary	
PBMCs	 from	 healthy	 volunteers	 found	 in	 this	 thesis.	 In	 neurons	 of	 a	 mouse	 experimental	
autoimmune	 encephalomyelitis	 model	 of	MS,	 mTOR	 activity	 was	 found	 to	 be	 constitutively	
reduced,	 and	 CBD	 elevated	 mTOR	 activity	 to	 normal	 levels	 (assessed	 by	 analysis	 of	 the	
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proportion	 of	 phosphorylated	 S6	 kinase,	 mTOR	 and	 PKB)	 (Giacoppo	 et	 al.,	 2017).	 CBD	 also	
treated	 symptoms	 of	 an	 amphetamine-induced	 rat	 model	 of	 schizophrenia,	 and	 elevated	
mTORC1	activity	(assessed	by	analysis	of	the	proportion	of	phosphorylated	S6	kinase	and	mTOR)	
(Renard	et	al.,	 2016).	The	mechanisms	behind	 these	apparently	 contradictory	effects	of	CBD	
treatment	are	unknown,	however,	this	thesis	finds	the	two	opposite	effects	of	CBD-dependent	
mTOR	regulation	occur	in	both	D.	discoideum	and	primary	PBMCs	from	humans.	In	this	study,	
the	 opposite	 effects	 of	 cannabinoid	 treatment	 on	mTORC1	 activity	 appear	 to	 be	 dependent	
upon	 the	 basal	 state	 of	 the	 cells	 examined,	 and	 in	D.	 discoideum	 the	 level	 of	 IPMK	protein.	
Therefore,	a	potentially	therapeutically	relevant	pro-homeostatic	role	of	CBG,	CBD	and	THC	in	
combination	with	CBD	in	mTOR	regulation	is	indicated.		
Since	previous	chapters	have	evidenced	a	role	for	IPMK	in	CBG-	and	CBD-dependent	mTORC1	
regulation,	levels	of	IPMK	were	investigated	in	PBMCs	from	healthy	volunteers	and	patients	with	
MS.	Unfortunately,	IPMK	was	not	detected	in	either	group	using	western	blot	analysis.	As	the	
antibody	against	IPMK	had	previously	been	used	to	detect	the	IPMK	protein	in	human	(KB-3-1)	
cells	(Pan	et	al.,	2019),	there	is	a	possibility	that	IPMK	levels	in	the	PBMCs	tested	were	too	low	
to	be	measured	by	western	blot.	Therefore,	further	analysis	of	IPMK	levels	in	these	cells	could	
be	analysed	using	techniques	such	as	immunoprecipitation	or	quantitative	analysis	of	protein	
by	ELISA	to	analyse	protein	levels	(Lin	et	al.,	2013)	or	qPCR	to	analyse	mRNA	expression	levels	
(Rocha	et	al.,	2016).	In	addition,	future	studies	may	examine	the	levels	of	IPMK	in	patients	with	
MS	and	examine	whether	mutations	in	IPMK	or	at	promoter	sites	surrounding	IPMK	correlate	
with	the	incidence	of	MS.	In	fact,	IPMK	has	been	demonstrated	to	have	a	noncatalytic	role	in	
enhancing	 toll-like	 receptor	 (TLR)	 signalling	 in	 macrophages,	 by	 stabilising	 tumour	 necrosis	
factor	 (TNF)	 receptor-associated	 factor	 6	 (TRAF6)	 (Kim	 et	 al.,	 2017).	 IPMK	 depletion	 in	
macrophages	reduces	TNF-signalling	and	reduces	pro-inflammatory	cytokine	production,	which	
would	 be	 consistent	with	MS	 patients	 showing	 higher	 IPMK	 activity	 giving	 rise	 to	 increased	
mTORC1	activity	compared	to	healthy	controls	(evidenced	in	our	analysis).	Due	to	these	central	
roles,	IPMK	could	play	in	regulating	disease	progression	of	multiple	sclerosis,	IPMK	expression	
should	be	examined	in	immune	cells	in	multiple	sclerosis	and	IPMK	should	be	further	explored	
as	a	potential	therapeutic	target.		
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7	Discussion	
7.1	Summary	
This	research	aimed	to	identify	and	characterise	molecular	mechanisms	of	the	cannabinoid	CBG,	
with	potential	translation	to	therapeutically	relevant	models.	CBG	is	of	importance	since	it	is	a	
component	of	C.	sativa	extracts	currently	prescribed	as	treatments	for	multiple	sclerosis	(MS)	
(Etges	et	al.,	2016)	and	epilepsy	(Abu-Sawwa	and	Stehling,	2020).	To	find	potential	molecular	
mechanisms	of	CBG,	the	simple	model	organism	Dictyostelium	discoideum	was	employed.	This	
model	organism	had	previously	been	used	to	identify	molecular	mechanisms	for	CBD	(Perry	et	
al.,	2020),	curcumin	and	 its	derivatives	 (Cocorocchio	et	al.,	2018),	valproic	acid	 (Chang	et	al.,	
2015),	naringenin	(Waheed	et	al.,	2014),	and	bitter	tastants	(Robery	et	al.,	2013).	These	various	
studies	have	confirmed	that	D.	discoideum	 can	be	used	to	 identify	molecular	mechanisms	of	
bioactive	and	pharmacologically	active	molecules.		
The	first	approach	to	identify	molecular	mechanisms	for	CBG	in	D.	discoideum	was	to	investigate	
if	CBG	shared	molecular	mechanisms	with	CBD.	Commonly	investigated	targets	of	cannabinoids,	
TRPs	(Otto	et	al.,	2016)	and	cannabinoid	receptors	(McPartland	et	al.,	2006(a);	McPartland	et	
al.,	2006(b);	Dey	et	al.,	2010),	are	not	present	in	D.	discoideum	and	thus	could	not	be	examined.	
However,	adenosine	transport	has	also	been	suggested	to	be	a	potential	target	of	CBD,	where	
CBD	 inhibits	 adenosine	 transport	 through	 the	 equilibrative	 nucleoside	 transporter	 1	 (ENT1)	
protein	in	rat	cells	(Liou	et	al.,	2008).	Bioinformatic	analysis	suggested	than	the	D.	discoideum	
ENT1	protein	was	an	orthologue	of	the	rat	and	human	protein	and	was	therefore	examined	for	
a	role	as	part	of	a	molecular	mechanism	of	CBG.	The	D.	discoideum	ENT1	protein	was	ablated,	
and	the	ENT1-	cell	 line	was	found	to	result	in	a	reduction	in	sensitivity	to	CBG	during	growth.	
Furthermore,	CBG	treatment	of	microglial	cells	was	found	to	increase	extracellular	adenosine,	
while	 leaving	 intracellular	 adenosine	 unchanged,	 implying	 that	 CBG	 may	 block	 adenosine	
transport	 into	microglia	 cells.	 As	 adenosine	 transport	 regulates	 DNA	methylation	 (Williams-
Karnesky	 et	 al.,	 2013),	 a	 cell	 line	 lacking	 a	 DNA	 methyltransferase	 protein	 (DNMA)	 in	 D.	
discoideum	was	explored	for	sensitivity	to	CBG	during	growth.	DNMA-	cells	also	showed	reduced	
sensitivity	to	CBG	during	growth,	consistent	with	that	shown	following	loss	of	ENT1.	Following	
this,	DNA	methylation	was	analysed	in	D.	discoideum	in	response	to	CBG	treatment.	Here,	CBG,	
pharmacological	 inhibition	 of	 ENT1,	 and	 ablation	 of	 ENT1	 were	 all	 found	 to	 elevate	 DNA	
methylation	 in	 D.	 discoideum,	 while	 ENT1	 ablation	 blocked	 the	 effects	 of	 CBG	 on	 DNA	
methylation.	These	results	indicate	that	CBG	functions	in	a	similar	mechanism	to	CBD	through	
the	 inhibition	 of	 ENT1	 activity	 in	 both	D.	 discoideum	 and	mouse	 astroglial	 cells	 to	 regulate	
adenosine	transport.	
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The	 second	 approach	 to	 identify	 molecular	 mechanisms	 for	 CBG	 in	 D.	 discoideum	 was	 an	
unbiased	approach.	Here,	a	mutant	library	was	screened	to	identify	proteins	responsible	for	CBG	
sensitivity	 during	 growth	 in	 D.	 discoideum.	 This	 method	 identified	 two	 potential	 proteins	
involved	in	the	molecular	mechanisms	of	CBG	which	had	H.	sapiens	orthologues,	thus	allowing	
for	translational	experiments.	The	two	proteins	identified	were	the	regulator	of	chromosome	
condensation	 1	 (RCC1)	 domain-containing	 (RC)	 protein	 and	 the	 inositol	 polyphosphate	
multikinase	(IPMK)	protein.	IPMK	contained	an	orthologue	of	the	protein	in	H.	sapiens,	while	RC	
only	shared	domains	with	a	H.	sapiens	protein.	The	mutant	identified	relating	to	IPMK	was	found	
to	have	a	mutagenic	insert	downstream	from	the	stop	codon,	and	with	RT-PCR	this	was	found	
to	elevate	IPMK	gene	expression.	To	confirm	the	role	of	IPMK	in	controlling	sensitivity	to	CBG	
during	growth,	a	D.	discoideum	cell	 line	over-expressing	the	D.	discoideum	 IPMK	(dIPMK-RFP)	
was	created.	Over-expression	of	IPMK	(dIPMK+	or	hIPMK+)	resulted	in	reduced	sensitivity	to	CBG	
during	growth.	As	IPMK	is	a	key	component	in	the	mTORC1	signalling	pathway,	mTORC1	activity	
was	measured	by	western	blot	analysis	of	4EBP1	phosphorylation.	 In	addition,	both	CBG	and	
CBD	were	found	to	elevate	mTORC1	activity	in	wild	type	D.	discoideum.	Interestingly,	IPMK	over-
expressing	cell	lines	(dIPMK	or	hIPMK)	were	found	to	have	elevated	mTORC1	activity	compared	
to	wild	type	cells,	and	CBG	and	CBD	treatment	reduced	mTORC1	activity	in	these	cells.	These	
experiments	 suggest	 that	 CBG	 and	 CBD	may	 have	 a	 homeostatic	 effect	 on	mTORC1	 activity	
dependent	upon	IPMK	levels.	In	D.	discoideum,	further	experiments	showed	that	the	CBG-	and	
CBD-dependent	elevation	of	mTORC1	activity	was	dependent	upon	 the	presence	of	PKB	and	
PI3K	activity.	From	these	experiments,	it	is	likely	that	CBG	and	CBD	function	through	modulation	
of	 IPMK	activity	 in	D.	discoideum	 in	a	PKB-	and	PI3K-dependent	manner	to	regulate	mTORC1	
activity.	
To	 confirm	 the	 therapeutic	 relevance	 of	 the	 IPMK	 dependent	 mechanism	 proposed	 in	 D.	
discoideum,	 two	models	were	 employed	 to	 determine	whether	 a	mechanism	 involved	 IPMK	
resulting	 in	the	regulation	of	mTORC1	activity	by	CBG	and	CBD	was	conserved	in	mammalian	
cells.	In	wild	type	mouse	embryonic	fibroblast	cells	(MEFs),	CBG	and	CBD	were	found	to	elevate	
mTORC1	activity,	consistent	with	findings	from	wild	type	D.	discoideum.	However,	in	MEF	cells	
lacking	 IPMK,	 or	 with	 pharmacologically	 inhibited	 PI3K	 activity,	 CBG	 and	 CBD	 did	 not	 affect	
mTORC1	 activity.	 This	 indicated	 that	 both	 CBG	 and	 CBD	 elevate	 mTORC1	 activity	 in	 D.	
discoideum	and	mammalian	cells	and	that	this	is	dependent	upon	IPMK	and	PI3K	in	mammalian	
cells.	 To	 investigate	 the	 therapeutic	 relevance	 of	 these	 findings,	 primary	 peripheral	 blood	
mononuclear	cells	(PBMCs)	from	healthy	volunteers	and	patients	with	MS	were	examined,	since	
these	 cells	 are	 the	 primary	 producers	 of	 pro-inflammatory	 cytokines	 which	 increase	 the	
progression	of	MS	(Simpson	et	al.,	2015).	PBMCs	from	patients	with	MS	were	found	to	have	an	
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elevated	basal	 level	 of	mTORC1	 compared	 to	 PBMCs	 from	healthy	 volunteers.	 Treatment	 of	
PBMCs	from	healthy	volunteers	with	CBG,	CBD	or	a	mixture	of	THC	and	CBD	(THC:CBD)	resulted	
in	the	elevation	of	mTORC1	activity,	consistent	with	that	observed	in	wild	type	D.	discoideum	
and	MEF	cells.	Treatment	with	CBG,	CBD	or	THC:CBD	resulted	in	a	reduction	of	mTORC1	activity	
in	 PBMCs	 from	 patients	 with	 MS	 with	 elevated	 basal	 mTORC1	 activity.	 Thus,	 the	 effect	 of	
cannabinoid	treatment	of	PBMCs	from	patients	with	MS	was	similar	to	that	found	in	IPMK-over-
expressing	D.	discoideum.	This	result	provided	significant	clinical	relevance,	since	in	MS	mTORC1	
signalling	results	in	activation	of	immune	cells	within	PBMCs	and	this	causes	myelin	damage	and	
axonal	degradation	 (Bar-Or	et	al.,	2003;	Yu	et	al.,	2007;	Carbone	et	al.,	2014;	Simpson	et	al.,	
2015),	and	thus	this	could	be	alleviated	using	CBG	or	CBD	
7.2	The	potential	of	synergistic	cannabinoid	treatment	
Research	has	indicated	that	cannabinoids	may	have	synergistic	therapeutic	effects	when	used	
together	(Mammana	et	al.,	2019).	This	is	consistent	with	our	findings	in	PBMCs	that	a	mixture	
of	THC	and	CBD	modified	mTORC1	activity	at	0.02	µM:0.017	µM,	while	CBG	and	CBD	were	found	
to	modify	mTORC1	activity	at	0.1	µM.	While	experiments	at	lower	concentrations	of	CBG	and	
CBD	were	 not	 carried	 out,	 this	 could	 indicate	 that	 cannabinoids	 have	 synergistic	 effects	 on	
molecular	mechanisms.	Similarly,	a	combination	of	CBG	and	CBD	was	more	effective	than	either	
alone	as	an	anti-inflammatory,	anti-oxidant	and	anti-apoptotic	agent	in	a	cellular	model	of	the	
neurodegenerative	disease	amyotrophic	lateral	sclerosis	(Mammana	et	al.,	2019).	Another	study	
found	 that	 THCA	 and	 CBGA	 had	 synergistic	 cytotoxic	 effects	 against	 colon	 cancer	 cells	
(Nallathambi	 et	 al.,	 2018).	 Further	 experiments	 found	 that	 a	mixture	 of	 THC,	 CBG	 and	 CBD	
showed	a	stronger	cytotoxic	effect	on	leukaemia	cells	than	CBD	alone	(Mazuz	et	al.,	2020).	In	
addition,	whole	extracts	of	C.	sativa	containing	multiple	cannabinoids	were	more	effective	at	
elevating	intracellular	calcium	levels	in	hippocampal	neurons	and	glia	than	individual	treatment	
with	THC	or	CBD	alone	(Ryan	et	al.,	2006).	Thus,	further	studies	on	different	combinations	of	
cannabinoids	 need	 to	 be	 carried	 out	 to	 establish	 the	 optimal	 combination	 for	 each	 specific	
potential	therapeutic	mechanism.		
7.4	Links	to	previously	suggested	molecular	mechanisms	of	cannabinoids	
Previous	 studies	 have	 indicated	 that	 the	molecular	mechanisms	 of	 phytocannabinoids	 could	
include	 cannabinoid	 receptors	 (Arévalo-Martín	 et	 al.,	 2003),	 adenosine	 (Carrier	 et	 al.,	 2006),	
TRPV1	(Borrelli	et	al.,	2014),	GPR55	(Devinsky	et	al.,	2014),	glycine	and	the	one-carbon	cycle	
(Perry	et	al.,	2020),	as	well	as	PI3K/PKB/mTOR	activity	(Giacoppo	et	al.,	2017).	This	thesis	adds	
to	 the	 current	 understanding	 of	 cannabinoid	 regulation	 of	 adenosine	 transport	 and	 mTOR	
activity	by	implicating	CBG	as	well	as	CBD	in	this	activity,	as	well	as	proposing	IPMK	as	a	potential	
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modulator	 of	 CBG	 and	 CBD	 activity	 on	 mTORC1	 signalling.	 Furthermore,	 the	 mechanisms	
proposed	 in	 this	 thesis	 may	 relate	 to	 or	 overlap	 with	 several	 of	 the	 existing	 mechanisms	
suggested	for	cannabinoids.	The	potential	CBD	molecular	mechanism	of	glycine	and	one-carbon	
cycle	 regulation	 may	 be	 related	 to	 adenosine	 transport	 and	 DNA	 methylation,	 as	 both	 are	
involved	in	the	same	pathway	(Perry	et	al.,	2020).	Furthermore,	TRPV1	has	been	implicated	as	
an	upstream	regulator	of	mTORC1,	potentially	through	AMPK	(Maiese,	2017;	Bort	et	al.,	2019),	
however	 since	 this	 cannabinoid	 receptor	 is	 not	 found	 in	 D.	 discoideum	 (McPartland	 et	 al.,	
2006(a);	 McPartland	 et	 al.,	 2006(b);	 Dey	 et	 al.,	 2010),	 this	 indicates	 that	 CBG-	 and	 CBD-
dependent	mTORC1	regulation	in	D.	discoideum	is	independent	of	TRPV1.	Thus,	this	thesis	adds	
to	prior	knowledge	on	the	mechanism	of	action	of	cannabinoids	and	indicates	a	potential	novel	
target	for	this	class	of	compounds,	IPMK.		
7.5	Adenosine	transport	regulation	as	a	molecular	mechanism	for	CBG	
The	data	 in	 this	 thesis	 indicate	 that	CBG	regulates	a	 signalling	pathway	 related	 to	adenosine	
transport	through	ENT1	 in	both	D.	discoideum	and	microglia.	This	 is	consistent	with	previous	
research	indicating	that	CBD,	similar	 in	structure	to	CBG,	 inhibited	adenosine	uptake	through	
ENT1	(Liou	et	al.,	2008).	Here,	CBD	was	found	to	block	diabetes-induced	retinal	damage	in	a	rat	
model	 through	 adenosine	 transport	 inhibition.	 In	 addition,	 CBD	 enhanced	 the	 adenosine-
dependent	suppression	of	TNF-α	in	the	diabetes	model	(Liou	et	al.,	2008).	The	suppression	of	
TNF-α	 reduced	 inflammation	 in	 the	 retina	 and	 therefore	 provided	 a	 potential	 treatment	 of	
diabetes-induced	neurodegeneration	through	adenosine	modulation	by	CBD	(Liou	et	al.,	2008).	
This	thesis,	therefore,	suggests	that	CBG	may	share	a	molecular	mechanism	involved	adenosine	
transport	regulation	with	CBD	and	may	therefore	also	be	a	potential	treatment	for	this	type	of	
neurodegeneration.	
Adenosine	is	an	endogenous	anticonvulsant	and	seizure	terminator	working	through	adenosine	
A1	receptor	activation	(During	and	Spencer,	1992;	Lado	and	Moshé,	2008;	Weltha	et	al.,	2019).	
This	 anticonvulsant	 effect	 occurs	 through	 upregulation	 of	 presynaptic	 inhibition	 of	 neurons,	
which	prevents	runaway	excitation	in	feed-forward	synaptic	circuits	(Huber	et	al.,	2001;	Boison,	
2012)	and	stabilises	the	postsynaptic	membrane	potential	(Figure	7.1	A)	(Baldwin	et	al.,	2004).	
Both	 of	 these	 mechanisms	 act	 to	 stop	 the	 spread	 of	 a	 seizure	 and	 as	 a	 result,	 elevated	
extracellular	adenosine	levels	can	reduce	seizure	frequency	(Li	et	al.,	2008;	Fukuda	et	al.,	2010).	
In	epilepsy,	a	reduction	in	extracellular	adenosine	levels	could	be	caused	by	over-expression	of	
adenosine	kinase	(ADK),	which	phosphorylates	adenosine	to	create	adenosine	monophosphate	
(AMP)	(Li	et	al.,	2008).	This	results	in	the	storage	of	adenosine	in	astrocytes	as	AMP,	ADP	and	
ATP,	leading	to	this	cell	type	becoming	an	adenosine	sink	(Figure	7.1	B)	(Lovatt	et	al.,	2012).	This	
reduction	in	extracellular	free	adenosine,	therefore,	increases	seizure	frequency.	CBD	inhibition	
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of	adenosine	uptake	through	equilibrative	nucleoside	transporters	into	astrocytes	would	elevate	
free	adenosine,	which	in	turn	could	act	to	reduce	seizure	frequency	and	severity	(Figure	7.1	C)	
(Pandolfo	et	al.,	2011;	Mijangos-Moreno	et	al.,	2014).	The	discovery	in	this	thesis	that	CBG	may	
also	 inhibit	 adenosine	 uptake	 through	 ENT1,	 mimicking	 the	 ENT	 inhibitor	 NBTI,	 implies	 a	
potential	shared	mechanism	with	CBD	and	future	therapeutic	possibilities	for	the	treatment	of	
epilepsy.	 To	 examine	 this,	D.	 discoideum	 intra-	 and	 extracellular	 adenosine	 levels	 could	 be	
measured	during	treatment	with	CBG	and	compared	to	CBD	treatment.		
Our	research	indicates	that	in	D.	discoideum	CBG	modulates	DNA	methylation,	a	downstream	
and	 intracellular	 component	 of	 adenosine	 signalling.	 This	 CBG-dependent	 elevation	 of	 DNA	
methylation	is	occurring	through	an	adenosine	transport-dependent	mechanism.	Some	studies	
have	examined	the	effects	of	cannabinoid	treatment	on	DNA	methylation.	For	example,	in	a	rat	
model	of	neurodegeneration,	iron	treatment	reduced	mitochondrial	DNA	methylation,	while	co-
treatment	with	CBD	mitigated	this	reduction	(da	Silva	et	al.,	2018).	In	human	keratinocytes,	CBD	
and	 CBG	both	 increased	DNA	methylation	 at	 the	 keratin	 10	 gene,	while	 only	 CBD	 increased	
global	 DNA	 methylation	 levels	 (Pucci	 et	 al.,	 2013).	 The	 CBG-dependent	 increase	 in	 DNA	
methylation	 in	 D.	 discoideum	 implies	 that	 CBG	 blocks	 the	 uptake	 of	 adenosine	 into	 D.	
discoideum,	leading	to	a	greater	extracellular	concentration	of	adenosine	and	lower	intracellular	
concentration,	consistent	with	 the	 findings	 in	microglia	cells.	This	 is	because	the	relationship	
between	adenosine	and	DNA	methylation	is	inverse,	as	DNA	methylation	relies	on	methyl	group	
donation	(Kredich	and	Martin,	1977;	Boison	et	al.,	2002).	Donation	of	a	methyl	group	from	s-
adenosylmethionine	results	 in	the	production	of	s-adenosylhomocysteine,	which	is	converted	
into	adenosine	and	homocysteine	and	occurs	at	equilibrium	and	is	 inhibited	if	adenosine	and	
homocysteine	are	not	continually	removed.	Therefore,	elevated	intracellular	adenosine	levels	
block	the	pathway	and	result	in	decreased	DNA	methylation,	and	decreased	adenosine	enables	
the	pathway	to	continue	and	results	in	increased	DNA	methylation	(Kredich	and	Martin,	1977;	
Boison	et	al.,	2002).	The	data	from	this	thesis	implies	that	adenosine	transport	into	the	cell	is	
blocked	by	CBG,	resulting	in	a	lower	intracellular	concentration	of	adenosine	and	elevated	DNA	
methylation	in	D.	discoideum.	This	is	consistent	with	the	finding	that	CBG	increased	extracellular	
adenosine	in	microglia,	potentially	by	blocking	adenosine	transport	into	the	cells.		
Regulation	 of	 DNA	 methylation	 in	 the	 context	 of	 adenosine	 levels	 may	 be	 an	 important	
mechanism	 for	 the	 progression	 of	 epilepsy	 and	 therefore	 treatment	 of	 the	 disease.	 DNA	
methylation	dysregulation	is	implicated	in	epileptogenesis	(Williams-Karnesky	et	al.,	2013).	In	a	
rat	epilepsy	model,	adenosine	was	found	to	inhibit	DNA	methylation,	leading	to	an	inhibition	of	
epileptogenesis.	Over-expression	of	adenosine	kinase	(ADK)	reduced	the	level	of	adenosine	in	
rat	cells,	resulting	in	DNA	hypermethylation	and	progression	of	epilepsy	(Williams-Karnesky	et	
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al.,	2013).	In	the	weeks	following	a	brain	injury	or	seizure,	inflammatory	processes	are	activated	
and	lead	to	astroglia	activation	which	results	in	increased	ADK	expression	(Li	et	al.,	2008;	Li	et	
al.,	 2012).	 Over-expression	 of	 ADK,	 therefore,	 results	 in	 an	 adenosine	 deficiency	 and	 a	
subsequent	increase	in	DNA	methylation.	Therapeutic	adenosine	augmentation	has	been	found	
to	restore	normal	DNA	methylation	levels	and	prevent	the	progression	of	epilepsy	in	the	long	
term	(Williams-Karnesky	et	al.,	2013).	A	block	in	adenosine	transport	through	ENT1	by	CBD	or	
CBG	indicated	that	these	cannabinoids	may	block	the	effects	of	astroglia	as	an	adenosine	sink,	
and	 counter	 the	 over-expression	 of	 ADK	 (Liou	 et	 al.,	 2008).	 However,	 this	 could	 also	 block	
adenosine	transport	into	other	cell	types,	which	would	be	deficient	in	adenosine	in	this	scenario.	
Therefore,	 future	 research	 must	 focus	 on	 the	 in	 vivo	 effects	 of	 cannabinoid	 treatment	 for	
epilepsy,	 specifically	 on	 adenosine	 transport	 into	 different	 cell	 types	 in	 the	 central	 nervous	
system	and	how	DNA	methylation	changes	in	each	cell	type.		
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Figure	7.1:	Adenosine	and	epilepsy.	A:	Astrocytes	act	as	adenosine	storage.	Adenosine	is	released	to	
inhibit	synaptic	signalling	and	then	taken	up,	back	into	astrocytes.		
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Figure	7.1:	Adenosine	and	epilepsy.	B:	In	an	epileptic	patient	with	a	mutated	ENT1	protein	or	over-
expressed	ADK,	adenosine	is	only	taken	up	into	astrocytes	and	not	released.		
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7.6	The	IPMK-	and	mTORC1-related	molecular	mechanism	of	CBG	
Previous	studies	of	the	mechanisms	of	action	of	cannabinoids	have	implicated	regulation	of	the	
PI3K/PKB/mTOR	 pathway	 as	 a	 target	 of	 these	 compounds.	 In	 this	 thesis,	 a	 CBG-	 and	 CBD-
dependent	mechanism	of	mTORC1	regulation	is	identified	in	D.	discoideum,	M.	musculus	and	H.	
sapiens	cells.	This	is	consistent	with	previous	studies	indicating	that	cannabinoids	regulate	the	
mTOR	pathway	(Shrivastava	et	al.,	2011;	Renard	et	al.,	2016;	Giacoppo	et	al.,	2017;	Sultan	et	al.,	
2018;	Serra	et	al.,	2019).	The	mechanism	described	in	both	D.	discoideum	and	M.	musculus	for	
CBG	and	CBD	is	through	an	IPMK-dependent	regulation	of	mTORC1	and	is	also	dependent	on	
the	presence	of	PI3K	activity.	This	adds	to	the	previous	understanding	of	the	role	of	cannabinoids	
in	mTOR	regulation	and	provides	a	possible	target	of	cannabinoids	in	the	signalling	pathway.		
Figure	7.1:	Adenosine	and	epilepsy..	C:	CBG	or	CBD	inhibition	of	adenosine	uptake	through	ENT1	
could	result	in	elevated	free	adenosine,	therefore	inhibiting	synaptic	activity.		
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IPMK	has	key	cellular	roles	related	to	mTORC1	activity	which	could	be	modulated	by	CBG.	These	
are	the	production	of	higher	order	inositol	phosphates	(Kim	et	al.,	2017(a)),	production	of	PIP3	
(Blind	et	al.,	2012),	and	non-catalytic	binding	of	IPMK	to	mTORC1	(Kim	et	al.,	2011)	and	AMPK	
(Bang	et	al.,	2012).	Although	the	data	found	 in	this	thesis	do	not	 identify	how	CBG	regulates	
IPMK	activity,	a	model	can	be	proposed.	The	model	would	indicate	that	IPMK	binding	to	mTORC1	
in	wild	type	cells	is	a	limiting	factor	for	mTORC1	activation	(Figure	7.2	A	i).	Here,	CBG	and	CBD	
would	increase	the	likelihood	of	IPMK	binding	to	mTORC1,	resulting	in	elevated	mTORC1	activity	
following	CBG	or	 CBD	 treatment	 in	wild	 type	D.	 discoideum,	MEFs	 and	PBMCs	 from	healthy	
controls	 (Figure	 7.2	 A	 ii).	 In	 IPMK	 over-expressing	D.	 discoideum	 cells	 (dIPMK+	 and	 hIPMK+),	
elevated	IPMK	expressions	leads	to	IPMK	becoming	a	major	source	of	PIP3	production	elevating	
mTORC1	 activity	 through	 PKB	 signalling	 (Figure	 7.2	 B	 i).	 In	 this	 case,	 when	 CBG	 and	 CBD	
treatment	 increase	 binding	 to	mTORC1,	 PIP3	 production	would	 decrease.	 Since	 PI3K	 activity	
represents	a	rate	limiting	factor	for	mTORC1	activation,	with	the	cell	unable	to	produce	as	much	
PIP3,	mTORC1	activity	would	decrease	to	similar	levels	as	in	wild	type	(Figure	7.2	B	ii).	The	effect	
observed	in	IPMK	over-expressing	cells	appears	similar	to	that	observed	in	both	D.	discoideum	
and	MEF	 cells	 following	pharmacological	 PI3K	 inhibition.	 In	 the	 absence	of	 PI3K	 activity,	 the	
mTORC1	 pathway	 is	 inactive,	 thus	 not	 responsive	 to	 enhanced	 binding	 of	 IPMK	 to	mTORC1	
through	cannabinoid	treatment	(Figure	7.2	C	i).	Instead	the	lack	of	PI3K	signalling	results	in	no	
change	in	mTORC1	activity	(Figure	7.2	C	ii).	In	cells	lacking	IPMK	(Figure	7.2	D	i),	CBG	treatment	
cannot	elevate	mTORC1	activity	(Figure	7.2	D	ii).		
Furthermore,	the	results	found	here	indicate	that	of	the	two	PKB	proteins	in	D.	discoideum,	PKBA	
may	be	more	likely	to	form	mTORC2	and	PKGB	more	likely	to	signal	mTORC1.	Therefore,	lack	of	
PKBA	 could	 result	 in	 an	 elevated	 amount	 of	mTOR	 and	 LST8	 proteins	 available	 for	mTORC1	
signalling,	 thus	 elevating	 mTORC1	 activity	 (Figure	 7.2	 E	 i).	 CBG	 and	 CBD	 treatment	 of	
PKBA-ablated	cells	would	result	in	an	increase	of	mTORC1	activity	due	to	the	same	mechanism	
as	occurs	in	wild	type	cells,	with	free	IPMK	likely	to	bind	and	activate	mTORC1	(Figure	7.2	E	ii).	
In	D.	discoideum	cells	lacking	both	PKBA	and	PKGB	(both	PKB	proteins),	PKB-signalling	could	no	
longer	act	on	mTORC1	signalling	(Figure	7.2	F	i),	thus	CBG	or	CBD	treatment	of	these	cells	would	
not	 result	 in	elevation	of	mTORC1	activity	 (as	 in	PI3K	 inhibitor-treated	cells)	 (Figure	7.2	F	 ii).	
These	proposed	mechanisms	require	further	exploration	to	verify.	Furthermore,	experiments	in	
mammalian	cells	are	necessary	 to	confirm	the	whole	mechanism	 is	conserved.	However,	 the	
outcomes	 of	 these	 proposed	mechanisms	 are	 consistent	with	 CBG	 and	 CBD	modulating	 the	
activity	of	IPMK	and	could	explain	the	effects	seen	in	human	PBMCs.		
Another	aspect	of	the	molecular	mechanisms	of	CBG	and	CBD	acting	via	IPMK,	is	that	treatment	
with	both	cannabinoids	elevated	IP6	levels	in	wild	type	D.	discoideum.	While	treatment	with	CBG	
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and	CBD	did	not	affect	IP6	levels	in	dIPMK-over	expressing	cells.	This	could	indicate	that	CBG	and	
CBD	may	increase	IPMK	binding	to	mTORC1,	decrease	the	production	of	PIP3	through	IPMK	and	
increase	the	catalytic	activity	of	IPMK	to	produce	IP6.	However,	in	cells	over-expressing	IPMK,	
there	is	likely	a	large	proportion	of	the	IPMK	protein	already	able	to	produce	IP6,	and	therefore	
the	limiting	factor	is	likely	to	be	a	substrate	for	this	production.	As	IP7	can	inhibit	PKBA	activity	
(Chakraborty	et	al.,	2010),	this	also	explains	the	elevated	mTORC1	activity	seen	in	PKBA-ablated	
cells.	In	these	cells,	IP7	would	no	longer	be	able	to	inhibit	mTORC1	activity	through	PKBA,	and	
therefore	an	elevated	mTORC1	activity	would	be	found.	Furthermore,	treatment	with	CBG	or	
CBD	would	allow	a	further	increase	in	mTORC1	activity	through	non-catalytic	binding	of	IPMK	to	
mTOR.		
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Figure	7.2:	CBG	and	mTOR.	A	i:	Wild	type	cells	have	a	basal	level	of	mTORC1	signalling.	Ii:	CBG	treatment	of	
wild	 type	 cells	 elevated	mTORC1	 signalling.	B	 i:	 IPMK	 over-expressing	 cells	 have	 elevated	 basal	mTORC1	
signalling.	Ii:	CBG	treatment	of	IPMK	over-expressing	cells	reduces	mTORC1	signalling.		
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Figure	7.2:	CBG	and	mTOR.	C	i:	PI3K	treatment	reduces	mTORC1	signalling.	Ii:	CBG	does	not	alter	mTORC1	
activity	 in	 PI3K	 inhibitor-treated	cells.	D	i:	Cells	 lacking	 IPMK	have	 lower	basal	mTORC1	signalling.	 Ii:	CBG	
treatment	of	cells	lacking	IPMK	does	not	alter	mTORC1	activity.		
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Figure	7.2:	CBG	and	mTOR.	E	i:	Cells	lacking	PKBA	have	elevated	mTORC1	activity.	Ii:	CBG	treatment	of	cells	
lacking	PKBA	elevates	mTORC1	activity.	F	i:	Cells	lacking	PKBA	and	PKGB	have	unaltered	mTORC1	activity	to	
wild	type	cells,	but	likely	lower	PKB-related	signalling.	Ii:	CBG	treatment	of	cells	lacking	PKBA	and	PKGB	does	
not	elevate	mTORC1	activity.	
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7.7	CBG	as	a	therapeutic	for	MS	treatment	
The	 results	 of	 this	 study	 could	 propose	 a	 molecular	 mechanism	 for	 cannabinoids	 in	 the	
treatment	of	MS.	In	healthy	central	nervous	systems,	immune	cells	do	not	attack	neurons	and	
myelin	sheaths	are	present	on	the	neurons	(Figure	7.3	A).	At	the	onset	of	MS,	immune	cells	are	
activated	by	elevated	mTOR	signalling	(Rajesh	et	al.,	2007;	Simpson	et	al.,	2015;	Gao	et	al.,	2015)	
and	begin	to	target	myelin	sheaths	(Figure	7.3	B).	This	process	leads	to	myelin	degradation,	and	
improper	and	interrupted	neuronal	signalling	(Linker	et	al.,	2011;	Wingerchuk	and	Carter,	2014),	
and	 reduced	 mTORC1	 signalling	 in	 neurons	 due	 to	 pro-inflammatory	 cytokines	 released	 by	
immune	 cells	 (Giacoppo	 et	 al.,	 2017).	 This	 thesis	 shows	 that	 cannabinoid	 treatment	 of	 MS	
reduces	mTORC1	signalling	in	immune	cells,	which	could	reduce	the	activation	of	these	cells	in	
vivo	and	thus	reduce	the	degradation	of	myelin	(Figure	7.3	C).	The	removal	of	pro-inflammatory	
cytokines	from	the	neurons	allows	the	myelin	repair	to	begin	as	a	result	of	restored	mTORC1	
signalling	(Giacoppo	et	al.,	2017).	Thus,	this	thesis	suggests	a	mechanism	of	cannabinoids	that	
could	 support	 myelin	 repair	 in	 MS	 due	 to	 the	 proposed	 stabilisation	 of	 IPMK/mTORC1	 in	
activated	cells.	
To	 determine	 the	 ability	 of	 cannabinoids	 to	 treat	MS,	 experimental	 procedures	 examining	 a	
reduction	in	disease-related	symptoms	are	necessary.	One	such	example	would	be	to	examine	
if	myelin	degradation	on	neurons	is	altered	by	cannabinoid	treatment	(Goebbels	et	al.,	2017).	In	
model	 mice,	 ablation	 of	 PTEN	 which	 catalyses	 the	 production	 of	 PIP2	 from	 PIP3	 resulted	 in	
elevated	 myelination	 due	 to	 increased	 axonal	 size	 (Goebbels	 et	 al.,	 2017).	 This	 implicated	
elevated	mTORC1	signalling	in	remyelination	and	indicated	a	method	by	which	the	therapeutic	
ability	of	cannabinoids	to	treat	MS	could	be	measured.	In	MS,	activated	immune	cells	degrade	
myelin	sheaths	on	neurons,	resulting	 in	misfiring	of	neurons	which	causes	symptoms	such	as	
spasticity	 associated	 with	 MS	 (Arévalo-Martín	 et	 al.,	 2003).	 Remyelination,	 or	 blocking	 of	
immune	cell	degradation	of	myelin,	 is	a	key	aspect	of	any	MS	treatment.	Other	studies	have	
found	 that	 cannabinoids	 can	 elevate	 mTOR	 activity	 in	 neurons	 (Giacoppo	 et	 al.,	 2017).	
Conversely,	this	thesis	indicates	that	in	immune	cells	from	patients	with	MS,	cannabinoids	can	
reduce	mTORC1	activity,	which	could	result	in	a	lower	quantity	of	activated	immune	cells	(Gao	
et	al.,	2015).	The	differential	modulation	of	mTOR	activity	in	different	cell	types	could	be	key	to	
any	therapeutic	use	of	cannabinoids	to	treat	MS,	and	further	experiments	such	as	myelination	
assays	in	vivo	could	be	employed	to	examine	this.		
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This	 study,	 along	 with	 previous	 studies,	 provides	 evidence	 of	 the	 necessity	 of	 personalised	
medicine.	The	PBMCs	from	patients	with	MS	displayed	elevated	mTORC1	activity,	which	was	
reduced	 by	 cannabinoid	 treatment,	whereas	 cannabinoid	 treatment	 of	 PBMCs	 from	 healthy	
controls	 elevated	 mTORC1	 activity.	 This	 indicates	 both	 a	 potential	 treatment	 of	 MS	 and	 a	
potential	negative	side	effect	of	treatment	in	healthy	individuals	(or	individuals	with	MS	without	
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Figure	7.3:	CBG	as	a	potential	therapeutic	for	MS.	A:	Neurons	in	healthy	individuals	have	myelin	
sheaths	and	immune	cells	do	not	attack	myelin.	B:	In	MS	immune	cells	are	activated	with	elevated	
mTORC1	signalling,	the	 immune	cells	attack	myelin,	and	this	 results	 in	myelin	degradation	and	
lower	 repair	 signalling	 through	mTORC1.	 C:	 CBG	 treatment	may	 reduce	 mTORC1	 signalling	 in	
immune	cells	during	MS,	this	reduces	the	attacking	of	myelin,	allowing	myelin	to	repair	through	
elevated	mTORC1	signalling.	
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an	 elevated	 mTORC1	 activity	 in	 immune	 cells).	 Other	 studies	 have	 indicated	 a	 therapeutic	
modulation	 of	mTOR	 activity	 to	 treat	MS	 is	 cell	 type-specific	 (Giacoppo	 et	 al.,	 2017).	 To	 be	
certain	 that	 cannabinoids	 can	 result	 in	 the	 treatment	of	MS	 in	 all	 cases	 analysis	 of	mTORC1	
activity	 for	 each	 patient	 before	 receiving	 treatment	 needs	 to	 be	 carried	 out.	 Alternatively,	
mTORC1	 activity	 in	 vivo	 could	 be	 analysed	 for	 different	 cell	 types	 in	 a	mouse	model	 of	MS	
(Giacoppo	et	al.,	2017).	Furthermore,	if	IPMK	over-expression	is	a	causative	factor	of	MS	and	the	
elevated	level	of	mTORC1	activity	in	PBMCs	from	patients	with	MS	observed	in	this	thesis,	then	
an	 examination	 of	 IPMK	 expression	 levels	 could	 provide	 a	 means	 to	 determine	 whether	
cannabinoid	treatment	could	be	effective.		
The	causes	of	MS	are	still	unknown,	although	there	are	probably	multiple	causes	and	are	likely	
to	be	highly	complex	(Tselis,	2012).	Therefore,	there	is	a	need	for	personalised	medicine	for	MS	
treatment	(Gafson	et	al.,	2017).	Clinical	trials	have	revealed	that	Sativex®	treatment	works	for	
around	half	of	patients	 (Zettl	 et	 al.,	 2016).	 In	PBMCs	 from	healthy	 volunteers	CBG,	CBD	and	
THC:CBD	elevate	mTORC1	activity,	which	enhances	immune	cell	activation	and	could	exacerbate	
MS-related	 symptoms	 (Carbone	 et	 al.,	 2014).	 Further	 in	 vivo	 experiments	 are	 therefore	
necessary	to	clarify	the	roles	of	cannabinoids	in	modifying	mTORC1	activity,	and	to	determine	
the	specific	therapeutic	effects	these	might	have	on	a	patient	by	patient	basis.		
7.8	Future	Work	
7.8.1	Characterising	the	mTOR	pathway	in	D.	discoideum	
This	thesis	indicates	that	IPMK	is	a	key	component	of	mTORC1	activity	in	D.	discoideum,	with	
what	appears	to	be	an	ability	to	up-	and	downregulate	activity	depending	on	conditions.	Very	
little,	if	anything,	had	been	examined	of	IPMK	in	D.	discoideum	prior	to	this.	Therefore,	future	
work	could	focus	on	a	 full	examination	of	how	IPMK	can	have	alternating	regulatory	roles	of	
mTORC1	in	D.	discoideum.	This	could	be	carried	out	by	blocking	the	ability	of	IPMK	to	carry	out	
each	of	its	three	main	actions:	higher	inositol	phosphate	production	(Kim,	Ahn,	et	al.,	2017),	PIP3	
production	(Blind	et	al.,	2012)	and	non-catalytic	mTORC1	binding	(Kim,	Ahn,	et	al.,	2017).	This	
could	be	carried	out	by	point	mutation	or	removal	of	sections	of	the	IPMK	protein	to	determine	
how	each	plays	a	role.	For	example,	if	the	PIP3	production	region	is	removed,	but	the	other	two	
left	intact,	and	this	is	not	lethal	to	the	cell,	then	it	could	be	examined	what	over-expression	of	
IPMK	has	in	this	cell	line	and	how	it	reacts	to	CBG.		
The	amount	of	 PIP3	produced	by	 IPMK	 should	also	be	analysed	 in	D.	discoideum	using	mass	
spectrometry	(Kielkowska	et	al.,	2014).	This	could	be	carried	in	wild	type	cells	compared	to	IPMK	
overexpressor	 cells,	 determining	 the	 proportion	 of	 PIP3	 made	 in	 the	 overexpressor.	 PIP3	
production	in	relation	to	CBG	treatment	in	both	cell	lines	could	also	be	determined,	thus	further	
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clarifying	the	role	of	CBG	in	mTORC1	regulation.	The	role	of	CBG	in	mTORC1	regulation	could	
also	 be	 analysed	 by	 examining	 the	 reaction	 of	 other	mTOR	 signalling	 pathway	 components	
undergoing	CBG	treatment,	for	example	LST8	(Rosel	et	al.,	2012),	TSC1	and	TSC2	(Serfontein	et	
al.,	2011),	AMPK,	RHEB,	Raptor,	Rictor	and	S6	kinase	(Jaiswal	et	al.,	2019)i.	
Furthermore,	given	that	it	appears	lethal	to	ablate	IPMK,	to	discover	why	this	is	lethal,	removal	
of	 the	 different	 key	 components	 of	 IPMK	 one	 at	 a	 time	 until	 no	 longer	 possible	 could	 help	
determine	 this.	 This	 would	 then	 help	 to	 understand	 the	 essential	 role	 IPMK	 plays	 in	 most	
eukaryotes	(Saiardi	et	al.,	2018).	It	is	possible	that	the	combination	of	components	in	IPMK	is	
what	 makes	 it	 essential,	 potentially	 carrying	 out	 multiple	 actions	 at	 a	 time	 and	 specifically	
localising	them.	This	would	be	indicated	if	ablation	of	any	component	of	IPMK	was	found	to	be	
lethal.		
Another	interesting	experiment	would	be	to	add	the	nuclear	localisation	signal	(Nalaskowski	et	
al.,	 2002)	 to	 the	 D.	 discoideum	 protein	 and	 determine	 if	 this	 has	 any	 impact	 on	 mTORC1	
signalling,	or	resistance	to	CBG,	for	example.	Then	also	add	the	section	of	the	H.	sapiens	IPMK	
protein	that	ensures	a	tighter	binding	of	IPMK	to	mTOR	(Kim	et	al.,	2011)	to	the	D.	discoideum	
protein	and	determine	how	this	affects	mTORC1	signalling.	 It	may	be	that	 the	D.	discoideum	
protein,	 though	 lacking	 the	 full	 mTOR	 binding	 domain,	 still	 binds	 as	 efficiently	 to	 the	 D.	
discoideum	mTOR.	To	determine	this,	pulldown	experiments	could	be	carried	out	with	different	
combinations	of	truncated	or	extended	IPMK,	and	examine	which	has	a	higher	binding	affinity	
to	mTOR.		
Although	it	was	not	possible	to	create	an	IPMK	knockout	mutant	in	this	thesis,	newer	techniques	
that	are	often	quicker	and	more	efficient	could	be	attempted,	for	example	using	CRISPR	(Sekine	
et	al.,	2018).	In	addition,	if	it	is	the	production	of	higher	order	inositol	phosphates	or	PIP3	that	
makes	IPMK	an	essential	protein,	these	could	be	artificially	added	when	knocking	out	the	gene.	
Furthermore,	knockdowns	of	IPMK	could	be	created	using	techniques	such	as	RNA	interference		
(Xu,	Sen,	et	al.,	2013),	inducible	CRISPR	(Zhang	et	al.,	2019),	transcription	activator-like	effector	
nucleases	(Kowalko	et	al.,	2016),	small	interfering	RNAs	(Kuhlmann	et	al.,	2005)	or	short	hairpin	
RNAs	(Pan	et	al.,	2019).	Creating	a	knockdown	could	allow	examination	of	IP	levels,	PIP3	levels	
and	mTORC1	activity	in	the	absence	of	the	vast	majority	of	IPMK	protein.	This	could	potentially	
indicate	 to	what	extent	 IPMK	carries	out	each	of	 the	 three	activities,	 showing	which	 it	has	a	
greater	or	lesser	impact	on.		
7.8.2	Characterising	the	role	of	CBG	in	adenosine	regulation	in	D.	discoideum	
This	thesis	indicates	that	CBG	regulates	adenosine	transport	through	ENT1	in	D.	discoideum.	To	
investigate	whether	or	not	CBG	blocks	adenosine	uptake	into	D.	discoideum	cells,	as	the	data	
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indicates,	 cells	 could	 be	 treated	 with	 CBG	 in	 the	 presence	 of	 tritium-labelled	 adenosine	
([3H]adenosine)	(Carrier	et	al.,	2006).	Previous	studies	have	found	that	 in	blocking	adenosine	
transport	through	ENT1,	CBD	blocks	the	uptake	of	tritium-labelled	adenosine.	However,	when	
CBD	 blocks	 adenosine	 uptake,	 the	 intracellular	 content	 of	 adenosine	 does	 not	 change,	 and	
instead	 the	 accumulated	 tritium-labelled	 adenosine	 increases,	 potentially	 because	 the	 cell	
makes	up	for	the	lack	of	taken	up	adenosine	by	synthesising	more	(Carrier	et	al.,	2006).	Similar	
experiments	in	the	D.	discoideum	model	set	up	would	reveal	both	if	CBG	has	the	same	effect	as	
CBD	on	ENT1	and	if	this	mechanism	is	consistent	between	mammals	and	the	amoeba.	Further	
to	this,	tritium-labelled	adenosine	could	be	used	to	determine	whether	ablation	of	ENT1	actually	
halts	 adenosine	uptake	 into	 cells.	 Another	method	 to	 define	 any	direct	 interaction	between	
adenosine	and	CBG	at	ENT1	would	be	to	carry	out	a	competitive	inhibition	assay	(Woodcock	et	
al.,	2019).	These	assays	would	be	used	to	determine	if	CBG	inhibits	adenosine	transport	through	
ENT1	and	if	it	does	this	by	blocking	the	active	site	of	ENT1	and	being	transported	instead.	If	it	
does	fully	or	mostly,	then	the	phenotypes	found	in	this	thesis	are	explained,	however,	if	it	does	
not,	the	other	ENT	proteins	in	D.	discoideum	could	be	ablated	and	the	phenotype	and	adenosine	
uptake	in	those	cells	examined.		
7.8.3	Confirming	the	mechanisms	of	action	of	CBG	in	mammals	in	vivo	
mTOR	
This	thesis	indicates	that	CBG	regulates	mTOR	activity	through	IPMK.	To	examine	if	this	is	the	
case	in	mammals,	first	a	cell	line	overexpressing	IPMK	could	be	treated	similarly	to	D.	discoideum	
in	this	thesis	with	CBG	and	examine	whether	IPMK	overexpressing	cells	have	elevated	mTORC1	
compared	 to	 wild	 type,	 whether	 CBG	 activates	 mTORC1	 in	 wild	 type,	 and	 whether	 CBG	
downregulates	 mTORC1	 in	 IPMK	 overexpressing	 cells.	 If	 this	 is	 the	 case	 in	 cell	 lines,	 then	
experiments	can	be	carried	forward	to	 in	vivo.	Remyelination	assays	in	a	complex	cell	culture	
could	 also	be	 a	useful	 experiment	 to	determine	 if	 CBG	has	 the	 capacity	 to	 actually	 enhance	
myelination	rather	than	just	slow	down	degradation	of	the	myelin.		
In	an	MS	mouse	model	(EAE),	 IPMK	expression	could	be	examined	both	in	the	CNS	(neurons,	
oligodendrocytes,	myelin	sheaths,	etc.)	and	in	the	 immune	system	(monocytes,	PBMCs,	etc.).	
This	would	perhaps	given	an	early	indication	to	the	relevance	of	IPMK	to	MS	disease	and	possible	
treatment.	Regardless,	as	cannabinoids	appear	to	successfully	treat	this	model	of	MS,	mTORC1	
activity	in	both	the	CNS	and	immune	cells	could	be	measured	in	wild	type	mice	and	MS	mice.	To	
examine	fully	the	effect	of	mTORC1	on	disease	progression	and	treatment,	multiple	timepoints	
should	be	analysed,	prior	to	inducing	of	the	disease	model,	immediately	after	inducing,	prior	to	
treatment,	 immediately	 after	 treatment	 and	 after	 long	 term	 treatment.	 Although	 this	 thesis	
finds	specific	effects	of	CBG	treatment	on	mTORC1	activity,	this	is	just	after	one	treatment	with	
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the	compound,	and	long	term	treatment	or	multiple	treatments	may	well	have	different	effects.	
Disease	progression	should	also	be	measured	in	the	model	and	health	of	the	wild	type	mouse	
should	be	measured.	If	in	the	wild	type	mice	immune	cells	have	elevated	mTORC1	activity	after	
CBG	 treatment,	 as	 occurs	 in	wild	 type	D.	 discoideum,	 then	 this	 could	 indicate	 the	 potential	
danger	 of	 mis-prescribing	 CBG	 to	 patients	 without	 elevated	 mTORC1	 in	 immune	 cells.	
Inflammation	markers,	such	as	TNF-α	and	IL-6	should	be	measured	in	both	the	wild	type	and	
disease	model,	in	treated	and	untreated	to	examine	the	effect	of	both	the	disease	and	treatment	
on	inflammation	(Gugliandolo	et	al.,	2018).	Again,	if	CBG	were	to	increase	these	markers,	then	
this	 would	 represent	 a	 potential	 risk	 in	 prescribing	 to	 certain	 patients	 or	 misuse	 of	 the	
compound.	
If	CBG	treatment	of	the	mouse	model	of	MS	appears	to	be	both	safe	and	effective,	then	trials	in	
humans	can	begin.	Again,	with	healthy	volunteers	and	MS	patients.	As	 the	causes	of	MS	are	
relatively	 unknown	 and	 various,	 the	 efficacy	 of	 CBG	 in	 treating	MS	 in	 humans	may	well	 be	
reduced	compared	to	a	mouse	in	control	conditions.	This	should	be	examined	and	the	specific	
differences	of	the	disease	in	those	in	which	CBG	is	effective	noted.	Measuring	IPMK	in	PBMCs	
may	be	one	way	to	determine	how	effective	CBG	will	be	in	treating	MS,	if	this	is	found	in	mice	
previously.	 If	 IPMK	 appears	 to	 be	 a	 key	 regulator	 of	 MS	 progression	 or	 treatment,	 and	 no	
mutation	is	found	within	the	gene	itself,	the	surrounding	area	of	the	gene	could	be	examined	
for	mutations	in	promoter	regions.	If	no	mutation	is	present,	then	other	aspects	of	the	mTOR	
signalling	pathway	could	be	examined	for	mutations	in	patients	with	MS.		
As	hyperactivation	of	mTOR	has	been	associated	with	drug-resistant	epilepsy	 (Samueli	et	al.,	
2016)	 and	 cancer	 (Alayev	 and	Holz,	 2013),	 it	would	 be	 essential	 to	 determine	whether	 CBG	
treatment	 can	 increase	 the	 risk	of	 this	 in	healthy	 individuals	 and	whether	CBG	 treatment	of	
patients	 with	 MS	 could	 result	 in	 any	 similar	 effects.	 CBG	 elevates	 mTORC1	 in	 wild	 type	D.	
discoideum	and	so	ensuring	this	does	not	happen	in	humans	would	be	a	key	finding	before	using	
it	as	a	treatment.		
Adenosine	
In	this	thesis	CBG	is	found	to	regulate	adenosine	transport	across	the	plasma	membrane.	This	
could	 be	 beneficial	 for	 the	 treatment	 of	 epilepsy,	 as	 astrocytes	 store	 a	 large	 amount	 of	
adenosine	as	AMP,	ADP	and	ATP	(Diógenes	et	al.,	2014).	If	CBG	prevented	the	accumulation	of	
adenosine	in	astrocytes	then,	this	could	be	beneficial.	However,	if	CBG	prevents	the	uptake	of	
adenosine	 into	 all	 cell	 types,	which	 it	may	well	 do,	 this	 could	 eventually	 result	 in	 adenosine	
depletion	after	long	term	treatment	and	could	also	reduce	the	ability	of	cells	to	proliferate	or	
repair	DNA,	as	adenosine	is	a	nucleotide.	Although,	adenosine	can	be	synthesised	by	cells,	so	
this	may	not	be	the	case,	it	should	still	be	examined.	If	intracellular	adenosine	in	all	cell	types	is	
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decreased	by	CBG	treatment	due	to	a	reduction	in	uptake,	this	could	increase	DNA	methylation	
would	actually	exacerbates	epileptogenesis	(Weltha	et	al.,	2019).	Direct	adenosine	treatment	in	
the	brain	of	mice	reduces	epilepsy	and	DNA	methylation,	CBG	may	have	the	opposite	effect	and	
therefore	a	key	experiment	would	be	how	long	term	CBG	treatment	affects	DNA	methylation	in	
the	 brain	 of	 epilepsy	 mouse	 models	 and	 wild	 type	 mice.	 If	 CBG	 treatment	 increases	 DNA	
methylation	in	both	mice	types,	it	may	be	worth	evaluating	the	risk	of	long	term	CBG	treatment.	
In	this	thesis	 it	 is	 found	that	CBG	treatment	does	 indeed	enhance	DNA	methylation	and	that	
ENT1	inhibition	or	ablation	has	the	same	effect,	it	would	therefore	seem	likely	that	this	would	
occur	in	all	cell	types,	if	CBG	inhibits	adenosine	uptake.		
7.8.4	CBG	in	the	treatment	of	other	diseases	
Schizophrenia	and	psychosis	
The	efficacy	of	cannabinoids	in	treating	schizophrenia	and	psychosis	has	also	been	examined	by	
previous	studies.	These	severe	mental	disorders	are	characterised	by	hallucinations,	delusions,	
increased	anxiety	and	cognitive	deficits,	occurring	in	around	1%	of	individuals	globally	(around	
24	million	 people)	 (Adams	 et	 al.,	 2005;	 Purcell	 et	 al.,	 2009).	Most	 schizophrenia	 treatments	
involve	the	use	of	dopaminergic	receptor	inhibition,	which	reduces	the	likelihood	and	threshold	
of	 action	 potentials	 in	 neurons,	 and	 therefore	 reduces	 the	 misfiring	 and	 spread	 of	 action	
potentials	 that	 occurs	 during	 schizophrenia	 (Renard	 et	 al.,	 2016).	 In	 amphetamine-induced	
schizophrenic	 rats,	CBD	 injected	directly	 into	 the	nucleus	accumbens	shell	 (a	common	target	
region	of	 anti-psychotic	 drugs)	 resulted	 in	 a	 reduction	 in	 schizophrenic	 symptoms	as	well	 as	
reduced	dopaminergic	neuronal	activation	in	the	ventral	tegmental	area	(Renard	et	al.,	2016).		
An	initial	study	on	a	rat	model	of	psychosis	found	that	CBD	was	an	effective	anti-psychotic	with	
few	side-effects	(Zuardi	et	al.,	1991).	In	a	mouse	model	of	schizophrenia	and	psychosis	lacking	
the	neuregulin	1	protein,	long-term	treatment	with	CBD	enhanced	social	interaction	and	in	wild	
type	mice	decreased	anxiety-related	behaviour	(Long	et	al.,	2012).	In	a	rat	model	of	emotional	
processing	impairment	in	schizophrenia,	CBD	decreased	freezing	response,	which	is	a	symptom	
of	schizophrenia	(Levin	et	al.,	2012).	Another	study	found	that	CBD	was	an	effective	treatment	
of	schizophrenia	in	amphetamine-induced	model	rats,	as	CBD	treatment	reduced	schizophrenia-
related	psychopathology	(Renard	et	al.,	2016).	The	same	research	group	discovered	the	need	to	
determine	effects	of	specific	cannabinoids	on	the	disease,	as	adolescent	rat	exposure	of	THC	
was	found	to	result	in	schizophrenia-like	symptoms	in	adult	rats	(Renard	et	al.,	2017(a)).	Further	
study	in	the	area	found	that	CBD	treatment	may	mitigate	the	anxiety-causing	effects	of	THC	in	
a	 dose-dependent	manner	 (Szkudlarek	 et	 al.,	 2019).	 For	 schizophrenia	 and	 psychosis,	 there	
appear	to	be	specific	effects	related	to	different	cannabinoids	as	treatments.	CBD	appears	to	
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ameliorate	 schizophrenia-	 and	 psychosis-related	 symptoms,	 while	 THC	 may	 cause	 these	
symptoms.		
Interestingly,	 the	 amphetamine-induced	 mouse	 model	 of	 schizophrenia	 had	 reduced	 mTOR	
signalling	 compared	 to	 healthy	 mice	 in	 the	 nucleus	 accumbens	 shell,	 while	 CBD	 treatment	
alleviated	symptoms	and	elevated	mTOR	signalling	even	more	than	in	healthy	mice	(Renard	et	
al.,	2016).	THC	exposure	in	adolescent	rats	that	cause	schizophrenia-like	symptoms,	also	caused	
hyperactivity	in	the	mesocorticolimbic	dopamine	pathway	and	dysregulation	and	alteration	in	
prefrontal	 cortical	 molecular	 pathways	 involved	 in	 dopaminergic	 regulation	 (Renard	 et	 al.,	
2017(a)).	THC	exposure	here	reduced	mTOR	signalling,	perhaps	indicating	that	mTOR	reduction	
is	either	causative	or	correlative	with	schizophrenia,	and	elevation	of	mTOR	could	again	be	a	
potential	treatment	of	schizophrenia,	or	a	side	effect	of	treatment.	As	CBG	and	CBD	were	able	
to	elevate	mTOR	signalling	 in	 this	 thesis	 in	wild	 type	D.	discoideum,	mouse	 cells	 and	human	
PBMCs,	 this	 suggests	a	potential	 shared	mechanism	and	a	potential	 therapeutic	use	 for	CBG	
along	with	CBD	in	treating	schizophrenia.		
There	is	also	a	theory	that	schizophrenia	develops	or	worsens	in	a	similar	way	to	epilepsy.	That	
is,	 over-expression	 of	 ADK	 (specifically	 in	 astrocytes	 and	 similar	 adenosine	 sinks)	 can	 cause	
schizophrenia	and	that	augmentation	of	adenosine	can	treat	the	disease	or	improve	symptoms	
(Shen	et	al.,	2012).	If	this	is	the	case,	then	CBG	may	have	a	similar	effect	as	it	would	on	epilepsy	
treatment,	 by	 blocking	 adenosine	 uptake	 into	 adenosine	 sinks,	 it	 would	 leave	 more	 in	 the	
extracellular	space	for	signalling	via	adenosine	receptors.	CBG	could	therefore	be	explored	as	a	
schizophrenia	treatment	through	two	different	mechanisms	explored	in	this	thesis.		
Cancer	
The	 therapeutic	 potential	 of	 cannabinoids	 for	 cancer	 treatment	 has	 also	 been	 explored	 in	
multiple	models	of	cancer	pathologies.	In	a	mouse	model	of	breast	cancer,	CBD	was	found	to	
have	 a	 low-toxicity	 profile	 and	 inhibited	 the	 proliferative	 and	 invasive	 phenotype	 of	 breast	
cancer	cells	(McAllister	et	al.,	2007).	Using	a	mouse	mammary	tumour	cell	line	implanted	into	
mice,	CBD	reduced	the	metastasis	of	cancer	cells	and	cell	proliferation,	potentially	through	an	
anti-oxidant	 mechanism	 (McAllister	 et	 al.,	 2011).	 CBD	 also	 enhanced	 apoptosis	 in	 multiple	
human	breast	cancer	cell	lines	at	a	higher	rate	than	non-cancer	cells	(Shrivastava	et	al.,	2011;	
Sultan	et	al.,	2018).	In	addition,	CBD	was	found	to	exert	chemo-preventive	effects,	to	protect	
DNA	from	oxidative	damage	and	to	reduce	cell	proliferation	in	an	azoxymethane-induced	mouse	
model	of	colonic	cancer	(Aviello	et	al.,	2012).	Furthermore,	CBG	was	found	to	selectively	inhibit	
the	growth	of	colonic	cancer	cells	in	a	mouse	model	(Borrelli	et	al.,	2014).	CBG	could	therefore	
be	 further	 explored	 as	 a	 potential	 treatment	 of	 cancer,	 given	 the	 effects	 of	 CBG	 on	 cell	
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proliferation	 in	 D.	 discoideum	 and	 the	 potential	 to	 reduce	 mTOR	 signalling	 in	 cells	 with	
hyperactivated	mTOR.	
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9	Appendix	
9.1	Materials	
9.1.1	Reagents	and	products		
0.2	μm	PVDF	membrane	(Fisher,	88520),	1-mm	width	electroporation	cuvette	(Sigma-Aldrich,	
Z706078-50EA),	100%	Ethanol	(VWR,	20821.330DP),	2-mercaptoethanol	(2-ME)	(Sigma-Aldrich,	
M6250),	5x	 loading	buffer	 (Bioline,	BIO-37045),	absorbent	 filter	pads	 (Millipore,	AP1004700),	
agarose	 (Bioline,	 B10-41026),	 Ampicillin	 (Sigma-Aldrich,	 A1593),	 blasticidin	 (Apollo	 Scientific,	
BIB4432),	 bromophenol	 blue	 (Sigma-Aldrich,	 B0126),	 DMSO	 (VWR,	 VWRV0231),	 Dulbecco's	
Modified	Eagle	Medium	(DMEM)	(Sigma-Aldrich,	D0819),	ethidium	bromide	(Bio-Rad,	1610433),	
Ethylenediaminetetraacetic	 acid	 (EDTA)	 (Sigma-Aldrich,	 E9884),	 fetal	 bovine	 serum	 (FBS)	
(ThermoFisher,	26140087),	G418	(PAA	laboratories,	11558616),	glucose	(Sigma-Aldrich,	G8270),	
HCl	(VWR,	20252),	glycerol	(Sigma-Aldrich,	G5516),	HEPES	(Sigma-Aldrich,	H3375),	HL5	media	
(ForMedium,	 HLB0103),	 Horse	 serum	 (Sigma-Aldrich,	 H0146-5ML),	 K2CO3	 (Sigma-Aldrich,	
P5833),	K2HPO4	 (Sigma-Aldrich,	1551128),	KCl	 (Sigma-Aldrich,	P9333),	KH2PO4	 (Sigma-Aldrich,	
NIST200B),	LY294002	(Cambridge	Bioscience,	CAY70920),Lymphoprep™	(Axis-Shield,	1114545),	
MgCl2	 (Sigma-Aldrich,	 M8266),	 MgSO4	 (Sigma-Aldrich,	 M7506),	 NaCl	 (Sigma-Aldrich,	 S9888),	
NaH2PO4	(Sigma-Aldrich,	S8282),	NaHCO3	(Sigma-Aldrich,	S5761),	nitrocellulose	filter	(Millipore,	
HABP04700),	 nuclease-free	water	 (Sigma-Aldrich,	W4502),	 nonyl	 phenoxypolyethoxylethanol	
40	 (NP40)	 substitute	 (Sigma-Aldrich,	 74385),	 Odyssey	 chemifluorescent	 substrate	 kit	
chemifluorescent	 substrate	 (Li-Cor,	 928-30005),	 OrangeG	 (Sigma-Aldrich,	 penicillin	 and	
streptomycin	 (Thermo	 Fisher	 Scientific,	 15140122),	 perchloric	 acid	 (Sigma-Aldrich,	 311421),	
Pictilisib	(AbCam,	ab141352),	protease	inhibitor	(ThermoFisher,	87786),	phosphatase	Inhibitor	
Cocktail	 2	 (Sigma-Aldrich,	 P5726),	 phosphatase	 Inhibitor	 Cocktail	 3	 (Sigma-Aldrich,	 P0044),	
plates	(Corning,	353801),	proteinase	K	(Fermentas,	EO0491),	radioimmunoprecipitation	assay	
(RIPA)	buffer	(ThermoFisher,	89900),	SM	agar	(ForMedium,	SMA0102),	sodium	acetate	(Sigma-
Aldrich,	 S2889),	 sodium	 dodecyl	 sulfate	 (SDS)	 solution	 (Sigma-Aldrich,	 L3771),	 tissue	 culture	
flasks	 (Corning®	 CellBIND®	 Surface	 cell	 culture	 flasks,	 Sigma-Aldrich,	 CLS3289)	 Tris	 acetate	
ethylenediaminetetraacetic	acid	(EDTA)	(TAE)	buffer	(Severn	Biotech	Limited,	20-6001-50),	Tris	
buffer	saline	(TBS)	(Fisher,	10776834),	Trizma	(Tris)-HCl	pH	8.3	(Sigma-Aldrich,	T1503),	Trypsin	
(Sigma-Aldrich,	 T4049),	 TWEEN	 Tween	 20	 (Sigma-Aldrich,	 P1379),	 and	whatman	 filter	 paper	
(Sigma-Aldrich,	WHA3030917),	O3756).	
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9.1.2	Cannabinoids	
Cannabigerol	 (CBG),	 cannabidiol	 (CBD),	 cannabidivarin	 (CBDV),	 cannabidiolic	acid	 (CBDA)	and	
THC:CBD	combinations	(20	nM:17	nM)	were	provided	by	GW	pharmaceuticals,	England.	Stock	
concentrations	of	these	were	100	mM.	Cannabinoids	were	dissolved	in	DMSO	(except	for	use	
on	 PBMCs,	 where	 ethanol	 was	 used).	 Use	 of	 cannabinoids	 in	 media	 resulted	 in	 media	
concentrations	of	0.5	%	(v/v)	DMSO	(or	ethanol).	In	all	experiments,	a	constant	solvent	level	of	
0.5	%	(v/v)	was	used.	
9.1.3	Molecular	weight	standards	
Page	rulerTM	prestained	protein	 ladder	 (Thermo	Scientific,	26616)	 for	western	blots	and	1	kb	
DNA	hyperladder	(Bioline,	BIO-33053)	for	gel	electrophoresis.	
9.1.4	Restriction	enzymes		
Enzymes	used	in	this	thesis:	SpeI	(ER1251),	PstI	(ER0611),	KpnI	(ER0521),	BamHI	(ER0052),	RsaI	
(ER1122),	BgIII	(ER0081),	NcoI	(ER0572).	Buffer:	Tango	buffer	(Thermo	Scientific,	BY5).	
9.1.5	Other	enzymes		
GoTaq®	G2	Flexi	DNA	Polymerase	 (Promega,	M7801),	Q5	high	 fidelity	DNA	polymerase	 (New	
England	Biolabs,	M0491),	T4	DNA	ligase	(Fermentas,	15224041).	
9.1.6	Antibodies	
Anti-phospho-4EBP1	 (rabbit,	 Cell	 Signalling	 Technology,	 9459),	 anti-total	 4EBP1	 (rabbit,	NEB,	
4923),	anti-actin	(mouse,	Sigma-Aldrich,	A1978),	anti-IPMK	antibody	(ab96753),	anti-RFP	(rat,	
Chromotek,	5F8),	Streptavidin	(Alexa	Fluor™	680	conjugate,	Thermo	Fisher,	S21378),	Anti-rabbit	
immunoglobulins	 (goat,	 Horseradish	 peroxidase	 (HRP),	 Agilent	 Technologies,	 P0448),	 Anti-
mouse	 immunoglobulins	 (rabbit,	 DyLight™	 680	 Conjugate,	 Cell	 Signalling	 Technology,	 5470),	
Anti-rat	immunoglobulins	(goat,	IRDye®	800CW,	Li-Cor	Biosciences,	926-32219).	
9.1.7	Commercial	kits		
DNeasy®	Blood	and	tissue	kit	(Qiagen,	69506),	Wizard	Genomic	DNA	Purification	Kit	(Promega,	
A1120),	 QIAquick®	 PCR	 purification	 kit	 (Qiagen,	 28104),	 TOPO	 TA	 Cloning®	 kit	 (Invitrogen,	
K450002),	 Plasmid	mini-prep	kit	 (Qiagen,	27104),	HiSpeed	Plasmid	Maxi	Kit	 (Qiagen,	12643),	
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RNeasy	mini-kit	 (Qiagen,	 74104),	 First-strand	 cDNA	 synthesis	 kit	 (Thermo	 Scientific,	 K1612),	
DNA-free	 kit	 (Ambion,	 AM1906),	 Methylated	 DNA	 Quantification	 Kit	 (Colorimetric)	 (Abcam,	
ab117128).	
	 	
190	
	
9.1.8	Primers		
	 	
Table	9.1:	Primer	 sequences,	name,	 function	 and	 restriction	enzyme	 cut	 sites.	All	primers	used	 in	 this	 thesis	 are	
contained	within	this	table. 
No. Name Use Sequence	5’-3’	(restriction	sites	underlined) Rest.	
enzyme
1 ENT1	KO	3’	genomic	
reverse
Production	of	ENT1	knockout	
plasmid
CCAGTGGATCCAGTTACTAAATAAC
2 ENT1	KO	3’	vector	
reverse
Production	of	ENT1	knockout	
plasmid
ATAGGTACCCAAAATGAGTTGATACCCAAATAC KpnI
3 ENT1	KO	3’	genomic	
forward
Production	of	ENT1	knockout	
plasmid
ATACCATGGTTGGTGATTTCATTGGAAG NcoI
4 ENT1	KO	5’	vector	
forward
Production	of	ENT1	knockout	
plasmid
ATAACTAGTGATATAACAGAAACATCAAAAGCAC SpeI
5 ENT1	KO	5’	genomic	
reverse
Production	of	ENT1	knockout	
plasmid
ATACTGCAGCCTGTATATTCGCCTGGAAAC PstI
6 ENT1	KO	5’	genomic	
forward
Production	of	ENT1	knockout	
plasmid
GACAAACAGAGATGAATATTCACC
7 ENT1	RT	PCR	5’	
forward
RT-PCR	analysis	of	ENT1	expression GATGGTGATGCCAAACCA
8 ENT1	RT	PCR	3’	
reverse
RT-PCR	analysis	of	ENT1	expression CAAAATGAGTTGATACCCAAATAC
9 ENT1	OE	5’	forward Production	of	ENT1	over-expressor	
plasmid
ATAAGATCTATGACAAACAGAGATGAATATTC BglII
10 ENT1	OE	3’	reverse Production	of	ENT1	over-expressor	
plasmid
ATAACTAGTGAAATTAATACCAGTGGATCCAG SpeI
11 Ig7F RT-PCR	for	Ig7	control GTACTGTGAAGGAAAGATGAAAAG
12 Ig7R RT-PCR	for	Ig7	control CTATGGACCTTAGCGCTC
13 p9 Inverse	PCR	of	mutant	
library/screening	Kos
TGTATGCTATACGAAGTTATCC
14 p10 Inverse	PCR	of	mutant	library GTAGAAGTAGCGACAGAGAAG
15 p13 Screening	KOs TGAATGGTGAAGATAAATATATGC
16 M13 Sequencing	TOPO	cloned	PCR	
products
CAGGAAACAGCTATGACC
17 T7 Sequencing	TOPO	cloned	PCR	
products
TAATACGACTCACTATAGGG
18 IPMK	RT	PCR	5’	
forward	primer
Examining	expression	of	dIPMK in	
CBG-resistant	mutant
GGGTATTGAAGATTTAACATATGG
19 IPMK	RT	and	PCR	3’	
forward	primer
Examining	expression	of	dIPMK in	
CBG-resistant	mutant
GTTGGTGGAGTTAATGGATCTAC
20 IPMK	qPCR	5’	forward	
primer
Examining	expression	of	dIPMK in	
CBG-resistant	mutant
GGTTTAAATACATACCCTTCATC
21 IPMK	OE	5’	forward Production	of	dIPMK over-
expressor	plasmid
ATAAGATCTATGTCATCATCATCACTTA BglII
22 IPMK	OE	3’	reverse Production	of	dIPMK over-
expressor	plasmid
ATAACTAGTATTTTCAGATAATAATTG SpeI
23 IPMK	KO	3’	genomic	
reverse
Production	of	dIPMK knockout	
plasmid
ATAGTTGGTGGAGTTAATGGATCTAC
24 IPMK	KO	3’	vector	
reverse
Production	of	dIPMK knockout	
plasmid
ATAGGTACCCCAATATTTGAGTCATC KpnI
25 IPMK	KO	3’	genomic	
forward
Production	of	dIPMK knockout	
plasmid
ATACCATGGGGTGCAAAACTT NcoI
26 IPMK	KO	5’	genomic	
reverse
Production	of	dIPMK knockout	
plasmid
ATACTGCAGCCATATGTTAAATCTTCA PstI
27 IPMK	KO	5’	vector	
forward
Production	of	dIPMK knockout	
plasmid
ATAACTAGTGGATGGAGGAAGTGAAAATAT SpeI
28 IPMK	KO	5’	genomic	
forward
Production	of	dIPMK knockout	
plasmid
ATACCATTAGAAGATCAAATTGCAGG
29 IhPMK OE	5’	forward Production	of	hIPMK over-
expressor	plasmid
AGATCTATGGCAACAGAACC BglII
30 hIPMK OE	3’	reverse Production	of	hIPMK over-
expressor	plasmid
ACTAGTATTATCTAAAATTGATC SpeI
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All	primers	were	obtained	from	Sigma	Aldrich.	The	primers	are	at	synthesis	scale	of	expected	
yields	of	0.025	µmole.	They	arrive	desalted	and	dry.	Primers	are	stored	at	-20	°C.	Primers	are	
dissolved	in	nuclease-free	water	to	100	µM,	then	aliquots	are	made	at	10	µM	for	general	use,	
the	final	concentration	of	each	primer	in	a	PCR	is	0.5	µM.	
	
9.1.9	Equipment		
Dissection	microscope	(Leica)	with	a	QICAM	FAST	1394	camera	(QImaging).	LCMS-8050	triple	
quadrupole	 mass	 spectrometer	 (Shimadzu	 Corp.,	 Japan).	 NanoDrop	 ND-1000	
spectrophotometer	 (Thermo	 Scientific).	 Odyssey	 CLx	 (Li-Cor).	 PowerWave	 Colorimetric	 plate	
reader	(Biotek).	Olympus	IX71	wide-field	fluorescence	microscope	at	96	x	magnification	with	
a	QICAM	FAST	1394	camera.	peqSTAR	Thermocycler	(VWR)	PCR	machine.	Rotorgene	Q	qPCR	
machine	(Qiagen)	Shimadzu	Nexera	UHPLC	system.		
9.1.10	Cell	lines	and	plasmids		
All	D.	discoideum	 cell	 lines	 and	plasmids	were	obtained	 from	 the	Dictyostelium	 stock	 center	
(https://www.dictybase.org/StockCenter).	
D.	discoideum	cells	from	stock	center:	
Wild	type	(AX3)	-	DBS0235543	
Wild	type	(AX2)	-	DBS0235535	
PKBA-	-	DBS0236784	
DNMA-	-	DBS0235917	
Plasmids	from	stock	center:	
pLPBLP	-	Plasmid-9	
pDM324	-	Plasmid-541	 	
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9.2	Data	tables	for	growth	curves	
Data	below	is	that	which	growth	curves	are	derived	from.	It	is	presented	as	normalised	to	0	µM	
CBG	for	each	biological	repeat	(n).	Where	data	is	missing,	it	was	not	recorded	for	that	repeat	
due	to	either	contamination	or	not	carrying	out	the	experiment.	For	each	concentration,	the	
rows	are	each	day	that	data	was	recorded.	
	
	
	
WT	(AX3)	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
1.6	 1.6	 2.7	 1.7	 5.1	 	 10.0	 3.9	 2.9	 0.9	 1.5	 	 3.18	 2.56	
6.9	 8.3	 9.3	 8.9	 37.2	 10.4	 47.1	 18.3	 9.6	 2.0	 12.0	 	 15.44	 13.27	
28.5	 27.9	 40.5	 43.6	 74.5	 56.7	 89.4	 114.5	 32.5	 8.5	 24.8	 	 49.21	 30.30	
66.1	 78.2	 111.0	 96.4	 80.7	 92.2	 104.2	 127.5	 90.4	 51.5	 70.2	 	 88.05	 20.72	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
	 	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
	 	 2.4	 1.3	 6.3	 	 8.5	 4.3	 1.9	 0.6	 1.5	 	 3.33	 2.60	
	 	 9.2	 7.7	 31.7	 11.0	 44.7	 16.8	 9.2	 1.1	 9.8	 	 15.67	 13.00	
	 	 32.3	 32.1	 74.3	 54.2	 82.4	 121.7	 27.7	 2.1	 23.8	 	 50.08	 34.82	
	 	 93.0	 97.8	 78.3	 83.9	 97.2	 121.7	 80.7	 4.7	 67.9	 	 80.58	 30.46	
	 	 86.0	 120.1	 87.9	 98.8	 94.1	 108.7	 103.6	 25.3	 95.2	 	 91.08	 25.30	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
0.9	 1.2	 1.7	 1.7	 3.8	 	 5.4	 2.2	 0.9	 0.2	 1.5	 	 1.94	 1.47	
3.8	 3.3	 6.7	 6.4	 18.0	 10.2	 23.0	 11.9	 3.2	 0.2	 4.4	 	 8.28	 6.63	
20.7	 14.9	 19.3	 28.5	 54.1	 35.6	 87.1	 34.8	 9.4	 0.6	 22.9	 	 29.80	 22.69	
16.5	 34.7	 91.0	 97.8	 77.8	 64.1	 81.2	 113.0	 37.3	 1.1	 51.2	 	 60.51	 33.82	
67.2	 69.2	 92.0	 118.7	 67.7	 81.1	 82.4	 121.7	 79.5	 3.9	 95.2	 	 79.89	 29.91	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.1	 	 0.10	 0.01	
0.4	 0.3	 0.4	 0.7	 0.6	 	 0.8	 1.4	 0.6	 	 0.3	 	 0.61	 0.33	
0.9	 1.1	 1.8	 2.4	 3.4	 2.4	 5.0	 4.3	 2.7	 	 2.2	 	 2.63	 1.25	
2.3	 2.3	 2.8	 11.8	 13.5	 9.2	 16.9	 14.5	 4.6	 	 2.1	 	 7.98	 5.54	
7.5	 9.3	 15.5	 39.9	 36.4	 43.7	 63.5	 46.4	 16.9	 	 9.0	 	 28.81	 18.61	
24.1	 20.7	 47.8	 99.2	 61.6	 70.0	 82.4	 72.5	 55.4	 	 32.8	 	 56.63	 24.34	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
0.3	 0.1	 0.2	 0.1	 0.2	 	 0.4	 0.3	 0.3	 0.0	 0.3	 	 0.21	 0.11	
0.3	 0.4	 0.4	 0.1	 0.1	 0.2	 0.5	 1.1	 1.0	 0.1	 0.7	 	 0.43	 0.34	
1.0	 0.8	 0.6	 0.2	 0.6	 0.3	 1.1	 0.9	 2.9	 0.1	 0.6	 	 0.82	 0.73	
2.3	 1.9	 2.8	 0.7	 1.1	 1.2	 3.0	 	 12.0	 0.3	 1.7	 	 2.70	 3.22	
6.9	 5.7	 6.5	 1.5	 1.8	 5.1	 10.6	 	 30.4	 0.6	 1.7	 	 7.07	 8.31	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.1	 	 0.10	 0.01	
0.0	 0.0	 0.0	 0.0	 	 0.0	 0.0	 0.1	 0.2	 	 0.1	 	 0.05	 0.06	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 	 0.1	 	 0.03	 0.04	
0.0	 0.0	 0.1	 0.1	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.1	 	 0.03	 0.04	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.2	 	 0.04	 0.07	
0.0	 0.0	 0.1	 0.1	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.3	 	 0.06	 0.09	
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ENT1-	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
2.3	 1.8	 3.8	 2.2	 4.5	 	 5.4	 1.8	 	 3.11	 1.35	
9.7	 10.6	 11.6	 8.6	 27.1	 15.6	 26.0	 8.7	 	 14.74	 7.13	
32.6	 27.9	 48.6	 38.6	 55.3	 63.0	 51.9	 24.2	 	 42.76	 13.08	
75.2	 64.3	 100.0	 85.8	 69.1	 130.2	 100.0	 78.9	 	 87.95	 20.12	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
	 	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.11	 0.05	
	 	 4.9	 2.0	 4.7	 	 6.5	 2.1	 	 4.05	 1.75	
	 	 18.0	 7.4	 17.6	 20.2	 23.4	 7.4	 	 15.68	 6.14	
	 	 72.2	 22.1	 53.4	 71.7	 54.5	 23.7	 	 49.61	 20.27	
	 	 117.8	 73.7	 92.1	 106.8	 102.6	 76.3	 	 94.89	 15.95	
	 	 88.9	 104.3	 131.6	 100.0	 103.9	 113.2	 	 106.96	 13.14	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
2.1	 1.4	 4.1	 1.7	 2.9	 	 4.7	 2.0	 	 2.72	 1.16	
5.1	 5.5	 9.9	 3.0	 28.4	 22.4	 14.0	 5.3	 	 11.71	 8.68	
22.2	 17.2	 43.6	 12.1	 27.6	 72.1	 42.9	 16.4	 	 31.76	 18.80	
61.0	 47.2	 108.9	 40.3	 66.8	 134.0	 87.0	 76.3	 	 77.69	 29.50	
113.0	 77.1	 91.1	 93.3	 84.2	 109.4	 102.6	 89.5	 	 95.03	 11.59	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
0.6	 0.6	 1.9	 1.0	 1.0	 	 2.9	 1.6	 	 1.38	 0.76	
4.7	 1.7	 5.5	 1.3	 2.3	 7.5	 14.0	 5.3	 	 5.29	 3.86	
13.2	 6.3	 11.4	 4.9	 4.6	 22.2	 35.1	 15.8	 	 14.19	 9.69	
39.6	 27.6	 41.1	 12.8	 15.9	 77.3	 71.4	 47.4	 	 41.63	 22.06	
75.3	 49.5	 104.4	 47.6	 36.8	 133.1	 106.5	 73.7	 	 78.38	 31.62	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
0.2	 0.3	 0.6	 0.2	 0.3	 	 2.9	 1.4	 	 0.83	 0.92	
1.0	 0.8	 1.5	 0.2	 0.3	 0.9	 7.0	 2.5	 	 1.79	 2.09	
1.9	 1.4	 4.1	 0.2	 0.7	 2.9	 10.1	 9.5	 	 3.85	 3.62	
4.7	 3.3	 11.1	 0.4	 2.0	 5.7	 53.2	 21.1	 	 12.69	 16.52	
18.5	 9.2	 21.9	 0.8	 5.3	 8.9	 68.8	 52.6	 	 23.25	 22.90	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
0.1	 0.0	 0.0	 0.1	 0.0	 	 0.3	 0.2	 	 0.10	 0.11	
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0.0	 0.0	 0.2	 0.1	 0.0	 0.0	 0.8	 0.3	 	 0.18	 0.27	
0.1	 0.0	 0.2	 0.1	 0.0	 0.0	 1.0	 0.4	 	 0.23	 0.33	
0.0	 0.1	 0.0	 0.0	 0.1	 0.0	 1.4	 1.3	 	 0.35	 0.56	
0.1	 0.1	 0.1	 0.1	 0.2	 0.0	 1.8	 1.3	 	 0.44	 0.63	
	
	
	
	
	
WT	(AX2)	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
7.6	 9.7	 11.2	 	 2.8	 2.0	 1.5	 	 5.80	 3.85	
15.8	 23.2	 22.9	 11.9	 5.4	 6.4	 12.0	 	 13.93	 6.64	
24.7	 34.8	 37.6	 22.2	 8.0	 30.8	 24.8	 	 26.13	 9.08	
57.0	 74.9	 54.1	 54.8	 54.5	 69.0	 70.2	 	 62.07	 8.27	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
8.2	 7.7	 8.2	 	 3.7	 1.8	 1.5	 	 5.20	 2.95	
12.7	 15.5	 21.8	 10.4	 4.8	 4.2	 9.8	 	 11.30	 5.65	
20.9	 30.0	 40.0	 18.5	 5.7	 23.5	 23.8	 	 23.20	 9.71	
39.9	 69.1	 84.1	 74.1	 40.8	 56.3	 67.9	 	 61.73	 15.54	
57.6	 81.2	 148.8	 139.3	 79.5	 60.5	 95.2	 	 94.59	 33.54	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
7.0	 8.7	 6.5	 	 2.6	 1.7	 1.5	 	 4.67	 2.81	
10.8	 16.4	 22.4	 9.6	 4.4	 3.9	 4.4	 	 10.26	 6.49	
19.6	 23.2	 45.9	 26.7	 5.3	 18.1	 22.9	 	 23.08	 11.26	
28.5	 53.6	 63.5	 68.1	 19.4	 56.3	 51.2	 	 48.67	 16.71	
43.0	 89.9	 107.6	 135.6	 52.2	 54.5	 95.2	 	 82.57	 31.45	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 	 	 0.1	 	 0.34	 0.39	
4.4	 6.3	 5.3	 	 	 	 0.3	 	 4.07	 2.28	
10.1	 13.0	 11.2	 9.6	 	 	 2.2	 	 9.23	 3.71	
10.8	 22.2	 37.1	 7.4	 	 	 2.1	 	 15.91	 12.46	
18.4	 46.4	 54.7	 36.3	 	 	 9.0	 	 32.96	 17.02	
56.3	 71.0	 77.1	 63.0	 	 	 32.8	 	 60.03	 15.34	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
1.9	 4.3	 4.7	 	 1.3	 1.2	 0.3	 	 2.29	 1.65	
2.5	 5.3	 13.5	 2.2	 2.1	 2.0	 0.7	 	 4.06	 4.07	
1.3	 10.1	 14.1	 2.2	 2.9	 10.8	 0.6	 	 6.00	 5.09	
2.5	 13.5	 23.5	 7.4	 9.4	 14.4	 1.7	 	 10.35	 7.04	
7.0	 19.8	 45.3	 17.8	 22.6	 25.3	 1.7	 	 19.93	 13.01	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
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0.0	 0.0	 4.1	 	 0.4	 0.0	 0.1	 	 0.76	 1.51	
0.0	 0.5	 11.8	 0.0	 0.4	 0.2	 0.1	 	 1.85	 4.05	
0.6	 0.0	 3.5	 0.0	 0.4	 0.3	 0.1	 	 0.71	 1.17	
0.0	 1.0	 6.5	 1.5	 2.6	 0.4	 0.2	 	 1.73	 2.09	
1.9	 1.0	 28.8	 5.2	 5.3	 0.5	 0.3	 	 6.14	 9.46	
	
DNMA-	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
	 	 3.5	 	 3.1	 	 5.8	 2.0	 2.4	 	 3.37	 1.32	
12.8	 11.7	 9.4	 15.8	 8.4	 36.8	 12.6	 3.9	 7.0	 	 13.17	 9.00	
41.0	 60.5	 59.9	 42.8	 21.6	 123.1	 22.2	 11.6	 11.4	 	 43.80	 33.13	
112.6	 122.4	 100.0	 91.4	 91.5	 147.8	 59.3	 44.7	 65.3	 	 92.77	 30.80	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
	 	 2.4	 	 3.3	 	 7.0	 1.4	 2.4	 	 3.31	 1.92	
13.4	 16.5	 7.5	 12.9	 13.5	 14.4	 8.7	 3.5	 6.7	 	 10.79	 4.07	
50.5	 61.8	 33.2	 29.8	 25.0	 47.6	 18.5	 12.1	 9.8	 	 32.05	 17.00	
92.6	 110.5	 75.0	 110.4	 91.5	 160.1	 55.6	 51.3	 61.2	 	 89.79	 32.48	
124.2	 119.8	 133.4	 100.0	 119.2	 100.0	 103.7	 102.6	 97.9	 	 111.19	 12.28	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.0	 	 0.0	 0.1	 	 0.3	 0.1	 0.3	 	 0.12	 0.13	
	 	 	 	 	 	 4.3	 1.4	 2.4	 	 2.72	 1.19	
13.2	 13.3	 	 19.1	 104.3	 	 6.7	 3.9	 4.9	 	 23.62	 33.31	
45.2	 47.3	 	 31.1	 168.1	 	 15.6	 15.8	 13.1	 	 48.02	 50.77	
102.1	 122.4	 	 84.4	 187.3	 	 55.6	 59.2	 61.2	 	 96.02	 43.77	
83.1	 147.4	 	 115.6	 106.4	 	 107.4	 102.6	 91.8	 	 107.78	 18.98	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
	 	 	 	 	 	 0.3	 0.1	 0.3	 	 0.24	 0.10	
	 	 	 	 	 	 1.6	 3.2	 2.6	 	 2.47	 0.63	
	 	 	 	 	 	 6.1	 4.7	 5.9	 	 5.56	 0.59	
	 	 	 	 	 	 13.3	 6.3	 11.4	 	 10.36	 2.96	
	 	 	 	 	 	 32.6	 34.2	 40.8	 	 35.86	 3.54	
	 	 	 	 	 	 74.1	 69.7	 81.6	 	 75.13	 4.89	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
	 	 2.1	 	 3.3	 	 2.5	 2.1	 2.0	 	 2.38	 0.51	
12.3	 10.2	 5.1	 10.0	 6.8	 12.2	 3.6	 4.2	 2.4	 	 7.43	 3.61	
33.6	 35.5	 16.9	 25.9	 18.2	 19.9	 11.1	 10.8	 9.0	 	 20.10	 9.18	
100.0	 77.6	 36.6	 61.0	 76.6	 84.6	 13.3	 30.3	 28.5	 	 56.50	 28.44	
80.0	 136.9	 83.3	 79.2	 122.4	 123.1	 30.4	 77.6	 61.2	 	 88.23	 31.83	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
	 	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.12	 0.13	
	 	 1.7	 	 2.3	 	 1.6	 1.8	 2.4	 	 1.98	 0.33	
	 	 4.4	 4.7	 4.1	 7.3	 1.9	 3.2	 3.1	 	 4.09	 1.56	
	 	 10.9	 16.8	 8.0	 12.8	 7.4	 4.3	 5.7	 	 9.41	 4.04	
	 	 26.6	 23.6	 20.4	 41.5	 8.1	 14.5	 24.5	 	 22.72	 9.68	
	 	 106.7	 61.7	 42.5	 76.9	 9.6	 30.3	 28.5	 	 50.88	 30.71	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
	 	 0.0	 0.0	 0.1	 0.0	 0.1	 	 	 	 0.04	 0.05	
	 	 2.4	 	 1.6	 	 0.9	 	 	 	 1.64	 0.62	
	 	 5.1	 6.1	 2.0	 4.5	 3.2	 	 	 	 4.16	 1.46	
	 	 11.5	 20.7	 3.2	 11.0	 3.5	 	 	 	 9.97	 6.44	
	 	 33.2	 33.7	 4.1	 21.4	 6.8	 	 	 	 19.86	 12.58	
	 	 78.3	 68.8	 11.4	 36.8	 17.6	 	 	 	 42.60	 26.80	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
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0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
0.5	 0.2	 0.9	 	 0.0	 	 0.3	 0.5	 1.5	 	 0.56	 0.47	
0.0	 0.0	 1.4	 8.2	 1.6	 1.7	 0.3	 2.1	 1.8	 	 1.91	 2.36	
0.0	 0.0	 2.6	 22.0	 7.2	 6.0	 6.4	 2.3	 2.0	 	 5.38	 6.39	
0.0	 0.0	 13.6	 48.0	 3.9	 16.8	 7.6	 7.9	 6.5	 	 11.58	 13.90	
0.1	 0.2	 18.6	 68.8	 7.6	 30.7	 7.9	 23.2	 8.3	 	 18.37	 20.30	
	
	
IPMK+	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
1.8	 4.6	 4.8	 7.1	 2.5	 4.2	 	 4.17	 1.72	
6.7	 25.0	 14.8	 20.0	 29.2	 33.6	 	 21.55	 8.99	
21.9	 65.0	 86.9	 51.3	 66.6	 78.3	 	 61.67	 20.99	
57.2	 77.0	 111.6	 117.2	 90.0	 96.7	 	 91.60	 20.33	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
1.3	 3.2	 6.0	 2.4	 2.2	 4.1	 	 3.19	 1.52	
2.9	 24.2	 22.4	 11.9	 29.6	 33.9	 	 20.81	 10.52	
19.1	 44.0	 65.2	 35.9	 70.0	 81.6	 	 52.63	 21.52	
57.2	 78.0	 105.8	 104.7	 91.7	 101.7	 	 89.83	 17.44	
96.9	 80.0	 100.0	 134.4	 101.7	 103.3	 	 102.71	 16.13	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
1.9	 3.9	 3.8	 4.1	 2.3	 2.7	 	 3.11	 0.87	
3.4	 23.2	 14.3	 22.5	 29.2	 33.6	 	 21.05	 9.88	
15.3	 58.0	 86.9	 38.1	 73.3	 78.3	 	 58.33	 24.84	
45.0	 61.0	 116.0	 112.5	 92.0	 86.6	 	 85.51	 25.63	
106.3	 70.0	 89.8	 109.4	 100.0	 87.3	 	 93.80	 13.29	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
0.9	 2.2	 1.3	 1.4	 2.3	 3.8	 	 2.00	 0.95	
2.8	 6.8	 2.3	 4.9	 29.6	 31.9	 	 13.04	 12.62	
11.8	 18.0	 10.7	 11.9	 73.3	 58.3	 	 30.66	 25.33	
35.3	 62.0	 40.5	 43.8	 90.0	 86.6	 	 59.71	 21.85	
79.7	 120.0	 66.6	 104.7	 100.0	 86.6	 	 92.95	 17.45	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
0.9	 0.3	 0.9	 0.3	 0.5	 0.3	 	 0.55	 0.28	
2.2	 1.4	 1.2	 1.9	 1.1	 3.1	 	 1.84	 0.69	
7.7	 2.4	 3.7	 4.1	 1.9	 5.3	 	 4.19	 1.91	
27.5	 5.3	 10.7	 14.4	 2.3	 6.6	 	 11.13	 8.27	
86.8	 13.8	 23.4	 35.9	 5.5	 12.2	 	 29.61	 27.31	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
0.1	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.01	 0.02	
0.2	 0.1	 0.0	 0.1	 0.0	 0.1	 	 0.08	 0.07	
0.0	 0.1	 0.0	 0.1	 0.1	 0.6	 	 0.14	 0.21	
0.1	 0.0	 0.0	 0.1	 1.1	 0.9	 	 0.37	 0.47	
0.1	 0.1	 0.0	 0.3	 1.5	 1.1	 	 0.51	 0.58	
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PKBA-	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
4.1	 	 	 	 3.8	 	 	 	 3.99	 0.15	
20.0	 20.6	 24.3	 6.7	 22.3	 23.0	 5.6	 	 17.50	 7.31	
93.0	 64.1	 70.0	 18.0	 80.0	 92.6	 14.5	 	 61.73	 30.42	
128.1	 149.1	 114.0	 81.8	 96.0	 115.4	 93.3	 	 111.10	 21.27	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
5.6	 	 	 	 4.4	 	 	 	 5.01	 0.60	
25.3	 14.2	 23.9	 15.6	 17.9	 16.8	 6.7	 	 17.19	 5.77	
93.0	 79.2	 74.5	 90.9	 78.0	 92.3	 15.7	 	 74.79	 25.13	
124.6	 151.0	 138.0	 242.7704*	 94.0	 110.8	 249.1541*	 123.68	 20.01	
110.5	 118.9	 100.0	 215.4	 80.0	 100.0	 125.8	 	 121.52	 40.74	
	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
3.6	 	 	 	 3.1	 	 	 	 3.35	 0.23	
17.9	 11.9	 24.7	 35.0	 13.9	 18.4	 7.0	 	 18.40	 8.51	
47.7	 51.9	 68.0	 145.6	 74.0	 90.8	 18.1	 	 70.84	 37.18	
140.4	 107.6	 114.0	 218.469*	 144.1	 124.6	 302.5824*	 126.13	 14.27	
112.3	 156.7	 112.0	 227.6	 134.1	 101.5	 135.6	 	 139.97	 39.70	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
0.7	 	 	 	 3.0	 	 	 	 1.83	 1.13	
4.6	 8.4	 10.7	 14.9	 15.5	 12.2	 3.7	 	 9.99	 4.35	
11.8	 37.6	 37.0	 42.3	 86.0	 89.2	 7.4	 	 44.47	 29.94	
122.8	 126.5	 100.0	 218.469*	 106.0	 112.3	 43.0	 	 101.77	 27.80	
138.6	 134.0	 138.0	 218.5	 154.1	 92.3	 115.6	 	 141.58	 36.35	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
	 	 	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 2.3	 	 	 	 2.32	 0.00	
	 	 	 4.1	 5.4	 27.9	 1.8	 	 9.82	 10.53	
	 	 	 18.6	 9.9	 75.4	 2.7	 	 26.62	 28.70	
	 	 	 91.5	 59.1	 140.0	 22.1	 	 78.19	 43.34	
	 	 	 154.7	 63.9	 100.0	 44.3	 	 90.74	 41.97	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
	 	 	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.4	 	 	 	 1.44	 0.00	
	 	 	 3.5	 1.3	 8.2	 0.8	 	 3.45	 2.93	
	 	 	 8.9	 1.8	 21.1	 0.9	 	 8.16	 8.10	
	 	 	 2.8	 2.5	 118.5	 1.1	 	 31.21	 50.39	
	 	 	 8.9	 3.8	 107.7	 5.6	 	 31.51	 44.03	
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4	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
0.1	 0.0	 0.0	 	 1.0	 	 	 	 0.26	 0.41	
0.0	 0.0	 0.1	 5.0	 0.7	 4.2	 0.7	 	 1.53	 1.97	
0.1	 0.2	 0.1	 14.9	 0.6	 8.2	 0.8	 	 3.55	 5.39	
0.1	 1.3	 0.1	 9.5	 0.8	 39.6	 0.8	 	 7.45	 13.49	
0.1	 4.1	 0.2	 20.4	 5.8	 107.7	 1.2	 	 19.92	 36.43	
	
PKBA-IPMK+	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
0.2	 	 	 	 	 2.3	 	 1.28	 1.06	
2.6	 2.9	 16.5	 3.0	 1.9	 20.7	 	 7.93	 7.64	
9.8	 13.8	 73.3	 18.5	 3.2	 42.8	 	 26.90	 24.15	
57.8	 71.3	 102.2	 49.9	 27.9	 81.2	 	 65.05	 23.61	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
1.2	 	 	 	 	 2.4	 	 1.78	 0.62	
3.7	 4.9	 13.0	 3.3	 1.9	 19.4	 	 7.69	 6.35	
9.8	 21.8	 48.8	 20.4	 3.2	 38.9	 	 23.82	 15.75	
60.4	 157.3	 120.0	 84.3	 25.9	 83.5	 	 88.58	 41.79	
113.2	 228.9	 131.2	 103.1	 94.0	 101.3	 	 128.62	 46.38	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
3.8	 	 	 	 	 2.1	 	 2.94	 0.86	
4.9	 4.0	 12.3	 4.1	 0.8	 19.4	 	 7.58	 6.32	
16.1	 6.3	 31.0	 15.4	 8.7	 36.3	 	 18.97	 11.05	
81.5	 24.9	 75.5	 43.6	 30.7	 81.8	 	 56.35	 24.01	
155.4	 200.3	 95.5	 84.3	 67.9	 98.7	 	 117.03	 45.97	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
2.2	 	 	 	 	 2.3	 	 2.25	 0.04	
5.6	 2.0	 11.6	 2.9	 3.4	 20.7	 	 7.69	 6.62	
13.5	 5.4	 32.1	 6.3	 11.5	 45.4	 	 19.04	 14.73	
100.0	 10.9	 64.4	 24.8	 57.9	 77.9	 	 55.99	 30.27	
150.1	 164.4699*	 115.6	 59.3	 102.0	 97.4	 	 104.87	 29.34	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
1.2	 	 	 	 	 2.0	 	 1.59	 0.43	
1.5	 2.3	 3.4	 2.0	 1.8	 3.3	 	 2.38	 0.71	
1.6	 4.0	 10.1	 3.8	 2.7	 14.7	 	 6.14	 4.68	
2.1	 7.7	 31.9	 8.5	 12.7	 71.4	 	 22.38	 23.82	
6.1	 22.6	 88.9	 19.2	 59.9	 88.3	 	 47.51	 33.33	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
0.7	 	 	 	 	 0.5	 	 0.60	 0.14	
0.7	 0.6	 0.8	 1.1	 0.9	 0.5	 	 0.77	 0.20	
0.6	 1.1	 2.4	 1.1	 1.0	 7.2	 	 2.24	 2.27	
1.8	 1.4	 6.1	 1.5	 3.8	 11.0	 	 4.27	 3.42	
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3.0	 5.4	 7.8	 4.1	 10.3	 37.6	 	 11.37	 11.97	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
0.5	 	 	 	 	 0.1	 	 0.32	 0.21	
0.9	 0.0	 0.1	 0.3	 0.6	 0.1	 	 0.34	 0.34	
0.8	 1.4	 0.7	 0.1	 1.0	 0.1	 	 0.70	 0.47	
0.7	 1.7	 3.4	 1.6	 1.8	 1.0	 	 1.72	 0.85	
1.6	 3.7	 3.8	 4.8	 6.7	 1.1	 	 3.62	 1.86	
	
hIPMK+	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.5	 1.1	 1.0	 	 1.22	 0.22	
9.7	 4.8	 7.2	 8.3	 3.8	 4.4	 3.7	 	 6.00	 2.21	
23.0	 18.7	 36.4	 50.8	 9.5	 26.5	 8.3	 	 24.73	 13.95	
92.6	 91.1	 104.8	 105.3	 27.9	 103.1	 37.8	 	 80.37	 30.62	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 2.3	 1.1	 0.8	 	 1.39	 0.67	
15.0	 4.7	 8.3	 13.2	 5.4	 4.6	 3.8	 	 7.87	 4.20	
36.3	 17.6	 38.0	 49.1	 12.3	 26.5	 8.6	 	 26.90	 13.82	
113.3	 88.6	 103.2	 105.3	 29.5	 100.0	 38.1	 	 82.56	 31.66	
109.1	 89.9	 103.2	 105.3	 104.0	 101.6	 98.3	 	 101.61	 5.70	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.0	 1.4	 0.7	 	 1.07	 0.29	
8.0	 4.8	 8.4	 8.6	 5.8	 4.0	 3.8	 	 6.20	 1.96	
37.2	 18.1	 23.7	 38.5	 9.9	 23.3	 9.7	 	 22.92	 10.79	
73.5	 88.6	 103.2	 87.7	 29.9	 95.0	 38.1	 	 73.70	 26.53	
107.0	 88.6	 101.6	 105.3	 108.0	 93.7	 95.4	 	 99.95	 6.90	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.4	 0.8	 1.1	 	 1.08	 0.22	
21.2	 4.1	 6.2	 12.5	 3.4	 3.0	 2.8	 	 7.61	 6.40	
64.6	 11.3	 17.4	 35.0	 4.2	 17.1	 8.3	 	 22.56	 19.44	
64.6	 49.3	 51.6	 57.8	 19.9	 33.0	 30.8	 	 43.86	 15.01	
175.2	 70.9	 58.7	 63.1	 63.9	 46.8	 42.0	 	 74.38	 42.21	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 0.2	 0.1	 0.3	 	 0.22	 0.07	
8.8	 2.4	 3.1	 2.3	 0.8	 0.5	 0.5	 	 2.64	 2.71	
9.7	 3.3	 2.7	 4.4	 1.4	 0.8	 0.7	 	 3.31	 2.91	
10.6	 6.2	 5.6	 8.5	 1.8	 1.1	 1.0	 	 4.99	 3.52	
15.9	 6.5	 6.9	 8.3	 3.2	 1.3	 1.0	 	 6.15	 4.78	
	 	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 	 	 	 0.00	 0.00	
	 	 	 	 0.1	 	 	 	 0.08	 0.00	
1.8	 0.9	 2.0	 1.3	 0.1	 	 	 	 1.20	 0.69	
2.7	 1.0	 1.5	 1.5	 0.3	 	 	 	 1.38	 0.77	
5.3	 1.9	 2.9	 3.2	 1.4	 	 	 	 2.95	 1.34	
200	
	
7.1	 2.1	 3.8	 2.9	 1.5	 	 	 	 3.46	 1.96	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 0.2	 0.1	 0.1	 	 0.11	 0.04	
2.7	 1.4	 2.7	 0.9	 0.2	 0.5	 0.2	 	 1.22	 1.02	
3.5	 1.2	 2.7	 0.9	 0.2	 0.7	 0.3	 	 1.36	 1.19	
2.7	 2.5	 4.0	 1.8	 1.5	 1.0	 0.5	 	 2.00	 1.08	
8.0	 2.6	 4.2	 2.2	 1.8	 1.1	 0.6	 	 2.91	 2.33	
	
